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Background: Chronic spinal pain is the most prevalent chronic disease with employment
of multiple modes of interventional techniques including epidural interventions. Multiple
randomized controlled trials (RCTs), observational studies, systematic reviews, and guidelines have
been published. The recent review of the utilization patterns and expenditures show that there
has been a decline in utilization of epidural injections with decrease in inflation adjusted costs
from 2009 to 2018. The American Society of Interventional Pain Physicians (ASIPP) published
guidelines for interventional techniques in 2013, and guidelines for facet joint interventions in
2020. Consequently, these guidelines have been prepared to update previously existing guidelines.
Objective: To provide evidence-based guidance in performing therapeutic epidural procedures,
including caudal, interlaminar in lumbar, cervical, and thoracic spinal regions, transforaminal in
lumbar spine, and percutaneous adhesiolysis in the lumbar spine.
Methods: The methodology utilized included the development of objective and key questions
with utilization of trustworthy standards. The literature pertaining to all aspects of epidural
interventions was viewed with best evidence synthesis of available literature and recommendations
were provided.
Results: In preparation of the guidelines, extensive literature review was performed. In addition
to review of multiple manuscripts in reference to utilization, expenditures, anatomical and
pathophysiological considerations, pharmacological and harmful effects of drugs and procedures,
for evidence synthesis we have included 47 systematic reviews and 43 RCTs covering all epidural
interventions to meet the objectives.
The evidence recommendations are as follows:
Disc herniation: Based on relevant, high-quality fluoroscopically guided epidural injections,
with or without steroids, and results of previous systematic reviews, the evidence is Level I
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for caudal epidural injections, lumbar interlaminar epidural injections, lumbar transforaminal epidural injections, and cervical
interlaminar epidural injections with strong recommendation for long-term effectiveness.
The evidence for percutaneous adhesiolysis in managing disc herniation based on one high-quality, placebo-controlled RCT is
Level II with moderate to strong recommendation for long-term improvement in patients nonresponsive to conservative
management and fluoroscopically guided epidural injections.
For thoracic disc herniation, based on one relevant, high-quality RCT of thoracic epidural with fluoroscopic guidance, with or
without steroids, the evidence is Level II with moderate to strong recommendation for long-term effectiveness.
Spinal stenosis: The evidence based on one high-quality RCT in each category the evidence is Level III to II for fluoroscopically
guided caudal epidural injections with moderate to strong recommendation and Level II for fluoroscopically guided lumbar
and cervical interlaminar epidural injections with moderate to strong recommendation for long-term effectiveness.
The evidence for lumbar transforaminal epidural injections is Level IV to III with moderate recommendation with
fluoroscopically guided lumbar transforaminal epidural injections for long-term improvement.
The evidence for percutaneous adhesiolysis in lumbar stenosis based on relevant, moderate to high quality RCTs, observational
studies, and systematic reviews is Level II with moderate to strong recommendation for long-term improvement after
failure of conservative management and fluoroscopically guided epidural injections.
Axial discogenic pain: The evidence for axial discogenic pain without facet joint pain or sacroiliac joint pain in the lumbar and
cervical spine with fluoroscopically guided caudal, lumbar and cervical interlaminar epidural injections, based on one relevant
high quality RCT in each category is Level II with moderate to strong recommendation for long-term improvement, with
or without steroids.
Post-surgery syndrome: The evidence for lumbar and cervical post-surgery syndrome based on one relevant, high-quality RCT
with fluoroscopic guidance for caudal and cervical interlaminar epidural injections, with or without steroids, is Level II with
moderate to strong recommendation for long-term improvement.
For percutaneous adhesiolysis, based on multiple moderate to high-quality RCTs and systematic reviews, the evidence is Level
I with strong recommendation for long-term improvement after failure of conservative management and fluoroscopically
guided epidural injections.
Limitations: The limitations of these guidelines include a continued paucity of high-quality studies for some techniques and
various conditions including spinal stenosis, post-surgery syndrome, and discogenic pain.
Conclusions: These epidural intervention guidelines including percutaneous adhesiolysis were prepared with a comprehensive
review of the literature with methodologic quality assessment and determination of level of evidence with strength of
recommendations.
Key words: Chronic spinal pain, interventional techniques, epidural procedures, caudal epidural, lumbar interlaminar epidural,
cervical interlaminar epidural, thoracic interlaminar epidural, lumbar transforaminal epidural, percutaneous adhesiolysis
Disclaimer: These guidelines are based on the best available evidence and do not constitute inflexible treatment recommendations.
Due to the changing body of evidence, this document is not intended to be a “standard of care.” There was no external funding
in the preparation of this manuscript.
Pain Physician 2020: 23:S27-S208
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1.0 Introduction
Chronic spinal pain is the most prevalent chronic
disease across the globe, negatively impacting the
quality of life (QoL) and function, impacting individuals, their families, communities, businesses, and health
systems, and straining the healthcare system as a leading cause of disability adjusted life years. Overall, the
impact of chronic pain, of which spinal pain is the major
component with low back pain as the leading cause,
continues to be disproportionate and enormous.
Chronic persistent spinal pain lasting longer than
one year is reported in 25% to 60% of patients (138). The prevalence of pain in various spinal regions,
while variable, is most present in the low back with
43%, followed by the neck at around 32%, and least
in the thoracic spine at 13% (29). Further, most painful
conditions increase with age and because there is an
increase in multi-morbidity, noncommunicable diseases,
and reduced physical activity associated with spinal
pain, the global burden related to pain is expected to
rise with an increasing global population of 65 years
and older, which also applies to the United States (US)
(5-8,13,33-38).
The assessments of the impact of spinal pain in the
US showed low back pain ranking number 1, neck pain
ranking number 3, with musculoskeletal disorders ranking number 2, and depression and anxiety ranking number 4 and 5, among the 30 leading diseases and injuries,
contributing to years lived with disability in 2010 (2).
In addition, Dieleman et al (39,40) evaluated the economic impact on healthcare in the US and showed an
estimated spending of $134.5 billion in 2016, a 53.5%
increase from 2013 or $87.6 billion spent for managing
spinal pain. The costs of other musculoskeletal disorders
also increased by 43.5% from $183.5 billion in 2013 to
$263.3 billion in 2016.
This analysis (40) also showed in 2016, among 154
conditions, low back and neck pain had the highest
amount of healthcare spending, of which 57.2% was
paid by private insurance, 33.7% paid by public insurance, and 9.2% by out-of-pocket payments. In addition,
the same group analyzing the costs (39,40) also performed an economic attribution analysis of healthcare
spending attributable to modifiable risk factors in the
Untied States (US) (41). In this analysis, they included
behavioral risks, such as smoking and dietary risks;
metabolic risks, such as high body mass index (BMI) and
high blood pressure; and environmental risks, such as
air pollution and occupational carcinogens. This study
(41) highlighted that 27% of healthcare spending in the
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US in 2016 can be attributed to this broad set of risk factors, with most spending attributable to high BMI, high
systolic blood pressure, high fasting plasma glucose,
dietary risks, and smoking tobacco.
National health expenditures (42) are projected
to grow at an average annual rate of 5.4% from 2019
to 2028 and to represent 19.7% of the gross domestic
product (GDP) by the end of the period. Among all
major payers, Medicare is expected to experience the
fastest spending growth, 7.6% per year, largely because
of having the highest projected enrollment growth.
In fact, these projected data show that Medicare and
Medicaid spending was 37% in 2019 and will grow to
41.6% in 2028. Similarly, federal and other governmental spending was 53.2% in 2019, and will increase to
58% in 2028.
Additionally, healthcare expenditures have been
escalating and the financial impact on the US economy
is growing with a perfect storm created by COVID-19,
the opioid epidemic, issues related to regulations, and
lack of reliable, unbiased, evidence-based medicine
(43-46). The COVID-19 epidemic resulted in severe access deficits for patients with undertreatment and a
lack of treatment for elective care, with severe economic consequences for providers because of reduced
reimbursement and increased costs, as well as a severe
psychosocial impact, not only on patients, but also on
healthcare providers (43-53).
Among multiple modalities of treatments available, epidural injections are one of the most performed
procedures in managing spinal pain with or without
extremity pain. Epidural injections are utilized in managing pain and disability secondary to herniated discs,
spinal stenosis, discogenic pain, and in post-surgery syndrome (7,54-77). Further, in patients with the post-lumbar surgery syndrome and spinal stenosis, percutaneous
adhesiolysis is administered frequently for targeted delivery of solutions following the adhesiolysis (7,71-74).
Adhesiolysis is also utilized occasionally in managing
recalcitrant disc herniation nonresponsive to epidural
injections (71). In fact, Best Practices in Pain Management, from the Department of Health and Human Services (HHS) has reviewed the available evidence in pain
management and described interventional techniques
as part of a continuum prior to surgical interventions
and neuromodulation (78,79). Despite their extensive
use, discordant conclusions have been brought on by
multiple challenges related to the conduct of the randomized controlled trials (RCTs) based on approach
(transforaminal, interlaminar, or caudal), control design
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(active-controlled versus placebo-controlled), and technical performance with or without fluoroscopy, alternative techniques, and outcome assessments ranging from
absolute difference between 2 groups to minimally
clinically important difference with assessment of proportion of patients (7,8,54-83).
Discordant conclusions are based on academicians
not following the fundamental rules in designing systematic reviews related to inclusion criteria, methodologic quality assessment of the trials or studies, outcome
assessments, and perceived intellectual bias with conflicts of interest. In fact, the Institute of Medicine (IOM)
(84) has described multiple issues related to the design
of the systematic review addressing multiple issues as
an example. Multiple systematic reviews have suffered
significant bias based on inclusion criteria by converting
all active controls to placebos, with conclusions based
on inappropriate analysis, leading to invalid results (6669,74,80-83). IOM extensively described the role of bias
and conflicts of interest and the need to minimize the
bias and conflicts of interest. IOM defined conflict of
interest as, “a set of circumstances that creates the primary interest will be unduly influenced by a secondary
interest” (84). Often, primary interests are well-known
and disclosed with financial conflicts (even though it
is not always the case). However, multiple secondary
interests such as pursuit of professional advancement,
future funding opportunities and recognition, personal
biases, and the desire to do favors for friends and colleagues are often not disclosed. Hidden conflicts of
interest have been identified in those with academic interests, but also by taxpayer paid agencies, which advise
the policy makers and those preparing reviews for these
organizations (74,82,84-87). Major conflicts of interest
and inappropriate assessments have been identified by
the Cochrane reviews (68,69,88-93). Further, the Institute for Transitional Medicine and Therapeutics (ITMAT)
(94) described the confluence (not conflict of interest)
in which conflicts of interest represent a complex ecosystem that requires the development of a uniform
approach to minimize bias in clinical research across
the academic sector. They showed that the conflict of
interest is pejorative and that disclosure policies have
focused on financial gains only, whereas in academia,
the prospect of fame may be even more seductive than
fortune. Multiple systematic reviews also have confused
facts (verifiable) with their own opinions (judgment
based on beliefs and conviction based on personal
values), ultimately leading to prejudicial statements –
opinions based on insufficient or unexamined evidence.
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Recently, Manchikanti et al (93) have published a methodologic review and evidence assessment in guideline
preparation in interventional pain management.
The study of the methodologic quality of systematic reviews published in the highest-ranking journals
in the field of pain medicine by Riado Minguez et al
(95), essentially showed a lack of improvement in the
methodological and reporting quality of systematic reviews before or after the publication of A Measurement
Tool to Assess Systematic Reviews (AMSTAR) (96), and
Preferred Reporting Items for Systematic Reviews and
Meta-Analysis (PRISMA) checklists (97). In this review
(95), authors reviewed evidence from multiple journals
from Anesthesiology and Pain across the globe, but had
not found any systematic reviews to be included from
the journal Pain Medicine. Pain Physician published
a large number of systematic reviews of moderate to
high-quality.
In another manuscript, Ross et al (98) assessed the
methodologic quality of systematic reviews from clinical practice guidelines for the treatment of opioid use
disorder and concluded that underperforming areas
and AMSTAR included conflicts of interest, funding,
and publication bias, whereas in PRISMA, protocol registration and risk of bias are issues of concern. In fact,
multiple issues were raised in reference to Cochrane
reviews and their discrepancies, which were even less
ominous than errors with interventional pain management techniques (89-91). Cochrane reviews have
been internationally regarded as one of the leading
resources for reliable information on healthcare interventions. Clark et al (89) reported misrepresentation
of evidence for vertebroplasty with early interventions
in severely affected patients. Clark et al (92) in fact
filed a complaint with the Editor in Chief of Cochrane
reviews. Clark et al (92) showed that the review did
not accurately report the evidence for vertebroplasty
in patients with severe symptoms and early fractures.
The way the data was presented in the Cochrane review, readers of the review would be unable to discern
this information. They alluded to multiple issues with
protocol breaches, misreporting of data in the trials,
undisclosed conflicts of interest, and faulty risk of bias
assessment in the Cochrane review. Kirkham et al (91)
analyzed outcome reporting bias (ORB) in trials and
concluded that evidence suggests that ORB is a threat
to the validity of the evidence base and contributes to
research waste. They have also highlighted up-to-date
approaches and recommendations for detecting these
problems and adjusting the results when performing
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sensitivity analysis in systematic reviews. Shah et al (90),
in a later publication, assessed ORB in Cochrane systematic reviews in a cross-sectional analysis. They described
that discrepancies in outcome reporting (DOR) between
protocol and published studies include inclusions of
new outcomes, omission of prespecific outcomes,
upgrade and downgrade of secondary and primary
outcomes, and changes in definitions of prespecified
outcomes. Thus, DOR can result in ORB when changes
in outcomes occur after knowledge of the results, which
essentially has a potential to overestimate treatment effects and underestimate harms at the level of systematic
reviews. Their analysis showed that 43%, or 150 of 350,
Cochrane review protocol pairings contained DOR. Further, 35%, or 53 of 150, reviews with DOR contained a
high risk of ORB, with changes being made after knowledge of results from individual trials. They concluded
that the presence of DOR and ORB in Cochrane reviews
is of great concern. Obviously, Cochrane review has
not identified these issues and has not ascertained to
resolve these issues, even though they can do so with
simple measures.
This discussion leads to various types of bias in
studies in interventional pain management in multiple
manuscripts (67,80-82). In fact, Manchikanti et al (81)
performed a comparative systematic review and metaanalysis assessing the publication by Chou et al (80),
which showed significantly different results when the
analysis was performed appropriately. Their conclusion was also not based on scientific evidence, as both
local anesthetic and steroids were equally effective.
Consequently, they concluded that neither one was
effective. Further, Agency for Healthcare Research and
Quality (AHRQ) funding has been significantly reduced.
The same philosophy was applied by Cochrane review
guidance by Pinto et al (67,68) who utilized a similar
philosophy with conversion of active control trials with
a lack of clinical experience or understanding by the
primary authors and lack of disclosures of conflict of
interest. These may be added to multiple other deficits
of the Cochrane reviews. Another issue is based on the
fact that providing pain relief after a single epidural
injection, which may last 3 to 13 weeks, the reviewers
are assessing their effectiveness for a year, and are also
comparing with long-term surgical procedures without
any clinical relevance.
Along the same lines, Manchikanti et al (74)
analyzed systematic findings of systematic reviews in
assessing the effectiveness of percutaneous adhesiolysis in post-lumbar surgery syndrome. The authors (74)
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found that a single systematic review by Brito-García
et al (87) of 4 randomized trials on this subject at that
time, had very low methodologic quality scores on all
AMSTAR, PRISMA, and Scottish Intercollegiate Guidelines Network (SIGN) checklist for systematic reviews.
The systematic review by Brito-García et al (87) also had
numerous deficiencies and improper and inappropriate
information. Contrary to the high-profile reviews by
Chou et al and others (67,68,80), Lewis et al (99,100) in
2 manuscripts funded by National Health Services (NHS)
and Health Technology Assessment Program (HTA) have
presented positive results for epidural injections. The
systematic review of health technology assessment (99)
also utilized an economic model of the clinical effectiveness and cost-effectiveness of management strategies
for sciatica, supporting the effectiveness of epidural
corticosteroid injections, and disc surgery. In the second
manuscript, Lewis et al (100), utilizing a network metaanalysis of comparative clinical effectiveness of management strategies for sciatica with review of 122 relevant
studies and 21 treatment strategies showed a statistically significant improvement with epidural injections.
In addition, Guo et al (101), in a comparative network
meta-analysis to compare the efficacy and tolerability of treatment for sciatica, showed that the epidural
steroid with local anesthetic demonstrated superiority
over the epidural steroid without local anesthetic and
intramuscular steroid. Further, they found subcutaneously injected antitumor necrosis factor-α (anti-TNF-α)
to be superior to the epidural steroid plus anesthetic at
reducing pain levels, but the epidural steroids demonstrated superior reductions in the Oswestry Disability Index (ODI) scores, compared to subcutaneous anti-TNF-α.
Further, Shanthanna et al (102), in a systematic review
and meta-analysis of RCTs in the review of addition of
corticosteroids to local anesthetics for chronic noncancer pain injections, after review of 73 trials, concluded
that the addition of corticosteroids to local anesthetic
has only small benefits and a potential for harm. They
found no meaningful improvement in pain scores or the
duration of pain relief. They recommended that clinical
decisions should consider the potential for harm with
steroids and the therapeutic benefit by the local anesthetic alone.
Consequently, despite the availability of numerous
systematic reviews (56-77,80-83,102), there have not been
guidelines systematically developed in assessing clinical
and cost effectiveness of epidural injections, including
percutaneous adhesiolysis, in managing spinal pain. The
American Society of Interventional Pain Physicians (ASIPP)

S31

Pain Physician: Epidural Guidelines 2021 24:S27-S208

guidelines in managing spinal interventional techniques
were published in 2013 (7), which included all modalities of treatments in managing spinal pain. Since then,
multiple other guidelines have been developed relevant
to interventional pain physicians, including facet joint
interventions (8), opioid therapy in chronic noncancer
pain (6), use of biologics in the management of low back
pain (5), antithrombotic guidelines (103), risk mitigation
and stratification during COVID-19 for return to interventional pain practice (51), triaging of interventional pain
procedures during COVID-19 or related elective surgery
restrictions (52), and a position statement on bone marrow concentrate (104). The present guidelines have been
developed specifically for epidural interventions, including percutaneous adhesiolysis. Since the US and the world
continue to be in the middle of a pandemic, with resurgences, the development of guidelines for epidural procedures is crucial. ASIPP has been at the forefront during
COVID-19 pandemic and its influence on interventional
pain management with publications related to guidance
(51,52), highlighting the value of nonsteroidal injections
as steroids were considered as a risk factor for COVID-19
patients (55,58,105-107), value of telemedicine (108,109),
influence on technological advances and multiple other
aspects including testing and therapeutics (43-45,110115). The impact of chronic pain has been described by
multiple others, with a continuing downturn of revenues
and simultaneous increases in expenses (43-53). Consequently, a triad of concurrent epidemics of COVID-19,
opioid epidemic, and a regulatory burden with declining
reimbursements has created a perfect storm (43) with
increasing practice costs, exacerbated by inappropriate
evidence-based medicine. Furthermore, the addition of
improper evidence-based assessments continues to add to
the ongoing storm with inadequate assessments leading
to inappropriate conclusions.
The development of these guidelines includes an
overview of the current literature regarding the use
of epidural injections and percutaneous adhesiolysis
procedures in managing spinal pain. These guidelines included evidence-based and evidence-informed strategies
utilizing the concepts of efficacy and effectiveness and
proper evidence synthesis as described in the literature
(5-8,51,52,104,116-126) to avoid conflicts and confluence
of interest.
Consequently, ASIPP has undertaken the development of guidelines for epidural interventions, based on
a rational and systematic approach to the application of
these interventions in managing spinal pain. This is an
update of epidural interventions from comprehensive

S32

guidelines published in 2013, which included all spinal
interventions (7).

2.0 Methods
2.1 Rationale
The National Uniform Claims Committee (NUCC)
defines interventional pain management as the discipline
of medicine devoted to the diagnosis and treatment of
pain related disorders principally with the application of
interventional techniques in managing subacute, chronic,
persistent, and intractable pain, independently or in
conjunction with other modalities of treatment (https://
www.nucc.org). The Medicare Payment Advisory Commission (MedPAC) defines interventional pain management
techniques as minimally invasive procedures including
percutaneous precision needle placement of drugs in targeted areas or ablation of targeted nerves; surgical techniques such as laser and endoscopic discectomy; and the
placement of intrathecal infusion pumps and spinal cord
stimulators for the diagnosis and management of chronic,
persistent, or intractable pain (http://medpac.gov/).
Chronic spinal pain is a complex and multifactorial disease process with numerous treatment modalities applied in the management of the problem, and
the growing social and economic costs continue to
influence medical decision-making. Intervertebral discs,
facet joints, sacroiliac joints, ligaments, fascia, muscles,
and nerve root dura are proven pain generators in the
spine (5-8,78,79,127-139). Interventional pain physicians
are familiar with various image-guided interventional
techniques for the management of spinal pain (5-8).
Many of the causes of spinal pain and other chronic
pain conditions are considered to be acute recurrent
problems characterized by periods of quiescence punctuated by flare-ups, or chronic diseases, like diabetes
or hypertension, requiring long-term treatment with
ongoing care. The importance of spinal interventional
techniques in managing chronic spinal pain has been
established on the basis of advances in imaging, neuroanatomic findings, the development of precision
diagnostic and therapeutic injection techniques, and
reported nonoperative treatment successes. Many
guidelines, systematic reviews, Cochrane Reviews,
and other articles pertaining to interventional pain
management (IPM) have been published (5-8,54-83).
Some of these guidelines, however, are ambiguous
and not based on appropriate evidence synthesis, with
the inclusion of extensive confluences of interest (6669,74,80-93,95,97,98,105,140-150). Consequently, these
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approaches may not be applicable in managing chronic
spinal pain utilizing contemporary IPM.

2.2 Objectives
The objective of these guidelines is to provide a
rationale and systematic approach to the application
of epidural interventions in managing spinal pain. The
guidelines are based upon the available evidence concerning the effectiveness and safety in the treatment of
spinal pain. The literature shows the value of evidencebased guidelines and the need for appropriate updating of the guidelines to practice with current concepts
(5-8,93,116-126).
These guidelines include the description and application of epidural interventions in managing spinal pain
due to disc, spinal stenosis and post-surgery syndrome.

2.3 Application
While these guidelines may be applied by any
specialty, they are specifically intended for use by interventional pain physicians. These guidelines do not
constitute inflexible treatment recommendations. It is
expected that a clinician will establish a plan of care on
a case-by-case basis, considering an individual patient’s
medical condition, personal needs, and preferences,
and the physician’s experience. Based on an individual
patient’s needs, treatment different from that outlined
here could be warranted. Consequently, these guidelines do not represent a “standard of care.” It is a wellknown fact that all treatments are not supported by
existing evidence and grading. However, there may be
strong clinical support for some interventions.
The goal of these guidelines is to provide patients,
practitioners, regulators, and payers, information that
may be used to determine whether the available evidence
supports the notion of a “standard” for interventional
techniques. “Standard” refers to what is applicable to the
majority of patients, with a preference for patient convenience and ease of administration without compromising
treatment efficacy or morbidity (5-8). It is essential to recognize the difference between “standard” and “standard
of care,” as utilized as a legal definition (151).

2.4 Key Questions
These guidelines focus on the following key questions regarding disc-related and stenotic spinal pain:
1. What is the impact of chronic spinal pain on healthcare resources?
2. What are the statistics regarding the trends in utilization of treatment modalities in managing spinal pain?
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3.

What is the evidence for the structural basis of spinal
pain?
4. What is the pathophysiologic basis of epidural interventions in spinal pain?
5. What are the noninterventional diagnostic methods in disc related pathology, spinal stenosis, and
post-surgery syndrome?
6. Are the available therapeutic epidural injections
and adhesiolysis in managing chronic spinal pain
effective?
7. What is the evidence for cost-effectiveness of epidural interventions including adhesiolysis in managing spinal pain?
8. What are the adverse consequences, harms,
and related precautions in providing epidural
interventions?
9. What are the implications of antithrombotic and
anticoagulant therapy and epidural interventions?
10. What are the guidelines for epidural injections and
adhesiolysis in managing chronic spinal pain?

2.5 Adherence to Trustworthy Standards
In preparation of guidelines for epidural interventions (epidurals and adhesiolysis), the standards from
the IOM and the National Guideline Clearinghouse
Extent Adherence to Trustworthy Standards (NEATS)
were followed (94,118-125). The NEATS instrument
was developed and tested as a tool to be used by the
trained staff at the AHRQ National Guideline Clearinghouse to provide assessment focused on adherence
(119).

2.5.1 Disclosure of Guideline Funding Source
Comprehensive evidence-based guidelines for
epidural interventions in managing chronic spinal pain
were commissioned, prepared, edited, and endorsed by
ASIPP without external funding.

2.5.2 Disclosure and Management of Financial
Conflicts of Interests
Potential conflicts of interest for all panel members
within the last 5 years were evaluated prior to the finalizing of these guidelines. Conflicts of interests extended
beyond financial relationships, including personal experience, practice patterns, academic interests, and promotions. The panel members with potential conflicts were
recused from discussion or preparation of the guidelines
in which they had conflicts of interest, and these members agreed not to discuss any aspect of a given guideline
with the related industry before data publication.
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2.5.3 Composition of Guideline Development
Group
A panel of experts in managing spinal pain and
interventional techniques from various medical fields,
convened by ASIPP, reviewed the evidence and formulated recommendations for epidural procedures,
including adhesiolysis. Overall, the panel provided a
broad representation of academic and nonacademic
clinical practitioners with interest and expertise in
interventional techniques as applicable to epidural
procedures.

2.6 Evidence Review
The evidence-based guidelines for epidural interventions were developed utilizing consensus among the
panel members after they had reviewed all published
literature concerning the use and safety of epidural
procedures, including adhesiolysis, in patients with
chronic spinal pain. The recommendations have been
developed using principles of best evidence synthesis
developed by the Cochrane Review, incorporating multiple guidelines modified by ASIPP (152).

2.6.1 Grading or Rating the Quality or Strength of
Evidence
The grading of evidence is based on RCTs, obserTable 1. Qualitative modified approach to grading of evidence
of therapeutic effectiveness studies.
Level I

Level II

Level III

Strong

Evidence obtained from multiple relevant
high-quality randomized controlled trials

Moderate

Evidence obtained from at least one
relevant high-quality randomized
controlled trial or multiple relevant
moderate or low-quality randomized
controlled trials

Fair

Evidence obtained from at least one
relevant moderate or low-quality
randomized trial
or
Evidence obtained from at least one
relevant high-quality non-randomized
trial or observational study with multiple
moderate or low-quality observational
studies

vational studies, and other clinical reports. In addition,
systematic reviews and meta-analyses were utilized. The
grading of evidence based on ASIPP guidelines is shown in
Table 1 (152), whereas Table 2 shows GRADE recommendation grading (125). This grading system specifies levels of
scientific evidence and offers an approach to grading the
quality of evidence and secondarily the strength of recommendations. AHRQ has recommended a similar approach
to the strength of a recommendation (121,125,152).

2.6.2 Assessment and Recommendations of
Benefits and Harms
These guidelines describe the potential benefits
and harms for the interventions and explicitly link the
information to specific recommendations.

2.6.3 Evidence Summary of Recommendations
Guideline-supporting documents summarize the
relevant supporting evidence and link this information
to the recommendations.

2.6.4 Rating or Grading the Strength of
Recommendations
IOM standards demand that for each recommendation, a rating of the strength of the recommendation
related to benefits and harms, available evidence, and
the confidence in the underlying evidence should be
provided. To meet the appropriate standards, the rating
schemes recommended by NEATS were utilized as shown
in Table 3 (119).

Table 2. Recommendation grade.

A

- At least one metaanalysis, systematic review, or RCT rated as
1 + + and directly applicable to the target population or
- A systematic review of RCTs or a body of evidence
consisting principally of studies rated as 1 + directly
applicable to the target population and demonstrating overall
consistency of results

B

A body of evidence including studies rated as 2 + + directly
applicable to the target population and demonstrating overall
consistency of results or
- Extrapolated evidence from studies rated as 1 + + or 1 +
- A body of evidence including studies rated as 2 + directly
applicable to the target population and demonstrating overall
consistency of results or
- Extrapolated evidence from studies rated as 2 + +
- Evidence level 3 or 4 or
- Extrapolated evidence from studies rated as 2 +

Level IV

Limited

Evidence obtained from multiple
moderate or low-quality relevant
observational studies

C

Level V

Consensus
based

Opinion or consensus of large group of
clinicians and/or scientists

D

Modified from: Manchikanti L, et al. A modified approach to grading
of evidence. Pain Physician 2014; 17:E319-E325 (152).
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Table 3. Guide for strength of recommendations.

Rating for Strength of recommendatrion
Strong

There is high confidence that the recommendation reflects best practice. This is based on: a) strong evidence for a true net effect
(e.g., benefits exceed harms); b) consistend results, with no minor exceptions; c) minor or no concerns about study quality; and/or
d) the extent the panelists’ agreement. Other compelling considerations (discussed in the guideline’s literature review and analyses)
may also warrant a strong recommendation.

Moderate

There is moderate confidence that the recommendations reflects best practice. This is based on: a) good evidence for a true net
effect (e.g. benefits exceed harms); b) consistent results, with minor and/or few exceptions; c) minor and/or few concerns about
study quality; and/or d) the extent of panelists’ agreement. Other compelling considerations (discussed in the guideline’s literature
review and analyses) may also warrant a moderate recommendation.

Weak

There is some confidence that the recommendation offers the best current guidance for practice. This is based on: a) limited
evidence for a true net effect (e.g., benefits exceed harms); b) consistent results, but with important exceptions; c) concerns about
study quality; and/or d) the extent of panelists’ agreement. Other considerations (discussed in the guideline’s literature review and
analyses) may also warrant a weak recommendation.

Source: National Guideline Clearinghouse Extent Adherence to Trustworthy Standards (NEATS) instrument (119).

2.6.5 Specificity of Recommendations
Evidence and best practices were utilized in forming
recommendations for epidural injections and adhesiolysis.

2.7 Methodologic Quality and Risk of Bias
Assessment
Key recommendations included transparency and
reproducibility of judgements, separating risk of bias
from other constructs such as applicability and precision, and evaluation of the risk of bias per outcomes.

2.7.1 Randomized Controlled Trials
Multiple instruments have been developed over the
years to assess the methodological quality, along with
bias, in RCTs (153,154). The criteria developed by the Cochrane review editorial board has been used extensively
and has been modified over the years. Appendix Table
1 shows Cochrane review criteria (154) and Appendix
Table 2 shows criteria developed by interventional pain
physicians with a specific item checklist for assessment
of RCTs of interventional pain management techniques
(153). A third criteria used is based on SIGN (74,155,156)
as shown in Appendix Table 3.
While Cochrane criteria is universally accepted and
was implemented in several trials, this was not specific
for interventional techniques. In contrast, Interventional Pain Management techniques - Quality Appraisal of
Reliability and Risk of Bias Assessment (IPM-QRB) was
specifically developed for interventional techniques,
specifically in patients suffering with chronic spinal
pain. This checklist includes various types of criteria,
including trial design and guidance report, along with
setting, physician, imaging, chronicity of pain, previous
treatments, and multiple other appropriate criteria. It
has been shown to be more robust than the Cochrane
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review criteria and was considered as providing better
information than the Cochrane review criteria when
compared head-to-head with both Cochrane review criteria and IPM-QRB. Both criteria have been extensively
utilized in IPM evidence synthesis.
The literature pertaining to SIGN (74,125,155,156) is
not extensive, even though it has been reported in some
studies related to interventional techniques (74,155).

2.7.1.1 Scoring IPM-QRB Criteria
Based on IPM-QRB criteria for randomized trials,
the studies meeting the inclusion criteria but scoring
less than 16 were considered as low-quality and were
excluded; studies scoring from 16 to 31 were considered
as moderate quality; and studies scoring from 32 to 48
were considered as high-quality.
2.7.1.2 Scoring Cochrane Review Criteria
Utilizing Cochrane review criteria, studies meeting
the inclusion criteria with at least 9 of 13 criteria were
considered high-quality; 5 to 8 were considered moderate quality. Those meeting criteria of less than 5 were
considered as low-quality and were excluded.
2.7.1.3 Scoring SIGN
Methodologic quality assessment of systematic
reviews was also conducted utilizing SIGN (74,155,156).
The quality assessment was based on 3 options, i.e.,
those which were designated as ++ (indicated all or
most of all standards are met), + (indicated some of the
standards are met), and – (indicated all or most of all
standards are not met).

2.7.2 Nonrandomized Studies
Similar to the checklist for RCTs, Manchikanti et
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al (157) developed a comprehensive instrument that
is helpful in assessing the methodological quality of
nonrandomized trials and is specific to interventional
techniques (Appendix Table 4).
IPM checklist with Interventional Pain Management
Techniques – Quality Appraisal of Reliability and Risk of
Bias Assessment for Nonrandomized Studies (IPM-QRBNR) has been evaluated in multiple assessments. With
the rapid development of RCTs, observational studies
are not as frequently used. Further, methodologic quality assessment for these is not utilized.
SIGN also has developed an instrument to assess
the methodologic quality and risk of bias assessment
in observational studies as shown in Appendix Table
3 (74,125,155,156). In contrast to RCTs, observational
studies have not been methodologically assessed as
frequently. Further instruments for assessment are also
limited.

2.7.2.1 Scoring For IPM-QRBNR
Based on IPM-QRBNR criteria, studies meeting the
inclusion criteria but scoring less than 16 were considered low-quality and were excluded, studies scoring
from 16 to 31 were considered moderate quality; and
studies scoring from 32 to 48 were considered highquality and were included.

2.7.3 Quality Assessment of Systematic Reviews
Risk of bias and methodological and reporting
quality assessment may be performed utilizing 3 tools:
AMSTAR, PRISMA, and SIGN.
In the past, we have performed such assessments
utilizing all 3 tools; however, it is not only very cumbersome, but also did not provide any meaningful informa-

tion. A low-quality meta-analysis may be high-quality
methodologically. To avoid such time issues, we have
categorized all the systematic reviews into 3:
1. Low-quality: This category with either a systematic
review or meta-analysis, with conversion of studies or moving them into a different category, such
as placebo to active control, against the intent of
the authors of the original manuscripts, without
consent, and without STRONG scientific basis, even
though they may be of high, moderate or low
methodologic quality based on PRISMA, AMSTAR,
or SIGN.
2. Moderate quality: This category included the majority of the systematic reviews, methodologically
sound, which followed the appropriate principles
without violation of practices, with either a systematic review or meta-analysis with conventional
dual-arm analysis only.
3. High-quality: In this category, the systematic reviews, methodologically sound, with the inclusion
of appropriate, high-quality principles, with conventional dual-arm meta-analysis and single-arm
meta-analysis without violation of standards and
keeping the intent of the original manuscripts.

2.8 External Review
Guidelines have been subjected to external peer
review as per the policies of the publishing journal, Pain
Physician.

2.9 Updating Guidelines
The epidural interventions for chronic spinal pain
guidelines will be updated within 5 years or less, based on
significant changes in scientific evidence, public policy, or
adverse events occurring
before January 2026.

3.0 Impact of
Chronic Spinal
Pain on Health
Care

Fig. 1. Prevalence of musculoskeletal pain and years lived with disability.

Source: Hoy D, March L, Brooks P, et al. The global burden of low back pain: Estimates from the Global
Burden of Disease 2010 study. Ann Rheum Dis 2014; 73:968-974 (21).
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Key Question 1:
What is the impact of
chronic spinal pain on
healthcare resources?
The
impact
of
chronic pain continues
to be enormous (130,39-43,46-50). Figure
1 shows musculoskeletal
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pain and years lived
with disability. Even
prior to the COVID-19 pandemic,
the annual US expenditures alone,
including
direct
medical costs and
lost wages due to
chronic pain have
been
estimated
to be higher than
those for cancer,
heart disease, and
diabetes combined
(2-7,39-42,104,158174). As described
by Dieleman et al
Fig. 2. Estimated health care spending by aggregated age group, type of payer, and aggregated health
(40), low back and
category in 2016.
neck pain constiSource: Dieleman JL, Cao J, Chapin A, et al. US health care spending by payer and health condition, 1996-2016.
JAMA 2020; 323:863-884 (40).
tute the number
one category of
expense in medical
pain (185). The 2016 US National Pain Strategy (NPS)
expenditures in the US. In spite of extensive expenditures and multiple measures undertaken to control
(181) placed a focus on those with high impact chronic
the expenditures (5-8,39-43,103,104,175-178), with
pain defined as that, “associated with substantial restriction of participation in work, social, and self-care
multiplying treatment options, disability continues to
activities for 6 months or more.” However, multiple
escalate (1-8,39,40,103,104,170-174). As shown in Fig.
studies have used different algorithms to identify those
2, Dieleman et al (40) illustrated the expenses related
with high impact chronic pain and to demonstrate
to musculoskeletal conditions, including back and neck
significantly higher healthcare costs, lower QoL, deprespain, as determined in 2016 based on spending on
sion, and increased absenteeism (180,181,185).
healthcare in the US.
A survey from the CDC (181), in 2016, estimated
The prevalence of pain in various spinal regions, is
that 20.4% of US adults, or 50 million, had chronic pain
variable, with the highest prevalence in the low back
and 8% of US adults, or 19.6 million, had high impact
at 43%, followed by the neck at 32%, with the lowest
chronic pain, and with higher prevalence associated
in the thoracic spine at 13% (29). The overall prevalence of low back pain and neck pain over a period of
with advanced age. Age-adjusted prevalences of both
one-year ranged from 22% to 65% with an estimated
chronic pain and high-impact chronic pain were significantly higher among women, adults who had worked
lifetime occurrence of 84% for low back and neck pain
previously, but were not currently employed, adults
from 20% to 40% with a lifetime prevalence of 67%
living in or near poverty, and rural residents. Further,
(3,28-35,103,104,174,179-185). Furthermore, chronic
the data also showed that non-Hispanic White adults
persistent spinal pain may last longer than one-year in
had a significantly higher age-adjusted prevalence of
as many as 60% of the patients, even after conservative
chronic pain than did all other racial and ethnic groups.
treatment or surgical interventions (1-35,174,179-185).
No significant difference in high impact chronic pain
The prevalence of chronic low back pain is about
prevalence by race or ethnicity were observed. Among
23%, with disabling pain in 11% to 12% of the population (183). A systematic review of the clinical course of
adults aged less than 65 years, prevalences were higher
nonspecific low back pain found that recovery was seen
after adjusting for age, for chronic pain, and high
in only 33% of the patients after the first 3 months,
impact chronic pain among those with Medicaid and
whereas after one year after onset, 65% still reported
other public healthcare coverage or other insurance
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than among adults with private insurance or those who
were uninsured. Additionally, among adults aged 65 or
greater years, those with both Medicare and Medicaid
had higher age-adjusted prevalences of chronic pain
and high impact chronic pain than did adults with all
other types of coverage, reflecting their disability status, finances, and education.
In fact, a significant proportion of rising morbidity and mortality in midlife among white non-Hispanic
Americans in the 21st century was attributed to opioid
poisonings related to chronic pain and subsequently
drug abuse (182) as shown in Figs. 3 and 4.
Freburger et al (35), in assessment of the rising
prevalence of chronic low back pain from 1992 to 2006
showed that the prevalence of chronic, impairing low
back pain rose significantly over the 14-year interval,
from 3.9% in 1992 to 10.2% in 2006. They reported
increases for all adult age strata, in men and women,
and in white and black races. However, symptom, severity and general health were similar for both years,
with some increase in individuals seeking care from a
healthcare provider in the past year, increasing from

Fig. 3. All-cause mortality, ages 45–54 for US White
non-Hispanics (USW), US Hispanics (USH), and six
comparison countries: France (FRA), Germany (GER),
the United Kingdom (UK), Canada (CAN), Australia
(AUS), and Sweden (SWE).

Source: Case A, Deaton A. Rising morbidity and mortality in
midlife among white non-Hispanic Americans in the 21st century.
Proc Natl Acad Sci USA 2015; 112:15078-15083 (182).
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73.1% to 84%, while the mean number of visits in all
providers were similar. They concluded that the prevalence of chronic, impairing low back pain has risen significantly in North Carolina, with continuing high levels
of disability and care utilization. They also concluded
that a substantial portion of the rise in low back pain
care costs over the past 2 decades may be related to the
rising prevalence. These studies have not been repeated
since then. However, based on the other studies of disability and healthcare costs, the prevalence, as well as
disability, may be increasing (2,21,22,36-42,167-173).
Further, Blyth et al (38), in assessing the global burden of musculoskeletal pain, summarized the current
understanding of the global burden of musculoskeletal
related conditions, applying evidence-based principles
generated the prevalence and identified key gaps in the
understanding of musculoskeletal pain, with proposals
to address these gaps. They identified key long-term
drivers of contemporary burden of disease estimates, including age, structure of populations, and their longevity. They identified the escalating growth of treatments,
along with harms associated with treatment, including
medication-based interventions, notably long-term
opioids, nonsteroidal, and steroidal immunosuppressive
therapies, and surgical interventions. However, these

Fig. 4. Mortality by cause, white non-Hispanics ages 45–54.
Case A, Deaton A. Rising morbidity and mortality in midlife
among white non-Hispanic Americans in the 21st century. Proc
Natl Acad Sci USA 2015; 112:15078-15083 (182).
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were not included in their estimated burden. Given
the importance of musculoskeletal pain with regard
to functional status in older age group, these findings
have profound implications for future disability burden
and treatments provided to reduce it (20).
A systematic review of the prevalence of musculoskeletal symptoms in the construction industry (37),
including back and neck pain, one-year prevalence of
low back pain was 51.1% whereas for neck pain it was
24.4 %, and 19.8% for upper back pain. Thus, some
prominent authors have indicated that guidelines must
be different for developing countries and developed
countries in reference to invasive and noninvasive treatments (37,172,174). Chou et al (174) and Acaroğlu et al
(37), synthesized recommendations on the use of common elective surgical and interventional procedures
for individuals with recommendation of epidural injections, as well as augmentation procedures with formation of clinical care pathways on patient presentation in
low- and middle-income communities, contrary to their
descriptions of earlier presentations of opposition to
these interventions in the US (80,174). In these guidelines, they theorized that epidural steroid injections and
vertebral augmentation procedures are less expensive
than most surgeries with fewer harms.
Healthcare expenditures have been escalating over
the years with estimates of the US healthcare spending reaching $3.814 trillion in 2019 (42). Furthermore,
healthcare expenditures are expected to continue to
grow at a rate of 5.4% from 2019 to 2028 (42). Overall, in
2019, cost of healthcare was $11,597 per person, the cost
per person in 2028 will rise to $17,611. In 2016, low back
and neck pain had the highest amount of healthcare
spending with an estimated $134.5 billion with 33.7%
of that spent by public insurance. Other musculoskeletal
disorders accounted for the second highest amount of
healthcare spending of $129.8 billion, totaling $264.3
billion (40,41). It appears that expenditures have increased disproportionately with low back and neck pain
with the highest healthcare spending, whereas diabetes
and ischemic heart disease ranked lower in spending in
2016, a reversal from 2013. However, the calculations of
healthcare spending drastically changed in 2020 due to
COVID-19. The COVID-19 pandemic not only increased
overall healthcare expenditures, but also affected the entire healthcare system with significant increases of costs
and reduced access to healthcare (43-53,115).
With increasing prevalence and disability as described above, it is obvious that healthcare expenditures
have been escalating and that the financial impact on
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the US economy is growing. Additionally, the calculus
of healthcare has drastically altered in 2020 and beyond
due to COVID-19 catapulted the country into one of the
deepest recessions in history, leading to poor health
and increase in cardiovascular disease, mental health
problems, cognitive dysfunction, and early death that
has affected chronic pain patients in numerous ways.
The pandemic also resulted in severe economic consequences for providers with reduced reimbursement and
increased costs, as well as severe psychosocial impact on
healthcare providers (43-53,115). Also, COVID-19 may
adversely affect the increasing prevalence of chronic
pain, health, anxiety, and behavioral changes (186). In
fact, the data shows that 81% of physicians surveyed
in July and August of 2020 said that revenue was still
lower than pre-pandemic levels. This study also showed
increased levels of expenses due to safety practices require use of more personal protective equipment (PPE).
Federal financial relief early in the pandemic was somewhat helpful and widely appreciated. However, the
core revenue issues these programs were intended to
address remain, both in terms of decreased revenue and
increased costs. At the same time, practices have been
hit with reduced reimbursement (https://www.cms.gov/
medicare/medicare-fee-for-service-payment/physicianfeesched). Furthermore, elective surgeries continue to
be reduced by approximately 20% or so and physician
burnout among interventional pain physicians is overwhelming as has been reported (44).
Annual healthcare costs for patients with high
impact chronic pain (overall and spine-related) ($14,661
SE: $814; and $5,979 SE: $471, respectively) were significantly higher than in patients with low impact chronic
pain ($6,371 SE: $557; and $2,300 SE: $328) (183). Patients with high impact chronic spinal pain who use opioids are at prevalent at much higher rates than those
with low impact chronic pain (48.4% versus 12.4%).

4.0 The Trends in Utilization of Healthcare
Modalities in Managing Disc-Related and
Spinal Stenosis Pain
Key Question 2: What are the statistics regarding the trends in utilization of treatment modalities
in managing spinal pain?
Overwhelming healthcare costs are a major burden
on the economy of the US leading to the implementation of various healthcare reform measures, regulations, and to the imposition of guidelines which have
often been based on public policy priorities to reduce
healthcare costs. These governmental actions have of-
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ten resulted from feigned evidence-based medicine and
comparative effectiveness research muddled with conflicts and controversies (5-7,19,22,26,39-46,103,104,166169,187-264). There has been escalating growth of
various modalities for the treatment of spinal pain,
including physical therapy, drug therapy, interventional
techniques, and surgical interventions.

4.1 Surgery
Ever since the description of the first discectomy to
treat disc herniation in 1932 by Mixter, a neurosurgeon,
and Barr, an orthopedic surgeon (255), the surgical
interventions to treat spinal pain have taken off with
evolution of multiple techniques with rapid increase
of surgical interventions, raising questions of the effectiveness of surgical treatments (256). Goldthwait and
Osgood in 1905 (257), and subsequently in 1929, Dandy
(258), an American neurosurgeon, surgically treated 2
patients who complained of back and leg pain. However, in the 1980s, Weber (259) and Hakelius (219) demonstrated significant improvement with nonoperative
treatment alone. Thus, the debate about surgical versus
nonoperative interventions ensued. Consequently, the
Spine Patient Outcomes Research Trial (SPORT) was
created to prospectively collect the data (260). In a
systematic review by Oster et al (221) of outcomes following 10 year mark of SPORT for intervertebral disc
herniation, patients that were likely to cross over to the
surgery group had lower incomes, worse baseline symptoms, more baseline disability on the ODI, and were
more likely to rate their symptoms as getting worse. In
contrast, patients that crossed over to the nonoperative group were older, had higher incomes, were more
likely to have upper lumbar disc herniation, less likely
to have a positive straight leg raise test, had less pain,
better physical function, less disability on ODI, and were
more likely to rate their symptoms as getting better
(260). They also identified multiple other factors with
subgroup analysis, which included level of disc herniation, duration of symptoms, presence of retrolisthesis,
patient functional status, effects of previous treatments
with epidural steroid injections and opioid medication,
outcomes after incidental durotomy, and reoperation
rates and associated risks with reoperation. In this assessment, patients who had not received an injection
preferred surgery, whereas those who have received
injections had a higher rate of crossover to nonsurgical
treatment, even though this was confounded by the
increased desire to avoid surgery (263). The authors
concluded that 4 years and 8 years as treated analysis
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showed statistically greater improvements in those
patients who were treated surgically. However, the
analysis of the RCT cohort failed to show a significant
difference based on the intent to principle due to significant patient crossover, which was around 50% (221).
National trends in surgical interventions have been
increasing rapidly (202,216,218,220,264,265). Best et al
(264) assessed the national surgical trends for intervertebral disc disorders and spinal stenosis between 1994
and 2006. The number of procedures increased from 6.1
to 34.2 for intervertebral disc disorders, and from 0.38
to 3.46 for spinal stenosis per 100,000 population. Yoshihara and Yoneoka (202), in an assessment of national
surgical trends of lumbar degenerative disc disease in the
U.S. from 2000 to 2009, showed a 2.4-fold populationadjusted increase. Bae et al (227) showed that from 2004
to 2009 there was an increase of spinal fusions for lumbar
spinal stenosis from 21.5 % to 31.2%, even though the
rate of decompressions decreased from 58.5 % to 49.2%.
Lopez et al (189), in a publication on trends in Medicare utilization and reimbursement for anterior cervical
discectomy and fusion, showed an annual increase in
procedure volume of 24.2% from 2012 to 2017. Furthermore, hospital reimbursements for cervical spine
fusion surgeries without complications or comorbidities
experienced nominal and inflation-adjusted increases
of 9.5% and 0.7% respectively from $12,030 in 2012 to
$13,168 in 2017. Similarly, surgeon reimbursements for
single level and multilevel anterior cervical discectomy
and fusion each nominally decreased from $958 and
$1,173 in 2012 to $950 and $1,138 in 2017.
Reoperation rates for disc herniation and spinal
stenosis have been shown to vary from 10 to 23%
(227). Overall, 40% of postoperative patients develop
postsurgery syndrome or failed back surgery syndrome,
requiring further treatment (221,228,265-268). Unfortunately, the numbers of pre- and post-operative patients with disabilities requiring surgical interventions
including complex fusions, those patients being treated
for failed back surgery syndrome, and patients with
refractory chronic low back pain continue to increase
(71-74,221-246,265-268).
Overall results of surgical interventions have been
lackluster, consequently, post-surgery syndrome, or pain
after operative procedures of the spine is observed in
a significant proportion of patients (221,228-235,265268). Fritsch et al (267) reported that epidural fibrosis,
recurrent disc herniation, instability, and facet joints
were responsible for recurring symptomatology.
Ideally, clinicians should first exhaust all treatment

www.painphysicianjournal.com

ASIPP Epidural Guidelines

modalities in the low to moderate risk tier with patients
enduring chronic lower back pain before pursuing a surgical intervention. A recent retrospective chart by Kim et
al (269) of more than 75 million individuals found that
guideline nonadherence in patients with newly diagnosed
low back pain (or lower extremity pain) contributed to a
substantial amount of economic burden in the US. Interestingly, 38.7% of patients that underwent surgery did
not receive conservative management (neither physical
therapy or epidural steroid injections) accounting for $265
million dollars’ worth of healthcare expenses in the first 12
months after diagnosis (269). This gap in proper care utilization indicates the need for a more informed perspective
regarding high-risk surgical solutions in order to achieve a
favorable outcome more effectively.
Multiple investigators have attempted to assess the
role of epidural injections in the prevention of surgery
for spinal pain in the form of systematic review and
meta-analysis of RCTs and retrospective observational
series (188,270-278) showing significant, but variable
success rate of epidural injections in avoiding surgery
ranging as high as 75% response rate. Despite the
demonstrated success rate of surgical interventions, the
struggle continues in managing patients after surgery
(279,280). One of the examples is back pain in surgically
treated degenerative lumbar spondylolisthesis (279).
Guidelines developed for the use of surgical interventions for the treatment of chronic refractory back pain
in degenerative spondylolisthesis have established a
poor quality level of evidence and the need for further
evidence with studies evaluating primary outcome of
back pain in patients with degenerative lumbar spondylolisthesis (281). Bond et al (279) showed improvement
in numeric rating scale (NRS) of back pain on average of
2.97 (SD 2.5 points at one year and clinically significant
improvement in back pain was observed in 75% of the
patients). Even then, 25% of the patients continue to
suffer even with minimal criteria used at 30% or so improvement, rather than 50% improvement. It was also
shown that rates of imaging in failed back surgery syndrome patients continue to increase, even in patients
with spinal cord stimulation (280), driving healthcare
costs and indicating lack of response to surgery and also
to spinal cord stimulation.
In this context, building on a stepwise strategy
stemming from a modest approach such as physical and
pharmacological therapy to interventional pain procedures before considering surgery. This strategy allows
an additional opportunity to make adjustments to the
course of action before escalating care and avoid po-
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tentially unnecessary or cost-prohibitive treatment. It is
worth noting that constant advancements in new lines of
treatment (chemonucleolysis, intradiscal therapies) and
regenerative medicine (nerve growth factor, stem cells,
plasma therapy) can bridge the gap between conservative and surgical intervention (269). While the results
from this novel approach provides encouraging improvements in lower back pain, the limited number of RCTs
warrants further study (270). Ultimately, the judicious
application of interventional tools in a multidisciplinary
healthcare setting has the potential to improve pain
outcomes in patients diagnosed with chronic spinal pain.

4.2 Interventional Techniques
The use of interventional techniques for the treatment of spinal pain and musculoskeletal disorders increased until 2009, at which point utilization began to
decrease (193-200). Recent analysis of growth of utilization of interventional techniques in managing chronic
pain in the Medicare population (193) showed an overall
decline in utilization of interventional techniques from
2009 to 2018 of 6.7%, with an annual decline of 0.8%
per 100,000 fee-for-service (FFS), despite an increase of
0.7% per year of population growth (3.2% of those 65
years or older), and a 3% annual increase in Medicare
participation from 2009 to 2018. Further, analysis of
utilization patterns of epidural procedures (194) showed
epidural procedures have declined at a rate of 20.7% per
100,000 Medicare enrollees from 2009 to 2018, with an
annual decline of 2.5 %. This analysis (194) also showed
a decline in all categories, with an annual decrease of
4.7% for lumbar interlaminar and caudal epidural injections, 4.7% decline for cervical/thoracic transforaminal
epidural injections, 1.1% decline for lumbar/sacral
transforaminal injections, and 0.4 % decline for cervical/
thoracic interlaminar epidural injections. Overall declines
were higher for lumbar interlaminar epidural injections
of 34.9%, compared to lumbar/sacral transforaminal epidural injections of 9.4% (Fig. 5).
The utilization data also shows patterns which continue to fluctuate. As shown in Fig. 6, epidural injections
constituted 58% of all procedures in 2000, declining to
39% of overall utilization of interventional techniques
in 2018. This graphic display also shows changing patterns of other procedures with increasing facet joint
interventions, even though they have plateaued or
declined in recent years (193,194). Figure 7 shows that
the pattern of utilization of the type of the procedures
also has significantly changed. As an example, in the
year 2000, lumbar interlaminar epidural injections con-
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Fig. 5. Frequency of utilization of epidural injections (annual change in the rate) by procedures from 2000 to 2018, in Medicare
recipients (194).
Reproduced with permission from authors and Pain Physician journal.
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Fig. 6. Distribution of procedural characteristics (rates) by type of procedures from 2000 to 2018 (193,194).
Reproduced with permission from authors and Pain Physician journal.
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Fig. 7. Frequency of utilization of epidural injections by procedures from 2000 to 2018, in Medicare recipients (194).
Reproduced with permission from authors and Pain Physician journal.

stituted 73.7% of all epidural procedures, declining to
34.5% in 2018. Similarly, lumbar transforaminal epidural
injections constituting 14.6% in 2000, increased to their
proportion of utilization to 53%. Cervical interlaminar
procedures were 9% in 2000, increasing to 10.1% in
2018 without any significant growth.
Manchikanti et al (282,283) published an analysis of
utilization trends and Medicare expenditures of spinal interventional techniques until 2008. The data showed that
spinal interventional techniques increased 186.8%, at an
annual rate of increase of 14.1% per 100,000 FFS Medicare
beneficiaries (283). They showed overall per patient costs
were $1,054.33 in 2000, which increased to $1,104.57 in
2008. The total approved amounts in FFS population were
$362,347,025 in 2000 compared to $1,231,180,420 in 2008,
a 240% increase for all spinal interventional techniques.
The study of expenditures of epidural procedures in
chronic spinal pain in FFS Medicare population from 2009
to 2018 (195) showed a decrease in total expenditures
after adjusting to inflation. Inflation adjusted cost per
procedure per patient also decreased. However, prior to
the inflation, total expenditures increased by 14.6% or
an annual increase of 1.5% from $723,981,594 in 2009
to $829,987,636 in 2018. Inflation adjusted costs were
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$847,058,465 in 2009 compared to $829,987,636 in 2018,
a reduction of overall 2%. Inflation adjusted cost per patient decreased from $988.93 in 2009 to $819.27 in 2018
with a decrease of 17.2% or an annual decline of 2.1%. In
addition, inflation adjusted costs per procedure decreased
from $399.77 to $377.94, with a 5.5% overall reduction or
0.6% annual reduction. The proportion of Medicare patients per 100,000 receiving epidural procedures decreased
9.1% or 1.1% annually. This evaluation also showed overall costs of transforaminal epidurals increased to 27.6% or
2% annually, whereas for lumbar interlaminar and caudal
epidural injections cost was reduced 2.7% or 0.3% annually prior to inflation adjustment. The proportion of patients receiving lumbar transforaminal epidural injections
reduced 6.5% or at an annual rate of 0.7% compared to
lumbar interlaminar and caudal epidural injections, which
decreased a total of 33.5% or an annual decline of 4.4%
(Fig. 8). Table 4 shows total allowed charges, which also
shows specific charges for each type of epidural injection.
Table 5 shows characteristics of Medicare beneficiaries and
utilization pattern of epidural interventions, whereas Fig.
9 shows epidural procedures and their utilization patterns
with number of patients visits and services, all of them
showing a decline, specifically services and visits showing
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Fig. 8. Frequency of utilizations of epidural injections in the FFS Medicare population per 100,000 participants from 20092018 (195).
Reproduced with permission from authors and Pain Physician journal.

4.3 Opioids in Spinal
Pain
The opioid epidemic
has once again taken a
central role, adding to new
pandemic of COVID-19 with
tightened restrictions and
worries about increasing COVID risk in opioid-receiving
patients, with declining
prescriptions for opioids,
and finally, recently reported
increases of opioid deaths in
2019 and 2020 (46,253). This
trend is followed by extensive increases of opioid drug
Fig. 9. Epidural procedures rate per 100,000 FFS Medicare population by services, episodes, and
overdoses, with a subsequent
patients from 2009-2018 (195).
increase of 18.2% death rate
Reproduced with permission from authors and Pain Physician journal.
in year ending from June
2019 to May 2020, due to
a more significant decline than the number of patients reCOVID-19 pandemic (43-53,79,114,115,253,254,285-302).
ceiving epidural procedures. This assessment included only
Over the years, multiple reviews have been performed in reference to opioid use, overuse, abuse, and
epidural procedures and has not included percutaneous
a multitude of adverse consequences including opioidadhesiolysis.
related deaths (5-8,46,103,104,168,213-215,247-254,285Cost expenditures analysis for facet joint interventions showed increases even after inflation adjust289,303-318). The US drug overdose data of drug-related
ment compared to declines for epidural procedures
deaths from 2018 shows an arrest of the escalation and
(284).
a dip in the curve towards reductions. However, recent
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Table 4. Total allowed charges by place of service, by type of procedures.
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Table 5. Characteristics of Medicare beneficiaries and utilization pattern of epidural interventional 2009-2018.
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Source: Manchikanti L, et al. Declining utilization and inflation-adjusted expenditures for epidural procedures in chronic spinal pain in the Medicare population. Pain Physician 2021; 24:1-15 (195).

reports by Health Alert Network of CDC Health Advisory (46)
showed a significant increase in fatal drug overdoses across
the US driven by synthetic opioids before and during the
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COVID-19 pandemic. This report showed based on the recent
provisional data that approximately 81,230 drug overdose
deaths occurred in the US in the 12 months ending in May
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Fig. 10. Twelve-month provisionala drug overdose death
counts for all drugsb, synthetic opioidsc, cocained, and
psychostimulantse, for 50 states, the District of Columbia,
and New York City: 12-months ending in June 2019 to
12-months ending in May 2020f.
Provisional drug overdose death counts are based on death
records received and processed by NCHS. Provisional drug
overdose death data are often incomplete, and the degree of
completeness varies by jurisdiction and 12-month ending
period.
b
Deaths were classified using the International Classification
of Diseases, Tenth Revision (ICD–10). The drug classes are
all nested within all drug overdose deaths, but multiple drug
classes may be involved in a single drug overdose death.
c
Drug overdose deaths, as defined, that involve synthetic opioids other than methadone (T40.4).
d
Drug overdose deaths, as defined, that involve cocaine
(T40.5).
e
Drug overdose deaths, as defined, that involved psychostimulants with abuse potential (T43.6).
f
Included time periods will have some amount of overlap.
a

2020, as shown in Fig. 10 (286). Thus, a worsening of the
drug overdose epidemic in the US has not only shown a resurgence, but also is the largest number of drug overdoses
for a 12-month period ever recorded (46,293). This report
is preceded by news of declining 4.1% from 2007 to 2018
(285). However, since then, the number of overdose deaths
increased 18.2% from the 12 months ending in June 2019
to the 12 months ending in May 2020 (Fig. 10) (286). Further, increases of the drug overdose deaths ranged more
than 20% in 25 states and the District of Columbia, 10%
to 19% in 11 states and New York City, and 0% to 9% in
10 states. However, overdose deaths decreased only in 4
states (Appendix Fig. 1).
The CDC report also delved into various issues related to COVID-19. The increases in overdose mortality
began in 2019, even before COVID-19 and continued
into 2020, exacerbated by the COVID-19 national emergency in the US in March. The acceleration of overdose
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deaths due to COVID-19 pandemic was clearly demonstrated (46,49,287-291). Due to the effect of COVID-19,
estimates indicate that the largest monthly increases in
drug overdose deaths occurred in 12 months ending in
May 2020 with 81,230 deaths. Further, the one-month
increases were shown to be 2,146 and 3,388 deaths
respectively for the 12-month period as shown in Fig.
10. These are the largest monthly increases documented
since provisional 12-month estimates began to be calculated in January 2015 (286).
As described earlier in our manuscripts and also
supported by overwhelming literature, the primary
driver of the increases in overdose deaths continues to
be synthetic opioids as shown in Figs. 11 and 12 (285287,293,294,296,298,303-317). The 12-month count
of synthetic opioid deaths increased 38.4% from 12
months ending in June 2019 compared with the 12
months ending in May 2020 (Fig. 10). Of the 38 jurisdic-
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Fig. 11. Number of opioid overdose deaths by category, 1999 to 2019.

Source(s): For 1999-2018: National Institute on Drug Abuse. Overdose death rates. May 7, 2020 https://www.drugabuse.gov/relatedtopics/
trends-statistics/ overdose-death-rates (253,285).
For 2019: Ahmad FB, Rossen LM, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. 2020 (286)
https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm

Fig. 12. Quantification of opioid deaths.

Source(s): NIDA. Overdose Death Rates. National Institute on
Drug Abuse website. https://www.drugabuse. gov/related-topics/
trends-statistics/overdose-death-rates (285).
Reproduced with permission from authors and Pain Physician
journal

tions, the reports were available for 37, which showed
an increase in synthetic opioid overdose deaths (286).
In these reports, 18 jurisdictions reported increases
greater than 50%, 11 reported increase of 25% to 45%,
7 reported increases of 10% to 24%, only one reported
an increase of less than 10%, as shown in Appendix Fig.
2 (46). Once again, it also has been confirmed by these
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jurisdictional reports and state and local health department reports that an increase in synthetic involved
opioid deaths is primarily linked to illicit manufactured
fentanyl (287,293,294,296). Fentanyl deaths have been
concentrated in the 28 states east of the Mississippi river,
where the heroin market has primarily been dominated
by white powder heroin (296,297). In contrast, states
west of the Mississippi river have seen the largest increases in synthetic opioid deaths occurring in 10 western states with a 98% increase. This is consistent with
large increases in illicitly manufactured fentanyl availability in western states (288) and increases in fentanyl
positivity in clinical toxicology drugs tested in the west
after the COVID-19 pandemic (289). However, synthetic
opioid overdose deaths have increased substantially in
multiple other regions including 12 southern states and
the District of Columbia (35.4%), 6 midwestern states
(32.1%), and 8 northeastern states and New York City
(21.1%), as shown in Appendix Fig. 2.
Apart from heroin and synthetic fentanyl, overdose
deaths involving cocaine increased by 26.5% during
this period as shown in Fig. 10 (46). In addition, data
have shown that recent increases in overdose deaths
involving cocaine are primarily related to overdose
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deaths and involved both cocaine and synthetic opioids
(primarily illicitly manufactured fentanyl) (290), but also
illicitly manufactured heroin (295).
Similar to synthetic opioids and cocaine, overdose
deaths involving psychostimulants, such as methamphetamine have been increasing with and without
synthetic opioid co-use and at a rate faster than
overdose deaths involving cocaine (290). Thus, provisional 12-month counts of overdose deaths involving
psychostimulants in the US increased by 34.8% from
the 12 months ending in June 2019 compared to the
12 months ending in May 2020. This leads to striking
statistics that the number of deaths involving psychostimulants now exceeds the number of cocaine involved
deaths as shown in Fig. 10 and 11. As CDC data shows,
these increases are consistent with the increased availability of methamphetamine in the illicit drug supply
and increases in the methamphetamine related treatment admissions (46,288,292).
Based on the CDC report, they have distanced from
calling the opioid epidemic and opioid deaths and

called it driven by synthetic opioids, confirming the appropriate name, illicit drug epidemic or synthetic opioid
epidemic. The previous reports also showed a decline of
overdose death rates of 14.5% for prescription opioids
from 2017 to 2018. Furthermore, the provisions data
from 2018 to 2019 showed a 4.2% decrease of prescription opioid deaths with total deaths of 14,347 in 2019.
However, the CDC report has not shown prescription
related opioid deaths in the present report (46). Consequently, prescription opioid deaths seem to be declining below the levels of cocaine, heroin, and maybe
even methamphetamine. The lower numbers may
be achieved if methadone deaths are separated from
prescription opioids, as methadone may be obtained by
multiple means with only a small proportion from prescription opioids for management of chronic pain (Fig.
11 and Table 6). During COVID-19, opioid prescriptions
and morphine milligram equivalent (MME) doses also
have significantly decreased and are expected to decrease further. Prescription opioid related deaths with
inclusion of methadone were 14,375 in 2019, whereas,

Table 6. National drug overdose (od) deaths, 2000-2018

2000

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019
(R)

2019
(P)

Total Overdose
Deaths

17,415

38,329

41,340

41,502

43,982

47,055

52,404

63,632

70,237

67,367

71,364

71,987

Any Opioid1
(T40.0-T40.4, T40.6)

8,407

21,088

22,784

23,164

25,050

28,647

33,091

42,249

47,600

46,802

50,343

50,806

Prescription Opioids2
(T40.2-T40.3)

3,785

14,583

15,140

14,240

14,145

14,838

15,281

17,087

17,029

14,975

14,252

14,375

Prescription
Opioids AND Other
Synthetic Narcotics

167

939

889

861

1,015

1,489

2,263

4,055

5,444

5,417

NA

NA

Prescription Opioids
WITHOUT Other
Synthetic Narcotics

3,618

13,644

14,251

13,379

13,130

13,349

13,018

13,032

11,585

9,558

NA

NA

Other Synthetic
Narcotics (fentanyl)3
(T40.4), other than
methadone

782

3,007

2,666

2,628

3,105

5,544

9,580

19,413

28,466

31,335

36,733

37,147

Heroin4 (T40.1)

1,842

3,036

4,397

5,925

8,257

10,574

12,989

15,469

15,482

14,996

14,157

14,282

Cocaine5 (T40.5)

3,544

4,183

4,681

4,404

4,944

5,415

6,784

10,375

13,942

14,666

16,071

16,207

578

1,854

2,266

2,635

3,627

4,298

5,716

7,542

10,333

12,676

16,356

16,528

1,298

6,497

6,872

6,524

6,973

7,945

8,791

10,684

11,537

10,724

NA

NA

Psychostimulants
With Abuse Potential
(methamphetamine)6
(T43.6)
Benzodiazepines7
(T42.4)

R – Reported; P – Predicted values
Source for 2000 to 2018: https://www.drugabuse.gov/drug-topics/trends-statistics/overdose-death-rates
For 2019: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm (data based on 12/6/2020)
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excluding methadone these deaths were 12,084 with
2,787 deaths attributed to methadone. Methadone is
obtained from multitude of sources with prescription
methadone contributing to a small proportion of the
deaths or a minority of deaths. It is also worrisome that
stricter regulations, lack of access to prescription opioids during COVID-19 epidemic may be fueling the illicit
drug market. Thus, previous postulations that if we can
control overdose deaths related to heroin and synthetic
opioids, the opioid epidemic will be resolved, may be
fine-tuned to state if we control illicit drug epidemic
and maintain access to appropriate opioid prescriptions.
In reviewing the prescription trends in the US, multiple reports over the years have captivated the country
with most attention paid to the opioid epidemic, which
changed this year in the face of COVID-19 pandemic.
Patients with chronic pain and addiction have been
affected by disruptions to life and healthcare during
COVID. Prescription opioid trends in the US published
by IQVIA Institute (313) in December 2020, showed
that prescription opioid use in the US continues to
decline rapidly, with only 100 billion MME expected to
be dispensed in 2020. This is a 60% decline from 246
billion MME dispensed at the peak of opioid prescribing in 2011 as shown in Fig. 13 and Appendix Fig. 3.
Reports also highlighted that between 2019 and 2020,
there is an expected 17.1% decline in MME, including
the effects of disruptions from the COVID-19 pandemic,
marking the ninth consecutive year of declines and the
third year of double-digit change. Prescription opioid

use was approximately 16 pills or 134 MME per adult
Americans in 1992, and rose to a peak of 55 pills or 790
MME in 2011. This use has since declined by 54% to 29
pills and 366 MME per capita in 2019, though population growth has been 5.4% since 2011.
In 2020, the projected decline in MME per capita
is 17.1%, meaning prescription opioid use will reach
mid 2000 levels. This represents a 20 years cycle, marked
by 11 years of gains and 9 years of reductions. Consequently, by the end of 2020, MME per capita is expected
to drop to 298, nearing the levels seen in 2000, which
was 270 MME per capita (Fig. 13) (313).
Even though overall prescriptions have seen a
significant reduction, Medicare Part D prescriptions
have increased by 2% since 2011, rising from 53 million
prescriptions to 54 million in 2019. The Medicare Part D
share of prescriptions has increased from 21% to 35%
over the same timeframe, as the over 65 population
has increased by 31% and seniors often require more
procedures and also suffer with multiple degenerative
conditions resulting in larger number of opioid prescriptions. Even then, compared to 2019, prescriptions
have declined 17% from 66 million in 2014; however,
prescriptions for commercial patients declined by 51%,
even though commercial prescriptions still comprised
the largest share of prescription opioids, with 48% of
the volume in 2019 down from 58% in 2011.
Overall, these decreases in volume and dosage
along with redistribution among the populations have
been driven by changes in clinical usage, regulatory

Fig. 13. Prescription opioid use in morphine milligram equivalents (MME) per capita, 1992-2020*.
Source: IQVIA Xponent, Mar 2020; IQVIA Prescription Audit; IQVIA Institute, Nov 2020
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and reimbursement policies, and progressively more
restrictive legislation enacted since 2012, and finally
the guidelines from the CDC. Multitude of these legislations including National All Schedules Prescription
Electronic Reporting (NASPER) Act have resulted in
prescription drug monitoring programs in all states
which facilitates decrease in inappropriate prescriptions
(286,296,303,314-328).
Manchikanti et al (303) described various issues related to the opioid epidemic and pointed out the tragic failures of the current systems to control opioid misuse. Thus,
multiple factors propagated the epidemic, starting with
the fifth vital sign pain movement together with a confluence of interest and a failure of oversight from the opioid
industry, which was largely responsible for the epidemic.
Multiple confluences of interests were reported, including
promotion of opioids based on inadequate evidence with
advocacy from Portenoy and Foley (329). Further fuel was
added with the establishment of pain as the fifth vital
sign, which was embraced by multiple organizations and
it was essentially forced on hospitals and other healthcare
professionals in assessing pain relief and quality improvement (6,303). Further contributing issues were the medical
boards themselves. Most of the guidelines although allegedly written for appropriate opioid use, were essentially
promoting excessive use and abuse patterns, as they were
developed by the opioid industry with confluence of interest. Further, multiple failures in the oversight of opioid
manufacturing, distribution, diversion and import, in addition to medical necessity and appropriate monitoring of
opioid prescriptions fueled the epidemic (303).
It is difficult to point out the reasons for the explosion of the fentanyl epidemic, along with increases
in the usage of heroin, as well as cocaine, as shown in
Figs. 10 to 12 (46,285,286,303-305,308). The significant
movement to control the opioid epidemic in the US was
initiated with prescription drug monitoring programs,
state regulations curbing opioid prescriptions, and increasing the focus on education. Overall federal spending increased 128% from 2017 to 2018 with the major
increases in federal spending due to treatment and recovery programs with costs ranging from approximately
$599 million to 2.1 billion (286,314). Overall, total opioid spending increased from $3.3 billion in 2007 to $7.4
billion in 2018 in the US (286).

4.4 Noninterventional Techniques in
Managing Spinal Pain
There are many noninvasive or noninterventional
techniques for managing spine pain including medica-
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tions, exercise programs, physical therapy, acupuncture,
massage, transcutaneous electrical nerve stimulation
(TENS), biofeedback therapy and chiropractic treatments.

4.4.1 Medications
Nonopioid medications for treating low back pain
include nonsteroidal anti-inflammatory drugs (NSAIDS),
antidepressants and acetaminophen (330). Multiple systematic reviews evaluated recent randomized trials of
medication treatment for patients with low back pain
(331-334).
In the treatment of patients with acute low back pain
with NSAIDS, there was a high certainty that these medications were more effective than placebo for improving
disability and a moderate certainty that they were more
effective at providing short-term pain reduction. There
was a low degree of certainty that NSAIDS were better
than placebo in regards to global improvement and
there was no difference in short-term pain reduction
when comparing the selective COX-2 inhibitors to nonselective NSAIDs. There was also a negligible difference in
the rate of adverse events in patients using either NSAIDs
or COX-2 inhibitors for acute low back pain.
In the treatment of chronic nonspecific low back
pain, 6 of the 13 trials showed that NSAIDs were significantly more effective than placebo for pain relief and
are slightly more effective at improving the patients’
disability. This systematic review by Enthoven et al (332)
showed no difference in efficacy between the different
NSAIDs, which included both selective and nonselective
NSAIDs and because the inclusion of RCTs that were at
low risk of bias there was an overall reduction in the
differences between the NSAIDs and placebos. Also due
to the small sample sizes, there could be no conclusion
regarding the occurrence of adverse events or whether
NSAIDs are safe for long-term use.
When examining the evidence for the treatment
of low back pain with acetaminophen, one recent systematic review concluded that there was insufficient
evidence to assess the efficacy of acetaminophen in
patients with low back pain (331). Another review focusing on the treatment of chronic low back pain with
medication concluded that there was no significant
difference between a NSAID (diflunisal) and acetaminophen for pain relief in patients with low back pain.
Other medications used to treat low back pain
include antiepileptics and antidepressants. A recent systematic review analyzed both classes of medications and
concluded that one type of antiepileptic (topiramate) was
both safe and effective agent in the treatment of chronic
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Table 7. Systematic reviews of exercise programs for the treatment of low back pain.

Treatment
Exercise

Author,
Year

Number and
Type of Studies

Results
Number of patients

Saragiotto
et al, 2016
(335)

29 RCTs

There is low to moderate quality evidence that MCE is
effective for improving pain at short, intermediate and
long-term follow-up with medium effect sizes (long-term,
MD -12.97; 95% CI -18.51 to -7.42) when compared to
minimal intervention.
There was also a clinically important difference for
function and global impression of recovery compared with
minimal intervention.

Conclusions
There is very low to moderate
quality evidence that MCE has
a clinically important effect
compared with a minimal
intervention for chronic low back
pain.

There is very low to low-quality
evidence that MCE has a clinically
important effect compared with
There is very low to low-quality evidence that MCE is
exercise plus electro-physical
clinically more effective than exercise and electro-physical agents.
agents for pain, disability, global impression of recovery
There is moderate to high-quality
and QoL with medium to large effect sizes (pain at shortevidence that MCE provides
term, MD -30.18; 95% CI -35.32 to -25.05).
similar outcomes to manual
Total patient number – 2,431
therapies and low to moderate
quality evidence that it provides
similar outcomes to other forms of
exercises.
Overall, MCE is not superior to
other forms of exercise
Byström
et al, 2013
(336)

1. Motor control exercises vs general exercise (n = 741)
7 trials
80% with chronic
• Short-term (6 trials, WMD −7.80 on 0 to 100 scale,
LBP
95% CI −10.95 to −4.65)
The review included • Intermediate term (3 trials, WMD −6.06, 95% CI
−10.94 to −1.18)
studies of subacute
• Effects were not statistically significant at long-term (4
duration (4 to 12
trials, WMD −3.10, 95% CI −7.03 to 0.83)
weeks) and of
chronic duration > 6 2. Motor control exercises vs minimal intervention (n =
541; 3 trials)
months)
• MCE was also associated with better function:
Short-term (6
• Short-term (6 trials, WMD −4.65 on 0 to 100 scale,
weeks to 4 months),
95% CI −6.20 to −3.11)
intermediate term
• Long-term (3 trials, WMD −4.72, 95% CI −8.81 to
(4 to 8 months) and
−0.63).
long-term (8 to 15
3.
Motor
control exercises vs multimodal physical therapy
months)
(n = 499) 4 trials
In CLBP, MCE was associated with lower pain scores
versus minimal intervention:
• Short-term (WMD −12.48 on a 0 to 100 scale, 95%
CI−19.04 to −5.93)
• Intermediate term (WMD −10.18, 95% CI −16.64
to −3.72)
• Long-term (WMD −13.32 95% CI −19.75 to −6.90)
16 RCTs (n = 1933)

For CLBP, motor control
exercises was associated with
lower pain intensity versus
general exercise:

4. MCE vs other components of that intervention (n =
152) 2 trials
MCE was also associated with better function:
• -Short-term (3 trials WMD -9.00 on 0 to 100 scale,
95% CI −15.28 to −2.73)
• Intermediate term (2 trials WMD -5.62, 95%
CI−10.46 to −0.77)
• Long-term (2 trials, WMD −6.64, 95% CI −11.72
to −1.57)
MCE = motor control exercise; RCTs = randomized controlled trials; MD = mean difference; N = number; LBP = low back pain; CLBP = chronic
low back pain; WMD = weighted mean difference; CI = confidence interval

low back pain and produced significantly positive changes
in pain sensitivity, patient disability, health-related QoL,
and weight loss (334). The review also concluded that antidepressants had a statistically significant improvement in

S52

low back pain when compared to placebo in patients being treated for chronic low back pain. The antidepressant
medications, however, were also associated with significantly more side effects when compared to placebo (334).
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4.4.2 Exercise Programs
Exercise has typically been viewed as a moderately
effective treatment for chronic low back pain but there
is no clear evidence that indicates one form of exercise
is more effective than another. Most of the current exercise recommendations are based upon motor control
exercise (MCE) that focuses on establishing and maintaining core muscle strength (Table 7).
Of the 45 RCTs presented evaluating MCE on low
back pain, there was supportive evidence that this
treatment was associated with better pain control and
patient function than minimal intervention (335,336).
There was low to moderate evidence that MCE was
clinically more important than minimal intervention
for treating chronic low back pain and that it provided
similar outcomes to other forms of exercise (335). This
was found regardless of whether the pain scores were
measured at short, medium or long-term follow-ups
(335). There was very low or low-quality of evidence
that MCE had a more clinically important effect than
electro-physical agents (EPA) and moderate to highquality of evidence that MCE provided similar outcomes
to other types of exercises. Overall, it was concluded
that MCE was not superior to other forms of exercise.
When comparing the results of MCE on patients
with mostly chronic low back pain and evaluating
different follow-up times to compare MCE with general exercise, minimal intervention, multimodal physical
therapy and other forms of intervention it was found
that MCE was associated with lower pain intensity than
general exercise in the short and intermediate term
but not in the long-term (336). It was found that MCE
was associated with better function at all follow-up
time points. As in previous systematic reviews, MCE was
associated with lower pain scores and better function
compared to minimal intervention at all follow-up time
points (335,336).

4.4.3 Physical Therapy and Multidisciplinary
Rehabilitation
The goal of physical therapy is to improve pain and
increase function to prevent unnecessary disability and
to keep the patient’s low back pain from worsening.
Physical therapy and multidisciplinary biopsychosocial
rehabilitation (MBR) include a number of different
treatment strategies such as exercise, rest, stretching,
tai chi, yoga, massage, spinal manipulation and other
treatments. In patients with chronic low back pain,
physical therapy with exercise approach is a first line
treatment that is routinely utilized.
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Of the 83 studies with 8,816 patients evaluating
physical therapy and rehabilitation interventions to
treat patients with chronic low back pain, it was found
that exercise therapy improved pain intensity, disability
and long-term function when compared to nonexercise
conventional care and behavioral therapy was effective
for decreasing pain intensity compared to no treatment
in the short-term (337). Multidisciplinary treatment was
also found to be effective at reducing pain intensity
and disability at short-term follow-up compared to no
treatment (337). The evidence from the RCTs showed
low-quality evidence for the efficacy of exercise therapy
compared to conventional care and low-quality evidence for the efficacy of behavioral therapy compared
to no treatment (337). There was moderate evidence
for the effectiveness of multidisciplinary treatment
compared to no treatment or other active treatments in
reducing pain in the short-term. The authors concluded
that there was an insufficient amount of data to draw
firm conclusions on the clinical effect of back schools,
low-level laser therapy, patient education, massage,
traction, superficial heat/cold, and lumbar supports for
chronic low back pain.
In a systematic review of 41 RCTs, Kamper et al (338)
found that MBR improves pain and disability more than
conventional care in the short and long-term but there
is no evidence that it improves work outcomes in the
short or long-term. The authors also found that MBR
improves pain and disability more than no MBR in the
short-term and there is additional evidence that MBR
improves pain, disability, and work outcomes more than
physical treatments in the short and long-term (338).

4.4.4 Acupuncture
In treating low back pain, patients may seek alternative medical approaches to address their low back
pain. One of the most common treatments among the
alternative approaches is acupuncture. Despite the fact
that it is interventional and invasive, it is included in this
section. Acupuncture is a very old medical treatment
that originated in the Far East and has gained increasing interest in the west as a treatment for low back pain
(339). Despite the increasing popularity of acupuncture,
the effectiveness is often disputed and many systematic reviews and meta-analyses have investigated its
effectiveness (340,341). Recently, three clinical practice
guidelines have also been published with differing recommendations on the treatment of low back pain with
acupuncture (342-344). Given these inconsistencies, the
recent systematic reviews and meta-analyses are very
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important for providing a systematic assessment of the
strength and completeness of the current evidence.
In 16 systematic reviews of over 35,000 patients with
acute low back pain, evidence shows acupuncture is
better at relieving pain than sham treatments but the
evidence was somewhat inconsistent (340). In addition
to providing substantive pain relief, this review showed
that acupuncture had a positive effect on improving patients’ function. The summary of this systematic review
showed that in patients with chronic low back pain, the
evidence demonstrated that acupuncture consistently
provides short-term pain relief and functional improvements when compared to no treatment or acupuncture
and another conventional treatment (340). Seven of the
systematic reviews were of varying quality but showed
that acupuncture produces more pain relief and functional improvement than no treatment at short-term
follow-up. Five systematic reviews found that acupuncture used in addition to conventional therapy provided
short-term improvements in pain and function in the
treatment of patients with chronic low back pain (340).
In another meta-analysis of 25 studies with over
6,200 patients, acupuncture had a clinically meaningful
reduction in pain when compared to sham treatments
and an improvement in function immediately after the
treatment when compared to other patients either not
receiving treatment or receiving conventional therapies
(341). When acupuncture was compared to medications
including NSAIDs, muscle relaxants, and analgesics as
well as conventional treatments, there were statistically
significant differences between the control groups and
the patients receiving acupuncture (341). Although
acupuncture improved pain and function immediately
after intervention and more than no treatment, sham
or medications (NSAIDs, muscle relaxants or analgesics),
the differences were small.
Patients who received acupuncture in addition to
conventional treatment had greater pain relief and
improved function directly following the intervention
and at the time of follow-up compared to those who
received conventional treatment only (341). This metaanalysis also reviewed electroacupuncture and found
that this technique resulted in significantly less pain and
improved activity immediately after the intervention
compared to the control group (341).

4.4.5 Massage
Massage has been traditionally thought to improve
symptoms by providing pain relief through physical and
mental relaxation and by increased the threshold of
pain by the release of endorphins (345). The thought
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behind the mechanism of pain relief is that massaging
a certain area stimulates large nerve fibers that have an
inhibitory effect on T‐cells and pain relief follows (346).
Massage may also have an effect on the autonomic nervous system by shifting it from a state of sympathetic
response to a state of parasympathetic response or
vice versa (347). The mechanism between massage and
symptom relief is not fully understood but there are numerous trials and some literature reviews and systemic
meta-analyses that investigate the efficacy of massage
(348,349).
In a meta-analysis by Farber et al (348), the quality
of evidence was found to be low to very low primarily because of risk of bias and imprecision. They found
that for acute low back pain, massage was better than
inactive controls in the short-term for pain but not for
function. It was also determined that for patients with
subacute and chronic low back pain, massage was better than inactive treatments for pain and function in
the short-term but not in the long-term. The analysis
also showed that when compared to active controls,
massage was better for pain both in the short-term and
at long-term follow-up. Functional improvement was
found in patients with sub-acute and chronic low back
pain as compared with inactive controls, but only at the
short-term follow-up.
The review by Furlan et al (349) included 8 of 13
articles with a high risk of bias. In two of the studies,
massage was superior to producing pain and functional
improvements at short and long-term follow-ups. Eight
studies showed that massage was similar to exercises,
and better than joint mobilization, relaxation therapy,
physical therapy, acupuncture, and self-care education
for decreasing symptoms when compared to other
active treatments. When positive effects of massage
were present, the duration of these effects was one
year after the end of treatment. Two studies showed
that acupuncture massage gave rise to better results
than Swedish massage and another trial concluded that
Thai massage produces similar results to Swedish massage. Overall, there was moderate evidence of short
and long-term improvement in pain and function with
massage as compared with sham or other treatments
but the differences in degree of improvement are small.
The review showed that massage might be beneficial
for patients with subacute and chronic low back pain,
especially when combined with exercises and education.

4.4.6 Transcutaneous Electrical Nerve Stimulation
(TENS)
Despite the common usage of TENS for pain man-
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agement, evidence for its effectiveness is not conclusive.
Due to this lack of optimal evidence TENS is not a treatment that is typically covered by insurance and is often
restricted for use in RCTs. Previous health technology assessments and society led meta-analyses have found no
benefit for TENS in patients with chronic pain (350,351).
Some have criticized the recent society meta-analysis
for a paucity of RCTs and the fact that the assessment
did not compare the effectiveness of TENS with other
nerve stimulation therapies (NSTs).
Studies comparing exercise therapy to passive therapies such as TENS, low-level laser therapy, ultrasound,
thermal therapy, and ultrasound found no statistically
significant difference between the exercise therapy and
the other therapies, including TENS, but there was some
serious limitations and inconsistencies in this low-quality
evidence (337). Two studies comparing TENS with acupuncture or percutaneous electrical nerve stimulation
(PENS) found that TENS was better for controlling pain
but three studies comparing the same modalities found
that PENS and acupuncture were better for controlling
pain in the short-term (337). The evidence quality was
very low in showing that PENS and acupuncture are
better than TENS at providing short-term pain relief.
Another study compared TENS to a new biphasic TENS
in regards to pain and functional outcomes and found
no difference. Five other studies comparing TENS with
sham TENS or PENS found no significant difference between the groups. Only one study showed a significant
benefit of TENS for pain relief compared to sham at
short-term follow-up. All of this comparison data comparing TENS to PENS and sham was of low-quality.
Overall, the meta-analysis by van Middlekoop (337)
found no difference between TENS and other treatments in regard to pain or functional outcomes when
TENS was compared to other active interventions. The
authors also noted that the findings of the Cochrane
review from Khadilkar et al, when compared to their
meta-analysis, were very similar in that they both conclude that TENS is not supported in the management of
chronic low back pain (337,352).
A meta-analysis from Wu et al (353) showed the efficacy of TENS was similar to that of controls for providing pain relief and that other types of NSTs were more
effective than TENS for providing pain relief. The only
benefit they found for TENS was that it was better than
control treatment in improving functional disability in
the short-term (353).
The overall results of the Wu et al meta-analysis of
RCTs comparing the effectiveness of TENS to controls
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and other NSTs suggest that TENS does not improve
symptoms of lower back pain, but could offer shortterm improvement of functional disability (353).

4.4.7 Chiropractic Treatments
The efficacy of spinal manipulative therapy (SMT)
for treating chronic low back pain is debated and the
recommendations for use are heterogeneous. In some
health systems SMT is treated as a first line option, but
in others it is most often recommended along with
other spinal treatments or not recommended at all
(354,355). There is also at least one recent review of
guidelines that suggests that SMT should be considered
as a second-tier treatment option after exercise and
behavior therapy (356).
In most reviews, SMT is considered to represent any
manual treatment of the spine. Mobilizations of the
spine are typically low velocity or passive movement
techniques as opposed to manipulation which uses
a high velocity thrust applied to a synovial joint near
the end of the range of motion (357). This thrust often
produces an audible pop or crack that results from cavitation of the joint.
There are many theories as to the mechanism of
action of SMT and most of the hypotheses can be separated into neurophysiological and biomechanical categories (358,359). The biomechanical theory proposes
that SMT acts on a spinal lesion to reduce the mechanical stresses and the neurophysiological theory suggests
that SMT affects the primary afferent neurons from the
paraspinal musculature and the neurons that control
pain processing (360,361).
In a Cochrane review by Rubinstein et al (362),
the authors found that there was moderate quality
evidence indicating that SMT was no different than
other treatments for short-term pain relief but that it
produced a small improvement in function. They also
found high-quality evidence that indicated that SMT
had a small positive effect for short-term pain relief
and small to moderate positive effects for improvement in function when compared to other nonrecommended therapies (362). These results were similar
for intermediate and long-term outcomes. One study
with a low risk of selection bias found no increased
risk of adverse events associated with SMT. Most of the
adverse events seen with SMT were transient and of
mild to moderate severity (362). Overall, the authors
found that SMT produces similar clinical results when
compared to recommended therapies for patients with
chronic low back pain and seemed to be better than
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nonrecommended interventions for improvement of
short-term function.
Coulter et al (184) published the results of a systematic review and meta-analysis of manipulation and
mobilization for treating chronic low back pain which
was composed of 51 trials meeting the inclusion criteria, and 9 trials with 1,176 patients with sufficient data
were included in the meta-analysis. They concluded that
there is moderate quality evidence that manipulation
and mobilization are likely to reduce pain and improve
function for patients with chronic low back pain. In
addition, they concluded that manipulation appears to
produce a larger effect than mobilization, even though
both therapies appear safe and that multimodal programs may be a promising option.
Coulter et al (171) also performed a systematic
review and meta-analysis for an appropriateness panel
for manipulation and mobilization for treating chronic
nonspecific neck pain. They included 47 randomized trials with low risk of bias, including 4,460 patients with
nonspecific chronic neck pain. They concluded that
studies published since January 2000 provide low-moderate quality evidence that various types of manipulation and/or mobilization will reduce pain and improve
function for chronic nonspecific neck pain compared to
other interventions. Further, it appears that multimodal
approaches, in which multiple treatment approaches
are integrated, might have the greatest potential impact. The studies comparing to no treatment or sham
were mostly testing the effect of a single dose, which
may or may not be helpful in clinical practice. They also
hypothesized that given the low rate of serious adverse
events, other types of studies with much larger sample
sizes would be required to fully describe the safety
of manipulation and/or mobilization for nonspecific
chronic neck pain.
Rothberg and Friedman (363) in a systematic
review of complementary therapies in addition to
medication for patients with nonchronic, nonradicular
low back pain concluded that available evidence does
not support the use of spinal manipulation or excessive
therapy in addition to standard medical therapy. They
also concluded that there was insufficient evidence to
determine if yoga or massage was beneficial. However,
this study was criticized (364) for not including any studies beyond 2009 and there were multiple RCTs which
were available for inclusion during the publication of
this systematic review.
Sherbourne et al (365) from RAND Corporation also
described coping and management techniques used
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by chronic low back pain patients receiving treatment
from chiropractors. The results showed that respondents reported using an average 9 coping behaviors in
the prior 6 months. Persons with chronic low back pain
were proactive in their coping strategies and frequently
used self-care coping strategies like those provided by
chiropractors in patient education. Along similar lines,
in another manuscript from RAND Corporation (366),
the results showed that 79% of the sample gave positive responses to the time spent with the provider item
and a majority of the patients rated their provider at
the top of the scale. The results also showed that more
chiropractic patients reported always getting answers
to questions the same day and always seen within 15
minutes of their appointment.
Overall, these experiences provide information to
interventional pain physicians and also the importance
of multimodal treatment, including chiropractic treatment apart from physical therapy, exercise program,
and drug therapy.

4.4.8 Biofeedback Therapy
Behavioral and psychological treatments have been
shown to be effective in the treatment of chronic pain
by decreasing pain and improving function, but reducing psychological distress (365). There is some evidence
that psychological treatments are more effective than
medication and physical therapy in the short-term (366).
Biofeedback is a psychological treatment that may
be performed independently or as an adjunctive therapy
along with physical therapy or cognitive behavioral
therapy (CBT). During biofeedback treatments, patients
receive sensory information about physiological processes from their central nervous system (CNS) such as respiratory rate, heart rate, or muscle tension. Biofeedback
teaches the patient to self-regulate their physiological
processes with the assistance of the biofeedback information (366,367). The goals of the biofeedback sessions
are to teach the patient to consciously reduce muscle tension or to positively affect their own coping mechanism.
There are different types of biofeedback treatments including electromyographic, heart rate variability and respiratory biofeedback with electromyographic
biofeedback being the most common. There has been
no obvious mechanism of action for biofeedback in
the treatment of chronic low back pain; however, the
benefits of biofeedback have been shown in a number
of different chronic pain conditions (368). In previous
meta-analyses, biofeedback has been shown to be more
effective than cognitive behavioral therapy and physical
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therapy (369,370). It has been difficult to establish conclusions on the efficacy of biofeedback therapy due to
the heterogeneity of the biofeedback treatments and
the common practice of including this treatment with
others as an additive treatment.
Sielski et al (370) in a meta-analysis included an
evaluation of controlled and uncontrolled chronic back
pain studies that included biofeedback, to evaluate
short-term and long-term effects of biofeedback on
pain. This meta-analysis focused on manuscripts that reported standalone biofeedback as a treatment or comprising at least one-fourth of the total treatment (370).
The goal was to determine the efficacy of biofeedback
compared to different control groups and to identify
important components of the treatment effects. The
authors found that biofeedback resulted in a significant
small-to-medium reduction of pain that was durable
out to an eight-month follow-up and that it was also
effective in reducing depression, disability and muscle
tension (370). Biofeedback was also found to improve
the patients’ cognitive coping skills and these results
remained stable at follow-up. The moderator analyses
showed that longer biofeedback treatments were more
effective for decreasing disability and that a greater
proportion of biofeedback in the overall treatment
strategy was more effective for reducing depression.
They concluded that biofeedback treatment can be used
as a standalone therapy or as an adjunctive intervention
and can produce improvement on various pain-related
outcomes both in the short-term and in the long-term.

to expensive diagnostic ventures, but to treatment
failures resulting in wasted healthcare dollars, and diversion of essential healthcare resources. Fundamental
to proper treatment is an accurate diagnosis, which is
based on the reliability of the test used to make the
diagnosis. There are no universally accepted gold standards for the diagnosis of spinal pain, regardless of the
suspected source (127-139,164,165,188,192,371-383).
The majority of pain problems are not related to an easily identifiable cause. In addition, chronic pain may be
confused with chronic pain syndrome, which is defined
as a complex pain condition with physical, psychological, emotional, and social components (7,384). Chronic
pain and chronic pain syndrome often appear similar,
and at times may coexist.
Epidural interventions including multiple types of
epidural procedures and percutaneous epidural adhesiolysis are administered in disc-related pathology including disc herniation, disc protrusion, discogenic pain,
spinal stenosis, and radiculitis.

5.0 Structural Basis

The spine is composed of five lumbar vertebrae
and, between them, intervertebral discs which together
constitute one quarter of the total length of the spine
(385). In a healthy back, the intervertebral discs, being
70-80% aqueous, are soft and compressive to preserve
spinal movements, absorb shock impact, and distribute
axial and torsional forces (386-388). Through the normal process of aging, the inner nucleus pulposus of
the discs becomes replaced with fibrocartilage as the
proteoglycan, water, and noncollagenous protein concentrations decrease, and the collagen concentration
increases (389,390). This loss of fluid due to dropped
oncotic pressure in the discs makes them thinner and
less flexible, hindering their function (386-388). Cartilaginous endplate erosion contributes to disc degeneration by compromising the flow of oxygen and nutrients
to the discs (388,391-393). Endplate defects, which may
result from disc degeneration or trauma, can stimulate
nociceptors within the discs (394-396).
Another age-related mechanism of disc degen-
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Spinal Pain

Key Question 3: What is the evidence for structural basis of spinal pain?
Chronic spinal pain is a complex and multifactorial
phenomenon. Consequently, the high prevalence of
chronic spinal pain, the numerous modalities of treatments applied in management of the problem, and the
growing social and economic costs continue to influence
medical decision-making. Despite its commonality, both
in primary care and tertiary care, it is often difficult to
reach a definite diagnosis of the origin of spinal pain.
Interventional techniques are based on the philosophy
of a neurophysiologic basis, in that when present, a
structural origin of pain is important with or without
coexisting psychosocial abnormalities and comorbid
conditions. A major source of exponential growth in
treatment modalities is the inherent difficulty in obtaining an accurate diagnosis. In the search of a diagnosis,
an inaccurate or incorrect diagnosis, may lead not only
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5.1 Lumbar Disc-Related Pathology, Spinal
Stenosis, Post-surgery Syndrome
Chronic, persistent low back, lower extremity pain,
and radicular pain may be secondary to disc herniation,
disc disruption, disc degeneration, spinal stenosis, or
post-lumbar surgery syndrome resulting in disc-related
pain with or without radiculitis.

5.1.1 Lumbar Disc-Related Degeneration
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eration is the formation of small tears into the outer
annulus fibrosis of the discs. This may be worsened by
injury from daily activities and sports. This leads to disc
space collapse and disc resorption as the nucleus pulposus streams out through the tears, causing the disks to
bulge, protrude or rupture, leading to herniated discs.
Herniated material may also contain cartilaginous endplate, fragmented apophyseal bone and annular tissue
(397-399). The resulting instability may lead to abnormal micro-motions, causing tension and irritation in the
surrounding structures. The loss of disc height can lead
to abnormal loading of apophyseal joints, which may
in turn cause osteoarthritic changes (400). The space
between vertebrae becoming narrower may lead to the
production of osteophytes, which in rare cases apply
pressure on the spinal cord or spinal nerve roots, further
worsening pain and nerve function (401).
Herniated lumbar disc is a displacement of disc
material (nucleus pulposus or annulus fibrosis) beyond
the intervertebral disc space. Over the past 78 years, voluminous literature has been published describing the
epidemiology, diagnosis, and numerous treatment modalities for herniated disc pain, following the description of disc herniation by Mixter and Barr in 1934 (255).
However, magnetic resonance imaging (MRI) findings
of a herniated disc are not always accompanied by clinical symptoms (402). The prevalence of a symptomatic
herniated lumbar disc is about 1% to 3% (402) with the
highest prevalence among people aged 30 to 50 years
(403), with a man to woman ratio of 2:1 (404). In individuals aged 25 to 55 years, about 95% of herniated
discs occur at the lower lumbar spine (L4/5 and L5/S1
level); disc herniation above this level is more common
in people aged over 55 years (405,406). Lumbar disc displacement may present as internal disc disruption, disc
prolapse, disc protrusion, disc extrusion, disc herniation,
or simply discogenic pain. The estimated prevalence of
lumbar radiculopathy or sciatica has been described as
9.8 per 1,000 cases (407,408). It has been estimated that
lumbar disc herniation occurs in 30% of the population
at some time in their lifetime. Studies also have shown
that sciatic symptoms may be present from 1.6% in the
general population to 43% in select working populations in the US (408-411). Additionally, spontaneous
resorption or regression of lumbar disc herniation has
been reported in multiple assessments. Zhong et al
(412), in a systematic review published in 2017 reported
incidence of spontaneous resorption was 66.66%. The
incidence in the United Kingdom was 82.94%, and in
Japan was 62.58%. On the other end of the spectrum,
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Chiu et al (413) found a rate of spontaneous regression
of 96% for disc sequestration, 70% for disc extrusion,
41% for disc protrusion, and 13% for disc bulging. They
also showed the rate of complete resolution of disc
herniation was 43% for sequestered discs and 15% for
extruded discs. Wang et al (414) performed a systematic
review and meta-analysis and also discussed multiple
systematic reviews performed. Overall, they showed an
incidence of regression of 63% among nonsurgically
treated symptomatic lumbar disc herniation patients. By
discussing multiple studies, they showed that there was
no significant regression before 4 months and after 10.5
months to be the ideal time to find regression after the
onset. The highest incidence rate (IR) of 96% was documented by Lee et al (415) with an average follow-up
of 341 days. Ahn et al (416) also reported an IR of 69%
with an average follow-up time of 8.5 months. Others
(417-421) reported an IR of 62% to 64%. Wang et al
(414) described that the follow-up time of the 6 studies
with IRs of approximately 63% ranged from 8.5 to 12.9
months with an average of 10.5 months. Furthermore,
a multitude of conservative managements including
epidural injections have been shown to be effective in
managing chronic disc herniation (7,55-57,60-65). One
study looking at alternative and integrative therapy
showed positive long-term results of lumbar disc herniation patients receiving nonsurgical, complementary,
and alternative medicine treatments with favorable results and high satisfaction rates. Lumbar radiculopathy
secondary to disc herniation resolves spontaneously in
23% to 48% of patients, but up to 30% to 70% will
still have pronounced symptoms after one year, with
5% to 15% of patients undergoing surgery (409,422).
Even though first described by Wirshow in 1857, the
pathophysiology and the mechanism of pain due to disc
herniation remain controversial (423,424).
The intervertebral disc has been implicated as a
source of spinal pain based on decades of pre-clinical,
clinical, and epidemiological research, though the
precise mechanisms continue to be debated as the
literature evolves (7,127,129,130,136,138,139,371,423,
424). Further, based on controlled evaluations, lumbar
intervertebral discs showed the prevalence of internal
disc disruption in 39% of a younger cohort of patients
following injury (128), and 42% in a heterogenous
population comprised of all age groups and all types
of low back pain (425). Further, in a study that sought
to determine the prevalence of discogenic pain without
assessing internal disc disruption, the reported prevalence rate was 26% (137).
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Disc herniation may cause mechanical compression or inflammation. The normal intervertebral disc is
avascular and aneural, except for the outer third of the
annulus fibrosus. Maintaining a dynamic equilibrium
between the synthesis and degradation of the extra cellular matrix is pivotal in intervertebral disc homeostasis,
but degeneration of the extra cellular matrix occurs in
patients with low back pain. Ingrowth of nociceptive
neural fiber into deeper parts of the degenerated intervertebral disc is considered as one of the most widely
accepted pathophysiological mechanisms related to
chronic discogenic pain (426,427). Disc inflammation
may promote axonal growth of afferent fibers innervating the disc by secreting pro-inflammatory mediators,
such as tumor necrosis factor (TNF) and interleukin 6
(IL-6) as disc degeneration proceeds (428-432). In addition, nerve growth factor (NGF) is known to be a trophic
growth factor for sympathetic and sensory nerve cells
and to stimulate their differentiation, growth, maintenance, and survival (433). Further, it also has been
shown that NGF also shows a hyperalgesic property by
sensitizing and sprouting sensory nerve fibers in painful
pathologic conditions (434,435). It has also been proposed that actions of NGF in painful intervertebral disc
not only sensitize the sensory neuron, but also stimulate
the peripheral nociceptive sensory neurons to grow into
the intervertebral disc tissue where the extracellular
matrix is degenerated in most cases (420). Inflammatory
involvement has been extensively described (127,427437). Consequently, the proposed etiologies and radiculitis may be summarized to include neural compression
with dysfunction, vascular compromise, inflammation,
and biochemical influences. Risbud and Shapiro (438)
described the pathophysiology of disc degeneration
and pain showing that in the inflammatory milieu
neurogenic factors, in particular NGF and brain-derived
neurotrophic factor (BDNF) generated by the disc and
immune cells along with a multitude of other factors
including TNF and IL-6. Phospholipase A-2 induces an
expression of pain associated with cation channels in
the dorsal root ganglia (DRG). Risbud and Shapiro (438)
also showed that disc degeneration is characterized by
3 distinct, but overlapping phases in which cytokines
play a central role with an initiating event resulting
in phenotypic changes in production of cytokines and
chemokines by both the nucleus pulposus and annulus
fibrosus cells in the first phase, followed by further application of the inflammatory response by infiltrating
immunocytes, as well as neovascularization and nerve
ingrowth into the structurally deficient disc tissues in
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the second phase. In the final phase, nerve endings are
sensitized and the modulation of DRG pain channel
activities are altered by inflammatory mediators and
neurotrophins resulting in pain. Further, Olmarker et
al (439,440) also showed that spinal nerve roots, when
compressed, exhibited interneural edema, deprived
nutritional supply (439) and loss of amplitude of nerve
conduction (440). In fact, these experimental findings
were confirmed by Kuslich et al (130), who reported that
noncompressed nerve roots did not reproduce the patients’ pain when stimulated intraoperatively in awake
surgical patients. Consequently, epidural procedures
are suited in managing chronic lumbar disc herniation,
with a natural history of radicular pain showing a favorable prognosis (55-65,70,71,75,76,436). Disc regression
or resorption have been shown to be most favorable
in disc sequestration (96%), disc extrusion (70%), and
disc protrusion (40%); however, it was only 13% in disc
bulging (413). Saal et al (420) reported that 90% of the
patients showed good to excellent outcomes and 92%
had achieved return to work status with nonoperative
treatment of disc extrusions.

5.1.2 Lumbar Spinal Stenosis
Spinal stenosis is the result of abnormal narrowing
of the spinal canal, lateral recess or the intervertebral
foramina, resulting in pressure on the spinal cord or
nerve roots (441,442). The two lower motion segments
(L3-L4 and L4-L5) are the most commonly affected
related to being more vulnerable to rotatory strains
(443). Spinal stenosis may develop by a combination
of chronic mechanical compression and cord instability. Along with ischemia, these factors may lead to
neurologic symptoms or claudication (444-451). Some
common causes of spinal stenosis include disc-related
degeneration, osteophyte formation, herniated discs,
arthritis, ligament or facet joint hypertrophy, epidural
fat deposition, spinal tumors, and traumas (447-451).
Adult degenerative scoliosis and degenerative spondylolisthesis may lead to instability and facet hypertrophy,
resulting in stenosis (441-444).
Lumbar spinal stenosis is a common source of
back and leg pain, and often involves weakness and
numbness (441-443). More severe cases may present
with neurological symptoms such as radiculopathy,
myelopathy or cauda equina syndrome. Permanent
numbness or paralysis can result from a long-term
compression of spinal nerves or of the spinal cord.
Lumbar spinal stenosis is the most common cause of
spinal surgery in patients over 65 years old (441-444).
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The prevalence of lumbar spinal stenosis increases with
age, and is approximately 19.4% among individuals
aged 60-69 years old (442,452). Nonetheless, it may develop earlier due to injury or congenital factors (442).
The rate of progression over time is variable, and may
not always exhibit symptoms. Some studies report that
approximately half of patients remain clinically stable,
while a quarter worsen or improve (399,453,454). The
symptoms of spinal stenosis may significantly affect
patients’ mobility, functional autonomy and performance in routine tasks (451).
The pathophysiologic mechanism is similar to disc
herniation, even though the mechanical component
is more significant with narrowing of the spinal canal
or the intervertebral foramen resulting in either neurogenic claudication or radiculitis. Epidural injections
have been shown to be effective in managing lumbar
spinal stenosis in multiple RCTs and systematic reviews
(7,55,58,60,65,70,77,81,83). In addition, spinal stenosis
patients have been shown to respond to percutaneous
adhesiolysis (72-74).

5.1.3 Lumbar Post-surgery Syndrome
Pain and disability in the low back and lower
extremities following lumbar spine surgery has been
hypothesized to be secondary to multiple causes including epidural fibrosis, sacroiliac joint pain, disc herniation, discogenic pain, spinal stenosis, arachnoiditis,
and facet joint pain, along with inappropriate surgery
(7,72-74,221,228,265-267,269,277,455-477). Failed back
surgery syndrome was defined by the International Association for the Study of Pain (IASP) as a phenomenon
of persistent or recurrent pain, mainly in the lower back
or legs, even after previously anatomically successful
surgeries (478). The review of literature of recurrent
pain after lumbar discectomy for lumbar disc herniation, in patients under the age of 70 years, showed frequent or recurrent leg pain in 5% to 36% of patients
2 years after the operation (477,479). Some literature
also has shown occurrence rates variable from 10%
to 40% (73,476,479,480). Even though the ongoing
debate continues in reference to epidural fibrosis and
its effect on multiple pain problems or lack thereof, debate continues without an end (458,459,460,481,482).
Nevertheless, Ross et al (460) showed that patients with
extensive epidural fibrosis were 3.2 times more likely to
experience recurrent radicular pain than those with less
scarring. Electrophysiological evidence of neurologic
disturbances caused by peridural scar formation was
shown in experimental studies (464). Various additional
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abnormalities including mechanical tethering of nerve
roots secondary to epidural fibrosis in the vertebral
canal (465,466), disturbances in blood flow (467), and
expression of proinflammatory cytokines causing irritation of exposed dorsal root ganglion and triggering
painful responses have been described (468). In addition, osteopontin has been shown to play a major role
in the formation of epidural fibrosis and a mark-up
DRG response to peridural scar formation (461). Additional experimental evidence has implicated paraspinal
muscle spasms, tail contracture, pain behaviors, tactile
allodynia, epidural and perineural scarring, and nerve
root adherence to the underlying discs and pedicle in
animal models (469).
Wound healing after tissue injury involves 4 major
coordinated and regulated steps: hemostasis, inflammation, proliferation, and remodeling. Different factors can interfere with these steps, causing improper
or impaired wound healing (473). Central to this is an
increased inflammatory response with recruitment of
polymorphonuclear neutrophils to the injury site. These
cells help in the clearance of pathogens and foreign
particles, but also lead to tissue injury with generation
of reactive oxygen species (ROS) (483), excessive migration of fibroblasts and collagen deposition. Thus, excessive scarring and adhesion formation occurs and can be
exacerbated by pathological process such as infection,
inflammation, and hematoma formation (484). Numerous strategies have been tested to reduce adhesion
formation post spinal surgery; however, there have not
been any therapeutic breakthroughs to achieve this
goal (473).
Consequently, in post-lumbar surgery syndrome,
a multitude of pathophysiologic bases have been described including recurrent disc herniation, scarring and
entrapment of the nerve roots and discogenic pain.
These can be addressed with epidural interventions,
either with epidural injections or percutaneous adhesiolysis. Multiple RCTs and systematic reviews have been
performed with caudal epidural injections, as well as
percutaneous adhesiolysis in post-lumbar surgery syndrome (56,58,60,72-74).

5.2 Cervical Disc-Related Pathology, Spinal
Stenosis, Post-Surgery Syndrome
Chronic, persistent neck and upper extremity pain
and radicular pain may be secondary to disc herniation,
discogenic pain, spondylosis, spinal stenosis, or post
cervical surgery syndrome resulting in disc related pain
with or without radiculitis.
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5.2.1 Cervical Disc-Related Pathology
Intervertebral disc-related pain can be caused by
structural abnormalities, such as disc degeneration and
disc herniation, and biochemical effects such as inflammation (7,134,436).
Disc degeneration can be broadly classified into
2 categories: internal disruption and herniation (485).
Internal disruption refers to a pathway that ends with
derangement of the internal nucleus pulposus and/or
annular fibers with little or no external deformation
(486). Initially, repetitive microtrauma slowly causes the
formation of small circumferential micro fissures. These
concentric fissures coalesce over time to cause formation of radial fissures that extend from the inner, gelatinous nucleus pulposus to the outer third of the annulus
fibrosus (487). While the nucleus pulposus of each disc is
not innervated, the outer annulus fibrosus is innervated
anteriorly by the vertebral nerve and posterolaterally
by the sinuvertebral nerve (488). Therefore, when the
radial fissures invade the annulus, it is thought that
they may become a source of discogenic pain (489,490).
However, it should be noted that annular fissure tears
can also be found in asymptomatic individuals.
Recent studies on the etiology of discogenic pain
have demonstrated that inflammatory cytokines such
as TNF-α, IL-1 α/β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-17, IL-20,
and IFN-γ are secreted by cells in degenerative discs
(491). The expression of these cytokines has multiple
effects. In particular, IL-1β has been found to increase
NGF expression and TNF-α has been associated with upregulation of substance P (492). Further, levels of NGF
and TNF-α have been found to be increased in painful
discs (493). The increased presence of NGF in the disc
is thought to contribute to discogenic pain by causing
infiltration of nerve fibers into otherwise aneural tissue
(492). Additionally, the increase in cytokine expression
causes chemokine production, which, in turn, leads to
recruitment of T-cells, B-cells, macrophages and mast
cells. These cells cause matrix degradation and continue
to amplify the inflammatory cascade (438,491).
The incidence of cervical disc herniation, however, is
less common than lumbar disc herniations (134,436,494500). The cervical disc herniation is a common source of
cervical radiculopathy. The incidence of cervical disc herniations has been reported from Rochester, Minnesota,
with the annual incidence as 18.6 per 100,000 or 0.186%
with incidence peaking in the sixth decade of life (501).
However, the etiology of cervical spine disc herniation is
multifactorial (497,502,503). The proposed risk factors
include male gender, present cigarette smoking, heavy
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lifting, and frequent driving or occupation involving driving (497,502,503). Further, evidence also shows that incidence of cervical disc herniation is higher in professional
drivers, army aviators, and those who operate vibrating
equipment (497,503). In addition, a study reported that
history of physical exercise or trauma preceded the onset
of symptoms in 14.8% of cases (501).
The mechanical compression on the nerve root that
is being irritated by the herniated disc material is an
important factor in the production of neck and upper
extremity pain. The mechanical, chemical, and inflammatory components produce ischemic neuropathy related to the alteration of blood flow patterns or defects
in the neuronal transport mechanism of the nerve root
itself. Radicular pain may occur in the absence of nerve
root compression secondary to nucleus pulposus extrusion or inflammatory reaction to the chemicals.
Multiple studies have shown the unique properties of spinal nerves and inflammatory mechanisms,
explaining various mechanisms other than mechanical
compression and compression affecting dorsal root ganglion (7,134,436,498,504-520). In fact, herniated cervical
intervertebral discs have been shown to produce metalloproteinases, nitric oxide, interleukin-6, and prostaglandin E2 (505). These substances are considered to be
potential irritants of spinal nerves or inflammation.
Cervical radiculopathy is a pathologic process that
involves neurophysiologic dysfunction of the nerve
root (521-523). This syndrome is characterized by myotomal weakness, paresthesias, sensory disturbances
and depressed muscle stretch reflexes, all of which
are sequelae of a hypofunctional nerve root (485). In
cervical radiculopathy, the hypofunctional nerve root is
the result of nerve root compression. Direct nerve compression causes a conduction block and interruption of
axonal flow, as well as hypoxia and all of its associated
effects (523).
Most often, the cervical nerve root injury present
in cervical radiculopathy is caused by intervertebral disc
herniation (524). This mechanism of injury was first described by Semmes and Murphey in 1943 (525). Since that
time, numerous studies have demonstrated that cervical
disk abnormalities are often present in asymptomatic
individuals (526-529). Why can a cervical disc herniation
cause radiculopathy in one patient, while another patient with a similar herniation may be asymptomatic?
The reasons for this difference are not completely clear.
However, it is thought that an inflammatory response
to the cervical disc herniation is responsible for initiating the neurophysiologic dysfunction characteristic of
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cervical radiculopathy (505-507,530,531). This theory is
supported by evidence that nerve root inflammation,
in the absence of frank compression may continue to
cause disruptions in nerve root physiology (532). Inflammatory mediators may be secreted from a degenerated
or herniated nucleus pulposus (491-493,523,533). Additionally, the gradient of compression may also play a
significant role in determining whether or not a disk
herniation becomes symptomatic (534).
Spondylitic changes represent the second most common cause of cervical radiculopathy. Spondylosis is an
umbrella term, which covers the degenerative changes
that develop in the spine over time: ligamentous hypertrophy, hyperostosis, disk degeneration, and facet and/
or uncovertebral joint arthropathy (535). Hypertrophy of
the facet or uncovertebral joints may cause stenosis of
the intervertebral foramina and subsequent nerve root
compression (535,536). Osteophytes may also compress
the adjacent nerve root. Other less common, but noteworthy causes of cervical radiculopathy include facet
joint cysts, nerve tumors (e.g., schwannomas), fibroproliferation, hematomas, and trauma (523,537,538).
The course and prognosis of cervical disc herniation
has been studied in multiple manuscripts (500,501,539).
A systematic review of the literature of the course and
prognostic factors of symptomatic cervical disc herniation with radiculopathy (500) concluded that most
patients with symptomatic cervical spine disc herniation
with radiculopathy recovered. In addition, a clinical
guideline (540) for the diagnosis and treatment cervical
radiculopathy from degenerative disorders concluded
that signs and symptoms of degenerative disorders of the
cervical spine resulting in radiculopathy will be self-limited
and will resolve spontaneously over a variable length of
time without specific treatment. In another manuscript
(539), it was shown that in the natural history of cervical
radiculopathy, 43% of the patients had no further symptoms after a few months, 29% had only mild or intermittent symptoms, and only 27% had disabling pain. The
authors of the large epidemiologic prevalence study from
Rochester, Minnesota (501) over a 5-year follow-up period
showed that 31.7% of patients with symptomatic cervical
radiculopathy showed symptoms recurrence, with only
26% needing surgical intervention for intractable pain,
sensory deficit or objective weakness (501).
Based on the pathophysiology of cervical disc degeneration, disc herniation, and resultant radiculopathy,
multiple investigators have shown the effectiveness of
cervical epidural injections in managing neck and upper
extremity pain (55,58,60,64,70,76).

S62

5.2.2 Cervical Spondylosis
Degenerative changes of the cervical spine reach a
prevalence of nearly 95% by age 65. These changes are
associated with disc protrusion, neuroforaminal narrowing, and spinal cord contour changes in up to 78%
of asymptomatic individuals (539-541).
Spondylosis is a chronic degenerative condition of
the cervical spine associated with the formation of osteophytes and compression of the spinal cord. Spondylosis
refers to degenerative changes of the spine involving the
intervertebral discs, uncovertebral joints of Luschka, facet joints, ligaments, and connective tissue of the cervical
vertebrae. Degenerative changes of the cervical spine are
seen in approximately 10% of individuals by age 25 and
in 95% by age 65. The levels most commonly affected
by both disc herniation and chronic spondylosis are C6/
C7, followed by C5/C6 as these are the cervical segments
where the most extension and flexion occurs.
In most symptomatic cases, spondylosis is associated
with aging and with compression of the spinal cord,
producing either central or neuroforaminal stenosis in
patients older than 55 (542).
Cervical spondylotic myelopathy refers to clinically
evident spinal cord dysfunction with the presence of
long-track signs due to compression of the spinal cord.
Weakness or stiffness in the legs with unsteady gait,
together with weakness or clumsiness in the hands,
is pathonomic of cervical spondylotic myelopathy.
The progression of weakness may be gradual in some
patients or sudden in others following minor trauma.
Some patients may complain of hesitancy on urination,
even though loss of sphincter control or urinary incontinence is rare and considered a late sign of myelopathy.
Cervical epidural injections, specifically in
radiculopathy, are known to be helpful in managing
cervical spondylosis. There are no specific studies conducted for this purpose. However, the mechanism is similar to spinal stenosis and disc herniation. Consequently,
epidural injections fit the pathophysiological basis for
epidural interventions. Epidural steroid injections are
not routinely recommended in those patients who go
on to develop spondylotic myelopathy.

5.2.3 Cervical Spinal Stenosis
Cervical spinal stenosis is a common disease that results in considerable morbidity and disability (543-546).
Degenerative change is the most common cause of
cervical stenosis and can be due to disc herniation, osteophyte formation, or a combination of both, namely
disc-osteophyte complex (547).
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The normal AP diameter of the mid-cervical spinal
canal is approximately 17-18 mm (548). Based on a large
cadaveric study, cervical stenosis, or narrowing of the
central cervical canal has an estimated US population
prevalence of 4.9% (549). Cervical stenosis may be congenital, in which case it is secondary to short pedicles
and bony abnormalities of the lateral masses and laminae (550). More frequently, however, cervical stenosis
is acquired--the result of cervical spondylosis. The pathway to acquired cervical stenosis begins with gradual
degeneration of the cervical intervertebral discs. As the
discs degenerate and shrink, they pull away from the
vertebral endplates, causing instability of the spinal
segments. This instability may lead to hypertrophy and/
or calcification of the ligamentum flavum and/or posterior longitudinal ligament, hypertrophy of the facet
and/or uncovertebral joints and the formation of cysts
on the joints and ligaments (551).
Tandem spinal stenosis is a degenerative disease that
describes a double stenotic lesion involving the cervical
and lumbar spine (546,552-555). Historically, tandem
spinal stenosis accounts for between 5% and 60% of all
cases of stenosis (546). However, cervical spinal stenosis is
less common than lumbar spinal stenosis. Asymptomatic
stenosis in the cervical and thoracic spines of patients
with symptomatic lumbar stenosis has been reported
in 23.9% in the cervical spine and 24.3% in the thoracic
spine, with 12.1% with combined radiologic cervical and
thoracic stenosis in addition to their symptomatic lumbar
stenosis or triple stenosis (554). With increasing age, a
large proportion of the population exhibits radiological
signs of discopathy or spondylosis, leading to constriction
of the spinal canal (543).
Cervical spinal stenosis may also cause myelopathy,
which is broadly defined as a symptomatic dysfunction of
the cervical spinal cord caused by compressive etiologies
(543,545,546,555-557). However, cervical myelopathy can
occur because of cord compression resulting from one
of several physiological factors including spondylolysis/
congenital stenosis, disc herniation, ossification of the
posterior longitudinal ligament, hypertrophy of the
ligamentum flavum, and degenerative subluxation. For
the past 4 decades, there have been several attempts
to correlate the clinical severity of spinal stenosis with
the degree of spinal cord compression on MRI (556-561).
However, no methodology has been validated. In a recent
manuscript, Karpova et al (545) assessed the reliability of
quantitative MRI methods in the assessment of spinal canal stenosis and cord compression in cervical myelopathy.
They concluded that the measurements of maximum ca-
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nal compromise, maximum spinal cord compression, and
compression ratio were reliable and correlated well with
the clinical severity of cervical myelopathy.
Based on the pathophysiologic basis of cervical spinal stenosis, cervical epidural injections have
been shown to be effective and are indicated
(55,58,60,64,70,76).

5.2.4 Cervical Post-surgery Syndrome
Cervical post-surgery syndrome represents a cluster
of symptoms following cervical spine surgery wherein
the expectations of the patient and spine surgeon are
not met. Animal models of post-lumbar laminectomy
syndrome demonstrated paraspinal muscle spasms, tail
contractures, pain behaviors, tactile allodynia, epidural
and perineural scarring, and nerve root adherence to
the underlying disc and pedicle (457,458,461,464,467477). It also has been postulated that there may be a final common pathway with all the described etiologies,
which results in peripheral and central facilitation potentiated by inflammatory and nerve injury mechanisms.
In a recent manuscript, Seichi et al (562) explored
the mechanism of post-operative axial neck pain which
is a common complication (563-574) even though neurological recovery after laminoplasty is appropriate
(566-568). They described that even though multiple
factors, including surgical trauma to the posterior
cervical muscles and the period of external immobilization, have been suggested as causative factors for
the development of pain (563-572), the precise mechanism underlying the development of post-operative
axial pain remains unclear (564). They described that
post-operative axial pain is multifactorial in nature
with soft tissue injuries, such as those that occur due
to intraoperative damage of the posterior extensor
musculature, are considered to be a major mechanical factor in the development of post-operative axial
pain (573,574). In addition to muscle damage, nerve
tissue injuries sustained during surgery also have been
suggested as a causative factor of post-operative axial
pain (563,564).
Based on the above pathophysiologic basis, epidural interventions are performed in the cervical spine
with appropriate outcomes (55,58,60,64,70,76).

5.3 Thoracic Disc-Related Pathology, Spinal
Stenosis, Post-surgery Syndrome
Thoracic disc related pathology, spinal stenosis, and
post-surgery syndrome produce symptoms related to
thoracic pain and radiculitis (7,135,546,575-580).
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5.3.1 Thoracic Disc Related Pathology
Thoracic discogenic pain is a much less frequent
occurrence than cervical/lumbar discogenic pain. When
considering the biomechanics of the spine, this is not
surprising because the cervical and lumbar regions
support more of the weight of the axial skeleton than
the thoracic and sacral regions (581). Additionally, the
coronal orientation of the thoracic zygapophyseal joints
makes them more stable than those found in the cervical and lumbar spine (582). The presence of the ribs also
provides additional stability to the thoracic vertebra. As
a result, the intervertebral discs in the thoracic spine are
less prone to degenerative changes than those in the
cervical and lumbar regions. However, when thoracic
discogenic pain does occur, it is typically the result of the
same degenerative pathway that takes place in cervical
and lumbar discs. Also, in similar fashion to the cervical and lumbar spine, thoracic disc herniations may be
found in asymptomatic patients. It is important to note
that the cord/canal ratio in the thoracic spine is 40%,
compared to 25% in the cervical spine (583). Moreover,
due to its tenuous blood supply, the thoracic spine is
particularly susceptible to ischemic damage. Therefore,
when thoracic disc herniations do lead to myelopathy, it
is typically more severe than in the cervical and lumbar
spine.
Thoracic disc herniation is rare, with an estimate
preference of 1 per million people or 0.0001%, constituting a small proportion of overall disc herniations
of 40 to 50 per 100,000 population or 0.04% to 0.05%
(584). Consequently, as expected, surgical procedures in
the thoracic spine make up only 0.15% to 4% of the
procedures for disc herniation (585). Thoracic disc herniations are associated with progression, dominated by
the risk of medullary compression; however, surgery for
thoracic disc herniation has a poor reputation because
of its technical difficulties and the risk of potentially
serious hard to treat complications (579).
Presence of asymptomatic stenosis has been estimated 11% to 37%. Thoracic disc herniation is most
common in adults 30 to 50 years of age (579). Thoracic
disc herniations are located below T7-T8 in 75% of the
cases. Further, T11 to T12 disc is the most vulnerable
because of greater mobility and posterior longitudinal
ligament weakness at this level. Only 4% of thoracic disc
herniations are located above T3-T4. The cases of thoracic disc herniations complicating proximal junctional
syndrome have been reported after the thoracolumbar
fusion (586). Thoracic disc herniations frequently calcify or ossify (584). However, spontaneous regression of
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thoracic disc herniations with or without calcification
or ossification have been reported (587). Thoracic disc
herniations have been reported to be more common in
Scheuermann's disease and also have been found in 3%
to 37% with a history of trauma.
The herniated disc can be very large in volume. In
fact, thoracic disc herniation is labeled as ‘giant’ when
it occupies more than 40% of medullary canal on computed tomography (CT) scan or MRI (585). The volume
and calcified nature of herniation increases the risk of
intradural extension due to erosion and progressive
thinning of the dura, even though intradural extension
is only present in 0.26% to 0.3% of all herniated discs,
whereas it is present in 15% to 70% of joint calcified
thoracic disc herniations.
The majority of patients may not present with radicular pain. Some may present only with thoracic pain.
The mechanism of radicular pain is similar to cervical
and lumbar spinal pain with mechanical compression
and inflammation.
Thoracic discs also have been shown to be the cause
of pain without disc herniation, mostly axial pain.
Based on pathophysiology of discogenic or radicular pain, epidural interventions are effective in
post-surgery syndrome. However, there is only one RCT
available in the literature (588) included in systematic
reviews (55,58,60). Nevertheless, based on the response
to discogenic pain in the lumbar and cervical spine, it
appears appropriate when medical necessity arises and
indications are met.

5.3.2 Thoracic Spinal Stenosis
Thoracic spinal stenosis is a relatively rare disease
characterized by narrow spinal canal and compression
of the spinal cord and/or nerve root (580). In a systematic
review, Chen et al (580) showed the results with diagnosis of ossification of the posterior longitudinal ligament
(OPLL) in 18.7%, ossification of the ligamentum flavum
(OLF) in 41.5% of the patients, and 7.4% were shown
to have both OPLL and OLF. In addition, 32.4% were
with thoracic disc herniation producing spinal stenosis.
Thoracic OPLL occured mostly at the middle thoracic
spine (43.4%), while OLF predominantly occurred at the
lower thoracic spine (63.1%). Thoracic disc herniation
was mainly localized in the middle (46%) and lower
thoracic (50.3%) spine. Tandem spinal stenosis was
observed in 52.1% with accompanying cervical diseases
and 35.9% with lumbar diseases.
Even though thoracic myelopathy caused by spinal
stenosis is less common than that of cervical and lum-

www.painphysicianjournal.com

ASIPP Epidural Guidelines

bar disease (588). The outcomes are poor if surgery is
performed (589). Multiple factors responsible for poor
prognosis have been described including tenuous blood
supply to the thoracic spinal cord (590,591), natural
kyphotic curve of the thoracic spine which limits backward movement of the spinal cord, especially during
ventral compression. Also, thoracic spinal stenosis is a
degenerative disease that progresses slowly and can be
asymptomatic for a long time, resulting in irreversible
neurological damage due to delayed diagnosis (592595). Finally, the multifactorial nature (589,596-598)
of the disease involving many pathologic changes and
a combination of multiple factors and co-existence of
other spinal pathologies frequently leads to misdiagnosis and incorrect treatment (599). Consequently, even
though options are poor, early diagnosis and optimal
treatment are recommended.
Based on the pathophysiologic basis, epidural injections are indicated with all the appropriate precautions
if medical necessity and appropriate indications are
present, based on the results in lumbar and cervical
spine (7,55,58,60,65,70,77,81,83).

5.3.3 Thoracic Post-surgery Syndrome
Post thoracic surgery syndrome is rare compared to
lumbar or cervical post-surgery syndromes due to the
fact that surgical interventions constitute only a small
proportion of overall surgical interventions for disc herniations for spinal stenosis. Even then, early diagnosis
and appropriate management has been recommended
(599). Surgical interventions are offered for managing
disc herniation, as well as thoracic spinal stenosis and
spondylosis. Meanwhile, thoracic surgical interventions
are performed for scoliosis and other congenital deformities (575,600-603).
Epidural interventions are performed less frequently than in the lumbar and cervical spine for disc herniation, spinal stenosis, and discogenic pain; however, for
thoracic post-surgery syndrome these procedures must
only be performed if there is appropriate access available below the surgical level or with catheterization
with or without adhesiolysis.

6.0 Pathophysiologic Basis
Interventions

of

Epidural

Key Question 4: What is the pathophysiologic
basis of epidural interventions in spinal pain?
Multiple therapeutic spinal interventional techniques are applied in managing chronic spinal pain. The
rationale includes the commonality and complexity of
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spinal pain problems and ability of diagnostic blocks to
identify sources of chronic spinal pain. The degenerative
processes of the spine and the origin of spinal pain are
complex without consistent correlation of radiographic
changes to the clinical picture and prognosis. The effectiveness of a large variety of therapeutic interventions used to manage chronic spinal pain has not been
demonstrated conclusively (7). In fact, Best Practices
in Pain Management from the HHS, has reviewed the
available evidence in pain management and described
interventional techniques as part of a continuum prior
to surgical interventions and neuromodulation (78,79).
Among multiple therapeutic interventional techniques
with available evidence that are commonly applied are
epidural injections including adhesiolysis.
Epidural injections have been in existence since
the first descriptions of caudal epidural with local anesthetic for low back pain in 1901, as described by Sicard
(604), Cathelin (605), and Pasquier and Leri (606). It is
also important to note that Sicard (604,607,608) administered an epidural injection with local anesthetic only
and reported several weeks of improvement. He acquired the reputation as the “pain doctor” for treating
patients from all over France (607,608). Consequently,
epidural injections during the first 50 years were limited
to local anesthetic alone (102,609-611), until reports of
administration of steroids through sacral nerve root by
Robecchi and Capra (612) and Lievre et al (613) in the
early 1950s.
Epidural injections are performed with an interlaminar or transforaminal approach in the lumbar, cervical,
or thoracic spine. Caudal procedures are performed
for lumbosacral disorders. Caudal and interlaminar
epidurals have been the common procedures, but more
recently, transforaminal epidural injections, specifically
in the lumbosacral spine, have been reversing the trend
(194,195). The caudal approach is the earliest described
technique delivering the medication into the lumbar
epidural space from the sacral hiatus, requiring larger
volumes of medication in order to reach the target site
(7,611,614). It is considered the safest and easiest technique. With the interlaminar approach, the medication
is delivered more commonly into the posterior epidural
space, but often into the ventral epidural space, specifically with paramedian or parasagittal techniques
(614-617).
In the lumbar transforaminal approach, the needle
is inserted close to the nerve root, either superiorly or
inferiorly, described as supraneural or infraneural approaches (7,614,618-623). However, the supraneural
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approach, classically described as the safe triangle approach, has been associated with a multitude of complications (621-624). Consequently, multiple infraneural
approaches have been described (618-625). The major
described advantage of transforaminal epidural injection appears to be the anatomical position and accurate needle placement to enhance the effectiveness of
epidural injection, even though safety is questionable
with the supraneural approach when using particulate
steroids. When performed under fluoroscopic guidance,
superiority of any of the techniques has not been demonstrated conclusively in the lumbar spine.
In reference to thoracic and cervical transforaminal
epidural injections, these have been associated with a
multitude of complications (626-633).
Percutaneous epidural adhesiolysis, also known
as epidural neuroplasty, neurolysis, or lysis of epidural
adhesions is an interventional pain management technique that has emerged over approximately the last 30
years (634). The procedure is performed utilizing a reinforced catheter with mechanical adhesiolysis and with
injection of multiple fluids. The goals of this procedure
are not only to break down fibrous adhesions that may
prevent free movement of structures in the intervertebral foramina and in the bony intervertebral canal,
but also to remove any barriers or scars that prevent
application of medication to structures believed to be
the source of pain, and to provide targeted application
of local anesthetics, corticosteroids, and other agents
(72-76).

6.1 Mechanism of Action Local Anesthetics
and Steroids
Several manuscripts have been published evaluating the role of steroids and local anesthetics for epidural
injections. In a neural blockade, the rationale for injecting local anesthetic is to block sensory signals. Even
though they are often used for diagnostic purposes and
believed to provide a temporary effect in acute pain,
when used in chronic pain, they provide long-term
relief very much beyond its pharmacological duration
of action due to a decrease in sensitization and various
other mechanisms (7,8,102,609,610). In clinical practice,
steroids are typically combined with local anesthetics,
with hopes of prolonging the duration of pain relief
(56-58,60,61,102).
The rationale for neuraxial steroid use is primarily
based on the benefits of neural blockade, which include
pain relief that outlasts by hours, days, and sometimes
weeks. Neural blockade effectiveness is based on the
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postulation that it alters or interrupts nociceptive input,
reflex mechanism of the afferent limb, self-sustaining
activity of the neuronal pools in the neuroaxis, and
the pattern of central neuronal activities (55-62). Consequently, the pharmacological and physical actions of
corticosteroids, along with local anesthetics have been
the basis of such explanations.

6.1.1 Steroids
Corticosteroids in neuraxial blockade have been
postulated to reduce inflammation, either by inhibiting
the synthesis or release of a number of proinflammatory
substances, or by causing a reversible local anesthetic
effect (55-62). There are several modes of action of
corticosteroids including membrane stabilization, inhibition of neural peptide synthesis or action, blockade
of phospholipase A2 activity, local anesthetic effect,
prolonged suppression of ongoing neuronal discharge,
and suppression of sensitization of dorsal-horn neurons
(102,635-646). Corticosteroids inhibit phospholipase
A2, which converts membrane phospholipids into
arachidonic acid and lysophospholipids (639,641,647).
It is further followed by conversion to proinflammatory
eicosanoids, including prostaglandins, thromboxanes,
and leukotrienes. Pain is exacerbated and peripheral
nociceptors are sensitized by inflammatory mediators.
Thus, corticosteroids not only provide antiinflammatory
effects, but also inhibit ectopic discharges from nerve
fibers (641). Despite extensive use, there is no evidence
that steroid injections are disease-modifying agents
with a direct effect on pain generation or transmission,
with an exception of inflammatory conditions such as
rheumatoid arthritis (102). Further, there are no studies
demonstrating the anti-inflammatory role of steroids
or differentiation of inflammatory radiculopathies
from noninflammatory radiculopathies (54,56-59,639).
During the search for confirmation of the anti-inflammatory effect of steroids in epidural injections, multiple
explanations relied on inflammatory component in
lumbosacral radiculopathy. The first evidence suggesting inflammation in patients with radiculopathy was
published in 1981 (642). Ryan and Taylor (642) examined
samples of cerebral spinal fluid during administration
of intrathecal and epidural injections, and theorized
that inflammation was a critical component of radicular
pain, and that intraspinal steroids were likely to be most
effective when this inflammation was still acute, before
the pathology had progressed to nerve root fibrosis or
axonal death. This led to the classification of 2 categories of radiculopathy, compressive and inflammatory.
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Lindahl and Rexed (648) described inflammation,
edema, and proliferative or degenerative changes in biopsy samples from the posterior nerve roots of patients
undergoing laminectomy. In lumbar disc herniation and
radiculopathic pattern of symptoms, consideration for a
primary biochemical inducement of pain over a mechanical mechanism is a contemporary topic of spinal research.
Even then, the exact pathomechanism by which a degenerative intervertebral disc leads to neural inflammation
and pain had not been determined. Using modern techniques of chemical analysis, biochemical markers which
participate in the degenerative cascade and possibly with
onset of pain (649) can be identified. While, Scuderi et
al (649) were unable to identify the presence of inflammatory peptides in the epidural lavage of patients with
symptomatic radicular pain due to herniated disc disease,
de Souza Grava et al (650) indicated that specific cytokines
released during the inflammatory process induced by the
herniated intervertebral disc play a fundamental role in
the development of mechanical and thermal hyperalgesia and that the maintenance of this inflammation may
be the most important point for the chronification of the
pain. In addition, Shamji et al (651) concluded that there
was evidence of altered gait in a model of noncompressive disc herniation with radiculopathy in a rat model.
However, systematic inflammation was absent, but mechanical allodynia, local inflammation, and autoreactive
immune activation were observed. Cuéllar et al (652) also
developed an animal model for the study of biochemical
changes that occur in the epidural space after intervertebral disc herniation. The performed epidural lavage in 48
rats after L5 dorsal root ganglion exposure to autologous
nucleus pulposus illustrating nucleus pulposus causing the
elevation of IL-6, TNF-α, and IFN-γ - all attenuated by IFN-γ
blockade. However, Brisby et al (653) showed inconclusive
results after the assessment of proinflammatory cytokines
in cerebrospinal fluid and serum in 39 patients with disc
herniation and sciatica. They (653) showed that concentrations of IL-8 in cerebrospinal fluid were increased in 12 out
of 39 patients, and these increased levels of IL-8 correlated
to a short duration of pain and to more pronounced herniation with normal concentrations of IL-1β, IL-6, IFN-γ,
and TNF-α in cerebrospinal fluid and serum in almost all
patients with lumbar disc herniation. However, they were
unable to demonstrate any relationship between IL-8
concentrations in cerebrospinal fluid and pain intensity,
positive neurological findings, or a positive straight leg
raising test.
Thus, the role of various chemicals and inflammation
has been extensively investigated with discogenic pathol-
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ogy and radicular pain. The complex mechanism of discogenic pain includes chemical nociception leading to low
back pain with or without disc herniation (7,134-136,654658). The research in animals has shown upregulation of
various pain regulated molecules, such as calcitonin gene
related peptide and Substance P, in the dorsal root ganglions neurons innervating degenerated intervertebral
discs (7,657-659). In fact, in recent years epidural TNF-α
inhibitory injections have been utilized to treat lumbar radiculitis rather than epidural steroid injections (7,659-667).
In earlier studies, Berg (668) and Green (669)
observed a consistent reduction in the swelling of involved nerve roots coincidental with improvement in
the patient’s sciatic symptoms with steroid administration. Thus, it is postulated that corticosteroids reduce
inflammation either by inhibiting the synthesis or
release of a number of pro-inflammatory substances
or by causing a reversible local anesthetic effect
(514,638,641,644,646,670-683). The various modes of action of corticosteroids include membrane stabilization,
inhibition of neural peptide synthesis or action, blockade of phospholipase A2 activity, prolonged suppression of ongoing neuronal discharge, and suppression of
sensitization of dorsal horn neurons.
Epidural injections of betamethasone in a model
of lumbar radiculopathy showed a significant effect
on thermal hyperalgesia, while the administration of
intravenous methylprednisolone significantly reduced
the nerve root injury produced by epidural application
of autologous nucleus pulposus in a pig experimental
model (635-638,643-645). Another study concluded that
lipopolysaccharide accelerated the process of herniated
intervertebral disc resorption, whereas high-dose steroids suppressed the process (644). Research studying the
effects of local methylprednisolone on pain in a nerve
injury model by inducing peripheral mononeuropathy
showed that the heat hyperalgesia and mechano-allodynia, but not mechano-hyperalgesia were depressed
in the animals receiving corticosteroids; however, not in
those treated with saline, with the effect remaining during the 11 day test period (645). The effects of systemic
methylprednisolone on acute nociception and on pain
behavior in hyperalgesia were studied in normal and
neuropathic rats (646). The results showed that chronic
steroid treatment prevented the development of neuropathic edema and completely blocked neurogenic
extravasation; however, the findings also showed that
corticosteroids did not affect nociceptive thresholds in
normal or neuropathic hyperalgesic rats.
Ever since the descriptions of Hollander et al (647)
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in 1951, enthusiasm erupted with the temporary improvement of symptoms in many cases, but it was also
tempered by warnings of the possibility of increasing the
damage in joints subjected to excessive use in periods of
freedom from symptoms. Their early publication in 1951
(684) also noted that the results of treatment of the knee
have been more encouraging than those of treatment of
other joints, presumably because of the ease with which
injection of the knee joint can be accomplished.

6.1.2 Local Anesthetics
Local anesthetics have been used ever since the
discovery of the medicinal properties of cocaine, long
before the compound was brought to Europe for
its local anesthetic properties to be discovered (5658,102). Based on this foundation, regional anesthesia
developed into interventional pain management. In
1899, Tuffer (685) described therapeutic nerve blocks in
pain management using spinal injections of cocaine to
control pain from sarcoma of the leg. In 1903, Cushing
described pain relief with nerve blocks (686), along with
reports of trigeminal alcohol blockade (687).
The development of caudal epidural injections for
pain management began in 1901 (604-608) and interlaminar epidural injections in 1933 by Dogliotti (688).
The effectiveness of local anesthetics in chronic pain
is based on anti-inflammatory actions and the alteration of multiple pathophysiologic mechanisms including noxious peripheral stimulation, excess nociception
resulting in the sensitization of the pain pathways, and
excess the release of neurotransmitters causing complex
central responses including hyperalgesia or wind-up,
resulting in an increase in nociceptive sensitization of
the nervous system, and phenotype changes which are
also considered as part of the neuronal plasticity (5558,102,689-699). Sato et al (691) showed the prolonged
analgesic effect of epidural ropivacaine in a rat model
of neuropathic pain. Along those same lines, Tachihara
et al (692) provided evidence that there is a lack of additional benefit with nerve root infiltration for lumbar
disc herniation by the addition of steroids to lidocaine.

7.0 Diagnosis of Disc-Related Pathology,
Spinal Stenosis, and Radiculitis
Key Question 5: What are the noninterventional
diagnostic methods in disc related pathology, spinal stenosis, and post-surgery syndrome?
Spinal pain is one of the most common chronic pain
conditions. Intervertebral discs, facet joints, sacroiliac
joints, ligaments, fascia, muscle and nerve root dura have
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been shown to be capable of transmitting pain in the
spine with resulting symptoms of axial and extremity pain.
Disc herniation and spinal stenosis are diagnosed
with physical examination, radiological assessment, and
neurophysiological assessment. For chronic axial pain
without disc herniation or radiculitis, the precision diagnostic blocks applied include facet joint nerve blocks,
provocation discography, and sacroiliac joint blocks,
and to a lesser extent, lumbosacral selective nerve root
blocks or transforaminal epidural injections in the diagnosis of difficult radicular pain syndromes.

7.1 Lumbar Spine
7.1.1 History and Physical Examination
The assessment of differential diagnoses is based
on history, and physical examination which includes
neurological examination, motor examination, sensory
examination, reflex examination, and application of
provocative maneuvers including straight leg raising
test, crossed straight leg raising test, bowstring sign,
and slump test. Deyo et al (700) showed that sciatica
was highly sensitive for a clinically important herniated
disc, as was old age for spinal stenosis and compression
fractures. Subjective symptoms of numbness are considered reasonably sensitive (0.76), but not specific (0.33)
as a sign of radiculopathy (136,701). Objective signs of
numbness are reasonably sensitive, although numbness
is not specific as a sign of radiculopathy.
The sensory examination should cover the bilateral
lower extremities to evaluate for all dermatomal or more
diffuse sensory loss as seen in the peripheral neuropathies with a stocking distribution of loss. Dermatomes
may define the area of skin innervated by a single nerve
root or peripheral nerve. A simple sensory examination
involves testing for sensation for 3 dermatomes in the
lower extremity, L4, L5, and S1. Sensation may be evaluated using many different modalities, including vibration, proprioception, temperature, light touch, and pin
prick (702). The sensitivity and specificity of the sensory
examination in the diagnosis of lumbar disc herniation
has been described to range from 16% to 66% for sensitivity, and 51% to 86% for the specificity (702).
Radiation of pain needs to be carefully interpreted.
Somatic referred pain is mostly in the buttock or lower
extremity with any type of pain generators in the lumbar spine and should not be confused with radicular
pain. The cardinal distinctions lie in the quality of pain
and its behavior. Table 8 shows the differences between
radicular and somatic pain.
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Rubinstein and van Tulder (703) in a best
evidence review of diagnostic procedures for neck
and low back pain, showed that a number of factors can be identified which can assist the clinician
in identifying sciatica due to disc herniation or
serious pathology. However, they were unable to
show any evidence based on history leading to a
diagnosis not related to radicular pain. A neurologic and musculoskeletal examination may assist
in the diagnosis of radiculopathy or radicular pain
with identification of disc herniation at various
levels. Figure 14 illustrates the clinical features
of posterolateral lumbar intervertebral disc herniation. Straight leg raising or cross straight leg
raising and motor examination may be crucial in
the assessment of disc herniation. Table 9 shows
the diagnostic features for various levels of nerve
root involvement.
Radiculitis, radicular pain, or radiculopathy
may be seen not only with herniation of the
nucleus pulposus, but, also with central and foraminal spinal stenosis, nerve root entrapment
in the lateral recess, and other causes such as
spondylolisthesis, spondylolysis, facet joint cysts,
and epidural fibrosis, internal disc disruption, or
discogenic pain without involvement of other
structures.
The presence of radiating pain needs careful
evaluation and interpretation. Somatic type pain
referred into the buttock and lower extremity can
be expected with any of the pain generators of
the lumbar spine. Determining the difference between referred pain and radicular pain is critical
to arriving at the correct diagnosis and treatment
plan (7). Anatomically, somatic/referred pain
sources arise from the posterior segments or elements of the spine while radicular pain arises from
the anterior segments. Typically, the presenting

Table 8. Features of somatic and radicular pain.

Somatic or Referred Pain Radicular Pain
Posterior segment or element Anterior segment
Segment
Causes

Facet joint pain

Disk herniation

Sacroiliac joint pain

Annular tear

Myofascial syndrome

Spinal stenosis

Internal disk disruption
Symptoms
Dull, aching, deep

Sharp, shooting, lancinating

Like an expanding pressure

Like an electrical shock

Poorly localized
Quality

Modification

Radiation

Back worse than leg

Leg worse than back

No paresthesia

Paresthesia present

Covers a wide area

Well defined and localized

No radicular or shooting
pain

Radicular distribution

Worse with extension

Worse with flexion

Better with flexion

Better with extension

No radicular pattern

Radicular pattern

Low back to hip, thigh, groin

Follows nerve root
distribution

Radiation below knee
unusual

Radiation below knee
common

Quasisegmental

Radicular pattern

Uncommon

Probably

Only subjective weakness

Objective weakness

Atrophy rare

Atrophy possibly present

None

Commonly described, but
seen only occasionally

Only low back pain

Reproduction of leg pain

No root tension signs

Positive root tensions signs

Signs
Sensory
Alteration
Motor
Changes
Reflex
Changes
Straight Leg
Raises

Source: Manchikanti L, et al. Low back and lumbar radicular pain. In:
Manchikanti L, Christo PJ, Trescot AM, Falco FJE (eds). Clinical Aspects of Pain
Medicine and Interventional Pain Management: A Comprehensive Review. ASIPP
Publishing, Paducah, KY, 2011, pp 87-114 (136).

Table 9. Diagnostic features for various levels of nerve root involvement.

Nerve
Root

Pain

Numbness

Atrophy

Motor
Weakness

Screening
Examination

Reflexes

L3-4

L4

Low back; hip; anterolateral
thigh, medial leg

Anteromedial
thigh and knee

Quadriceps

Extension of
quadriceps

Squat and rise

Knee jerk
diminished

L4-5

L5

Above S1 joint; hip; lateral
thigh and leg; dorsum of foot

Lateral leg and
first 3 toes

Minor or
nonspecific

Dorsiflexion of
great toe and foot

Heel walking

None reliable

L5-S1

S1

Above S1 joint; hip;
posterolatera and thigh
leg; heel

Back of calf;
lateral heel and
foot; toe

Gastrocnemius
and soleus

Plantar flexion
of great toe and
foot

Walking on
toes

Ankle jerk
diminished

Herniation

Source: Manchikanti L, et al. Low back and lumbar radicular pain. In: Manchikanti L, Christo PJ, Trescot AM, Falco FJE (eds). Clinical Aspects of
Pain Medicine and Interventional Pain Management: A Comprehensive Review. ASIPP Publishing, Paducah, KY, 2011, pp 87-114 (136).
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Fig. 14. Clinical features of a posterolateral lumbar
intervertebral disc herniation.

Source: Manchikanti L, et al. Low back and lumbar radicular
pain. In: Manchikanti L, Christo PJ, Trescot AM, Falco FJE
(eds). Clinical Aspects of Pain Medicine and Interventional Pain
Management: A Comprehensive Review. ASIPP Publishing,
Paducah, KY, 2011, pp 87-114 (136). Reproduced with permission
from authors and Pain Physician journal.

symptoms of somatic or referred pain will be a deep dull
ache, while lightening like, sharp shooting pain is found
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with radicular pain. Finally, finding on examination with
somatic/referred pain will typically be without sensory,
motor or reflex changes while the opposite is true for
radicular pain (Table 8) (7).
Physical examination for lumbar radiculopathy related to disc herniation in patients with low back pain often provides inaccurate and incomplete information. In a
Cochrane database systematic review (704), the conclusion
of 16 cohort studies and 3 case-controlled studies, the authors concluded that in isolation diagnostic performance
of most physical tests (scoliosis, paresis or muscle weakness,
muscle wasting, impaired reflexes, sensory deficits) was
poor. Some tests (forward flexion, hyperextension test,
and slump test) performed slightly better, but the number
of studies was small. Most studies assessed the straight leg
raising test. The results in surgical populations were variable compared to those with imaging. In surgical populations, characterized by a high prevalence of disc herniation
(58% to 98%), the straight leg raise showed high sensitivity (pooled estimate 0.92, 95% CI: 0.87 to 0.95) with widely
varying specificity (0.10 to 1.00, pooled estimate 0.28, 95%
CI: 0.18 to 0.40). However, results of studies using imaging
showed more heterogeneity and poorer sensitivity. The
crossed straight leg raise showed high specificity of 0.90
with consistently low sensitivity (0.28). Tawa et al (705) in
a 2017 systematic review of accuracy of clinical neurological examination in diagnosing lumbo-sacral radiculopathy,
with inclusion of 12 studies assessed neurological examination. The diagnostic performance of sensory testing using
MRI as a reference standard demonstrated a sensitivity of
0.61 and a specificity of 0.63. Motor tests sensitivity was
poor to moderate, ranging from 0.13 to 0.61. They showed
that generally, the diagnostic performance of reflex testing was notably good with specificity ranging from 0.60
to 0.93 and sensitivity ranging from 0.14 to 0.67. They also
showed that the straight leg raise test recorded a mean
sensitivity of 0.84 and specificity of 0.78. Bellier et al (706)
assessed a range of the different nerve root movements
in cadavers to identify them during a passive straight leg
raise. They concluded that the lumbo-sacral nerve roots
in the spinal canal region move statistically significantly
in response to the clinically applied straight leg raise test,
except for L2 root during the left straight leg raise. This
movement was symmetric and greater when a bilateral
straight leg raise was applied. The anatomical results correlated with those observed empirically in clinical practice.
Thus, the results may be variable with multiple observers.
In an older study assessing the sensitivity and specificity of
the slump and straight raising test in patients with lumbar disc herniation (707), the authors concluded that the
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slump test might be used more frequently as a sensitive
physical examination tool in patients with symptoms of
lumbar disc herniations. However, they also concluded
that moving to its high specificity; the straight leg raise
may especially help identify patients who have herniations
with root compression requiring surgery. In this study, the
results found that the slump test was more sensitive 0.84
than the straight leg raise 0.52 in patients with lumbar disc
herniations; however, straight leg raise was found to be
a simply more specific test 0.89 than the slump test 0.83.
As mentioned above, central spinal stenosis can
present with radiculitis, however, it will more typically
present much differently than radiculopathy secondary
to disc herniation. This clinical presentation will typically
feature neurogenic claudication type symptoms. These
patients will have little pain at rest or while sitting,
however, upon standing and walking the patient will
report heaviness in the legs, sensation of the legs going
numb, and even the onset of low back pain. Classically,
these symptoms are consistent and reproducible with
the distance ambulated, relieved by forward flexion,
recumbency or sitting. Lateral recess stenosis and resultant nerve impingement in the foramen will present
with or without back pain and leg pain radiating into
the ankle or toes. Diagnosis of the other conditions
mentioned require radiologic evaluation. Certainly, radiologic evaluation can help to differentiate different
types of spinal stenosis from a lumbar disc herniation,
as well as conditions of the spine, which can result in
radicular pain (7).
Lateral recess stenosis with nerve entrapment
mostly presents without low back pain and rare muscle
weakness. The pain may radiate into the ankle and
occasionally into toes. Further, radiologic examination
often differentiates it from lumbar radiculopathy from
disc herniation.
The correlation of symptoms with MRI findings was
assessed by Albert et al (708) in a cross-sectional diagnostic accuracy study of adult patients with radicular leg
pain with positive neurological signs (average 2.8 signs
– hypoalgesia, diminished reflexes, muscle weakness,
positive straight leg raise test). They studied 93 patients
with their pain charts and MRI correlation in an MRI
confirmed single-level radiculopathy. The results show a
wide overlap in pain patterns from compromised L5 and
S1 nerve roots, but some distinguished features. The
pain patterns had approximately 50% to 80% overlap
with published dermatomes. However, clinicians were
unable to determine with any accuracy above chance
whether an individual pain drawing was from a person
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with a compromised L5 or S1 nerve root, and use of
composite pain drawings did not improve that accuracy.
As shown in Table 9, motor weakness may present at
all levels. Lumbar radiculopathy is usually characterized
by weakness affecting 2 or more muscles from the same
spinal segment, but different peripheral nerves (186).
Thus, an L5 radiculopathy may affect both the dorsal
flexors of the foot and toes (peroneal nerve) and abduction of the hip (superior gluteal nerve). Consequently,
strength examination should include the assessment of
hip flexors L1 to L3, quadriceps L2 to L4, tibialis anterior
L4 to L5, extensor hallucis longus L5, and the gastrocnemius – soleus (S1).
The sensitivity and specificity of muscle strength
testing in patients with lumbar radiculopathy has been
evaluated. Kerr et al (709) demonstrated reduced ankle
dorsiflexion in 54%, in plantar flexion 13% of those with
lumbar disc protrusions from L4 to S1 with an overall
specificity of 89%. Multiple studies have shown sensitivity as low as 20%, whereas, specificity as high as 99%.

7.1.2 Imaging
In managing low back pain, basic imaging with
plain films and advanced imaging with CT scan and MRI
are utilized. Due to its greater resolution of soft tissues
and interosseous tissues, MRI is considered superior to
CT scan for the demonstration of condition such as nerve
tumors, cysts, infection, and other disorders. However,
CT scan is superior to MRI in the demonstration of bone
and the preferred modality for diagnosing of complex
fractures or deformities. However, the studies show that
sensitivity and specificity for plain CT, CT myelography,
and MRI are the same, with an approximate sensitivity of 0.90 and specificity of 0.70 (710,711). Further, a
positive and negative predictive value of 0.82 is also the
same for all 3 modalities.
Studies in asymptomatic volunteers have shown a
high prevalence of disc abnormalities with a herniated
nucleus pulposus in 20% of individuals younger than 40
years and in 27% of individuals older than 40 years on
CT scan (711). MRI findings showed disc bulges and disc
herniations with increasing frequency with age, with
a high prevalence of asymptomatic disc herniations
(712,713). Further, a positive relationship with symptoms and disc herniation has been shown in some cases
even though it was not universal (714). The grading
of lumbar disc herniation and nerve root compression
(715) and interobserver and intraobserver variability in
MRI evaluation of patients with suspected disc herniation continues to be debated (716).
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7.1.3 Electrodiagnostic Studies

extremities. The distinguishing features of cervical radicular pain and somatic referred pain are illustrated in Table
10 (7). The cervical pain secondary to the disc can extend
to the upper back and head and is associated with referred
pain into the upper extremity. In the patients where disc
and facet related conditions co-exist, the differentiation
due to the overlapping symptoms can be challenging.
Radicular pain is most likely to travel below the elbow,
and somatic referred pain is most often limited to above
the elbow, but radicular pain may be restricted to the
upper back or shoulder girdle, and somatic pain may radiate below the elbow (134,373). In contrast to the lumbar
spine, paresthesia is considered to be more valid than the
distribution of pain. The distribution of paresthesia in the
hand is also considered more valid than the distribution of
paresthesia in the forearm. In addition, paresthesia, with
7.2 Cervical Spine
or without pain, occurs in 90% of patients with surgically
proven radiculopathy due to disc prolapse (498,718). Ap7.2.1 History and Physical Examination
proximately 45% of patients are unable to localize the
Cervical spine pain is a common clinical condition af- paresthesia to a distinct region; and they present with diffecting activities of daily living and QoL in people around fuse, nondermatomal symptoms. In general, paresthesia
the world. It can manifest as neck pain as well as pain in affecting the thumb or index finger is attributed to the C6
the shoulder, trapezius, scapular areas as well as the upper dermatome; the middle finger, with or without involvement of the index finger, is
assigned to the C7 dermatome;
Table 10. Distinguishing features of cervical radicular pain and somatic referred pain.
and the little finger is assigned
to the C8 dermatome (Fig. 15)
Somatic Pain
Radicular Pain
(7).
Facet joint pain
Disc herniation
Assessment of pain in the
Causes
Myofascial syndrome
Annular tear
Discogenic pain
Spinal stenosis
cervical region is based on a
patient’s history and an exDeep
Sharp
Shooting
Aching
tensive physical examination
Poorly localized
Well localized
which includes a neurological
Symptoms Quality
Neck worse than arm
Arm worse than neck
examination; motor examinaParesthesia are very reliable
No paresthesia
tion; sensory examination;
Covers a wide area
Well defined area
No radicular or shooting pain
Radicular distribution
reflex assessment; application
Worse with extension
Worse with flexion
of provocative maneuvers,
Modification
Better with flexion
Better with extension
including Spurling’s neck comNo radicular pattern
Radicular pattern
pression test, shoulder abducNeck to head, shoulder blades,
Follows nerve root distribution,
tion test, neck distraction test,
Radiation
upper back, radiation below elbow –
radiation below elbow common,
Lhermitte sign, Hoffman sign,
unusual, no radicular pain
radicular and shooting pain
and Addison’s test (719).
Signs
Table 11 shows the signs
Sensory alterations
Uncommon
Probable
and symptoms of nerve root
Only subjective weakness
Objective weakness
compression in the cervical reMotor changes
Atrophy is rare
Atrophy may be present
gion (7,314). Rubinstein and van
Commonly expressed but seen
Reflex changes
None
Tulder (703), in a best evidence
occasionally
review, showed that a positive
Source: Manchikanti L, et al. Neck and cervical radicular pain. In: Manchikanti L, Christo PJ, Trescot
Spurling’s, traction/neck disAM, Falco FJE (eds). Clinical Aspects of Pain Medicine and Interventional Pain Management: A Compretraction, and Valsalva can be
The utility of electrophysiologic studies has been
based on the ability to objectify abnormalities of nerve
conduction resulting from radiculopathy and to identify
the particular segment. Andersson and colleagues (717)
in a consensus summary on the diagnosis and treatment
of lumbar disc herniation concluded that, “although
neurophysiological testing is frequently used to diagnose
patients with radiculopathy associated with disc herniation, these tests are not clinically necessary to confirm the
presence of radiculopathy.” However, neurophysiologic
testing might be appropriate when the clinical situation
is less clearly delineated and for differentiation of disc
herniation from other neurologic disorders, such as neuropathy or peripheral nerve entrapment.

hensive Review. ASIPP Publishing, Paducah, KY, 2011, pp 35-60 (134).
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used to establish a diagnosis of cervical radiculopathy.
In a systematic review, the same authors found that no
single provocative test had both a high sensitivity and
high specificity (720). The Spurling’s test, neck traction
test (lifting the head and relieving pain), and Valsalva
maneuver were found to be highly specific.
The other existing literature appears to support
the high specificity, but indicates low sensitivity, and
good to fair inter-examiner reliability for Spurling neck
compression test, the neck distraction test, and shoulder
abduction (relief test) (721). For Hoffman’s sign, the existing literature does not address inter-examiner reliability,
but appears to indicate fair sensitivity and fair to good
specificity (719). Numbness in the upper limb is a reasonably reliable sign (722), even though it is not a universal
feature in patients with radiculopathy. The prevalence
rate of numbness has varied significantly from 24% to
48%, and 60% to as high as 86% (723). Numbness is most
often seen in the C6 and C7 dermatomes, indicating the
most frequent involvement of these nerve roots. The
predictive validity of numbness was calculated to be 0.7.
Consequently, Wainner and Gill (724) stated that with regard to cervical radiculopathy, many investigators believe
that, “given the paucity of evidence, the true value of the
clinical examination is unknown at this time.”
Along the same lines, in a manuscript published
in 2018, Thoomes et al (373) described the findings of a
systematic review examining the value of physical tests in
diagnosing cervical radiculopathy. They identified 5 diagnostic accuracy studies; however, only Spurling’s test was
evaluated in more than one study, showing a high specificity ranging from 0.89 to 1.00, with sensitivity ranging from
0.38 to 0.97. They also showed that no studies were found
that assessed the diagnostic accuracy of widely used neurological tests such as key muscle strength, tendon reflex-

es, and sensory impairments. They concluded that there
is limited evidence for the accuracy of physical examina-

Fig. 15. Dermatomal distribution of C4, C5, C6, C7 spinal
nerves.

Source: Manchikanti L, et al. Neck and cervical radicular pain. In:
Manchikanti L, Christo PJ, Trescot AM, Falco FJE (eds). Clinical
Aspects of Pain Medicine and Interventional Pain Management: A
Comprehensive Review. ASIPP Publishing, Paducah, KY, 2011, pp
35-60 (134). Reproduced with permission from authors and Pain
Physician journal.

Table 11. Signs and symptoms of nerve root compression of the cervical region.

Root
Involvement

Location
of Lesion

Referred Pain

C5

C4/5

Shoulder and
upper arm

C6

C5/6

Radial aspect of
forearm

C7

C6/7

C8

C7/T1

Motor Dysfunction

Sensory Dysfunction

Reflex Changes

↓ Upper and lateral aspect
of the shoulder

↓ Biceps reflex

Biceps and brachialis muscles
↓ flexion of the elbow and supination

Radial aspect of forearm

↓ Thumb reflex and
brachioradialis reflex

Dorsal aspect of
forearm

Triceps muscle
↓ extension of the elbow

↓ Index and middle digits

↓ Triceps reflex

Ulnar aspect of
forearm

Intrinsics of the hand
↓ adduction and abduction

↓ Ring and little digits

No change

Shoulder muscles
(deltoid-supraspinatus-infraspinatus)
↓ abduction and external rotation

Source: Manchikanti L, et al. Neck and cervical radicular pain. In: Manchikanti L, Christo PJ, Trescot AM, Falco FJE (eds). Clinical Aspects of Pain
Medicine and Interventional Pain Management: A Comprehensive Review. ASIPP Publishing, Paducah, KY, 2011, pp 35-60 (134).
www.painphysicianjournal.com
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tion tests for the diagnosis of cervical radiculopathy. They
further stated that when consistent with patient history,
clinicians may use a combination of Spurling’s, axial traction, and an arm squeeze test to increase the likelihood of
a cervical radiculopathy, whereas as a combined result of
4 negative neurodynamic tests (upper limb, neurodynamic
test, arm squeeze test, shoulder abduction (relief) test, and
traction-distraction test) and an arm squeeze test could be
used to rule out the disorder.

7.2.2 Imaging
In reference to imaging, Rubinstein and van Tulder
(703), in a best evidence review of diagnostic procedures
for neck and low back pain, concluded that in patients 50
years of age or older, plain spinal radiography together
with standard laboratory tests are highly accurate in
identifying the underlying systemic disease; however,
plain radiography is not a valuable tool for nonspecific
neck pain. They also showed that no systematic reviews
were identified which examined the diagnostic accuracy
of diagnostic imaging in those with neck pain.
When applicable, the American College of Radiology recommends a cervical spine series of x-rays as
an initial study including lateral, anteroposterior, and
oblique views. Disc-space narrowing, subchondral sclerosis, and osteophyte formation can be evaluated on
lateral views. Attention to comparing disc height at one
level to adjacent levels as well as foraminal stenosis can
be pertinent in some cases (725,726). CT imaging may be
required to visualize C7 adequately. Flexion and extension and lateral bending films can be used to diagnose
instability.
Based on the above discussion, plain radiography is not of much significant use in neck pain or
radiculopathy. Myelography is an invasive and stressful investigation. This can show the deformations
produced by intradural, dural, and some extradural
lesions of the cervical vertebral canal. However, it does
not demonstrate a lesion directly, and it demonstrates
those affecting the lateral reaches of the cervical spine
nerves poorly, if at all (727). Conventional CT scan provides axial images, in which the lateral reaches of the
intervertebral foramina can be seen. CT myelography is
considered to be an accurate and reliable test and has
proven to be superior to myelography in the diagnosis
of cervical disc protrusions; however, it is an expensive
and invasive test. MRI is the choice of imaging in the
modern era, replacing myelography, CT scan, and CT
myelography. MRI is considered to be as accurate as
CT myelography for detecting cervical nerve root com-
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pression, even though it may be slightly inferior for
detecting bony impingement of nerve roots (545,728).
As observed with MRI, the prevalence of numerous
abnormalities of the cervical spine in asymptomatic
individuals is a concern (546,728,729). Boden et al (526)
demonstrated in a study of asymptomatic subjects,
10% of patients under age 40 had disc herniations, and
in patients over 40, 20% have foraminal stenosis and
8% had disc herniations. Hence, a diagnosis of cervical
radicular pain is considered definite only after careful evaluation and corroboration of history, physical
examination, imaging, electrodiagnostic and in some
cases, diagnostic injectional studies.

7.2.3 Neurophysiologic Testing
Neurophysiologic testing with electromyography
and nerve conduction studies offers no advantage in
radiculopathy. However, they are of significant value
in the identification and differentiation of cervical
radiculopathy with a peripheral lesion (549,730,731).
According to Narayanaswami et al (730), the specificity
of EMG for diagnosing radiculopathy has been reported
to be 77%, while average sensitivity is 73%. This review
further noted the sensitivity lower, 40% for mild to
moderate radiculopathy and higher, 80% moderate to
severe radiculopathy. The diagnosis changed in only 2/60
cases with the addition of clinical information. Intrarater reproducibility was 80%, 87% for radiculopathy
and 73% for normal studies. Inter-rater agreement was
63%, 70% for radiculopathy and 53% for normal studies. Inter-rater agreement for denervation was 90% and
re-innervation was only 60%. They further noted the 2
to 3-week delay in the onset of the positive sharp waves
and fibrillation potentials could yield falsely negative
results done at onset of radiculopathy. In their 2011
clinical guidelines, the North American Spine Society
notes insufficient evidence to make a recommendation
for or against the use of electromyography for patients
in whom the diagnosis of cervical radiculopathy is unclear after clinical examination and MRI (540).
The most common causes of cervical nerve root
compression are cervical spondylosis, disc degeneration,
disc herniation, and spinal stenosis. However, numerous
other causes exist. Radiculopathy is a shooting, radiating pain that extends into the hand, or with paresthesia
in forearm and hand, accompanied by objective neurologic signs with sensory loss, objective motor weakness,
or hyporeflexia. In difficult cases, without radicular
symptoms, diagnostic interventions applied include very
rarely selective nerve root blocks, associated with high
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risk, and more commonly, cervical provocation discography. Thus, for these guidelines cervical nerve root blocks
have not been assessed.
In most cases, cervical disc herniation, spinal stenosis, radiculitis, and symptomatic spondylosis are diagnosed by imaging and neurophysiologic testing. However, when there is no correlation between radiologic
pathology and clinical assessment, cervical provocation
discography and cervical selective nerve root blocks
have been recommended (127,732,733).

7.3 Thoracic Spine
7.3.1 History and Physical Examination
Assessment is based on history, physical examination, neurological examination, and imaging. Quite
often it is difficult to identify the differences between
somatic and radicular pain which is more complex in
the thoracic spine than lumbar or cervical spine in
that symptoms are similar in various conditions in the
thoracic spine based on the description of neurological
myotomes and dermatomes in multiple reviews and
textbooks. Neurological assessment includes tone, coordination, proprioception, and abdominal and lower
limb reflexes. As it is well known, the plantar reflex is
particularly important in assessing spinal cord function.
Dura mater signs include neck flexion and the slump
test (135).

7.3.2 Imaging
In reference to imaging, age-related changes are extremely common in the thoracic spine in asymptomatic
subjects. The great majority of patients with radiologic
osteoarthritis are asymptomatic. A high prevalence of
anatomic irregularities has been found in asymptomatic
patients (734,735). Even though plain radiograph is the
most common imaging technique, it does not satisfy the
objective of identification of the cause of the pain and
there is concern that plain radiographs are not sensitive enough to exclude disease. CT myelography is an
alternative investigation in patients who have contraindications to MRI (736). MRI though commonly utilized,
raises concerns that it is too sensitive, thus giving rise to
false-positive findings. In most instances, it can reliably
distinguish infection, fracture, and tumor (726).

7.3.3 Neurophysiologic Testing
The utility of electrophysiologic/electrodiagnostic
studies have been based on the ability to objectify abnormalities of nerve conduction and electromyography
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resulting from radiculopathy and to identify the particular segment.
Although the majority of patients who are diagnosed with thoracic spine pain due to the previously
mentioned conditions, may undergo conservative modalities and treatments (737). These may also include
noninvasive interventions, and are based on diagnostic
imaging, as well as in some cases noninvasive diagnostic
interventions (737).
In the cases of patients where further diagnostic
procedures, separate from imaging need to be performed, may require diagnostic interventions with
provocation discography to identify discogenic pain
and/or controlled diagnostic facet joint nerve blocks to
diagnose or eliminate facet joint pain (737).

8.0 Therapeutic Epidural Interventions
Key Question 6: Are the available therapeutic
epidural injections and adhesiolysis in managing
chronic spinal pain effective?
Epidural interventions are provided through caudal,
interlaminar, and transforaminal approaches. Percutaneous adhesiolysis is provided through caudal, interlaminar and transforaminal approaches in the lumbar
spine. Inherent variations, differences, advantages, and
disadvantages applicable to all epidural interventions,
including percutaneous adhesiolysis, with assessment of
effectiveness and outcomes, all of the procedures are
considered as separate entities. Furthermore, response
is also considered separate, along with indications for
various pathological conditions (disc herniation and/or
radiculitis, central spinal stenosis, foraminal stenosis,
post-surgery syndrome, and discogenic pain without disc
herniation) which are variable. Consequently, outcomes
are assessed based on pathology for each approach.

8.1 Evidence Review and Synthesis
Methodology is described in Section 2. Briefly,
identification of systematic reviews and studies for the
review, which included relevant RCTs and observational
studies when indicated with description of appropriate
outcomes and follow-up was performed. All the studies,
including systematic reviews, RCTs, and observational
studies must have included the primary outcome parameter of pain relief and other secondary outcomes
such as functional status improvement. Short-term relief
was considered as less than 6 months of improvement
in pain and function, whereas at least one year of pain
relief with improvement in functional status was considered as long-term improvement.
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As described in the methodology section: literature
search, search strategy, methodologic quality or bias assessment, data collection and analysis were performed.
If each region had at least 5 RCTs meeting the inclusion criteria, no observational studies were included.
However, if there were less than 5 in RCTs, observational
studies are considered. Assessment was limited to caudal, interlaminar, and transforaminal in the lumbar
region, along with percutaneous adhesiolysis in the
lumbar region. In cervical and thoracic regions, only
interlaminar epidural procedures were assessed.

8.1.1 Literature Search
Available published literature in different languages and from all countries was considered for inclusion
in the study provided it discussed relevant interventions
with outcome evaluations. The literature search included the period from 1966 through November 2020, and
was performed utilizing the following sources:
1. PubMed at https://pubmed.ncbi.nlm.nih.gov/
2. Cochrane Library at https://cochranelibrary.com/
3. Systematic reviews and cross references
4. Google Scholar at https://scholar.google.com/
5. Clinical trials at https://clinicaltrials.gov
6. All other sources including non-indexed journals
and abstracts
The search was filtered to identify RCTs and systematic reviews.

8.1.2 Search Strategy
The search strategy emphasized chronic spinal pain
conditions and therapeutic epidural injections including
caudal, interlaminar, transforaminal or percutaneous
adhesiolysis interventional approaches.
Search criteria were as follows: (((((((((((((((((chronic
low back pain) OR chronic mid back OR upper back
pain) OR chronic neck pain) OR disc herniation) OR discogenic pain) OR herniated lumbar discs) OR nerve root
compression) OR lumbosciatic pain) OR postlaminectomy) OR lumbar surgery syndrome) OR cervical surgery
syndrome) OR thoracic surgery syndrome) OR radicular
pain) OR radiculitis) OR sciatica) OR spinal fibrosis) OR
spinal stenosis) AND ((((((((((epidural injection) OR perineural injection) OR interlaminar injection) OR periradicular infiltration) OR transforaminal injection) OR caudal injection) OR percutaneous adhesiolysis) OR epidural
neuroplasty) OR facet joint adhesiolysis) OR “Injections,
Epidural”[Mesh]) and applied Filters for Clinical Study,
Clinical Trial, Meta-Analysis, Randomized Controlled
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Trial, Review, Systematic Review, Technical Report, Twin
Study, Validation Study Sort by: Publication Date

8.1.3 Methodologic Quality or Bias Assessment
Methodologic quality assessment of RCTs was performed using Cochrane review criteria and the IPM-QRB
criteria for RCTs.
Quality assessment of systematic reviews was performed into 3 categories:
1. Low-quality: This category with either a systematic
review or meta-analysis, with conversion of studies
or transferring them into a different category, such
as placebo to active control, against the intent of the
authors of the original manuscripts, without consent,
and without STRONG scientific basis, even though
they may be of high, moderate, or low methodologic
quality based on PRISMA, AMSTAR or SIGN.
2. Moderate quality: This category included the majority of the systematic reviews, methodologically
sound, which followed the appropriate principles
without violation of practices, with either a systematic review or meta-analysis with conventional
dual-arm analysis only.
3. High-quality: In this category, the systematic reviews methodologically sound, with inclusion of
appropriate, high-quality principles, with conventional dual-arm meta-analysis and single-arm metaanalysis without violation of standards and keeping
the intent of the original manuscripts.
Systematic reviews and meta-analysis were performed if they were not performed in the past.

8.1.4 Results
Our comprehensive literature search criteria lead to
the inclusion of 47 systematic reviews (56-58,60-68,7077,81,83,87,155,188,271,615,667,738-756). The results
are shown in Fig. 16.

8.2 Systematic Reviews
We identified 47 systematic reviews, ranging from
evaluating the placebo effect of sodium chloride solution to multiple network analyses, comparative analysis
of local anesthetics and steroids, particulate versus
nonparticulate steroids, technical comparisons of 3 approaches, and effectiveness in various conditions.
Among major systematic reviews comparing multiple modalities, 4 systematic reviews met inclusion
criteria (99-101,155,753).
Guo et al (101), in a network meta-analysis compar-
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ing the efficacy and tolerability of the treatments
for sciatica, concluded that
epidural steroid was recommended as a good intervention due to superiority in
reducing ODI. Further, in
this manuscript, they also
identified intravenous and
subcutaneous
anti-TNF-α
as the optimal treatment
for both acute and chronic
sciatica patients.
Lewis et al (99,100) in
a systematic review and
network
meta-analysis
of comparative clinical
effectiveness of management strategies for sciatica,
including surgical interventions, concluded that this
was the first manuscript
comparing many different
strategies for sciatica in
the same systematic review
and meta-analysis. Their
findings supported the efFig. 16. Flow diagram illustrating the literature used for evaluating therapeutic lumbar, cervical,
fectiveness of epidural inand thoracic epidural.
jections in the same line as
disc surgery and nonopioid
medication.
A single systematic review of high-quality by
Lee et al (753) comparing the nonsurgical treatments for patients with radicular pain from lumbosacral Manchikanti et al (56) evaluated if epidural injection
disc herniation concluded that epidural injection was of sodium chloride solution was a true placebo or it is
strongly recommended with high degree of evidence an active control agent. In this systematic review, they
and transforaminal approach was more strongly recom- also performed conventional dual arm and a single arm
mended than caudal approach.
analysis. In this analysis, they used 20% improvement
Cho et al (155) also performed a systematic review from baseline pain scores or disability as clinically sigof treatment outcomes for patients with failed back nificant parameter, even though in all other reviews,
surgery syndrome and concluded that percutaneous ad- they used 50% improvement in pain and disability as
hesiolysis provided better improvement than spinal cord the criterion standard. They included 8 trials meeting
stimulation. Cho et al showed in this review significant inclusion criteria, with 2 trials utilizing fluoroscopic imevidence for both percutaneous adhesiolysis and spinal aging and one study utilizing ultrasound. With dual arm
cord stimulation with a recommendation of Level A for meta-analysis, there was no significant difference beepidural adhesiolysis for 6 to 12 months of pain relief tween epidural sodium chloride solution and epidural
and functional improvement and Level B for spinal cord steroids with sodium chloride solution. However, with
single arm analysis, both epidural saline and epidural
stimulation.
Among the 47 systematic reviews, 3 systematic re- steroids with saline were effective in reducing 20% of
views addressed the questions related to placebo and pain; however, only reducing disability scores by 10% to
active-control agents (56-58).
12%. The authors concluded that both epidural saline
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and epidural steroids with saline showed effect beyond
placebo with strong evidence, that neither epidural
saline, nor epidural steroids with saline or placebo and
that both are effective.
One such systematic review and meta-analysis by
Manchikanti et al (57) assessed the effectiveness of
epidural bupivacaine, with or without steroids, administered for low back and lower extremity pain. It included
4 independent studies; one on interlaminar approach
and three on transforaminal epidural injections, all of
which were ranked as high-quality based on Cochrane
review criteria and IPM-QRB criteria. In this review also,
the authors utilized a conventional dual arm and single
arm meta-analysis showing significant effectiveness of
both bupivacaine and bupivacaine with steroids with
a single arm analysis, even though both of them were
similar with dual arm analysis. The review concluded
that epidurally administered bupivacaine acts as an
active agent rather than a placebo (Level I evidence),
and that bupivacaine administered alone was almost
equally effective as when administered with steroids
(Level II evidence). These findings clearly show that local
anesthetic is not a placebo and the approach in all the
active-controlled trials with local anesthetic converting
into placebo-controlled with conclusion of local anesthetics as ineffective leads to inappropriate conclusions
and misinformation (67-69,80).
A similar systematic review and meta-analysis by
Knezevic et al (58) of high-quality investigated the
evidence supporting the effectiveness of epidural lidocaine, with or without steroids, in managing spinal
pain. In this analysis, the authors utilized extensive
methodologic quality assessment criteria, along with
conventional dual arm and single arm meta-analysis.
Of the 15 manuscripts meeting the inclusion criteria, 4
addressed caudal epidural injections, 2 lumbar transforaminal injections and 5 lumbar interlaminar epidural
injections. The results showed similar improvements
in pain and function with the epidural administration
of lidocaine alone or with steroids, both for short-and
long-term (Level II evidence). This study also once again
demonstrated that utilizing single arm analysis clear effect of each modality was demonstrated with lidocaine,
as well as lidocaine with steroids. It is inappropriate to
judge that lidocaine is a placebo. They also showed lack
of publication bias. Consequently, both had similar effectiveness, but translated into lack of effectiveness of
any modality with negative conclusions. Once again, this
study clearly shows that local anesthetic lidocaine is not
placebo and it is inappropriate assessments performed
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provides erroneous conclusions and misinformation.
Similar to the above manuscripts, a systematic review and meta-analysis by Lee at al (61), which was of
moderate quality, assessed the effectiveness of epidural
injections consisting of local anesthetic or saline with
or without steroids for the management of lumbosacral disc herniation. The qualitative study included 14
manuscripts, and the quantitative study included 13
manuscripts. The included studies were considered as
high-quality, but the evidence was deemed moderate
due to inconsistencies and lack of single arm analysis.
The study found that the addition of steroids to local
anesthetic or saline provided better effectiveness compared to injections of local anesthetics or saline without
steroid, at 6-month follow-up to one year, with no significant differences after one year.
Mesregah et al (64), in a moderate quality review,
also evaluated the clinical effectiveness of interlaminar
epidural injections of local anesthetic with or without
steroids for managing chronic pain utilizing 4 studies
available meeting inclusion criteria, they showed the
addition of steroids to anesthetic injected was not associated with better pain and functional score outcomes
compared with anesthetic injected alone in patients
with chronic neck pain based on conventional dual arm
analysis. Overall, the conclusions are similar to other systematic reviews shown above indicating local anesthetic
lidocaine is not a placebo. Such conclusions are misleading and are misinformation.
Zhao et al (65) in a systematic review and conventional meta-analysis of moderate quality confirmed the
similar effects associated with lidocaine alone versus in
combination with steroids in the management of lumbar disc herniation and lumbar central spinal stenosis
with the inclusion of 7 trials. These results again confirm
the impressions shown above.
Bicket et al (66) in a moderate quality systematic
review and meta-analysis evaluating the “control” injections in RCTs included 43 studies with 3,641 patients.
Under the control injections, they included sodium
chloride solution, as well as local anesthetic solutions.
Nevertheless, they concluded that epidural nonsteroid
injections may provide improved benefit compared with
nonepidural injections on some measures. However,
they have not performed a single arm analysis. They also
have not utilized appropriate methodologic criteria.
In addition, they utilized manuscripts which included
epidural injections performed without fluoroscopy.
Even then, in other manuscripts published by Cochrane
review (68,69), one of the senior authors of the above
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manuscript (66) as a coauthor claimed that due to lack
of effectiveness of local anesthetics, they were considered as placebo, providing conflicting and contradicting
information, leading to inappropriate conclusions and
misinformation to communities in general.
Manchikanti et al (76) in a moderate quality review
also published a comparison of efficacy of saline, local
anesthetics, and steroids in epidural and facet joint
injections for the management of spinal pain in a systematic review of RCTs; however, without meta-analysis.
They included a total of 13 trials. They showed the effectiveness of local anesthetic alone and local anesthetic
with steroids to be equally effective except in lumbar
disc herniation, where the superiority of local anesthetic
with steroids was demonstrated in short-term followup, whereas there was no difference with long-term
follow-up.
Shanthanna et al (102) in an extensive high-quality
systematic review and meta-analysis of RCTs assessed
the effectiveness of the addition of corticosteroids to
local anesthetics for chronic noncancer pain injections.
They included 71 trials and reached the conclusion that
addition of corticosteroids to local anesthetics has only
small benefits and a potential for harm. They further
concluded that injection of local anesthetic alone could
be therapeutic, beyond being diagnostic. They recommended that a shared decision based on patient preferences should be considered and high doses must be
avoided, along with a series of steroid injections.
Multiple systematic reviews were conducted assessing the effectiveness beyond comparison of local anesthetic alone or local anesthetic with steroids. Among
these, 2 moderate quality systematic reviews (60,76)
assessed multiple spinal regions. The description of the
manuscript by Manchikanti et al (76) is provided above.
The results applied to multiple spinal regions. Similarly,
Kaye et al (60) assessed the efficacy of epidural injections in managing chronic spinal pain utilizing a best
evidence synthesis with assessment of multiple spinal regions. This systematic review was performed, however,
without meta-analysis. It was considered as a moderate
quality publication. In this review, they included 52
RCTs with a placebo control or an active control design
meeting inclusion criteria. The results showed that the
evidence in managing lumbar disc herniation or radiculitis was Level II for long-term improvement, either with
caudal, interlaminar, or transforaminal epidural injections with no significant differences among the groups.
The evidence was Level II for long-term management
of cervical disc herniation with interlaminar epidural
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injections. The evidence was Level II to III in managing
thoracic disc herniation with an interlaminar approach.
The evidence was Level II for caudal and lumbar interlaminar epidural injections with Level III evidence for
lumbar transforaminal epidural injections for lumbar
spinal stenosis. The evidence was Level III for cervical
spinal stenosis management with interlaminar epidural
injection. They also showed evidence of Level II for axial
or discogenic pain without facet arthropathy or disc
herniation treated with caudal or lumbar interlaminar
epidural injections in the lumbar region, whereas it was
Level III in the cervical region treated with cervical interlaminar epidural injections. The evidence for post-lumbar surgery syndrome was Level II with caudal epidural
injections and for post cervical surgery syndrome. It was
Level III with cervical interlaminar epidural injections.
Among the multiple systematic reviews available,
the majority were conducted in the lumbar spine. In
addition, systematic reviews included prevention of
surgery with epidural injection administration, comparisons between steroids (particulate vs. nonparticulate
steroids), the role of etanercept, and comparative analysis of techniques.
Lee et al (62) conducted a systematic review of 27
studies to compare the benefits of transforaminal versus
interlaminar epidural injections in patients with lumbosacral disc herniation in this moderate quality systematic review. Despite the low-grade evidence due to the
inconsistency and imprecision of the included studies,
the authors reported more favorable, though not significant, outcomes for the transforaminal epidural for
short-term (2 weeks to 1 month) and long-term (4 to 6
months) pain reduction, as well as short- and long-term
functional improvement.
Similar to the above review, Lee et al (63), in a
moderate quality systematic review and meta-analysis,
compared clinical efficacy of transforaminal and caudal
epidural steroid injection in lumbar and lumbosacral
disc herniation. In this assessment, they utilized 6 studies, showing 4 articles supporting the superiority of
transforaminal epidural injection over caudal epidural
injection, one article showed no significant difference,
and one article supported the superiority of caudal
epidural steroid injection to transforaminal epidural injection. Even though they concluded that meta-analysis
showing short- and long-term trends towards better
clinical efficacy with transforaminal epidural injections
than caudal epidural injections, there was no statistical
significance, and the evidence level was low because of
inconsistencies and imprecisions.
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Manchikanti et al (75) performed a moderate quality systematic review without meta-analysis assessing
short and long-term relief for lumbar disc herniation.
With literature search up to June 2013, they included
23 RCTs of high and moderate methodologic quality
for analysis. The results showed that evidence for the
efficacy of all 3 approaches for epidural injection under fluoroscopy was strong for short-term (less than 6
months) and moderate for long-term (greater than 6
months) based on the Cochrane rating system with 5
levels of evidence best evidence synthesis.
Manchikanti et al (81) performed a comparative
systematic review and meta-analysis assessing epidural
injections for lumbar radiculopathy and spinal stenosis
in response to a publication by Chou et al (80). Chou
et al converted all active-controlled trials into placebocontrol with inappropriate conclusions as others (67-69).
In a high-quality comparative systematic review and
meta-analysis, Manchikanti et al (81) included 39 RCTs
with 9 placebo-controlled trials evaluating epidural
corticosteroid injections, either with sodium chloride
solution injection or bupivacaine compared to placebo
injections. In addition, they used 12 studies comparing
local anesthetic alone to local anesthetic with steroids.
They also performed a meta-analysis of 5 studies utilizing sodium chloride or bupivacaine with steroid showing
lack of efficacy. A comparison of lidocaine to lidocaine
with steroids in 7 studies showed significant effectiveness from baseline to long-term follow-up periods. Meta-analysis showed a similar effectiveness for pain and
function without noninferiority of lidocaine compared
to lidocaine with steroids at 3 months and 12 months.
This review highlighted the differences between appropriate and inappropriate analysis and reviewers of systematic reviews downgrading the manuscripts without
appropriate information and most importantly, utilizing
lidocaine as a placebo.
Manchikanti et al (77) in a moderate quality systematic review assessed the efficacy of epidural injections
in the treatment of lumbar central spinal stenosis. With
assessment through 2014, the author showed Level II evidence for long-term improvement for caudal and lumbar
interlaminar epidural injections, whereas they showed
Level III evidence for transforaminal epidural injections
for short-term improvement only. They also concluded
that the interlaminar approach appears to be superior to
the caudal approach and the caudal approach appears to
be superior to the transforaminal approach.
Bhatia et al (754) in a moderate quality systematic
review and meta-analysis assessed the effectiveness of
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transforaminal epidural steroid injections for treating
lumbosacral radicular pain from herniated intervertebral discs. They included 8 RCTs. They concluded that
transforaminal epidural steroids provide modest analgesic benefit at 3 months in patients with lumbosacral
radicular pain secondary to herniated intervertebral
discs, but they have no impact on physical disability or
incidence of surgery. There was a high degree of heterogeneity among the publications.
Liu et al (752) evaluated the effectiveness of transforaminal versus caudal routes for epidural steroid
injections in managing lumbosacral radicular pain, in a
moderate quality systematic review and meta-analysis
in 2016. They utilized 6 prospective and 2 retrospective
studies involving 664 patients. They concluded that
both transforaminal and caudal approaches are effective in reducing pain and improving functional scores,
and they also demonstrated similar effectiveness in the
management of lumbosacral radicular pain, in contrast
to Lee et al (63).
Meng et al (750) evaluated epidural injections with
or without steroids in managing chronic low back pain
secondary to lumbar spinal stenosis in a low-quality
systematic review. Overall, they included 13 RCTs; however, some of them were duplicates. They concluded
that both epidural injections with steroids or with local
anesthetic alone provided significant pain relief and
functional improvement in managing chronic low back
pain secondary to lumbar spinal stenosis, and the inclusion of steroids confers no advantage compared to local
anesthetic alone. This is another manuscript emphasizing that lidocaine is not a placebo.
Sharma et al (743) assessed the effectiveness and
risks of fluoroscopically guided lumbar interlaminar
epidural steroid injections in a systematic review with
comprehensive analysis of published data in a lowquality systematic review. They assessed 71 primary
studies. They reported that there were no explanatory
or placebo-controlled studies and all pragmatic studies
identified were of low-quality, yielding evidence comparable to observational studies. However, they have
not performed methodologic quality analysis and also
inappropriately assessed the RCTs converting them into
active-controlled RCTs. Nevertheless, they concluded
that the body of evidence regarding the effectiveness of
fluoroscopically guided interlaminar epidural steroid injections is of low-quality. They also concluded that studies suggested a lack of effectiveness of fluoroscopically
guided lumbar interlaminar epidural steroid injections
in treating primarily axial pain, regardless of etiology.
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They further commented that most studies on radicular pain due to lumbar disc herniation and stenosis do,
however, report statistically significant short-term improvement in pain. Their analysis and conclusions are
rather confusing and indicates their clear bias towards
transforaminal epidural injections.
Smith et al (742) described transforaminal injections
of steroids for treatment of radicular pain performed a
comprehensive review of the published data. However,
they considered it to be a comprehensive systematic
review; however, it appears to be a narrative review or
very low-quality systematic review. They concluded that
there was strong evidence that lumbar transforaminal
epidural injection of steroids is an effective treatment
for radicular pain due to disc herniation. There is lack of
high-quality evidence demonstrating their effectiveness
for the treatment of radicular pain due to spinal stenosis, though small studies suggest a possible benefit.
They also made a statement that lumbar transforaminal injection of nonparticulate steroids is as effective
as injection with particulate steroids. Apart from lack
of methodologic quality assessment and lack of metaanalysis, their bias is clear in favor of transforaminal
epidural injections.
The same group of authors from the Spine Intervention Society (SIS) performed a systematic review
with comprehensive analysis of the published data of
the effectiveness and risks of nonimage guided lumbar
interlaminar epidural steroid injections. With inclusion
of a large number of publications (92), they concluded
that in patients with lumbar radicular pain secondary
to disc herniation or neurogenic claudication due to
spinal stenosis, nonimage guided lumbar interlaminar
epidural steroid injections appear to have clinical effectiveness limited to short-term pain relief. Therefore,
in a contemporary medical practice, these procedures
should be restricted to the rare settings where fluoroscopy is not available. However, these results are similar
to the results they published with fluoroscopy guided
lumbar interlaminar epidural steroid injections (743)
raising multiple questions of their own biases.
Zhai et al (738) evaluated epidural injections with
or without steroid in managing chronic low back and
lower extremity pain with a meta-analysis of RCTs in a
low-quality assessment. The authors utilized multiple
duplicates and have not performed single arm analysis.
Nevertheless, this meta-analysis confirms that epidural
injections of local anesthetic with or without steroids
have beneficial but similar effects in the treatment of
patients with chronic low back and lower extremity pain.
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Yang et al (739) assessed epidural steroid injection
versus conservative treatment for patients with lumbosacral radicular pain with a meta-analysis of RCTs in a
moderate quality publication. With the inclusion of 6
RCTs, they concluded that the use of epidural steroid
injections is more effective for alleviating lumbosacral
radicular pain than conservative treatment in terms
of short-term and intermediate-term. In addition, the
patients also reported more successful outcomes after
receiving epidural steroid injections when compared to
conservative treatment. However, this effect was not
maintained at long-term follow-up.
Wei et al (740) published comparison of transforaminal versus interlaminar epidural steroid injections
in low back pain with lumbosacral radicular pain in a
moderate quality meta-analysis of the literature in
2016. They included 931 patients from 9 RCTs and 4
observational studies. They concluded that transforaminal epidural steroid injection to manage low back pain
provided superior short-term pain relief and equal functional improvement when compared to interlaminar
epidural injection. There was no statistically significant
difference between groups with regard to procedure,
frequency, surgery rate, and ventral epidural spread.
Pairuchvej et al (744) performed a systematic review
and meta-analysis of moderate quality comparing short
and mid-term outcomes of lumbar transforaminal epidural injections with preganglionic and postganglionic
approach in lumbosacral radiculopathy published in
2018. They concluded that postganglionic epidural steroid injection has a statistically significant higher chance
of effectiveness when compared to preganglionic epidural steroid injection. They concluded that in terms of
pain scores and complications, there were no statistically
significant differences between the 2 groups. The results
were generally homogenous and with little publication
bias, they believed that these should be generalizable.
Due to multiple complications related to transforaminal
epidural injections with particulate steroids, infraneural
and supraneural approaches have been suggested. Preganglionic refers to supraneural approach and postganglionic refers to infraneural approach.
Manchikanti et al (70) performed a systematic review without meta-analysis for epidural injections to
assess if they provide long-term relief of neck and upper
extremity pain. They included 7 manuscripts meeting
inclusion criteria. Of these, 4 assessed the role of interlaminar epidural injections for managing disc herniation
or radiculitis, and 3 assessed these injections for managing central spinal stenosis, discogenic pain without facet
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joint pain, and post-surgery syndrome. They concluded
that with qualitative best evidence synthesis, there is
Level II evidence for the efficacy of cervical interlaminar
epidural injections with local anesthetic with or without
steroids, based on at least one high-quality relevant RCT
in each category for disc herniation, discogenic pain
without facet joint pain, central spinal stenosis, and
post-surgery syndrome.
In contrast to the mostly positive systematic reviews, 2 systematic reviews with one update (67,69,80)
have shown lack of effectiveness of epidural steroids.
They all showed lack of effectiveness of epidural steroids. The common denominator being conversion of
active-controlled trials into placebo-controlled trials
and considering local anesthetic as placebo. They also
have additional issues with their publications, including
conflicts of interest, publication bias, and inappropriate
data synthesis. Manchikanti et al (81) performed a comparative analysis of Chou et al’s publication (80) which
also applies to other systematic reviews showing their
deficiencies and providing contrary results.
Bui and Bogduk (749) performed a systematic review
of the effectiveness of CT guided, lumbar transforaminal
injection of steroids in a low-quality systematic review.
They were only able to include 4 studies with success rate
being reported between 34% and 62%. They concluded
that evidence-base for CT guided lumbar transforaminal
injection of steroids is meager. Further, this intervention is not more effective than fluoroscopically guided
injection and is not demonstrably safer. The authors also
commented that with using techniques of “As Low As
Reasonably Achievable” (ALARA) fluoroscopy times are 5
times less than that of low dose CT protocol and 18 to 40
times less than a standard CT protocol.
Chang Chien et al (615) in a systematic review of
comparative studies for lumbosacral radicular pain
of transforaminal versus interlaminar approaches to
epidural steroid injections, in a low-quality systematic review without meta-analysis utilized 5 prospective
studies with 249 patients. Their results showed that only
in short-term the results were in favor of transforaminal
with 15% difference compared to interlaminar epidural
injections for pain relief. However, there was no difference at 1 or 6 months. They concluded that both transforaminal epidural steroid injections and interlaminar
epidural steroid injections are effective in reducing pain
and improving functional scores. In addition, transforaminal epidural steroid injections provided nonclinically significant superiority to interlaminar epidural steroid
injections only at 2-week follow-up. Further, based on 2
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studies, interlaminar epidural steroid injection provided
nonclinically significant superiority to transforaminal
epidural injections in function improvement.
Arirachakaran et al (756) assessed comparative outcomes of epidural steroids versus placebo after lumbar
discectomy in lumbar disc herniation in a systematic
review and meta-analysis of RCTs of moderate quality.
They included a total of 12 studies and analyzed the
pooled data with 9 studies having undergone conventional discectomy and 3 studies having undergone minimally invasive surgery discectomy, with a total of 1,006
patients. They concluded that there were no significant
differences in reference to morphine consumption and
hospital stay or complications between the 2 groups. This
systematic review is a very unusual review and the studies they included are also extremely unusual. Epidural
steroids are not recommended following the surgery in
the immediate intraoperative period. This manuscript
provides an opportunity to discourage such usage.
Jing et al (667) assessed efficacy and safety of etanercept in the treatment of sciatica in a systematic review
and meta-analysis which was of moderate quality. They
concluded that etanercept treatment was associated
with a significantly reduced pain in leg and back compared to placebo and may possibly improve leg pain
relief compared to steroids, but failed to improve ODI.
They also concluded that etanercept should be recommended for sciatica with caution because of heterogeneity. However, the drug is not approved or available in
the US for epidural usage purposes.
Three systematic reviews were performed assessing particulate and nonparticulate steroids in epidural
injections (745,747,748).
Feeley et al (747) performed a systematic review
and meta-analysis of moderate quality assessing particulate and nonparticulate steroids in spinal epidurals.
They concluded that particulate steroids were not demonstrably better in relieving pain compared to their
nonparticulate counterparts. These conclusions are
based on 4 studies with 300 participants.
Mehta et al (745) in a systematic review of moderate quality assessed efficacy of particulate versus nonparticulate corticosteroids in epidural injections. From
inclusion of multiple heterogenic studies, they concluded that there was no statistically significant difference
in terms of pain reduction or improved functional outcome between when performing cervical transforaminal
epidural injection, whereas lumbar radiculopathy due
to stenosis or disc herniation, transforaminal epidural
using particulate versus nonparticulate was equivocal
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in reducing pain and improving function. Consequently,
the authors recommended nonparticulate steroids.
Makkar et al (748) published a systematic review and
meta-analysis of the current literature of particulate and
nonparticulate steroids for transforaminal epidural injections. In this analysis, they included 7 studies comprising
3,542 patients in the particulate group and 856 patients
in the nonparticulate group. The results showed better
improvement with Visual Analog Scale (VAS) by 0.53 in
the particulate group compared to the nonparticulate
group. However, nonparticulate group had a larger proportion of patients with more than 50% pain relief than
the particulate group. They concluded that since the use
of particulate steroids seems to be associated with slightly better VAS scores only, clinicians need to weigh their
clinical relevance in light of complications and US Food
and Drug Administration (FDA) recommendations on the
use of particulate steroids. However, FDA recommendation is for all types of steroids. Consequently, it appears
that all 3 studies show there was no significant difference; however, all 3 systematic reviews included cervical
transforaminal epidural injections, even though Makkar
et al (748) included predominantly lumbar transforaminal epidural injections. Considering that local anesthetics
alone are equally effective to particulate steroids in most
instances, these differences are minimal, specifically with
clinical relevance.
Helm et al (83) in a recent publication evaluated
transforaminal epidural steroid injections in a systematic review and meta-analysis, which was of high-quality.
In this analysis, they included 18 RCTs with 11 trials
evaluating radicular pain due to disc herniation. They
also performed single arm meta-analysis in addition
to conventional dual arm analysis. They showed Level
I evidence for use of transforaminal epidural injections
for radicular pain from disc herniations. However, the
evidence was Level IV for central stenosis, failed back
surgery syndrome, and Level V for radicular pain from
foraminal stenosis and for axial pain.
There have been multiple publications of systematic
reviews with percutaneous adhesiolysis. The effectiveness of percutaneous adhesiolysis for managing chronic
pain due to lumbar central spinal stenosis was examined
in a high-quality systematic review and meta-analysis (9
studies) by Manchikanti et al (73). The authors found
Level II evidence for both the short- and long-term
improvement in pain and function in response to the
intervention. The authors in this manuscript also utilized conventional dual and single arm meta-analysis
illustrating effectiveness with both types of analysis.
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Another high-quality systematic review and metaanalysis by Manchikanti et al (72) looked at the efficacy
of percutaneous adhesiolysis in the treatment of chronic
refractory lower back and lower extremity pain due to
post-laminectomy surgery syndrome. Their analysis
included 4 systematic reviews and 4 RCTs. All but one
systematic review, which was deemed low-quality, demonstrated Level I evidence for the efficacy of percutaneous adhesiolysis in this patient population.
Manchikanti et al (74) in a systematic analysis of
findings of reviews looked at various systematic reviews
performed on the subject of percutaneous adhesiolysis
and determined that except for a few of them, one particular systematic review by Brito-García et al (87) was
inappropriately performed. Manchikanti et al (74) in this
manuscript also reexamined the evidence and performed
the systematic review of 4 RCTs utilized in the previous
systematic reviews and concluded that there was Level I
evidence for percutaneous adhesiolysis based on significant evidence from published RCTs and 3 of the 4 systematic reviews in post-lumbar surgery syndrome.
Systematic reviews were also performed to assess
surgery sparing effect of epidural injections, both in
lumbar spine and cervical spine. Bicket et al (271) in a
review of 26 randomized controlled studies with metaanalysis showed that patients receiving epidural steroid
injections were less likely to undergo surgery than those
who received control treatment, providing moderate
evidence. The results also showed that evidence suggested that between one-third and half of patients considering surgery who undergo epidural steroid injection
can avoid surgery; however, with low level of evidence.
Koltsov et al (272) in assessment of incidence and
risk factors of subsequent surgery in patients receiving
lumbar epidural steroid injections showed that within
6 months, 12.5% of epidural steroid injection patients
underwent lumbar surgery, whereas by one year, 16.9%
had surgery, and by 5 years, 26.1% had surgery. The
authors concluded that in the long-term, more than
one out of every 4 patients undergoing epidural steroid
injection for lumbar herniation or stenosis subsequently
had surgery, and nearly one of 6 had surgery within the
first year. While the authors attempted to present a
negative view because of surgical orientation, avoiding
surgery in 76% of the patients, specifically on a longterm basis, is considered phenomenal. These authors
also started with the negative connotation that up to
30% of patients had surgery within one to 2 years following lumbar epidural steroid injection and up to 49%
had surgery within 5 years (273-277), with roughly half
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of patients requiring a second epidural steroid injection
to achieve their surgery-sparing results (273,274,278)
implying that one epidural steroid injection must provide total relief, similar to surgery, or better. Further, all
the studies assessing these factors also misunderstand
active-controlled trials to placebo-controlled trials as do
Cochrane reviews and other academicians.
In contrast, in the cervical spine, Kleimeyer et al
(188) from the department of orthopedic surgery, in the
assessment of cervical epidural steroid injections and the
incidence of subsequent surgery, showed that within 6
months of cervical epidural steroid injections, 11.2% of
patients underwent surgery, increasing to 14.5% by one
year, and 22.3% by 5 years. Overall, they concluded that
following cervical epidural steroid injections, over 1 in
5 patients underwent surgery within 5 years, showing
75% response rate as in lumbar spine, again which will
be considered as excellent improvement and outcomes.

8.3 Randomized Controlled Trials
Based on extensive search criteria, numerous manuscripts were identified and considered for inclusion. Of
the 180 manuscripts of epidural interventions, including adhesiolysis trials, identified, multiple trials were
excluded for not meeting inclusion criteria. Only studies
performed under fluoroscopic guidance with a minimum
of 6 months follow-up were included. Subsequently, 43
trials and 2 observational studies were included. Only
fluoroscopic guided procedures were utilized, based on
philosophy that fluoroscopy provides the best results as
described in the literature and also preferred method
from Centers for Medicare and Medicaid Services (CMS),
and other medical policies. While ultrasound is evolving,
it continues to be in infancy with comparative studies.
Further, 6-month follow-up as minimum was utilized as
it indicates long-term follow-up of the patients with epidural injections, mostly multiple procedures, rather than
expecting a single procedures and expecting to last on a
long-term basis. It becomes difficult to extrapolate the
short-term results to long-term; consequently, 6-month
follow-up was utilized. Further, multiple manuscripts
which have been excluded from the inclusion have
been listed with description of characteristic features in
manuscripts by Kaye et al (60) and Knezevic et al (58).
Knezevic et al (58) also showed lack of publication bias.

8.3.1 Methodological Quality Assessment
A methodological quality assessment of the RCTs
meeting inclusion criteria was carried out utilizing Cochrane review criteria (154) and IPM-QRB criteria (153)
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as shown in Appendix Tables 2 and 3. Nonrandomized
studies were assessed utilizing IPM-QRBNR (157) as
shown in Appendix Table 4.

8.4 Caudal Epidural Injections
Thirty-three studies examined caudal epidural
injections for effectiveness (757-789). Following the
application of our criteria for inclusion, 10 RCTs (765770,779,783,784,786) met the inclusion criteria with
procedures being performed under fluoroscopic guidance and with a minimum of 6 months of follow-up,
with publication of appropriate outcome parameters
(765-770,779,783,784,786). Twenty-three studies were
excluded due to many of them being performed without fluoroscopy, and some studies describing short-term
outcomes or inadequate reporting. Multiple studies
published at various intervals were utilized as one
study with the final publication. Consequently, multiple
studies utilized in previous systematic reviews failed to
meet the inclusion criteria (56,57,67,69,75-77). Using
Cochrane and IPM-QRB criteria, 6 of the 10 studies were
determined to be high-quality (762,765-767,770,784)
and 4 of 10 were determined to be moderate quality
(769,779,783,786). Appendix Table 5 shows methodologic quality assessment utilizing Cochrane review criteria, Appendix Table 6 shows methodologic quality assessment utilizing IPM-QRB criteria and Table 12 shows
descriptive characteristics of caudal epidural injections.
Manchikanti et al conducted 4 studies (762,765767). They used an identical protocol in each study: an
active control design with a 2-year follow-up. These
studies evaluated the efficacy of epidural injections in
2 groups: one group received a local anesthetic only
and the other group received a local anesthetic with a
steroid. In these 4 studies, a total of 480 patients were
evaluated for one of the following conditions: lumbar
disc herniation; lumbar discogenic pain without facet
joint or sacroiliac joint pain; lumbar central spinal stenosis; and lumbar post-surgery syndrome.
Each of these trials reported that caudal epidural
injections, whether with local anesthetic only or local
anesthetic with steroid, were efficacious in 50% to 80%
of those treated. These patients were divided into those
who responded to the treatment and those who did not.
A responsive patient was one who had at least a 50%
improvement in both pain and function for 3 weeks
with the initial 2 injections. Those who responded and
those who did not, were not significantly different for
any of the pathologies studied, no matter which injection was received.
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Overall: LA
62% vs. LA with
steroid 72%
Responsive: LA
77% vs LA with
steroid 80%

Overall: LA
58% vs LA with
steroid 48%
Responsive: LA
78% vs. LA with
steroid 65%

NRS, ODI,
employment status,
opioid intake
Responsive
category was
defined as at least 3
weeks of significant
improvement
with the first
2 procedures.
Significant
improvement: 50%
improvement in
pain and function.

NRS, ODI,
employment status,
opioid intake
Responsive
category was
defined as at least 3
weeks of significant
improvement
with the first 2
procedures.
Significant
improvement: 50%
improvement in
pain and function.

Total = 120
Lidocaine = 60
Lidocaine with
steroids = 60
Lidocaine vs
lidocaine mixed
with steroid
Number of
injections = 1 to 5

Total = 100
Lidocaine = 50
Lidocaine + steroid
= 50
Lidocaine 0.5% vs.
lidocaine mixed
with steroid.
Average number of
injections = 5 to 6
for 2 years

Manchikanti et al,
2012 (765)
RA, AC, F
Disc herniation or
radiculopathy
Quality Scores:
Cochrane = 12/13
IPM-QRB = 44/48

Manchikanti et al,
2012 (767)
RA, AC, F
Central spinal
stenosis
Quality Scores:
Cochrane = 12/13
IPM-QRB = 44/48

3 mos.
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Overall: LA
54% vs LA with
steroid 50%
Responsive: LA
73% vs. LA with
steroid 68%

Overall: LA
72% vs LA with
steroid 73%
Responsive: LA
87% vs LA with
steroid 86%

6 mos.

Pain Relief and Function
Outcome
Measures

Participants and
Interventions

Study
Characteristics
Methodological
Quality Scoring

Overall: LA
44% vs LA with
steroid 46%
Responsive: LA
54% vs. LA with
steroid 62%

Overall: LA
67% vs LA with
steroid 72%
Responsive: LA
85% vs LA with
steroid 84%

12 mos.

Table 12. Characteristics of fluoroscopic randomized trials of caudal epidural injections.

Overall: LA
38% vs LA
with steroid
44%
Responsive:
LA 51% vs
LA with
steroid 57%

Overall: LA
60% vs LA
with steroid
65%
Responsive:
LA 77% vs
LA with
steroid 76%

24 mos.

Both treatments
effective

Lidocaine &
lidocaine with
steroid effective

Short-term
≥ 6 mos

Results

Both treatments
effective

Lidocaine &
lidocaine with
steroid effective

> 6 mos.

Long Term

Both
treatments
effective

Lidocaine
& lidocaine
with steroid
effective

≥ 12 mos.

Both
treatments
effective

Lidocaine
& lidocaine
with steroid
effective

24 mos.

• Double-blind
design in a practical
setting.
• Similar results
with local anesthetic
or with local
anesthetic and
steroids.
• Nonresponsive
patients: local
anesthetic = 13,
steroids = 13.
• A total of 5-6
injections on
average were
provided over
a period of 2
years; compared
to all patients
with significant
improvement
of 38% in local
anesthetic group,
44% in steroid
group.

• Positive
double-blind
randomized trial
with superiority
of steroids with
average pain relief
for steroids. Overall
improvement with
local anesthetic
alone or with
steroids was similar.
• Nonresponsive
patients were also
similar with 13
and 10 in local
anesthetic only and
with steroids group.
• Over a period
of 2 years, on
average, a total of
5-6 injections were
provided.

Comments
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Overall: LA
60% vs LA with
steroid 72%
Responsive: LA
87% vs LA with
steroid 88%

Overall: LA
56% vs LA with
steroid 54%
Responsive: LA
76% vs. LA with
steroid 67%

NRS pain scale,
ODI, employment
status, opioid
intake
Responsive
category was
defined as at least 3
weeks of significant
improvement
with the first
2 procedures.
Significant
improvement: 50%
improvement in
pain and function.

NRS, ODI,
employment status,
opioid intake
Responsive
category was
defined as at least 3
weeks of significant
improvement
with the first
2 procedures.
Significant
improvement: 50%
improvement in
pain and function.

Total = 120
Lidocaine = 60
Lidocaine with
steroids = 60
Lidocaine vs.
lidocaine mixed
with steroid
Average number of
injections = 5 to 6
for 2 years

Total = 140
Lidocaine = 70
Lidocaine + steroid
= 70
Lidocaine vs.
lidocaine mixed
with non-particulate
betamethasone
Average number of
injections = 5 to 6
for 2 years

Manchikanti et al,
2012 (762)
RA, AC, F
Axial or discogenic
Quality Scores:
Cochrane = 12/13
IPM-QRB = 44/48

Manchikanti et al,
2012 (766)
RA, AC, F
Post-surgery
syndrome
Quality Scores:
Cochrane = 12/13
IPM-QRB = 44/48

3 mos.

Overall: LA
56% vs LA with
steroid 61%
Responsive: LA
74% vs. LA with
steroid 78%

Overall: LA
62% vs LA with
steroid 72%
Responsive: LA
89% vs. LA with
steroid 93%

6 mos.

Pain Relief and Function
Outcome
Measures

Participants and
Interventions

Study
Characteristics
Methodological
Quality Scoring

Overall: LA
53% vs LA with
steroid 59%
Responsive: LA
70% vs. LA with
steroid 75%

Overall: LA
56% vs LA with
steroid 68%
Responsive: LA
84% vs. LA with
steroid 85%

12 mos.

Table 12 (con’t). Characteristics of fluoroscopic randomized trials of caudal epidural injections.

Overall: LA
47% vs LA
with steroid
58%
Responsive:
LA 62% vs
LA with
steroid 69%

Overall: LA
54% vs LA
with steroid
60%
Responsive:
LA 84% vs
LA with
steroid 73%

24 mos.

P

P

Short-term
≥ 6 mos

Results

P

P

> 6 mos.

Long Term

P

p

≥ 12 mos.

P

p

24 mos.

• Positive results
with local
anesthetics with or
without steroids.
• Similar results
with local anesthetic
or with local
anesthetic and
steroids.
• Nonresponsive
patients: local
anesthetic = 17,
steroids = 15.
• On average,
5-6 injections
were provided
over a period of 2
years; compared
to all patients
with significant
improvement
of 47% in local
anesthetic group,
58% in steroid
group.

• Positive
randomized doubleblind trial with
similar results with
local anesthetic or
with local anesthetic
and steroids.
• There was an
inordinately high
proportion of
patients failing to
respond initially
in both groups, 23
in local anesthetic
group, and 19 in
steroid group.
• On average,
a total of 5-6
injections were
provided over a
period of 2 years.

Comments
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Pain relief,
SF-MPQ, HADS
scores

VAS, ODI, BDI,
NPI

VAS, ODI

Total = 60
Caudal = 30
Endoscopy =30
Lidocaine with
triamcinolone
Number of
injections = 1

Group A = 50
control conservative
management
Group B = 52
caudal epidural
with lidocaine and
methylprednisolone
Total = 102 patients
Conservative
management or
caudal epidural
steroid injections

Transforaminal = 30
Number of
injections = 1-3
Interlaminar = 30
Number of
injections = 1-3
Caudal = 30
Number of
injections = 1-3

Dashfield et al, 2005
(784)
RA, AC, F
Disc herniation or
radiculopathy
Quality Scores:
Cochrane = 10/13
IPM-QRB = 33/48

Murakibhavi &
Khemka, 2011 (786)
RA, NTC, F
Disc herniation or
radiculopathy
Quality Scores:
Cochrane = 8/13
IPM-QRB = 27/48

Kamble et al, 2016
(770)
RA, AC, F
Single level disc
prolapse
Quality Scores:
Cochrane = 9/13
IPM-QRB = 32/48

Numeric pain
score (0 - 10),
rating of pain
relief, ODI,
BDI, contrast
dispersion pattern
Follow-up: 24
weeks

Total = 90
Caudal = 30
Interlaminar = 30
Transforaminal = 30
Methylprednisolone
+ saline
Number of
injections = 1 to 3

Ackerman &
Ahmad, 2007 (783)
RA, AC, F
Disc herniation or
radiculopathy
Quality Scores:
Cochrane = 8/13
IPM-QRB = 25/48

Outcome
Measures

Participants and
Interventions

Study
Characteristics
Methodological
Quality Scoring
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N/A

Group A = 32%
Group B = 92%

SI

Caudal = 57%
Interlaminar
= 60%
Transforaminal
= 83%

3 mos.

N/A

N/A

Transforaminal =
VAS baseline 7.1
± 0.7 to 2.6 ± 0.7
ODI = 37.7 ±
2.83 to 16.8 ±
2.53
Interlaminar =
VAS baseline 7.0
± 0.7 to 3.4 ± 1.4
ODI = 36.9 ±
2.82 to 21.4 ±
6.08
Caudal = VAS
baseline 7.2 ± 0.6
to 3.5 ± 1.0.
ODI = 38.3 ±
2.78 to 21.9 ±
3.35

N/A

N/A

12 mos.

Group A = 24%
Group B = 86%

SI

Caudal = 57%
Interlaminar =
60%
Transforaminal
= 83%

6 mos.

Pain Relief and Function

Table 12 (con’t). Characteristics of fluoroscopic randomized trials of caudal epidural injections.

N/A

N/A

N/A

N/A

24 mos.

All 3 techniques
were effective

Steroids
effective

Lidocaine with
triamcinolone
effective

Effective in all
arms

Short-term
≥ 6 mos

Results

N/A

Steroids
effective

Lidocaine with
triamcinolone
effective

Effective in all
arms

> 6 mos.

Long Term

N/A

N/A

N/A

N/A

≥ 12 mos.

N/A

N/A

N/A

N/A

24 mos.

While all 3
techniques
were effective,
transforaminal
group showed
superiority.
However, there
was no difference
between caudal
and interlaminar
approaches.

Positive shortterm results, with
methylprednisolone
and lidocaine.

Positive mid-term
results in a relatively
small trial.

Positive midterm results in a
relatively small
trial.

Comments
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JOA score

VAS, ODI &
significant pain
relief of 50%

Total = 140 patients
Caudal = 82
Transforaminal = 40
Interlaminar = 18
All were treated
with steroid and
local anesthetic with
or without sodium
chloride solution

Number of patients
= 80
Caudal with steroids
group = 40
2 mL of
methylprednisolone,
80 mg along with
lignocaine 2%
diluted in 20 mL of
normal saline
3 caudal epidural
injections were given
at an interval of 3
weeks irrespective
of previous epidural
injection effect
SRNB = 40
A single injection
of 2 mL of
methylprednisolone,
80 mg, mixed with 5
mL of lignocaine 2%

Pandey, 2016 (769)
RA, AC, F
Disc prolapse
Quality Scores:
Cochrane = 8/13
IPM-QRB = 29/48

Singh et al, 2017
(779)
RA, AC, F
Single level prolapsed
lumbar intervertebral
disc
Quality Scores:
Cochrane = 8/13
IPM-QRB = 30/48
VAS
Caudal vs.
SNRB = 61.5%
vs. 55.5%
ODI decreased
caudal vs. SNRB
= 64.6% vs.
52.8%

N/A

3 mos.

VAS
Caudal vs.
SNRB= 59.6% vs.
52.9%
ODI decreased
caudal vs. SNRB
= 65.1% vs.
48.6%

JOA scores
Caudal = baseline
15.39 to 24.30
Transforaminal =
baseline 15.57 to
26.65
Interlaminar =
baseline 15.33
to 25

6 mos.

Pain Relief and Function

N/A

N/A

JOA scores
Caudal =
baseline 15.39 to
24.02
Effectiveness =
74.3%
Transforaminal
= baseline 15.57
to 26.55
Effectiveness
= 90%
Interlaminar =
baseline 15.33 to
24.72
Effectiveness =
77.7%

VAS
Caudal vs.
SNRB= 58.2%
vs. 46.8%
ODI decreased
caudal vs. SNRB
= 65.4% vs.
46.7%

24 mos.

12 mos.

Caudal epidural
superior to
SNRB with
steroids

P

Short-term
≥ 6 mos

Results

Caudal epidural
superior to
SNRB with
steroids

P

> 6 mos.

Long Term

Caudal
epidural
superior to
SNRB with
steroids

P

≥ 12 mos.

Caudal
epidural
superior to
SNRB with
steroids

N/A

24 mos.

Positive short-term
and long-term relief
in both caudal and
SNRB; however,
relief in the caudal
group was superior.
However, this
study suffered with
multiple limitations
of 3 caudal epidural
injections compared
to one SNRB and
high volumes of
injections, which
are clinically
inappropriate in
both caudal and
SNRB groups.

In comparing
caudal epidural
with interlaminar
and transforaminal,
authors showed
response in 74.3%
with caudal
route, 77.7% with
interlaminar,
and 90% with
transforaminal
approach.
Overall results are
positive. There
is no significant
difference
between caudal
and interlaminar;
however,
transforaminal
appears to be
superior.

Comments

Source: Manchikanti L, et al. Assessment of methodologic quality of randomized trials of interventional techniques: Development of an interventional pain management specific instrument. Pain Physician 2014; 17:E263-E290 (153).
RA = Randomized; AC = Active Control; F = Fluoroscopy; NRS = Numeric Rating Scale; ODI = Oswestry Disability Index; IPM-QRB = Interventional Pain Management techniques - Quality Appraisal
of Reliability and Risk of Bias Assessment; LA = local anesthetic; BDI = Beck Depression Inventory; SF-MPQ = Short-Form McGill Pain Questionnaire; HADS = Hospital Anxiety and Depression Scale;
NTC = No treatment control; VAS = Visual Analog Scale; NPI = Numerical Pain Intensity; JOA – Japanese Orthopaedic Association; SNRB – selective nerve root block; SI = significant improvement;
NA = Not Applicable; P = Positive; N = negative

Outcome
Measures

Participants and
Interventions

Study
Characteristics
Methodological
Quality Scoring

Table 12 (con’t). Characteristics of fluoroscopic randomized trials of caudal epidural injections.
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Responsive group patients in all 4 studies had superior outcomes; however, it should be noted that none of
the studies had a placebo control. But each study only
enrolled patients with chronic pain, and homogeneity
was maintained because the patients in each study had
a similar diagnosis. Each study established the efficacy of
local anesthetic with steroid for the pathology treated;
in addition, the patients in the disc herniation study had
a higher quality of pain relief at 6 and 12 months. The
mechanisms of action of local anesthetics and steroids
have an abundance of experimental and clinical evidence (55-58,102,604-608,689-699). Further, there have
been previous descriptions concerning the effectiveness
of sodium chloride injected into the epidural space and
joint spaces (76,436,698).
Among the newer studies published in 2017,
Singh et al (779), in a prospective randomized assessment, studied transforaminal epidural injections versus
caudal epidural injections for single level prolapsed
lumbar intervertebral disc. In this study, they utilized 80
patients with 40 patients in each group. Both groups
received steroids and local anesthetic; however, there
was significant difference in the volumes, which were
rather high. Patients in the caudal group received 2 mL
of methylprednisolone (80 mg) with 10 mL of lignocaine
2% diluted in 20 mL of normal saline. Further, a total of
3 caudal epidural injections were given at intervals irrespective of previous epidural injection effect. However,
transforaminals were given by a single injection of 2 mL
of methylprednisolone 80 mg mixed with 5 mL of lignocaine (7 mL total), a high volume, using a supraneural
technique. For the outcomes, they utilized pain relief as
well as ODI. More importantly, they assessed the patients
with more than 50% relief. In the transforaminal group,
pain was reduced by more than 50% until 6 months,
while in the caudal group, more than 50% reduction
of pain was maintained until one year. The reduction
in ODI in the transforaminal group was 52.8% until 3
months, 48.6% until 6 months, and 46.7% at one year,
while in the caudal group, the improvement was 64.6%,
65.1% and 65.4% at corresponding follow-up periods.
They concluded that caudal epidural was more effective
or superior to transforaminal, with an increased ease of
administration.
Pandey (769) assessed the efficacy of epidural steroid injection in the management of lumbar prolapsed
intervertebral disc in comparative evaluation with caudal, interlaminar, and transforaminal approaches. They
included a total of 140 patients with randomization into
3 groups with 80 patients utilizing the caudal approach,
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40 patients by transforaminal approach, and 8 patients
by interlaminar approach using a simple randomization;
however, this randomization is not uniform. Utilizing
Japanese Orthopaedic Association (JOA) scores they calculated the improvement at 6 months and one-year and
effectiveness of the medication for each route. Their
results showed that one-year after injecting the steroid,
all three routes were found to be effective in improving
JOA scores with caudal route showing improvement in
74.3%, interlaminar showing improvement in 77.7%,
and transforaminal route in 90%. They also showed that
the transforaminal route was significantly more effective than the caudal and interlaminar at both 6 months
and one-year after injection. No significant differences
were seen between the caudal and interlaminar approaches. The limitations of this study include unequal
randomization and lack of data showing significant
improvement.
Kamble et al (770) studied 90 patients randomized
to 3 groups with approaches of caudal, interlaminar, and
transforaminal with randomization with 30 patients in
each group in a single level disc prolapse patients confirmed by MRI. They followed the patients for 12 months
and the results were compared using change in VAS
score and ODI; however, they presented only 6 month
results. Their results showed the change in pain scores
were statistically different at 1 and 6 month intervals
such that a higher change was observed by the transforaminal route as compared to the other two. There
was no difference in change of scores between the interlaminar and caudal routes. For ODI scores, a greater
change was seen in delivery at all times, as compared to
the other 2. There was no difference in change of scores
between the interlaminar and caudal routes at any
time of the assessment. The VAS scores changed from
7.1 to 2.6 at 6-month follow-up in the transforaminal
group compared to 7.0 to 3.4 in the interlaminar group,
and 7.2 to 3.5 in the caudal group. Similarly, ODI scores
changed from 37.7 to 16.8 in the transforaminal group
compared to 36.9 to 21.4 in the interlaminar group and
38.3 to 21.9 in the caudal group. Overall, these findings
showed positive results. However, as shown above, positive results with transforaminal were superior. It should
be noted that the 12-month results were not published
and also 50% relief was not assessed.
Among the older studies, Ackerman and Ahmad
(783) compared the efficacy of caudal epidural injections with lumbar interlaminar and transforaminal epidural injections. This was a relatively small study showing the superiority of both lumbar interlaminar and
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transforaminal epidural injections over caudal epidural
injections. The authors utilized both local anesthetic
and steroids.
Dashfield et al (784) assessed and compared caudal
epidural steroid injections with targeted steroid placement during spinal endoscopy for chronic sciatica. Their
study showed that epidural injections without passage
of endoscopy equipment was superior.
Murakibhavi and Khemka (786) compared caudal
epidural steroid injections in a RCT of disc herniation
with conservative treatment measures which included
medication as well as physiotherapy, whereas the
intervention group received caudal epidural steroid
injections with 20 mL of normal saline, 2 mL of 2%
preservative-free lidocaine, and 2 mL or 80 mg of triamcinolone acetate. The authors showed complete
long-term relief in 86% of the patients in the caudal
epidural group compared to 24% in the conservative
management group. This was a moderate quality trial,
without blinding, comparing conservative modalities to
epidural injections.
Among the excluded studies, there was only one
study by Iversen et al (785), utilizing a placebo design,
however, without fluoroscopy, but with ultrasound and
injection of steroid without local anesthetic. The study
was highly deficient in multiple aspects with substantial
criticism advanced (790-792). This study illustrates numerous flaws. As a first concern, the selection criteria
are overtly broad. A significant proportion of patients
(n = 17) did not even have to undergo randomization
because their symptoms improved between assessment
and randomization indicating the inclusion of shortterm or subacute pain. In addition, after the randomization, 5 patients had spontaneous improvement before
the first injection. A large proportion of patients were
excluded due to neurologic compression, including cauda equina syndrome. They also attributed most of their
results to natural course. Patient selection appears to be
quite inappropriate. In chronic pain settings with longlasting pain, patients undergoing various modalities of
treatments would already have responded to a natural
course or placebo effect. Further, while MRI was utilized
as the criteria for disc herniation, ultimately the authors
included clinically proven radiculopathy for inclusion
criteria. Multiple flaws with the procedure include ultrasound identification of caudal epidural space, which
the authors claim is appropriate for caudal even though
they concede it was not appropriate for transforaminal.
Ultrasound identification is not appropriate for either
caudal or for transforaminal. Further, the injection was
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not only nontargeted with an unproven technique,
namely ultrasound, but also included large volumes of
sodium chloride solution without local anesthetics and
relatively small volumes of triamcinolone. It also appears, somewhat surprising, that only 17 patients of the
345 declined to participate in the study, even though it
is a placebo-control study.
Sayegh et al (782) studied patients with either
acute or subacute sciatica. This randomized controlled
study reported significant improvement for those receiving local anesthetic alone or with steroids. However,
they reported that adding steroids provided a superior
outcome because the onset of relief was faster, longer
lasting, and of a higher quality.
Park et al (773) studied the role of caudal epidural
steroid injection for the treatment of unilateral lower
lumbar radicular pain utilizing a single-blinded randomized design comparing ultrasound-guided versus
fluoroscopy-guided procedures. They included a total of
110 patients with 55 patients in each group. In a shortterm follow-up of 12 weeks, they showed improvement
with pain and function in both groups.
Revel et al (787) studied forceful epidural injections
for the treatment of lumbosciatic pain with postoperative lumbar spine fibrosis. They included 60 patients
with persistent or recurrent lumbosciatic pain after
surgery and with epidural fibrosis. This was a moderate
quality study with positive results.
Datta and Upadhyay (776) compared 3 different
steroid agents for treatment of low back pain through
caudal approach with allocation of patients into 4
groups with one group receiving local anesthetic alone
(bupivacaine), whereas 3 groups received 3 types of
steroids utilizing bupivacaine and with total dose
equivalent to 210 mg of methylprednisolone or 3 injections with methylprednisolone acetate, triamcinolone
acetonide, or betamethasone acetate. All injections
were administered with 10 to 15 mL volume of 0.125%
bupivacaine alone or bupivacaine mixed with 80 mg of
methylprednisolone, 80 mg of triamcinolone, or 15 mg
of dexamethasone. The procedures were performed
blindly without fluoroscopy and a significant proportion
of patients had disc herniations at L3/4, either individually or in combination, in the majority of the patients
(the level at which caudal epidural has poor spread pattern), specifically when performed without fluoroscopy.
VAS improved the most in the methylprednisolone and
triamcinolone groups from baseline scores of 7.4 to
4.9 in the methylprednisolone group and 4.8 in the
triamcinolone group. In contrast, the dexamethasone
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group improved from 7.3 to 5.2 and local anesthetic
alone group improved from 7.2 to 6.18. These results in
a short-term follow-up show that methylprednisolone
and triamcinolone with local anesthetic in rather high
doses were more effective than high dose dexamethasone and bupivacaine alone. Thus, the results show that
there is significant improvement with steroids when
local anesthetics are added.
Huda et al (789), utilizing a blind approach, assessed
70 patients. They compared methylprednisolone or triamcinolone mixed with bupivacaine and normal saline
with a total of 20 mL volume. In the methylprednisolone
group, at the end of 6 months, 68.5% of the patients
reported improvement, whereas improvement was seen
in 40% of the patients in the triamcinolone group. The
results are impressive considering that patients received
only one injection of steroid with bupivacaine.

8.4.1. Evidence Synthesis
Based on the available studies, qualitative and
quantitative analysis were performed. Qualitative analysis data was derived from the data from this assessment.
Quantitative analysis data was derived from a multitude
of previous systematic reviews, which included conventional dual-arm analysis and single-arm analysis.
In the present assessment, there were 2 RCTs
(769,770) comparing caudal, interlaminar and transforaminal groups in managing disc herniation. In both
studies, caudal and interlaminar epidurals were equivalent, whereas transforaminal was shown to be somewhat superior. In contrast, Ackerman and Ahmad (783),
which was included in this analysis, showed superiority
of both lumbar interlaminar and transforaminal epidural injections over caudal epidural injections. It must
be noted that this was a very small study.
However, Singh et al (779) compared selective nerve
root blocks and caudal epidural injection for single level
prolapsed lumbar intervertebral disc in a prospective
randomized study. They showed significantly better improvement with caudal epidural injections at 6 months
and one year. They utilized 3 caudal epidural injections
compared to one transforaminal epidural injection.
Consequently, the value of this study and results in
reference to superiority are questionable, even though
they show that both approaches are effective.
In the present review, there were no studies meeting inclusion criteria with placebo control. All of the
studies meeting inclusion criteria were of an active control nature. Four studies by Manchikanti et al presented
2-year relief with positive response in disc herniation,
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central spinal stenosis, axial or discogenic pain, and
post-lumbar surgery syndrome.
Overall, 7 studies provided the results of
caudal epidural injections in disc herniation
(765,769,770,779,783,784,786). All of them were judged
to be positive. Consequently, the evidence for caudal
epidural injections in disc herniation, with inclusion of
7 relevant medium to high-quality studies is Level I with
strong recommendation. Comparative studies of caudal,
interlaminar, and transforaminal show equal effectiveness of caudal and interlaminar. However, superiority of
transforaminal epidural injections was demonstrated in
two studies (769,770). Thus, based on relevant studies,
there is Level III evidence that transforaminal are superior to caudal epidural injections and Level III evidence
that caudal epidural injections are equivalent to lumbar
interlaminar epidural injections.
The evidence for central spinal stenosis is Level III to
II based on a single RCT (767), which is an active control,
with inclusion of 100 patients with 24-month followup with moderate to strong recommendation in select
patients.
The evidence for axial or discogenic pain after
elimination of facet joint pain and sacroiliac joint pain
is Level II based on one active control RCT (762) with
inclusion of 120 patients and a 2-year follow-up with
moderate to strong recommendation.
For post-surgery syndrome, based on one highquality relevant RCT (766), the evidence is Level II with
moderate to strong recommendation.
Cost utility analysis was also favorable for caudal
epidural injections in all 4 conditions studied, namely,
disc herniation, central spinal stenosis, post-lumbar
surgery syndrome, and axial discogenic pain (795). The
cost utility analysis showed cost for one-year qualityadjusted life year (QALY) of $2,172.50 for direct costs
and $3,627.24 for total cost with addition of indirect
costs. There was no significant difference among the
groups; however, among various conditions, for disc
herniation total cost was $3,682.35 per one-year QALY.
For axial or discogenic pain after ruling out the facet
joint and sacroiliac joint pain, it was $3,567.42, spinal
stenosis it was $3,598.85, and for post-surgery syndrome
it was $3,658.43 for one-year QALY.
Multiple systematic reviews have assessed the role
of caudal epidural injections with or without steroids in
managing pain in the lumbar spine for various conditions, including disc herniation, discogenic pain without
disc herniation, central spinal stenosis, and post-surgery
syndrome. Only a few systematic reviews focused on
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analyzing the evidence for caudal epidural injections,
either alone or comparatively. Manchikanti et al (7577,81) and Kaye et al (60) evaluated caudal epidural
injections separately and in combination with interlaminar and transforaminal epidural injections in the
lumbar spine. All of these studies uniformly showed the
effectiveness of caudal epidural injections and basically
included the same studies.
In addition, Lee et al (63), compared the clinical efficacy of transforaminal and caudal epidural steroid injections in a systematic review utilizing 6 studies showing
somewhat the superiority of transforaminal epidural injections over caudal epidural injection in 4 articles, with
one article showing no significant difference, and one
article supporting the superiority of caudal epidural steroid injection to transforaminal epidural injection. Their
conclusion was towards better clinical efficacy with
transforaminal epidural injections. However, there was
no statistical significance and the evidence was low because of inconsistencies and imprecisions. Consequently,
the clinical relevance is not determined.
Manchikanti et al compared caudal epidural studies with interlaminar and transforaminal epidural
studies (614,793,794). In one of those studies (614),
they compared the efficacy of caudal, interlaminar, and
transforaminal epidural injections in managing lumbar
disc herniation by looking at whether one method was
superior to the other. They included 3 RCTs with 120
patients in each trial with 60 patients receiving local
anesthetic only and 60 patients in each trial receiving
local anesthetic with steroids. Analysis showed similar
efficacy for caudal, interlaminar, and transforaminal
approaches in managing chronic pain and disability
from disc herniation. While there were differences in
relief patterns, they were not statistically significant. At
12 months, significant improvement (considered as at
least 50% pain relief and improvement in ODI scores for
function from baseline) of 72% was shown in the caudal
group, 85% in the interlaminar group, and 57% in the
transforaminal group. However, further analysis with
only responsive patients showed 84% improvement in
the caudal group, 86% in the interlaminar group, and
73% in the transforaminal group. Overall, there was no
significant difference between groups. However, it appears that interlaminar may be somewhat better than
caudal.
Manchikanti et al (793) also compared the effectiveness of caudal epidural with lumbar interlaminar
epidural in central spinal stenosis. Similar to the above
study, they derived the data from 2 previously published
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RCTs. Results showed significant improvement in patients suffering with chronic lumbar spinal stenosis with
caudal and interlaminar epidural approaches up to 2
years. However, the interlaminar group showed significant difference between caudal and interlaminar with
interlaminar being superior to caudal in spinal stenosis.
Manchikanti et al (794) also studied the difference
between caudal and lumbar interlaminar injections in
chronic lumbar axial discogenic pain. They utilized 2
RCTs from each group. In this assessment, the lumbar
interlaminar approach was shown to be superior to the
caudal approach. The primary outcome measure, with
significant improvement being defined as pain relief
and functional status improvement of at least 50% from
baseline, was reported at 20-month follow-up in 72%
who received local anesthetic only utilizing the lumbar
interlaminar approach and 54% who received local
anesthetic only utilizing a caudal approach. Further, in
patients receiving local anesthetic with a steroid, the response rate was 67% of those who had a lumbar interlaminar approach and 68% of those who had a caudal
approach at 12 months. Consequently, they concluded
that the response was significantly better in the lumbar
interlaminar group who received local anesthetic only,
77% versus 56% at 12 months, and 72% versus 54% at
24 months.

8.5 Lumbar Interlaminar Epidural Injections
Lumbar interlaminar epidural injections were studied for effectiveness in 53 studies (617,769,770,783,796843). Of the 53 studies considered for inclusion, only 13
RCTs met inclusion criteria. (617,769,770,783,797,799,8
01,804,817,818,821,823,843). Appendix Table 7 shows
Cochrane review criteria assessment results, whereas,
Appendix Table 8 shows criteria by IPM-QRB. Table 13
shows characteristic features of fluoroscopic RCTs of
lumbar interlaminar epidural injections. Using both
Cochrane and IPM-QRB criteria, 10 studies (617,770,797
,799,801,804,817,821,823,843) were rated high, while 4
were rated moderate quality (769,783,818).
Manchikanti et al conducted 3 of these studies
(797,799,801). They used an identical protocol in each
study: an active control design with a 2-year follow-up.
These studies evaluated the efficacy of epidural injections in 2 groups: one group received a local anesthetic
only and the other group received a local anesthetic
with a steroid. In these 3 studies, a total of 360 patients
were evaluated for one of the following conditions:
lumbar disc herniation; lumbar discogenic pain without
facet joint or sacroiliac joint pain; and lumbar central

www.painphysicianjournal.com

Outcome
Measures

NRS, ODI,
employment
status, opioid
intake, significant
improvement
50% or greater of
NRS scores and
ODI scores
Responsive
category was
defined as at
least 3 weeks
of significant
improvement
with the first
2 procedures.
Significant
improvement:
50%
improvement
in pain and
function.

NRS and
functional
disability using
Modified
Oswestry
Disability
Questionnaire
Follow-up: 1 year

Participants and
Interventions

Total = 120
Local anesthetic = 60
Local anesthetic and
steroids = 60
Xylocaine or
Xylocaine with
non-particulate
Celestone
Average number of
injections = 5 to 6
for 2 years

Total = 69
Lidocaine = 34
Lidocaine +
methylprednisolone
= 35
Local anesthetic
group: 8 mL of 0.5%
lidocaine
Lidocaine +
methylprednisolone:
6 ml of 0.5%
lidocaine mixed with
80 mg (2 mL) of
methylprednisolone
acetate
Average procedures:
2

Study
Characteristics
Methodological
Quality Scoring

Manchikanti et al,
2014 (797)
RA, AC, F
Disc herniation or
radiculopathy
Quality Scores:
Cochrane = 11/13
IPM-QRB = 44/48

Ghai et al, 2015
(804)
RA, DB, AC, F
Disc herniation or
radiculopathy
Quality Scores:
Cochrane = 10/13
IPM-QRB = 39/48
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Lidocaine: 50%
Lidocaine with
methylprednisolone:
86%,

Overall: Lidocaine
72% vs. lidocaine
with steroid 82%
Responsive:
Lidocaine 86% vs.
lidocaine with steroid
83%

3 mos.

Lidocaine: 56%
Lidocaine with
methylprednisolone:
86%

Overall: Lidocaine
63% vs. lidocaine
with steroid 85%
Responsive:
Lidocaine 76% vs.
lidocaine with steroid
86%

6 mos.

Pain Relief and Function

Lidocaine: 59%
Lidocaine with
methylprednisolone:
89%

Overall: Lidocaine
67% vs. lidocaine
with steroid 85%
Responsive:
Lidocaine 80%
vs. lidocaine with
steroid 86%

12 mos.

N/A

Overall:
Lidocaine
60% vs
lidocaine
with steroid
70%
Responsive:
Lidocaine
72% vs.
lidocaine
with steroid
71%

24 mos.

Table 13. Characteristics of fluoroscopic randomized controlled trials of lumbar interlaminar epidural injections.

Both arms
effective.
Steroids
superior

Both
treatments are
effective

Short-term
≤ 6 mos.

Results

Both arms
effective.
Steroids
superior

Both
treatments are
effective

> 6 mos.

Long-Term

Both arms
effective.
Steroids
superior

Both
treatments are
effective

≥ 12 mos.

N/A

Both
treatments
are
effective

24 mos.

This active control
trial with a longterm follow-up
comparing
lidocaine alone
with lidocaine with
methylprednisolone
showed similar
results after 3
months, even
though quality of
relief was superior in
the local anesthetic
with steroid group.

• Positive
randomized trial
with long-term
follow-up.
• Overall, similar
results with local
anesthetic or with
local anesthetic
and steroids
with significant
improvement.
• Steroids were
superior at 6 months
with pain relief and
12 months with
functional status
• A significantly
higher proportion
of patients nonresponsive to the
first 2 injections in
the local anesthetic
group 10 vs one.
• On average, a total
of 5-6 injections
were provided over a
period of 2 years.
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Outcome
Measures
NRS, ODI,
employment
status, opioid
intake
Responsive
was defined as
those patients
responding with
at least 3 weeks
of improvement
with the first
2 procedures.
Significant
improvement:
50%
improvement
in pain and
function.

VAS, ODI
Follow-up: 1 to
12 months

NRS, RMDQ

Participants and
Interventions

Total = 120
Local anesthetics
= 60
Local anesthetics
and steroids = 60
Lidocaine alone or
with Celestone
Average number of
injections = 5 to 6
for 2 years

Total = 120
Epidural bupivacaine
0.25%, 10 mL = 60
Epidural
bupivacaine 0.25%,
10 mL + 40 mg of
methylprednisolone
= 60
Procedures
administered at L4-5
under fluoroscopic
guidance
Number of
injections = 1-2

Total = 400
Lidocaine Group:
Interlaminar = 139
Transforaminal = 61
Glucocorticoids plus
Lidocaine Group:
Interlaminar = 143
Transforaminal = 57
Lidocaine alone or
glucocorticoid plus
lidocaine
Variable doses

Study
Characteristics
Methodological
Quality Scoring

Manchikanti et al
2015 (799)
RA, AC, F
Central spinal
stenosis
Quality Scores:
Cochrane = 11/13
IPM-QRB = 43/48
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Ökmen & Ökmen
2017 (817)
RA, AC, F
Disc herniation
Quality Scores:
Cochrane = 12/13
IPM-QRB = 40/48

Friedly et al, 2014
(278,818)
RA, AC, F
Central and
foraminal spinal
stenosis
Quality Scores:
Cochrane = 8/13
IPM-QRB = 30/48

Significantly better
results in epidural
bupivacaine and
steroid group
Both groups
showed significant
improvement from
baseline, more
significant in the
steroid group than
bupivacaine alone
group.

No significant
differences or
improvement in
observational study

Significant
improvement. At 3
weeks and 6 weeks
RMDQ scores were
significantly less
in glucocorticoidlidocaine group
compared to
lidocaine group.
Leg pain was also
significantly less
in the steroid
group compared
to lidocaine alone
group.

Overall: LA 72% vs
LA with steroid 75%
Responsive: LA 78%
vs LA with steroid
83%

6 mos.

Significantly better
results in epidural
bupivacaine and
steroid group
Both groups
showed significant
improvement from
baseline, more
significant in the
steroid group than
bupivacaine alone
group.

Overall: LA 83% vs
LA with steroid 77%
Responsive: LA 90%
vs LA with steroid
86%

3 mos.

Pain Relief and Function

No significant
differences or
improvement in
observational study

Significantly better
results in epidural
bupivacaine and
steroid group
Both groups
showed significant
improvement from
baseline, more
significant in the
steroid group than

Overall: LA 77% vs
LA with steroid 67%
Responsive: LA 84%
vs LA with steroid
71%

12 mos.

N/A

N/A

Overall: LA
72% vs LA
with steroid
73%
Responsive:
LA 84% vs
LA with
steroid 85%

24 mos.

Both
treatments
effective with
superiority of
steroid with
lidocaine

Bupivacaine
steroids
superior

Both
treatments
effective

Short-term
≤ 6 mos.

Results

Table 13 (con’t). Characteristics of fluoroscopic randomized controlled trials of lumbar interlaminar epidural injections.

None

Bupivacaine
steroids
superior

Both
treatments
effective

> 6 mos.

Long-Term

None

Bupivacaine
steroids
superior

Both
treatments
effective

≥ 12 mos.

N/A

N/A

Both
treatments
effective

24 mos.

Large trial with
flawed design and
assessment with
positive results at
3 months. Even
though based on
flawed analysis it
shows negative
results. Multiple
flaws include not
only the design
and analysis of the
data, but patient
selection, technical
considerations, and
inherent bias.
Follow-up
observational
study has not
provided additional
information.

• Positive results
for both epidural
bupivacaine and
epidural bupivacaine
with steroids.
• Significant
improvement in
epidural bupivacaine
and steroid group
from baseline
with pain and
function, as well as
ODI compared to
bupivacaine.

• Positive results in a
large active control
trial.
• Both local
anesthetic alone
or with steroids
were effective with
no significant
difference between
the groups.
• On average, a total
of 5-6 injections
were administered
over a period of 2
years.

Comment(s)
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Overall: LA 83% vs
LA with steroid 77%
Responsive: LA 90%
vs LA with steroid
86%

Caudal = 57%
Interlaminar = 60%
Transforaminal =
83%

NRS, ODI,
employment
status, opioid
intake
Responsive
was defined as
those patients
responding with
at least 3 weeks
of improvement
with the first
2 procedures.
Significant
improvement:
50%
improvement
in pain and
function.
Numeric pain
score (0 - 10),
rating of pain
relief, ODI,
BDI, contrast
dispersion
pattern
Follow-up: 24
weeks

VAS, ODI, 50%
pain relief
Follow-up: 6
months

Visual analog
scale, Oswestry
Disability
questionnaire,
significant
improvement,
greater than
50% pain relief
from baseline,
Patient Global
Impression

Total = 120
Local anesthetics
= 60
Local anesthetics
and steroids = 60
Lidocaine alone or
with Celestone
Average number of
injections = 5 to 6
for 2 years

Total = 90
Caudal = 30
Interlaminar = 30
Transforaminal = 30
Methylprednisolone
+ saline
Number of
injections = 1 to 3

Total = 64
IL = 32
TF = 32
Lidocaine with
methylprednisolone
Number of
injections = 1 to 3

Total = 62
Parasagittal
interlaminar = 32
Transforaminal = 30
2 mL of
methylprednisolone
(80 mg) mixed with
2 mL of normal
saline for both PIL
and transforaminal
groups
Number of epidural
steroid injections:
Transforaminal
group: 60
PIL group: 58
Average procedures:
2

Manchikanti et al,
2013 (801)
RA, AC, F
Axial or discogenic
Quality Scores:
Cochrane = 11/13
IPM-QRB = 44/48

Ackerman &
Ahmad, 2007 (783)
RA, AC, F
Disc herniation or
radiculopathy
Quality Scores:
Cochrane = 8/13
IPM-QRB = 25/48

Rados et al, 2011
(821)
RA, AC, F
Disc herniation or
radiculopathy
Quality Scores:
Cochrane = 9/13
IPM-QRB = 30/48
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Ghai et al, 2014
(617)
RA, AC, F
Disc herniation or
radiculopathy
Quality Scores:
Cochrane = 10/13
IPM-QRB = 42/48
PIL group: 78%
Transforaminal
group: 77%

N/A

3 mos.

PIL group: 69%
Transforaminal
group: 77%

N/A

Interlaminar
lidocaine with
methylprednisolone
= 53%
Transforaminal
lidocaine with
methylprednisolone
= 63%

PIL group: 75%
Transforaminal
group: 77%

N/A

Overall: LA 77% vs
LA with steroid 67%
Responsive: LA 84%
vs LA with steroid
71%

12 mos.

Caudal = 57%
Interlaminar = 60%
Transforaminal
= 83%

Overall: LA 72% vs
LA with steroid 75%
Responsive: LA 78%
vs LA with steroid
83%

6 mos.

Pain Relief and Function
Outcome
Measures

Participants and
Interventions

Study
Characteristics
Methodological
Quality Scoring

N/A

N/A

N/A

Overall: LA
72% vs LA
with steroid
67%
Responsive:
LA 78% vs
LA with
steroid 70%

24 mos.

Effectiveness
in both arms

Effective
with both
approaches

Effective in all
arms

P

Short-term
≤ 6 mos.

Results

Table 13 (con’t). Characteristics of fluoroscopic randomized controlled trials of lumbar interlaminar epidural injections.

Effectiveness
in both arms

N/A

Effective in all
arms

P

> 6 mos.

Long-Term

Effectiveness
in both arms

N/A

N/A

P

≥ 12 mos.

N/A

N/A

N/A

P

24 mos.

This is relatively
small active control
trial with a longterm follow-up
assessing the role
of parasagittal
interlaminar
epidural injections
and transforaminal
epidural injections
showing equal
improvement with
steroids without
local anesthetic.

• Positive results
with short followup period in
comparison of 2
approaches with
lidocaine with
methylprednisolone

• Positive mid-term
results in a relatively
small trial.
• Shows
effectiveness of
steroids with all
approaches with
superiority of
transforaminal

• Positive results in a
large active control
trial.
• Both local
anesthetic alone
or with steroids
were effective with
no significant
difference between
the groups.
• On average, a total
of 5-6 injections
were administered
over a period of 2
years.
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Pain relief,
disability,
NRS, ODI,
use of opioid
medication
Follow-up: 12
months

Pain scores,
Oswestry low
back pain
disability
questionnaire

VAS, ODI

106 patients
Midline interlaminar
= 53
Parasagittal
interlaminar = 53
120 mg
methylprednisolone
with 2 mL of 0.5%
lidocaine
Number of
Injections: Not
available

Total = 200
Local anesthetic +
steroid = 100
Local anesthetic +
steroid + ketamine
= 100
Triamcinolone plus
preservative free
ketamine and 0.9%
saline
Number of
injections = 1

Transforaminal = 30
Number of
injections = 1-3
Interlaminar = 30
Number of
injections = 1-3
Caudal = 30
Number of
injections = 1-3

Candido et al, 2013
(843)
RA, AC, F
Disc herniation or
radiculopathy
Quality Scores:
Cochrane = 10/13
IPM-QRB = 37/48

Amr, 2011 (823)
RA, AC, F
Disc herniation or
radiculopathy
Quality Scores:
Cochrane = 12/13
IPM-QRB = 38/48

Kamble et al, 2016
(770)
RA, AC, F
Single level disc
prolapse
Quality Scores:
Cochrane = 9/13
IPM-QRB = 32/48

Outcome
Measures

Participants and
Interventions

Study
Characteristics
Methodological
Quality Scoring

N/A

Significant
improvement in
ketamine group

ODI
Midline = 36%
Parasagittal = 51%
Pain:
Midline = 29%
Parasagittal = 50%

3 mos.

Significant
improvement in
ketamine group

N/A

Transforaminal =
VAS baseline 7.1 ±
0.7 to 2.6 ± 0.7
ODI = 37.7 ± 2.83 to
16.8 ± 2.53
Interlaminar = VAS
baseline 7.0 ± 0.7 to
3.4 ± 1.4
ODI = 36.9 ± 2.82 to
21.4 ± 6.08
Caudal = VAS
baseline 7.2 ± 0.6 to
3.5 ± 1.0.
ODI = 38.3 ± 2.78 to
21.9 ± 3.35

ODI
Midline = 15%
Parasagittal = 56%
Pain:
Midline = 28%
Parasagittal = 55%

12 mos.

Significant
improvement in
ketamine group

ODI
Midline = 21%
Parasagittal = 55%
Pain:
Midline = 29%
Parasagittal = 53%

6 mos.

Pain Relief and Function

N/A

N/A

N/A

24 mos.

All 3
techniques
were effective

Effective with
addition of
ketamine to
bupivacaine
and
triamcinolone

Parasagittal
superior

Short-term
≤ 6 mos.

Results

Table 13 (con’t). Characteristics of fluoroscopic randomized controlled trials of lumbar interlaminar epidural injections.

N/A

Effective with
addition of
ketamine to
bupivacaine
and
triamcinolone

Parasagittal
superior

> 6 mos.

Long-Term

N/A

Effective with
addition of
ketamine to
bupivacaine
and
triamcinolone

Parasagittal
superior

≥ 12 mos.

N/A

N/A

N/A

24 mos.

While all 3
techniques
were effective,
transforaminal
group showed
superiority.
However, there
was no difference
between caudal
and interlaminar
approaches.

• Positive
randomized trial
for ketamine with
long-term follow-up
with ketamine with
local anesthetic and
steroid.

• The authors
showed significant
evidence that
parasagittal
approach with
injection of
local anesthetic
and steroids
was superior to
midline approach
of interlaminar
epidural injections.
• This study shows
combination of
methylprednisolone
with lidocaine
was superior
administered
with a parasagittal
approach compared
to midline approach.

Comment(s)
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P
N/A
JOA scores
Caudal = baseline
15.39 to 24.30
Transforaminal =
baseline 15.57 to
26.65
Interlaminar =
baseline 15.33 to 25

JOA scores
Caudal = baseline
15.39 to 24.02
Effectiveness =
74.3%
Transforaminal =
baseline 15.57 to
26.55
Effectiveness = 90%
Interlaminar =
baseline 15.33 to
24.72
Effectiveness =
77.7%
N/A
JOA score
Total = 140 patients
Caudal = 82
Transforaminal = 40
Interlaminar = 18
All were treated
with steroid and
local anesthetic with
or without sodium
chloride solution
Pandey, 2016 (769)
RA, AC, F
Disc prolapse
Quality Scores:
Cochrane = 8/13
IPM-QRB = 29/48
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RA = Randomized; AC = Active Control; F = Fluoroscopy; DB = Double-Blind; P = Positive; N = Negative; NA = Not Applicable; LA = local anesthetic; NRS = Numeric Rating Scale; ODI = Oswestry
Disability Index; VAS = Visual Analog Scale; PIL = Parasagittal Interlaminar; RMDQ = Roland Morris Disability Questionnaire; JOA = Japanese Orthopaedic Association; IPM-QRB = Interventional
Pain Management techniques - Quality Appraisal of Reliability and Risk of Bias Assessment

P
P

> 6 mos.

Short-term
≤ 6 mos.
24 mos.
12 mos.
6 mos.
3 mos.

Results
Pain Relief and Function

Outcome
Measures
Participants and
Interventions
Study
Characteristics
Methodological
Quality Scoring

Table 13 (con’t). Characteristics of fluoroscopic randomized controlled trials of lumbar interlaminar epidural injections.

Long-Term

≥ 12 mos.

N/A

24 mos.

Comment(s)

In comparing
caudal epidural
with interlaminar
and transforaminal,
authors showed
response in 74.3%
with caudal
route, 77.7% with
interlaminar,
and 90% with
transforaminal
approach.
Overall results are
positive. There is no
significant difference
between caudal
and interlaminar;
however,
transforaminal
appears to be
superior.
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spinal stenosis. Similar outcomes were seen in
60% to 84% of the patients in these studies. Both
Cochrane and IPM-QRB rated these studies as
high-quality (10 of 12 and either 43 or 44 of 48,
respectively).
These studies divided patients into responsive and nonresponsive groups. A patient was
considered responsive if a 50% improvement
in pain and function was achieved in the first 3
weeks with the initial 2 injections. Nonresponsive
patients in each pathology studied were: interlaminar injections of local anesthetic only - 10
with disc herniation, 5 with discogenic pain, and
9 with central stenosis; local anesthetic with steroids—1 with disc herniation, 6 with discogenic
pain, and 7 with central stenosis. These results
show that there were many in the nonresponsive
local anesthetic disc herniation group, but no
differences were noted between the subgroups
in the other pathologies studied. Also, the addition of steroids to the local anesthetic appears to
result in superior outcomes for pain at 6 months
and functional status at 12 months for those
with disc herniation (797). Patients who do not
respond to local anesthetic alone for disc herniation may achieve a better outcome with the addition of steroids. Of interest is the fact that none
of these studies had a placebo group.
Two studies were conducted by Ghai et al
(617,804). In the first study (617), they compared
parasagittal interlaminar and transforaminal epidural steroid injections without local anesthetic
in 62 patients. The results showed significant improvement at 3 months, 6 months, and 12 months
in 78%, 75%, 69% of patients in the parasagittal
interlaminar group compared to 77%, 77%, 77%
in the transforaminal epidural group. This was a
relatively small active control trial with a longterm follow-up assessing the role of parasagittal
interlaminar epidural injections and transforaminal epidural injections, showing equal improvement with steroids without local anesthetic. In
the second study, Ghai et al (617) compared local
anesthetic alone with local anesthetic with steroids in disc herniation or radiculitis. In an activecontrol trial of 34 patients in the local anesthetic
group and 35 in the local anesthetic with steroid
group, they administered 8 mL of local anesthetic
of 0.5% lidocaine, or 6 mL of local anesthetic with
steroid of 80 mg of methylprednisolone. The re-
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sults showed effectiveness in both groups at the end of
12 months. There was a superiority of steroids at the
3-month assessment; however, this dissipated over time.
Ökmen and Ökmen (817) published a randomized,
blinded, prospective study of efficacy of interlaminar
epidural steroid administration in multilevel intervertebral disc disease with chronic low back pain in 2017.
Their inclusion criteria were low back pain of more than
6 months, pain unresponsive to conservative treatment
methods, presence of MRI findings, disc bulge and protrusion for the definite diagnosis of lumbar disc pathology, the presence of nerve root compression symptoms,
and VAS above 5. They also had significant exclusion
criteria. They studied 98 patients with injection of 10
mL of 0.25% bupivacaine in 50 patients and bupivacaine
and steroid in 48 patients receiving 10 mL of 0.25% bupivacaine in addition to 40 mg of methylprednisolone
with all procedures performed at L4/5 intervertebral
space in prone position under the guidance of C-arm
fluoroscopy. They treated patients with a second epidural injection if they did not exhibit 50% reduction in
VAS score on day 15. Results showed a statistically significant difference between the groups in the VAS and
ODI scores measured at 3, 6, and 12 months between
the groups less than 0.05. The VAS and ODI scores were
higher in the local anesthetic group compared with the
steroid group at all time points. They also showed that
patients requiring a second injection did not show any
significant difference between the groups. Overall, this
is a well-designed study and showed effectiveness of
local anesthetic mixed with steroids. Further, this is the
first study utilizing the interlaminar approach showing
effectiveness of mixture with bupivacaine in contrast to
lidocaine (58,759,762,765,797,799,801).
Friedly et al (278,818) conducted a large study with
a poor and complicated design, which was not practical,
with high volume glucocorticoid steroid injection, but
low volume lidocaine alone injections. They provided
interlaminar epidural injections with lidocaine of 1-3
mL, 0.5% to 1%, whereas either interlaminar or transforaminal epidural injections with 1-3 mL of 0.25% to
1% of lidocaine. In addition to this, glucocorticoid was
added in rather high doses in the group for glucocorticoid as much as 60-120 mg of triamcinolone, 6-12 mg of
betamethasone, and 60-120 mg of methylprednisolone.
There was no equivalency in these doses. Administrations were highly variable based on practice patterns.
There was a total of 200 patients in each group. However, the interlaminar approach with lidocaine alone was
139 compared to 143 in the groups with steroids and
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61 had transforaminal lidocaine alone, whereas 57 had
transforaminal lidocaine with glucocorticoids with extremely high doses. The study period lasted 6 weeks. The
authors failed to assess the most common parameter,
i.e., 50% improvement, with pain and physical function
and the proportion of the patients. After 6 weeks, the
analysis was performed. without separation of interlaminar and transforaminal and with a large crossover
of the patients. Thus, it became an observational study.
Further, repeat injections were very infrequent. During
the first 6 weeks, only 76 patients (38%) in lidocaine
alone group, and 80 patients (40%) in corticosteroid
plus lidocaine group received a second injection. None
of them received 3 injections (818). It is not a practical
approach. In addition, during 6 to 12 weeks, 91 patients
(47.2%) in the lidocaine alone group received one injection and 26 patients (13.5%) received 2 injections, while
none received 3 or more. During the same period, in the
corticosteroid and lidocaine groups, 67 patients (34.7%)
received one injection and 28 or 14.5% received 2 injections. Finally, from 12 weeks to 12 months, over 66%
did not receive any additional injections (278). Only 12,
or 6.6%, in the lidocaine alone group, and 16.4%, or
31, in the corticosteroid plus lidocaine group received
one additional injection, while 12.6% and 13.8%, with
lidocaine alone or lidocaine with steroids, respectively,
received 3 or more injections. Overall, very few patients
received more than 3 injections. This is not a common
practice. Generally, responsive patients receive one injection once in 3 months, that is at least 4 injections if
they are not responding in the therapeutic phase, and
2 to judge in the diagnostic phase. Further, analysis was
not very clear. There was no analysis performed using
the proportion of patients obtaining 50% or greater relief. Further, there was no analysis separately provided
for lumbar interlaminar epidural injections compared
to transforaminal epidural injections. They also reported significant side effects because of the high dose
of steroids in the steroid group. Based on the strictest
criteria, this manuscript did not meet inclusion criteria.
However, to avoid criticism, this manuscript was utilized
in the analysis, which essentially showed similar effectiveness with lidocaine alone or lidocaine with steroids
and significant effectiveness from baseline to follow-up
periods utilizing mean improvement with leg pain intensity and disability index. Overall, despite a multitude
of issues related to the study, this can be considered
to be a positive study which shows lidocaine alone is
also effective, similar to with steroids, and also provides
basis that it is not a placebo. Finally, their conclusion
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was that epidural injections of corticosteroid plus lidocaine offered no benefit from 6 weeks to 12 months
beyond that of injection of lidocaine alone. Further,
they also opined that repeated injections of either type
offered no additional long-term benefit if injection in
the first 6 weeks did not improve pain. While this was
affirmed by Manchikanti et al in multiple manuscripts
(759,762,765,797,799,801,844), lack of effectiveness
was contradictory. If they consider a 2-point change in
leg pain intensity as a significant difference and their
results showed that leg pain intensity was reduced by a
minimum of 2.2 ± 2.9 to 2.9 ± 3.1, the study presented a
successful outcome rather than a lack of outcome with
similar effects of lidocaine alone and lidocaine with
steroids. This study also received extensive importance
being published in the New England Journal of Medicine and also AHRQ funded. However, it also received
substantial criticism in a full manuscript publication
(844) and letters to the editor (845-848).
Candido et al (843) assessed the correlation of pain
relief with concordant pressure paresthesia during
parasagittal interlaminar lumbar epidural injections
with local anesthetic alone or with local anesthetic and
steroids with 53 patients randomized to each group. Patients were administered 120 mg of methylprednisolone
acetate, combined with preservative free lidocaine, and
normal saline with a total volume of 4 mL. They showed
effectiveness of steroid mixed with local anesthetic with
lateral parasagittal interlaminar approaches in 55% of
the patients at one-year follow-up with pain and function. The results were superior in the parasagittal group
with pain relief, disability, and opioid intake.
Pandey (769) studied a comparison of caudal, transforaminal, and interlaminar routes in a randomized
trial. However, the number of patients were unevenly
distributed with 82 patients treated by the caudal
route, 40 by the transforaminal route, and 18 by the
interlaminar route. One of the disadvantages in this
study is disproportionate randomization with a small
proportion of patients in the transforaminal group
showing significant improvement and therefore may
not be statistically or clinically significant. Outcome
scores were calculated at 6 month and one year and
the effectiveness of medication was calculated for each
route. All patients were treated with methylprednisolone 80 mg in 2 mL. The steroid was mixed with normal
saline, 26 mL, plus 2% xylocaine 2 mL for the caudal
route, 2% xylocaine 4 mL for the interlaminar route, 2%
xylocaine 1 mL for the transforaminal route. However,
the volume was high for caudal route procedures. The
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results showed, at one year, average JOA scores of 15.39
baseline changing to 24.02 for caudal, 15.57 to 26.55 for
transforaminal, whereas for interlaminar, it was 15.33
to 24.72. The rate of improvement was 50% to 100%
in 74% of the patients in the caudal group, 78% in the
interlaminar group, and 90% in the transforaminal
group. Analysis showed significantly more effectiveness
of transforaminal than caudal and interlaminar routes
at both 6 months and one year after injection. However,
no significant difference was seen between the caudal
and interlaminar routes. The manuscript did not provide
the number of injections in any of the groups.
Kamble et al (770) in an RCT of comparison of
transforaminal epidural, lumbar interlaminar epidural,
and caudal epidural steroids included 90 patients with
30 patients in each group. Even though the manuscript
stated that all patients were followed up to 12 months
and the results were compared using change in VAS and
ODI, the published results, in fact, were only up to 6
months. In the transforaminal group, the patients were
given 40 mg of triamcinolone acetate with 1 mL of bupivacaine and 2 mL of lignocaine at each level. For the
interlaminar epidural injections, they provided 40 mg of
triamcinolone acetate with 1 mL of bupivacaine and 1
mL of lignocaine in a dilution of 10 mL of normal saline.
Similarly, for caudal epidural injections, they injected 40
mg of triamcinolone acetate with 1 mL of bupivacaine
and 2 mL of lignocaine in a dilution of 10 mL of normal saline. A maximum of 3 injections were used per
patient with a minimum interval of 2 weeks between
subsequent injections. The results showed significant
change at 6-month follow-up of VAS for transforaminal
from 7.1 ± 0.7 to 2.6 ± 0.7, and for interlaminar from
7.0 ± 0.7 to 3.4 ± 1.4. For caudal, the VAS was 7.2 ± 0.6
at baseline, which reduced to 3.5 ± 1.0. Two patients
in the transforaminal group and 3 patients in each of
the interlaminar and caudal groups underwent surgical intervention with a change from 6.672% to 10%.
It would have been interesting to see their results at
one year; however, these were not available. There
was no significant difference between interlaminar and
caudal epidural steroids. However, transforaminal was
judged to be superior for both short and long-term as
compared to interlaminar and caudal epidural steroid
injections for a single level disc prolapse.
Ackerman and Ahmad (783) compared caudal, interlaminar, and transforaminal epidural injections. They
reported similar efficacy for caudal and transforaminal
injections, but superiority for transforaminal in midterm results in a small, moderate-quality trial.
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In a study that received widespread attention, but
failed to meet inclusion criteria, Carette et al (827) reported that at 3 months neither normal saline nor saline with
depo-methylprednisolone injected in the lumbar epidural
spine was effective, despite some initial improvement
reported with the saline and steroid injection. Their methodology and conclusions have been criticized (849-852).

8.5.1 Evidence Synthesis
Based on the available studies, qualitative and
quantitative analysis was performed. Qualitative analysis data was derived from the data from this assessment.
Quantitative analysis data was derived from a multitude
of previous systematic reviews, which included conventional dual-arm analysis and single-arm analysis. Of the
13 studies included in this assessment (278,617,769,770
,783,797,799,801,804,817,818,821,823,843), there were
no placebo-controlled trials meeting the inclusion criteria. Among these, 4 studies assessed the role of epidural
procedures with local anesthetic with or without steroid
(797,804,817,823). One study (799) exclusively included
central spinal stenosis with interlaminar epidural injections with local anesthetic with or without steroids. One
study (801) was performed in axial or discogenic pain
with local anesthetics or local anesthetics with steroids
in axial or discogenic pain after eliminating facet joint
pain, as well as sacroiliac joint pain. Eight of the 14
studies were comparative analysis with interlaminar
compared to transforaminal epidural injections (617,7
69,770,783,818,821,823,843). Among these, 3 studies
(769,770,783) studied and compared all 3 modalities
including caudal, interlaminar, and transforaminal epidural injections. Four (278,617,818,821,843) compared
interlaminar with transforaminal epidural injections.
All of them included disc herniation patients except for
Friedly et al (278,818), including only patients suffering
with spinal stenosis. All the studies evaluating disc herniation without other modality of treatment showed
positive results. One of these studies had 24-month
follow-up and all others had at least one year follow-up.
While all the studies utilized lidocaine with or without
steroids, Ökmen and Ökmen (817) utilized bupivacaine
instead of lidocaine. The comparative studies showed
generally superiority of transforaminal epidural injections over interlaminar epidural injections in managing
disc herniation. With central stenosis, overall, 3 studies
were identified. The first study by Manchikanti et al
provided a 24-month follow-up with 120 patients in a
randomization of 60 patients in each group showing
positive results at 24 months with repeat injections.
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Friedly et al (818) showed inconclusive results in a poorly
designed and performed trial despite its publication in
New England Journal of Medicine and AHRQ funding.
Based on these high and moderate quality studies, the
level of evidence is Level I for disc herniation with strong
recommendation, Level II for spinal stenosis with moderate to strong recommendation, Level II for axial or discogenic pain with moderate to strong recommendation.
Multiple systematic reviews have been performed
assessing lumbar interlaminar epidural injections. The
focus has been either on transforaminal or lumbar interlaminar epidural injections. Overall, the results have
been positive except in reviews of inappropriate analysis. Manchikanti et al (75-77,81), Knezevic et al (58), and
Kaye et al (60) performed analysis separating into caudal, interlaminar, and transforaminal epidural injections
with evidence levels of I to II based on the RCTs.
Appropriately performed cost utility analysis also
showed lumbar interlaminar epidural injections to be
cost effective within the range of multiple interventional techniques and significantly better than surgical interventions at 2-year follow-up (853). However,
inappropriately performed cost utility analysis showed
lack of cost effectiveness (854). Manchikanti et al (853)
performed cost utility analysis of lumbar interlaminar
epidural in the treatment of lumbar disc herniation,
central spinal stenosis, and axial or discogenic low back
pain in 360 patients with 3 RCTs, with a total estimated
cost including direct and indirect costs of $3,425 for disc
herniation, $3,527 for axial or discogenic pain without
disc herniation, $2,961 for central spinal stenosis, and
an overall average cost for lumbar interlaminar epidural
injections of $3,301 respectively.

8.6 Lumbar Transforaminal Epidural Injections
Lumbar
transforaminal
epidural
injections’
effectiveness were evaluated in 43 studies (273276,617,618,660,662-664,666,699,700,783,820,821,855881). After application of inclusion criteria with fluoroscopic guidance, 6-month follow-up with reporting of
appropriate outcomes, 13 RCTs met inclusion criteria (2
73,276,617,769,770,783,818,821,856,857,860,879,881).
Methodologic quality assessment was performed utilizing Cochrane review criteria as shown in Appendix Table
9 and IPM-QRB criteria as shown in Appendix Table 10.
Table 14 shows the descriptive characteristic features of
included studies. Evaluation with both Cochrane and
IPM-QRB criteria, 9 were high-quality (273,276,617,77
0,821,856,857,860,881), and 5 were moderate-quality
(769,770,783,818,879).
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71% of steroid
group chose not
to have surgery
and 33% of
bupivacaine
group chose not
to have surgery

71% of
steroid
group chose
not to have
surgery
and 33% of
bupivacaine
group chose
not to have
surgery

Overall: LA
75% vs LA
with steroid
67%
Responsive:
LA 90% vs
LA with
steroid 82%

71% of
steroid
group chose
not to have
surgery
and 33% of
bupivacaine
group chose
not to have
surgery

Total = 120
Lidocaine = 60
Lidocaine with steroids = 60
Lidocaine vs lidocaine
mixed with steroid with
infraneural approach
Average number of
injections = 5 to 6 for 2 years

Total = 55
Bupivacaine alone (1 mL,
0.25%) = 27
Bupivacaine (1 mL,
0.25%) with steroid (1 mL
betamethasone) = 28
Number of injections = 1-4

Manchikanti et al,
2014 (860)
RA, AC, F
Disc herniation or
radiculopathy
Quality Scores:
Cochrane = 11/13
IPM-QRB =
44/48

Riew et al, 2000 &
2006 (275,276)
RA, AC, F
Disc herniation or
radiculopathy
Quality Scores:
Cochrane = 9/13
IPM-QRB =
32/48
Need for operative
treatment,
North American
Spine Society
Questionnaire
Follow-up: 1
months to 28
months

Overall: LA
75% vs LA with
steroid 57%
Responsive LA
92% vs LA with
steroid 73%

Overall: LA
73% vs LA
with steroid
67%
Responsive
LA 88% vs
LA with
steroid
87%

NRS pain scale,
ODI, employment
status, opioid intake
Responsive category
was defined as
at least 3 weeks
of significant
improvement
with the first 2
procedures.
Significant
improvement: 50%
improvement in
pain and function.

There were
no treatment
effects in
favor of either
treatment.

The
treatment
effects in
both leg
pain and
back pain
favored
the saline
treatment.

A significant
treatment
effect in
favor of
saline
treatment
for back
pain.

VAS, ODI,
Nottingham
Health Profile,
cost, physical
examination
Follow-up: 12
months with only
initial procedures

Total=160
Methylprednisolonebupivacaine = 80
Saline = 80
Sodium chloride solution, or
methylprednisolone (40 mg)
and bupivacaine (5 mg)
Number of injections = 1

Karppinen et al,
2001 (856)
RA, PC, F
Disc herniation or
radiculopathy
Quality Scores:
Cochrane = 13/13
IPM-QRB =
34/48

N/A

Overall: LA
65% vs LA
with steroid
57%
Responsive
LA 80% vs
LA with
steroid 73%

N/A

24 mos.

P

Effectiveness
in both
groups.
Lidocaine
alone or
with steroids
effective.

Lack of
effectiveness
of steroid
with
bupivacaine

P

Effectiveness
in both
groups.
Lidocaine
alone or
with steroids
effective.

Lack of
effectiveness
of steroid
with
bupivacaine

P

Effectiveness
in both groups.
Lidocaine alone
or with steroids
effective.

Lack of
effectiveness
of steroid with
bupivacaine

Short-term Long-Term
≤ 6 mos.
> 6 mos.
≥ 12 mos.

12 mos.

3 mos.

6 mos.

Results

Pain Relief and Function

Outcome
Measures

Study
Characteristics Participants and
Methodological Interventions
Quality Scoring

Table 14. Characteristics of fluoroscopic randomized controlled trials of lumbar transforaminal epidural injections.

N/A

Effectiveness
in both
groups.
Lidocaine
alone or
with steroids
effective.

N/A

24 mos.

• Epidural bupivacaine with
steroids was significantly
more effective than
transforaminal bupivacaine
with steroids was
significantly more effective
than epidural bupivacaine
alone in avoiding surgery.

• Similar results with local
anesthetic or with local
anesthetic and steroids.
• Nonresponsive patients:
local anesthetic = 11, steroids
= 15.
• Local anesthetics were
somewhat superior, though
not statistically significant.
• On average, a total of 5-6
injections were administered
over a period of 2 years.

• An ineffective or
inappropriate placebo
design, without applicable
results.
• Overall saline appears
to have been superior at 3
months and 6 months, but
no significant difference
at one year between both
groups.
• Leg pain decreased on
average by 65% in both
groups.
• Surgery was avoided in the
majority of the patients with
18 patients in the steroid
group and 15 in the saline
group undergoing surgery.
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Outcome
Measures

VAS, ODI, LBOS
Avoidance of
surgery
Outcomes: 12
weeks
1 year for surgery
Excellent
outcome

Outcome
measures
included visual
numeric score,
Roland-Morris
score, finger to
floor distance,
and patient
satisfaction score.
Outcomes were
measured at 3
weeks, 6 weeks,
3 months, 6
months, and 12
months.

Participants and
Interventions

Total: 150 patients
Lumbar disc
herniation: 76
Local anesthetic = 34
Local anesthetic with
steroid = 42
Local anesthetic
group: Injection
of 2 mL of 0.25%
bupivacaine
Local anesthetic
with steroid group:
Injection of 2 mL of
0.25% bupivacaine
and 40 mg of
methylprednisolone.
Bupivacaine only:
Lumbar disc
herniation: 34
Foraminal stenosis:
25
Bupivacaine with
steroids
Lumbar disc
herniation: 42
Foraminal stenosis:
23
Number of
injections = 1 to 3

Total: 50 patients
Transforaminal: 25
Trigger point
injections: 25
Transforaminal
injections were
performed by safe
triangle approach
or sacral foramen
injection utilizing
contrast followed
by 1.5 mL of
betamethasone
acetate 9 mg and
1.5 mL of 2%
preservative free
Xylocaine. Trigger
point injections were
performed with 3
mL of normal saline

Study
Characteristics
Methodological
Quality Scoring
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Tafazal et al, 2009
(881)
RA, AC, F
Disc herniation or
radiculopathy and
spinal stenosis
Quality Scores:
Cochrane = 11/13
IPM-QRB = 32/48

Vad et al, 2002
(879)
RA, AC, F
Disc herniation or
radiculopathy
Quality Scores:
Cochrane = 5/13
IPM-QRB = 16/48

In
transforaminal
group 84%
showed
improvement
in trigger point
injection group
48% showed
improvement

ODI:
LA 13.8 ± 3.7
versus LA with
steroid 13.6
± 3.1
VAS leg pain:
LA 24.3 ± 5.5
versus LA with
steroid 27.4.6
± 4.7

In transforaminal
group 84% showed
improvement.
in trigger point
injection group
48% showed
improvement

N/A

In
transforaminal
group 84%
showed
improvement
in trigger
point injection
group 48%
showed
improvement.

Disc herniation
group showed
greater
reduction in
the ODI with
a mean change
of 15 points
from baseline
of 46.6 in the
bupivacaine
only group
and 43.4 in
bupivacaine
and steroid
group. There
was a mean
change in the
VAS of 26 mm
in the disc
prolapse group.

N/A

N/A

24 mos.

Transforaminal
steroids with
lidocaine
effective

Excellent to
good outcomes
in 54%
Bupivacaine
alone and
bupivacaine
with steroid are
both effective

Short-term
≤ 6 mos.

12 mos.

3 mos.

6 mos.

Results

Pain Relief and Function

Table 14 con’t. Characteristics of fluoroscopic randomized controlled trials of lumbar transforaminal epidural injections.

Transforaminal
steroids with
lidocaine
effective

N/A

> 6 mos.

Long-Term

Transforaminal
steroids with
lidocaine
effective

The
requirements
for treatments
were the
same in local
anesthetic
alone group or
local anesthetic
with steroids.
Overall surgery
rates was 18%,
the surgery rate
was 22% in the
bupivacaine
only group
and 14% in the
bupivacaine
and steroid
group.

≥ 12 mos.

N/A

N/A

24 mos.

This is a randomized
trial, but
randomization was
by patient choice with
patients receiving
either a high dose
transforaminal
epidural steroid
injection or
saline trigger
point injection.
Study yielded
positive results
for transforaminal
epidural injections at
one-year follow-up.

• There was no
significant difference
between both groups.
Surgery was avoided in
both groups.
• Corticosteroid
addition to local
anesthetic failed to
provide any additional
benefit when
compared to local
anesthetic injection
alone.
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Outcome
Measures
Numeric pain
score (0 - 10),
rating of pain
relief, ODI,
BDI, contrast
dispersion
pattern
Follow-up: 24
weeks

VAS, ODI, 50%
pain relief
Follow-up: 6
months

VAS
Follow-up: 7-30
days
6 months

Visual analog
scale, Oswestry
Disability
questionnaire,
significant
improvement,
greater than
50% pain relief
from baseline,
Patient Global
Impression

Participants and
Interventions

Total=90
Caudal = 30
Interlaminar = 30
Transforaminal = 30
Steroid and saline
with local anesthetic
Number of
injections = 1 to 3

Total=64
Interlaminar = 32
Transforaminal = 32
Lidocaine with
methylprednisolone
Number of
injections = 1 to 3

Total=193
Ganglionic = 104
Preganglionic = 89
0.5 mL of
bupivacaine
hydrochloride and
40 mg of 1 mL of
triamcinolone
Number of
injections = 1

Total = 62
Parasagittal
interlaminar = 32
Transforaminal = 30
2 mL of
methylprednisolone
(80 mg) mixed with
2 mL of normal
saline for both PIL
and transforaminal
groups
Number of epidural
steroid injections:
Transforaminal
group: 60
PIL group: 58
Average procedures:
2

Study
Characteristics
Methodological
Quality Scoring

Ackerman &
Ahmad, 2007 (783)
RA, AC, F
Disc herniation or
radiculopathy
Quality Scores:
Cochrane = 8/13
IPM-QRB = 25/48

Rados et al, 2011
(821)
RA, AC, F
Disc herniation or
radiculopathy
Quality Scores:
Cochrane = 9/13
IPM-QRB = 30/48

www.painphysicianjournal.com

Jeong et al, 2007
(857)
RA, AC, F
Disc herniation or
radiculopathy
Quality Scores:
Cochrane = 10/13
IPM-QRB = 31/48

Ghai et al, 2014
(617)
RA, DB, AC, F
Disc herniation or
radiculopathy
Quality Scores:
Cochrane = 10/13
IPM-QRB = 42/48
PIL group: 78%
Transforaminal
group: 77%

Preganglionic =
88.4%
Ganglionic =
70.9%

N/A

Caudal = 57%
Interlaminar
= 60%
Transforaminal
= 83%

PIL group: 75%
Transforaminal
group: 77%

PIL group: 69%
Transforaminal
group: 77%

N/A

N/A

Interlaminar
lidocaine with
methylprednisolone
= 53%
Transforaminal
lidocaine with
methylprednisolone
= 63%

Preganglionic =
60.4%
Ganglionic = 67.2%

N/A

Caudal = 57%
Interlaminar = 60%
Transforaminal
= 83%

N/A

N/A

N/A

N/A

24 mos.

Effectiveness
in both arms

Both
approaches
effective

N/A

Effective in all
arms

Short-term
≤ 6 mos.

12 mos.

3 mos.

6 mos.

Results

Pain Relief and Function
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Effectiveness
in both arms

Both
approaches
effective

Effective
with both
approaches

Effective in all
arms

> 6 mos.

Long-Term

Effectiveness
in both arms

N/A

N/A

N/A

≥ 12 mos.

N/A

N/A

N/A

N/A

24 mos.

This relatively small
active control trial
with a long-term
follow-up assessed
the role of parasagittal
interlaminar
epidural injections
and transforaminal
epidural injections
showing equal
improvement with
steroids without local
anesthetic.

Moderate quality
study with mid-term
positive results.

• Positive results
with short follow-up
period in comparison
of 2 approaches
with lidocaine with
methylprednisolone

• Positive mid-term
results in a relatively
small trial.
• Shows effectiveness
of steroids with
all approaches
with superiority of
transforaminal

Comment(s)
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Outcome
Measures

NRS, RMDQ
Follow-up: 6
weeks

NRS, ODI,
at least 50%
reduction in pain
and disability
scores

VAS, ODI

Participants and
Interventions

Total = 400
Lidocaine Group:
Interlaminar = 139
Transforaminal
= 61
Glucocorticoids
plus lidocaine
Group:
Interlaminar = 143
Transforaminal
= 57
Lidocaine alone or
glucocorticoid plus
lidocaine
Variable doses

Total patients = 78
Dexamethasone 15
mg or 1.5 mL = 41
patients
Triamcinolone 60
mg or 1.5 mL = 37
patients
Number of
Injections: 1 to 3

Transforaminal = 30
Number of
injections = 1-3
Interlaminar = 30
Number of
injections = 1-3
Caudal = 30
Number of
injections = 1-3

Study
Characteristics
Methodological
Quality Scoring

Friedly et al, 2014
& 2017 (278,818)
RA, AC, F
Spinal stenosis
Quality Scores:
Cochrane = 8/13
IPM-QRB = 30/48

Kennedy et al,
2014 (273)
RA, AC, F
Disc herniation or
radiculopathy
Quality Scores:
Cochrane = 10/13
IPM-QRB = 30/48

Kamble et al, 2016
(770)
RA, AC, F
Single level disc
prolapse
Quality Scores:
Cochrane = 9/13
IPM-QRB = 32/48

N/A

Transforaminal =
VAS baseline 7.1 ±
0.7 to 2.6 ± 0.7
ODI = 37.7 ± 2.83
to 16.8 ± 2.53
Interlaminar = VAS
baseline 7.0 ± 0.7 to
3.4 ± 1.4
ODI = 36.9 ± 2.82
to 21.4 ± 6.08
Caudal = VAS
baseline 7.2 ± 0.6 to
3.5 ± 1.0.
ODI = 38.3 ± 2.78
to 21.9 ± 3.35

N/A

N/A

Dexamethasone
group 73%
reduction in
pain scores, 71%
reduction in ODI
scores
Triamcinolone
group 76%
reduction in
pain scores, 65%
reduction in ODI
scores

Dexamethasone
group 73%
reduction in
pain scores,
68% reduction
in ODI scores
Triamcinolone
group 73%
reduction in
pain scores,
68% reduction
in ODI scores

N/A

N/A

All 3
techniques
were effective;
however,
transforaminal
group showed
superiority.
There was
no difference
between
caudal and
interlaminar
approaches

Both drugs
effective

Both
treatments
effective

No significant
differences or
improvement
in
observational
study

No significant
differences or
improvement in
observational
study

Significant
improvement.
At 3 weeks and
6 weeks RMDQ
scores were
significantly
less in
glucocorticoidlidocaine group
compared
to lidocaine
group. Leg
pain was also
significantly
less in the
steroid group
compared to
lidocaine alone
group.
N/A

Short-term
≤ 6 mos.

24 mos.

6 mos.

3 mos.

12 mos.

Results

Pain Relief and Function
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N/A

Both drugs
effective

Neither
treatment was
effective

> 6 mos.

Long-Term

N/A

N/A

Neither
treatment was
effective

≥ 12 mos.

N/A

N/A

N/A

24 mos.

While all 3 techniques
were effective,
transforaminal group
showed superiority.
However, there
was no difference
between caudal
and interlaminar
approaches.

• This is one of the
studies showing
effectiveness of
steroids without local
anesthetic.
• Relatively small study
with short-term followup only

Large trial with flawed
design and assessment
with positive results
at 3 months. Even
though based on
flawed analysis
it shows negative
results. Multiple flaws
include not only the
design and analysis of
the data, but patient
selection, technical
considerations, and
inherent bias.

Comment(s)
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RA = Randomized; AC = Active Control; F = Fluoroscopy; PC = Placebo Control; DB = Double-Blind; P = Positive; N = Negative; NA = Not Applicable; LA = local anesthetic; IPM-QRB = Interventional Pain Management techniques -- Quality Appraisal of Reliability and Risk of Bias Assessment; NRS = Numeric Rating Scale; ODI = Oswestry Disability Index; VAS = Visual Analog Scale; LBOS = Low
Back Outcome Score; PIL = Parasagittal Interlaminar; RMDQ = Roland Morris Disability Questionnaire; JOA = Japanese Orthopaedic Association; BDI = Beck Depression Inventory

P
N/A
JOA score
Total = 140 patients
Caudal = 82
Transforaminal = 40
Interlaminar = 18
All were treated
with steroid and
local anesthetic with
or without sodium
chloride solution
Pandey, 2016 (769)
RA, AC, F
Disc prolapse
Quality Scores:
Cochrane = 8/13
IPM-QRB = 29/48

N/A

JOA scores
Caudal = baseline
15.39 to 24.30
Transforaminal =
baseline 15.57 to
26.65
Interlaminar =
baseline 15.33 to 25

JOA scores
Caudal =
baseline 15.39
to 24.02
Effectiveness =
74.3%
Transforaminal
= baseline
15.57 to 26.55
Effectiveness
= 90%
Interlaminar =
baseline 15.33
to 24.72
Effectiveness =
77.7%

P

P

> 6 mos.

Short-term
≤ 6 mos.
6 mos.

24 mos.
3 mos.

12 mos.

Results
Pain Relief and Function

Outcome
Measures
Participants and
Interventions
Study
Characteristics
Methodological
Quality Scoring

Table 14 con’t. Characteristics of fluoroscopic randomized controlled trials of lumbar transforaminal epidural injections.

Long-Term

≥ 12 mos.

N/A

24 mos.

Comment(s)

In comparing
caudal epidural with
interlaminar and
transforaminal, authors
showed response in
74.3% with caudal
route, 77.7% with
interlaminar, and 90%
with transforaminal
approach.
Overall results are
positive. There is no
significant difference
between caudal and
interlaminar; however,
transforaminal appears
to be superior.

ASIPP Epidural Guidelines

Karppinen et al (856) conducted a high-quality
study as graded by both Cochrane and IPM-QRB criteria.
Their study looked at the efficacy of a single injection
of either sodium chloride solution or local anesthetic
with steroid. They followed patients for up to one year.
Patients who received sodium chloride fared better at
3 months and 6 months, but there was no significant
difference at one year. However, in a subgroup analysis (882), they reported that in patients who had disc
protrusions, local anesthetic with steroid had a better
efficacy than just sodium chloride. There has been
significant related criticism (883,884). In addition, Karppinen et al (882) also calculated cost effectiveness of
periradicular infiltration for sciatica based on subgroup
analysis of an RCT. Obviously, these types of assessments
never yield appropriate cost effectiveness results.
Manchikanti et al (860) conducted an active control
trial that followed 120 patients for 2 years. They used
an infraneural approach, injecting either local anesthetic alone or local anesthetic with steroid. At the end
of the 2-year study period, 65% of those who received
local anesthetic alone and 57% who received local anesthetic with steroid had significant improvement in all
measured categories: pain intensity, function, and medication reduction. A subcategory analysis of patients
who responded to the treatment—determined as those
who had at least a 50% improvement in pain and function for 3 weeks with the first 2 injections—reported
that 80% of those who received local anesthetic alone
saw improvement and 73% of those who received local
anesthetic with steroid saw improvement.
Tafazal et al (881) conducted a study on spinal
stenosis and disc herniation treated either with local
anesthetic alone or local anesthetic with steroid. Only
disc herniation inclusion criteria were met. Superior results were reported for sciatica with similar efficacy for
local anesthetic alone and local anesthetic with steroid.
Cohen et al (876), in a seemingly flawless study, assessed epidural steroid injections compared to gabapentin for lumbosacral radicular pain. However, the study
had numerous flaws including using a safe triangle
approach when injecting particulate steroids, a flawed
design and analysis of the data, and an inordinately
high proportion of patients who withdrew from the
study even at the 3-month follow-up (632,633,885,886).
Consequently, the study was excluded. The inclusion criteria were also extremely weak with some patients who
had less than 3 months of pain and some who had 3 to
6 months. The gabapentin dosage was higher than usually administered in clinical settings at 1800 to 3600 mg
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per day without proven efficacy (211). Overall, this trial
showed no significant improvement in either group.
Ghahreman et al’s (274) follow-up period was even
shorter - only one month. Their study was also small but
included multiple arms. Consequently, the study was
excluded. They reported that local anesthetic with steroids was vastly superior to local anesthetic alone: 54%
improvement versus only a 7% improvement. This study
also had an arm that received a true placebo—sodium
chloride solution injected away from the nerve root.
They reported a lack of efficacy for this placebo, but
when one study arm was injected with sodium chloride
into the source of pain, there was a significant effect,
though not as great as local anesthetic with steroids.
In a small study by Riew et al (275,276), patients
with disc herniation were injected either with local
anesthetic alone or local anesthetic with steroid. Their
outcome measure was avoidance of surgery; 33% of
those in the local anesthetic alone group and 71% in
the local anesthetic with steroid group avoided surgery.
While both treatments were deemed effective, local
anesthetic with steroid was deemed superior.
The remaining trials were of an active control
nature with Vad et al (879) comparing transforaminal
epidural injections with local anesthetic with steroid
with trigger point injections, demonstrating an overwhelming superiority for transforaminal epidural injections; however, this was a moderate quality trial, barely
meeting inclusion criteria. Ackerman and Ahmad (783)
compared caudal, interlaminar, and transforaminal approaches which showed transforaminal to be superior
to interlaminar and caudal; however, this was a small
trial with only a 6-month follow-up; it was also of
moderate quality. Jeong et al (857) compared a ganglionic and pre-ganglionic approach in a large population;
however, with only a 6-month follow-up, no significant
difference was shown between pre-ganglionic and ganglionic approaches. Similarly, Park et al (618) assessed
the role of transforaminal epidural injections using a
supraneural approach, otherwise known as a safe triangle approach, comparing it to the Kambin triangle
approach. This was a relatively small study showing no
significant difference between both approaches at 3
months, not included in evidence synthesis. Rados et al
(821) and Ghai et al (617) compared interlaminar epidural injections with transforaminal, while Rados et al
(821) utilized a standard epidural injection technique;
Ghai et al (617) utilized a parasagittal interlaminar
approach. Rados et al (821) showed the superiority of
transforaminal in a small study and they (617) showed
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no significant difference with a parasagittal approach
compared to a transforaminal approach.
As described in the section on interlaminar epidural
injections, Friedly et al (818) conducted an inappropriate
and flawed assessment combining lumbar interlaminar
epidural injections with lumbar transforaminal epidural
injections. There were multiple flaws in the design as
well as the analysis leading to an inappropriate interpretation and conclusions (844).
In one trial (273), transforaminal epidural injections were compared with particulate versus nonparticulate corticosteroids. Comparative effectiveness of
transforaminal with particulate versus nonparticulate
corticosteroid showed effectiveness of triamcinolone
and dexamethasone with pain relief and improvement
in functional status up to 6 months, without clear differences between groups.
Among the newer studies (769,770), Pandey (769)
assessed the efficacy of epidural steroid injection in
management of lumbar prolapsed intervertebral disc in
comparative evaluation with caudal, interlaminar, and
transforaminal approaches. They included a total of
140 patients with randomization into 3 groups with 80
patients using the caudal approach, 40 patients by the
transforaminal approach, and 8 patients with interlaminar approach by a simple randomization; however, this
randomization is not uniform. Utilizing JOA scores they
calculated the improvement at 6 months and one-year
and effectiveness of the medication for each route. Their
results showed that one-year after injecting the steroid,
all three routes were found to be effective in improving
JOA scores with caudal route showing improvement in
74.3%, interlaminar showing improvement in 77.7%,
and transforaminal route in 90%. They also showed that
the transforaminal route was significantly more effective than caudal and interlaminar at both 6 months and
one-year after injection. No significant differences were
seen between the caudal and interlaminar approaches.
The limitations of this study include unequal randomization and lack of data showing significant improvement.
Kamble et al (770) studied 90 patients randomized
to 3 groups with approaches of caudal, interlaminar, and
transforaminal with randomization with 30 patients in
each group in a single level disc prolapse patients confirmed by MRI. They followed the patients for 12 months
and the results were compared using change in VAS
score and ODI; however, they presented only 6-month
results. Their results showed the change in pain scores
were statistically different at 1- and 6-month intervals
such as that a higher change was observed by trans-
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foraminal route as compared to the other two. There
was no difference in the change of scores between interlaminar and caudal routess. For ODI scores, a greater
change was seen in transforaminal at all times as compared to the other 2. There was no difference in change
of scores between interlaminar and caudal route at any
time of the assessment. The VAS scores changed from
7.1 to 2.6 at 6-month follow-up in the transforaminal
group compared to 7.0 to 3.4 in the interlaminar group,
and 7.2 to 3.5 in the caudal group. Similarly, ODI scores
changed from 37.7 to 16.8 in the transforaminal group
compared to 36.9 to 21.4 in the interlaminar group and
38.3 to 21.9 in the caudal group. Overall, these results
showed positive results; however, as shown above,
positive results with transforaminal being superior, but
the 12-month results were not published and also 50%
relief criteria was not performed.
While the studies considered here concentrated on steroids, there is also significant literature
on tumor necrosis factor alpha (TNF-α) inhibitors
(660,662,666,861,863,865,887-890).
Freeman et al (863) performed a randomized, double-blind, placebo-controlled trial of transforaminal epidural TNF-α for the treatment of symptomatic lumbar
disc herniation. They included 49 subjects with lumbosacral radicular pain secondary to lumbar disc herniation
and treated them with either TNF-α or placebo. Inclusion criteria were lumbosacral radicular pain secondary
to lumbar disc herniation and an average leg pain intensity of 5/10 or more. Patients received 2 transforaminal
epidural injections, 2 weeks apart, and were assessed
for efficacy up to 26 weeks for the second injection.
The primary outcome measure was the change in mean
daily worse leg pain. They utilized multiple outcome
measures. The results showed transforaminal epidural
injection was carried out with the injection of 2 mL of
injectate. The injectate was variable, ranging from 0.5
mg, 2.5, 12.5 mg of etanercept, and placebo. Essentially,
there were 12 patients in each group, except for 2.5 mg
of etanercept group, where there were 13 patients. The
results showed that 43 of the 49 randomized patients
completed the study. Patients receiving 0.5 mg of etanercept showed a clinically and statistically significant
reduction in mean daily worst leg pain compared with
the placebo cohort from 2 to 26 weeks for both the per
protocol population and the intention-to-treat analysis.
Fifty percent of these subjects reported 100% reduction
in worst leg pain at 4 weeks post treatment compared
with 0% subjects in the placebo cohort. Improvement
in all secondary outcomes were also observed in the 0.5
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mg etanercept cohort. The overall incidence of adverse
events was similar in placebo and all etanercept cohorts.
Improvement was seen in all groups; however, the best
results were obtained in 0.5 mg etanercept group,
rather surprisingly.
Dagar et al (865) in a study of transforaminal epidural etanercept followed the patients for 2 months
with injection of 2 transforaminal epidural injections
of etanercept, 2 mg, 2 weeks apart, assessing the efficacy up to 3 months after the second injection. Results
showed 31 of 33 enrolled patients completed the study
and showed clinically and statistically significant reduction in VAS for leg pain and back pain and ODI.
Cohen et al (660) performed transforaminal
epidural injection of etanercept with 3 groups of 6
patients who received etanercept in escalating doses.
Two patients in each group received sham saline injection. They also conducted concurrent animal studies
to assess the histologic changes and functional deficits
in beagle dogs treated with perineural transforaminal
etanercept. Clonidine was safety tested extensively,
and only after these studies demonstrated no histological damage or neurologic deficits, open-label and
prospective trials conducted, ultimately resulting in
the FDA approval for epidural administration in cancer
neuropathic pain (887,888). After the initial phase of
this epidural etanercept study the authors were advised
of the need for investigational new drug requirement
for nonfood drug administration approved drugs for
neuraxial administration. The human study was temporarily halted until the patients who had been studied
to date received MRI showing absence of pathology,
and screening MRI procedures were then mandated for
subsequent patients. Since then, multiple other studies
have been conducted. Cohen et al (660) did not show a
dose response relationship with increasing doses of the
active agents as others. However, this aspect is troubling
because the mechanism of binding and inactivation of
TNF-a suggests that there should be a dose response.
There was very little difference in ODI numerical improvement, particularly in the higher dose etanercept
group as compared to saline.
Other studies included intravenous administration of etanercept (662). Some included short-term
follow-up, whereas a few other studies included intravenous administration. Okoro et al (662) in a 3-month
follow-up with intravenous administration concluded
that small numbers of trial participants limited the
statistical analysis; however, they also concluded that
the trend appears to show no benefit to the use of
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etanercept over placebo in the pharmacological treatment of sciatica. Korhonen et al (664), also administering intravenous, with one-year follow-up showed
the long-term results of this randomized trial did not
support the use of TNF-α compared with placebo for
lumbar radicular pain. A further study in a subgroup of
patients, especially in the presence of Modic changes,
appears to be warranted. Ohtori et al (666) studied
transforaminal approach and provided only 2 weeks of
follow-up, comparing with dexamethasone. They concluded that epidural administration with only 2 weeks
of administration TNF-a inhibitor into the spinal nerve
produced pain relief.
Wei et al (861) compared lidocaine with steroids
and lidocaine with TNF-α inhibitor in the treatment of
lumbar stenosis. In this RCT, they included 30 patients in
each group and also followed them through 6 months.
Overall results showed significant improvement in
patients receiving lidocaine and TNF-α inhibitor with
VAS and the disability index. There was no significant
difference in the groups with lidocaine with steroids
(Diprospan) or lidocaine only groups.
Overall, it appears that TNF-a inhibitor drugs may
have an effect in lumbar radicular pain. In an editorial, Huntoon (887) reviewed pre-clinical and clinical
evidence of TNF-a inhibitor. It appears that there may
be a role for TNF-a blockers in managing radicular pain.
The risk may be that the FDA has a Black Box Warning placed in May 2008, because of the potential for
several adverse occurrences. Thus, the use of etanercept
must be weighed against these risks (anaphylaxis, immune deficiency, sepsis, tuberculosis, reactivation or
novel infection), and the rare possibility of lymphoma.
To understand the true incidence of infections of the
neuraxis would likely require thousands of applications
of these drugs over many years to compare them to steroids (887). Further, the high incidence of radicular pain
worldwide mandates a safe therapy, because of the potential for high incidence of sciatica worldwide and also
high incidence of high prevalence of epidural injections
in the elderly which mandates a safe therapy. Thus,
many trials have to be shown to be safe and effective.
Huntoon (887) raised the possibilities of issues related to
inadvertent injection into a radicular artery. The authors
thus far do not comment on these issues. Further, all
of them utilized supraneural approach, which is prone
to causing intraarterial injections. Consequently, it is
strongly cautioned against attempting to inject etanercept until further studies have been performed. In
addition, cost is also a major factor.
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8.6.1 Evidence Synthesis
The evidence was synthesized based on qualitative and quantitative analysis. Qualitative analysis was
performed based on present assessment, whereas quantitative analysis was utilized from previous systematic
reviews, which included conventional dual-arm and single-arm analysis in multiple manuscripts. In this analysis,
with the inclusion of 13 RCTs (273,275,617,769,770,783
,818,821,856,857,860,879,881), there was only one RCT
utilizing sodium chloride solution (856), which was considered as placebo even though there are a multitude of
questions in relation to injecting sodium chloride solution over an active structure (56). The remaining were
all active-controlled trials. Consequently, a total of 12
of 13 studies focused on disc herniation with transforaminal epidural injections. Friedly et al (278,818) studied central and foraminal spinal stenosis. Other studies
were comparative analysis between lumbar interlaminar and transforaminal epidural injections or caudal,
interlaminar, and transforaminal epidural injections or
preganglionic and postganglionic approaches or comparative analysis among the drugs with dexamethasone
and triamcinolone (273,617,843) and all 3 approaches
were utilized (699,700,783). In disc herniation, among
the 5 RCTs included, the only trial which is considered
as placebo-controlled has shown lack of effectiveness
even though in subgroup analysis, they felt it was effective and also they performed cost utility analysis. The
remaining 4 trials (275,860,879,881) showed positive
results. The larger studies by Manchikanti et al with
120 patients and 24-month follow-up showed positive
results at 24 months (860). However, these results were
not superior to interlaminar epidural injections or caudal
epidural injections (614). Tafazal et al (881) in studying
150 patients with radiculitis secondary to disc herniation
or spinal stenosis showed positive results with no significant difference with local anesthetic alone or with local
anesthetic and steroid. Vad et al (879) in a moderate
quality study showed positive results with a 12-month
follow-up in 50 patients receiving transforaminal epidural injections. Further, multiple other studies comparing
interlaminar and transforaminal in disc herniation also
showed positive results (617,699,700,783,841,857). The
quantitative analysis and previous systematic reviews
also showed positive evidence. Consequently, the evidence for transforaminal epidural injections in lumbar
disc herniation is Level I with strong recommendation.
Riew et al (275) in a small study of 55 patients utilized bupivacaine alone or bupivacaine with steroids to
assess the avoidance of surgery. They showed that 71%
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of the steroid group chose not to have to surgery and
33% of bupivacaine group not to have surgery. Overall,
bupivacaine with steroids were effective even though
bupivacaine alone was not effective.
For spinal stenosis, Friedly et al (818) performed
a poorly designed and executed study with negative
results for transforaminal epidural injections. Tafazal et
al (881) also studied spinal stenosis, along with disc herniation in a total of 150 patients with 64 patients with
spinal stenosis. They also showed positive results with
local anesthetic, as well as steroids. However, there was
no significant difference between steroid and local anesthetic. Consequently, the level of evidence is Level IV
to III with moderate recommendation of transforaminal
epidural injections in managing central spinal stenosis.
One study (273) also evaluated the role of dexamethasone versus triamcinolone showing equivocal results in a relatively small study without local anesthetic.
One study (857) compared ganglionic and preganglionic
approaches with a 6-month follow-up showing the effectiveness of both approaches. The studies comparing
interlaminar epidural injections with transforaminal
(617,699,700,783,821) showed either equivalent improvement or superiority of transforaminal epidural
injections in managing disc herniation. Thus, overall
evidence is Level III with moderate to weak recommendation for transforaminal epidural injections for disc
herniation over lumbar interlaminar or caudal epidural
approaches.
Multiple systematic reviews also have been performed assessing lumbar transforaminal epidural injections. Overall, the results have been positive except in
reviews with inappropriate analysis.

8.7 Percutaneous Adhesiolysis
Literature search for percutaneous adhesiolysis in
the lumbar spine yielded a total of 29 studies (891-919)
and 9 RCTs (891-901) meeting inclusion criteria.
For this analysis, we also utilized observational studies for post-lumbar central spinal stenosis
(908,910). There were 6 RCTs of post-surgery syndrome (893,894,896-899,901), 2 RCTs of spinal stenosis
(891,892,900), and only one RCT assessing disc herniation
(895). Appendix Table 11 shows Cochrane review criteria
for RCTs. Appendix Table 12 shows IPM-QRB criteria for
RCTs, whereas Appendix Table 13 shows IPM-QRBNR
for nonrandomized or observational studies. Table 15
shows characteristic features of various randomized and
nonrandomized studies in assessing effectiveness data.
Manchikanti et al (72) performed a systematic
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review and meta-analysis of the effectiveness of percutaneous adhesiolysis in managing post-lumbar surgery
syndrome and showed Level I or strong evidence with
inclusion of 6 RCTs (893,894,896,897,901,902) and 4
observational studies (903-906), with 7 of the studies
providing results of at least 12 months of follow-up. All
of the studies included in the analysis showed positive
results. The randomized trials assessing response rate
based on significant improvement of 50% pain relief
and functional status have shown 70% (893,894) and
72% (897) of the patients with significant improvement at 1-year follow-up, and 88% at 2-year follow-up
(893,894). Other studies also have shown significant
improvement (903,906). Meta-analysis also showed significant improvement with percutaneous adhesiolysis in
comparison with epidural injections and with a singlearm meta-analysis for the active control studies.
Manchikanti et al (73) also performed a systematic review and meta-analysis with inclusion of 2 RCTs
(891,892,900) and 4 observational studies (892,908-910)
with Level II or moderate evidence in the systematic review and meta-analysis. The primary outcome or hard
endpoint was the proportion of patients with 50% pain
relief and improvement in functionality, whereas secondary outcome measures, or soft endpoints, were pain
relief and/or improvement in functionality. The positive
results were observed from all the studies included in this
analysis, even though balloon inflated catheters showed
superior results compared to catheter adhesiolysis. Among
the randomized trials, one randomized trial (891,892) assessing response rate based on significant improvement of
50% pain relief and functional status has shown a success
rate of 76% at 12 months, compared to 4% in the caudal
epidural group. The second RCT (900) with only 6-month
followup available comparing catheter-based adhesiolysis
with inflatable balloon catheter showed superior results
with the balloon inflatable catheter. Further, among the
observational studies, one study followed the patients for
24 months with a 71% improvement rate. Surprisingly
enough, in this systematic review, superior results were
observed in appropriately conducted long-term studies
(891,892). Single arm meta-analysis also showed significant improvement from baseline with 38% improvement
of pain relief and 30% improvement of functional status
overall combining all the studies. Further, the available
data shows superior results when significant improvement
was utilized as the primary outcome parameter at 12
months as well as 24 months in over 70% of the patients.
All the studies had at least 12 months of appropriate outcomes available.
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Participants and
Interventions

Total = 120
Percutaneous adhesiolysis
= 60
Caudal epidural = 60
- Percutaneous
adhesiolysis with lidocaine,
betamethasone and 10%
hypertonic solution;
- Caudal epidural
injection with lidocaine,
betamethasone and 0.9%
NaCl solution

Total = 76
Percutaneous adhesiolysis
= 38
Epidural injection = 38
- Percutaneous adhesiolysis
with saline and
dexamethasone;
- Epidural injection of
dexamethasone

Total = 75
Control with normal saline
= 25
Adhesiolysis with normal
saline = 25
Adhesiolysis with hypertonic
saline = 25
- One-day adhesiolysis
with 0.9% saline and local
anesthetic and steroid;
- One-day adhesiolysis
with 10% saline and local
anesthetic and steroid;
- Epidural injection with local
anesthetic, steroid and 0.9%
saline

Total = 99
Adhesiolysis = 47
Physiotherapy = 52
- One-day adhesiolysis with
10% saline, ropivacaine and
triamcinolone;
- Physical therapy
99 patients with chronic low
back pain and sciatica based
on disc protrusion/prolapse
or failed back surgery

Manchikanti et al,
2009, 2012 (893,894)
RA, AC, DB
Post-lumbar surgery
syndrome
Quality Scores:
Cochrane: 11/13
IPM-QRB: 42/48

Chun-jing et al, 2012
(896)
RA, AC, DB
Post-lumbar surgery
syndrome
Quality Scores:
Cochrane: 12/13
IPM-QRB 34/48

Manchikanti et al,
2004 (897)
RA, PC, DB
Predominantly postsurgery syndrome
Quality Scores:
Cochrane: 12/13
IPM-QRB: 37/48

Veihelmann et al,
2006 (898)
RA, AC
Post-surgery
syndrome and disc
prolapse
Quality Scores:
Cochrane: 8/13
IPM-QRB: 30/48

LUMBAR POST-SURGERY SYNDROME

Study
Characteristics
Methodological
Quality Scoring

VAS, ODI, GHS,
use of analgesics

VAS, ODI,
employment
status, opioid
intake, range
of motion,
psychological
evaluation by P-3

VAS, McNabb
lumbar disease
evaluation, opioid
use

NRS, ODI,
employment
status,
opioid intake

Outcome
Measures

Mean
improvement of
the adhesiolysis
group was >50%
in VAS and
>40% in ODI.
Physical therapy
group had ~10%
relief

72% of 10%
saline group,
64% of 0.9%
group and 0%
of control group
had >50% pain
relief

NA

78% in
adhesiolysis
group
experienced
>50% relief
compared to
23% in control
group

3 mos.

Mean
improvement of
the adhesiolysis
group was >50%
in VAS and >40%
in ODI. Physical
therapy group
had ~10% relief

72% of 10%
saline group, 60%
of 0.9% group
and 0% of control
group had >50%
pain relief

Intervention
group VAS score
>3 VAS points
lower than
baseline, control
group VAS score
<1 point lower
than baseline

73% in
adhesiolysis
group
experienced
>50% relief
compared to 7%
in control group

6 mos.

Pain Relief and Function

Mean
improvement of
the adhesiolysis
group was
>50% in VAS
and >40% in
ODI. Physical
therapy group
had ~10% relief

72% of 10%
saline group,
60% of 0.9%
group and 0%
of control group
had >50% pain
relief

NA

70% in
adhesiolysis
group
experienced
>50% relief
compared to
5% in control
group

12 mos.

NA

NA

NA

82% in
adhesiolysis
group vs.
5% in caudal
group

24 mos.

Table 15. Effectiveness of percutaneous adhesiolysis assessed by randomized controlled trials and observational studies.

P

P

P

P

Short-term
≤ 6 mos.

Results

P

P

NA

P

> 6 mos.

Long-Term

P

P

NA

P

≥ 12 mos.

NA

NA

NA

P

24 mos.

Short and long- term
effectiveness of
adhesiolysis over
physiotherapy in
patients with sciatica

Short- and longterm effectiveness
and equivalency
between normal and
hypertonic saline
adhesiolysis in chronic
low back pain

Short-term
effectiveness of
adhesiolysis in
patients with
failed back surgery
syndrome

Short- and longterm effectiveness
of adhesiolysis on
post-lumbar surgery
syndrome

Comment(s)
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60 patients
3 groups:
Caudal = 20
S1 foraminal = 20
L5 transforaminal = 20
All patients underwent
placement of 16 gauge RX
Coude needle in the Racz
catheter with 3 approaches
along with adhesiolysis. They
also received exercises with
neural flossing 3-4 times daily
for 3 months.

Akbas et al, 2018
(901)
RA, AC
Post-lumbar surgery
syndrome
Quality Scores:
Cochrane: 9/13
IPM-QRB: 35/48

Manchikanti et al,
2009, 2013 (891,892)
Central spinal
stenosis
RA, AC
Quality Scores:
Cochrane: 11/13
IPM-QRB: 36/48

Total = 50
Percutaneous adhesiolysis
= 25
Additional 45 patients
followed for 2 years in
adhesiolysis group
Caudal epidural = 25
- Percutaneous adhesiolysis
with lidocaine, 10% NaCl
solution and betamethasone;
- Caudal epidural injection
with catheterization,
lidocaine, normal NaCl
solution and betamethasone

LUMBAR SPINAL STENOSIS

Total = 59
Group I (hypertonic saline
plus hyaluronidase) = 17
Group II (hypertonic
saline) = 15
Group III
(isotonic saline) = 17
Group IV
(isotonic saline plus
hyaluronidase) = 10
3-day adhesiolysis with either
0.9% or 10% saline and with
or without hyaluronidase

Participants and
Interventions

Heavner et al, 1999
(899)
RA, DB
Post-surgery
syndrome and disc
prolapse
Quality Scores:
Cochrane: 10/13
IPM-QRB: 23/48

Study
Characteristics
Methodological
Quality Scoring

NRS, ODI,
opioid intake,
employment
status

VAS, ODI
1 month, 3
months, 6
months after the
procedure

SFM, VAS for
back, right leg,
and left leg pain

Outcome
Measures

80% of
adhesiolysis had
>50% relief vs
28% for caudal

Significant
improvement
was seen with
pain and
functional status
with reduction in
scores with all 3
approaches with
no significant
differences
between the
approaches.

About 50%
of subjects
had more
than 10/100
improvement
in VAS

3 mos.

80% of
adhesiolysis had
>50% relief vs
12% for caudal

Significant
improvement was
seen with pain
and functional
status with
reduction in
scores with all 3
approaches with
no significant
differences
between the
approaches.

About 50% of
subjects had
more than 10/100
improvement
in VAS

6 mos.

Pain Relief and Function

76% of
adhesiolysis
had >50% relief
(3.5 average
injections) vs
4% for caudal

Significant
improvement
was seen with
pain and
functional
status with
reduction in
scores with all 3
approaches with
no significant
differences
between the
approaches.

About 50%
of subjects
had more
than 10/100
improvement
in VAS

12 mos.

71% of
patients in
adhesiolysis
group only

NA

NA

24 mos.

P

P

P

Short-term
≤ 6 mos.

Results

Table 15 (con’t). Effectiveness of percutaneous adhesiolysis assessed by randomized controlled trials and observational studies.

P

P

P

> 6 mos.

Long-Term

P

P

P

≥ 12 mos.

P

NA

NA

24 mos.

Short- and longterm effectiveness
of adhesiolysis on
chronic intractable
pain secondary to
lumbar central spinal
stenosis

The 3 approaches
result in the same
outcome with regard
to pain relief and
complication rate.
Adhesiolysis is an
effective technique
in managing postlumbar surgery
syndrome pain.

Short- and long-term
effectiveness and
equivalency between
adhesiolysis groups
with 0.9% and 10%
saline and with or
without hyaluronidase
in patients with
low back pain and
radiculopathy

Comment(s)
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61%

51.1%
successful
response

NRS, ODI
measures at
1, 3, 6, and
12 months,
30% or more
than 2-point
reduction in
NRS

Pain relief.
Assessment of
proportion of
patients based
on severity of
the stenosis.

61 patients
Adhesiolysis with a single
combined treatment with
balloon inflatable catheter
ZiNeu.

78 patients studied with
percutaneous adhesiolysis
with caudal approach.
Following appropriate
adhesiolysis, 5 mL of
0.25% ropivacaine
containing 1,500 units
or hyaluronidase was
injected in the recovery
room. 6 mL of 10%
sodium chloride
solution was injected.
Following this, 2 mL of
0.9% sodium chloride
solution containing 40
mg of triamcinolone was
injected.

Choi et al, 2016
(908)
Single arm,
prospective
observational
study
Severe spinal
stenosis
Quality Score:
IPM-QRBNR =
28/48

Choi et al, 2013
(910)
Retrospective
assessment
Post-lumbar
surgery syndrome
or spinal stenosis
Quality Score:
IPM-QRBNR =
24/48

Successful
response of
40% in
balloon-less
group and 58%
in inflatable
balloon group

NRS, ODI,
GPES, MQS

Total = 44
Balloon adhesiolysis = 24
Balloon-less adhesiolysis
= 20
2-day percutaneous
adhesiolysis with
inflatable balloon catheter
or balloon-less catheter

Karm et al, 2018
(900)
RA, AC, DB
Refractory central
lumbar spinal
stenosis who
suffered from
chronic lower back
pain and/or lumbar
radicular pain
Quality Scores:
Cochrane: 11/13
IPM-QRB: 34/48

3 mos.

Outcome
Measures

49% successful
response

57%

Successful
response
of 25% in
balloon-less
group and 58%
in inflatable
balloon group

6 mos.

Pain Relief and Function

Participants and
Interventions

Study
Characteristics
Methodological
Quality Scoring

NA

36%

NA

12 mos.

NA

NA

NA

24 mos.

P

P

N=
(balloonless),
P=
(inflatable
balloon)

Short-term
≤ 6 mos.

Results

Table 15 (con’t). Effectiveness of percutaneous adhesiolysis assessed by randomized controlled trials and observational studies.

NA

P

NA

> 6 mos.

Long-Term

NA

P

NA

≥ 12 mos.

NA

NA

NA

24 mos.

Small retrospective
assessment in 78
patients with positive
results with a single
treatment in 51%
of the patients at 3
months and 49%
of the patients at 6
months.
Authors also included
a large number of
patients with previous
surgery of 37% of the
patients. They also
included 33% with
foraminal stenosis.
In addition severe
stenosis was seen in
13% of the patients
and root compression
in 46% of the patients
providing somewhat
mixed results.

Patients with severe
stenosis and also
significant proportion
of patients with
foraminal stenosis,
31%, were included.
There was large
number of patients
missing followup at
end of one-year.
Improvement of
30% or NRS of 2
considered

Negative study for
adhesiolysis with
balloon-less catheter,
positive study for
inflatable balloon
catheter on chronic
lower back pain and/
or lumbar radicular
pain

Comment(s)
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P
NA
28/31 of
treated group
had >50%
improvement
in ODI
compared
to 9/26 of
placebo group
31/42 of
treated group
had >50%
improvement
in ODI
compared to
4/37 of placebo
group

12 mos.

26/45 of
treated group
had >50%
improvement
in ODI
compared to
7/42 of placebo
group

6 mos.

Gerdesmeyer et
al, 2013 (895)
RA, PC, DB
Chronic lumbar
radicular pain
lasting longer
than 4 months
Quality Scores:
Cochrane: 13/13
IPM-QRB 44/48

DISC HERNIATION

Total = 90
Percutaneous adhesiolysis
= 46
Placebo = 44
- Percutaneous
adhesiolysis with steroids
and 10% saline solution;
- Placebo (no spinal canal
insertion, saline solution)

ODI, VAS

3 mos.
Outcome
Measures
Participants and
Interventions

www.painphysicianjournal.com

RA = randomized; DB = double-blind; AC = active control; PC = placebo-controlled; P = positive; N = negative; NA = not applicable; NRS = Numeric Rating Scale; ODI = Oswestry disability index;
VAS = Visual Analog Scale; GHS = Gerbershagen score; SFM = Short Form McGill Pain Questionnaire; GPES = Global Perceived Effect of Satisfaction; MQS = Medication Quantification Scale III; IPMQRB = Interventional Pain Management techniques - Quality Appraisal of Reliability and Risk of Bias Assessment; IPM-QRBNR = Interventional Pain Management Techniques – Quality Appraisal of
Reliability and Risk of Bias Assessment for Nonrandomized Studies

P
P

> 6 mos.
Short-term
≤ 6 mos.
24 mos.

Results
Pain Relief and Function

Study
Characteristics
Methodological
Quality Scoring

Table 15 (con’t). Effectiveness of percutaneous adhesiolysis assessed by randomized controlled trials and observational studies.

Long-Term

≥ 12 mos.

NA

24 mos.

Comment(s)

Short- and longterm effectiveness
of adhesiolysis on
chronic lumbar
radicular pain
Most relevant
placebo-controlled
trial
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In reference to disc herniation, multiple studies
have been performed; however, there has been only
one high-quality randomized, double-blind, placebocontrolled trial (895). Other studies (897-899) also included a small number of patients with disc herniation.
None of the observational studies met inclusion criteria.
Gerdesmeyer et al (895) performed the trial in patients with chronic radicular pain lasting longer than 4
months, which failed to respond to conservative treatment. After screening 381 patients, 90 patients were
enrolled. They were randomly assigned to receive either
percutaneous neurolysis or placebo with concealed allocation. The primary outcome measure was differences
in percentage of change of ODI scores 3 months after
intervention. Secondary outcome measures were difference in percent change of ODI scores and VAS at 6 and
12 months after intervention and success rates defined
as at least 50% reduction in ODI and VAS scores (mean
change from baseline) at 3, 6, and 12 months after
treatment. With strict criteria, they also used extensive
statistical analysis. The methodology included a 3-day
lysis procedure in both groups. The lysis procedure was
performed with adhesiolysis and following the placement of the catheter with injection of 10 mL of 0.25%
bupivacaine through the catheter followed by 10 mL
of preservative free saline containing 150 units per mL
of hyaluronidase, saline (10 mL 10%) containing 40 mg
of triamcinolone being injected slowly along with 2 mL
of 0.25% bupivacaine. The catheter was left in place
and on each of the next 2 days, 10 mL of 0.25% bupivacaine was injected through the catheter, followed
by the slow injection of 10 mL of 10% saline and 2 mL
of 0.25% bupivacaine, then the catheter was removed.
In the placebo group, however, a needle and catheter
were inserted, similar to lysis group, except the needle
was intentionally inserted so it did not enter the spinal
canal and the catheter was inserted into the subcutaneous tissues overlying the effected level. Each patient
received through the catheter 10 mL of preservative
free saline on each of the next 2 days, then the catheter
was removed. Subsequent to the 3 injection series, all
subjects were prescribed physical therapy with no activity restrictions. Patients were provided with rescue
medication of paracetamol. The results showed the ODI
and VAS scores, as well as the success for ODI versus
VAS were significantly better at 3, 6, and 12 months in
the lysis group versus the control group. The ODI in the
lysis group improved 55.3 ± 11.6 to 26.4 ± 10.8 after 3
months. The placebo group improved from 55.4 ± 11.5
to 41.8 ± 14.6. In addition, VAS improved 6.7 ± 1.1 to 2.9
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± 1.9 in the active group and from 6.7 ± 1.1 to 4.8 ± 2.2
after placebo. Twelve-month follow-up showed further
improvement and the differences were significant. The
main advantages of this study have been that they truly
utilized a placebo response by placing the catheter subcutaneously without entering the spinal canal. Twelvemonth outcomes showed 50% improvement in VAS in
69% of patients in the placebo group and 94% of the
patients in the lysis group, whereas, ODI greater than
50% improvement was seen in 35% of the patients in
the placebo group and 90% of the patients in the lysis
group with significant differences as shown in Table 16.

8.7.1 Evidence Synthesis
Evidence synthesis in this manuscript was derived
from qualitative and quantitative analysis. Qualitative
analysis was performed based on the present assessment, whereas quantitative analysis was utilized from
previous systematic reviews, which included conventional dual-arm and single-arm analysis in multiple
manuscripts. In the present analysis 6 RCTs assessed the
role of adhesiolysis in post-lumbar surgery syndrome
(893,894,896-899,901). All studies were subjected to
Table 16. Follow-up data 3, 6, and 12 months after intervention.

Outcome of primary criteria 3 months after intervention

ODI
VAS

Placebo
group

Lysis
group

P-value

41.8 ± 14.6

26.4 ± 10.8

< 0.01 **

4.8 ± 2.2

2.9 ± 1.9

< 0.01 **

> 50% improvement ODI

7/42 (17%)

26/45 (58%)

< 0.01 **

> 50% improvement VAS

12/42 (29%)

31/45 (69%)

< 0.01 **

Outcome of primary criteria 6 months after intervention
ODI

37.3 ± 13.1

11.9 ± 8.7

< 0.01 **

VAS

3.8 ± 1.6

1.4 ± 0.9

< 0.01 **

> 50% improvement ODI

4/37 (11%)

31/42 (74%)

< 0.01 **

>50% improvement VAS

14/36 (39%)

32/42 (76%)

= 0.01 **

Outcome of primary criteria 12 months after intervention
ODI

30.7 ± 14.2

9.6 ± 9.3

< 0.01 **

VAS

2.8 ± 1.5

1.2 ± 1.0

< 0.01 **

> 50% improvement ODI

9/26 (35%)

28/31 (90%)

< 0.01 **

> 50% improvement VAS

18/26 (69%)

29/31 (94%)

< 0.032 **

** indicate significance P < 0.05
ODI = Oswestry disability index; VAS = Visual Analog Scale
Adapted and modified with permission from: Gerdesmeyer L, et al.
Percutaneous epidural lysis of adhesions in chronic lumbar radicular
pain: A randomized, double-blind, placebo-controlled trial. Pain Physician 2013;16:185-196 (895).
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conventional dual-arm and single-arm analysis by
Manchikanti et al (72). There was one study with 2-year
follow-up (893,894) showing short-term and long-term
effectiveness of adhesiolysis on post-lumbar surgery syndrome in 82% of the patients in the adhesiolysis group
with multiple procedures. The 5 RCTs assessed patients
for one-year (893,894,897,898,899,901), and all of them
showed positive results with short-term and long-term
improvement. One trial (896) provided only 6 month
relief showing short-term improvement. Thus, evidence
for lumbar post-surgery syndrome is Level I with strong
recommendation.
In spinal stenosis, percutaneous adhesiolysis was
studied in 2 RCTs (891,892,900) and 2 observational studies (908,910). A single study (891,892) showed positive
results with 71% of patients responding in adhesiolysis
group at 24-month follow-up. The results were 76%
at end of one-year with significant improvement with
average procedures of 6.4 per 2 years. The second RCT
(900) compared balloon adhesiolysis with percutaneous adhesiolysis in 44 patients. They showed successful
adhesiolysis in inflatable balloon group, consequently
this study is considered as negative for percutaneous
adhesiolysis and positive for balloon adhesiolysis. Another observational study with a single-arm (908), also
showed adhesiolysis with a single combined treatment
of balloon inflated catheter with positive results. The
study had a small number of patients and also several
patients were missing. The second retrospective (910) assessment which included patients with spinal stenosis as
well as post-lumbar surgery syndrome showed 45% successful response at 6 months in 78 patients considered
as positive. Thus, the level of evidence is considered as
Level II with moderate to strong recommendation based
on lack of other available treatments.
For chronic recalcitrant disc herniation, there is one
high-quality RCT as described here (895). Other randomized trials also utilized a small proportion of patients with
chronic disc herniation (897-899). Overall the results have
been positive in all the studies, consequently, the level of
evidence is II with moderate to strong recommendation
in patients with chronic disc herniation failing to respond
to conservative modalities including epidural injections.
Cost utility analysis by Manchikanti et al (920) assessing post-lumbar surgery syndrome and lumbar
central spinal stenosis with percutaneous adhesiolysis
showed direct costs of $2,652 for post-lumbar surgery
syndrome and $2,649 for lumbar central spinal stenosis for one-year QALY. Overall costs for one-year QALY
were $4,428.84 for post-lumbar surgery syndrome and
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$4,423.83 for lumbar central spinal stenosis, which included direct and indirect costs.
As described earlier, Manchikanti et al (72) performed a conventional dual-arm and a single-arm
meta-analysis in post-lumbar surgery syndrome showing
significant improvement in pain relief and ODI scores.
Similarly, Manchikanti et al (73) in a systematic review
and meta-analysis of spinal stenosis showed the results
of single-arm analysis with significant improvement
with percutaneous adhesiolysis.

8.8 Cervical and Thoracic Interlaminar
Epidural Injections
For this analysis, cervical and thoracic interlaminar
epidural injections were combined based on the recommendation of CMS and the American Medical Association (AMA) Current Procedural Terminology (CPT) Committee as a single region and due to the lack of multiple
studies in the thoracic region. Our search criteria yielded
a total of 22 studies (588,921-941) meeting the initial
inclusion criteria. However, with elimination of nonfluoroscopic guided treatments and also short-term followups, a total of 7 RCTs were included in the analysis with
6 trials in the cervical spine (922,924,925,927,932,941),
and one trial in the thoracic spine (588). We also included 2 observational studies (937,940) in the cervical
spine with long-term follow-up. Appendix Table 14
shows Cochrane criteria, Appendix Table 15 shows IPMQRB criteria for RCTs, whereas Table 17 shows descriptive characteristics of cervical and thoracic interlaminar
epidural injections.
Seven randomized trials (588,922,924,925,927,932,941)
and 2 observational studies (937,940) met the inclusion criteria. Cochrane and IPM-QRB criteria graded 6 of the RCTs
to be of high-quality (588,922,924,925,927,941) and one of
them to be of moderate quality (932).
Manchikanti et al conducted 4 active control studies
in the cervical spine (922,924,925,927) and one (588) in
the thoracic spine. These studies enrolled 416 patients in
the cervical spine and 110 patients in the thoracic spine
and examined the use of local anesthetic alone or local
anesthetic with steroid for the following etiologies: disc
herniation, discogenic pain without facet joint pain,
central spinal stenosis, and post-surgery syndrome. Only
one study (925) had a minimum one-year follow-up and
the other 4 had a 2-year follow-up. Both Cochrane and
IPM-QRB criteria graded all of them as high-quality.
All 5 of these studies found there to be similar results for the efficacy of the 2 injectates in each etiology.
These studies analyzed outcomes based on subgroups
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that were either responsive or nonresponsive to the
treatment that was received. A responsive patient was
one who received at least 3 weeks of 50% improvement
with the first 2 treatments. Responsive group patients
in all etiologies had superior outcomes. All the studies
showed positive results achieving 68% to 80% pain relief with functional status improvement.
McCormick et al (941) published a prospective randomized comparative trial of targeted steroid injection
via epidural catheter compared to standard interlaminar
approach for the treatment of unilateral cervical radicular
pain at C5-6 with 76 participants. The criteria were rather
strict with radicular pain, MRI pathology, consistent with
clinical symptoms and signs, a numeric pain score of 4 or
higher, nonresponsiveness of conservative therapy, but
utilized 4-week duration of pain as the inclusion criteria.
Procedures were performed under fluoroscopic guidance
with injection of 2 mL of triamcinolone acetate 40 mg/mL
diluted in 1 mL of 1% preservative free lidocaine. They had
multiple primary and secondary outcome measures including pain relief, NDI, and pain disability index, along with
Global Impression of Change, daily morphine equivalent,
and medication quantification scale (MQS) III scores. At
one-month follow-up in the catheter and standard epidural injection groups, 26 or 72% and 23 or 60% of the
participants reported 50% or greater NRS reductions and
a similar number reported improvement in NDI. The authors did not report 50% pain relief beyond one-month;
however, other parameters showed at 3 months and 6
months significant reductions in pain from the baseline of
6 to 2.5 at 3 months, 2 at 6 months in the standard group;
whereas, it was 7 and 2 at 3 months, and 2 at 6 months
in the targeted catheter group. NDI scores also improved
from 21 to 15.5 at 3 months and 8 at 6 months in the
standard intervention group compared to a baseline of 19
with changes of 10.5 and 7.5 at 3 months and 6 months in
the targeted catheter group. It appeared that both were
effective, however, the targeted group tended to do better. Further, they also reported that there was a trend of
lower incidence of cervical spine surgery in the targeted
group during the 6-month follow-up.
Cohen et al (932) performed a double-blind RCT assessing a conservative management group that received
medication and physical therapy with an epidural injection group that received steroid alone and with a combination group that received epidural steroids as well as
conservative management. The study may be criticized
for various flaws in the design as well as its analysis with
a large number of noncompliant patients; it appears
that patients may have done better around 3 months
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Total = 120
Local anesthetic = 60
Local anesthetic with
steroids = 60
Local anesthetic or with
Celestone
Average number of
injections = 5 to 6 for
2 years

Total = 76
Standard interlaminar
epidural injection at
C5-C6 = 40
Targeted cervical
interlaminar epidural
steroid injections = 36
Injectate was 2 mL of
triamcinolone acetonide
(80 mg) diluted in 1 mL
of 1% preservative free
lidocaine in both groups.

Total = 169
Conservative treatment
group = 59 (medical
therapy and physical
modalities)
Epidural steroid
injection group
= 58 (3 mL of
solution containing
60 mg of depomethylprednisolone and
normal saline)
Combination therapy
group = 55 (epidural
steroid injection and
pharmacotherapy with
gabapentin and physical
modalities)

McCormick et al, 2017
(941)
RA, SB, AC, F
Unilateral cervical
radicular pain C5-C6
Quality Scores:
Cochrane = 10/13
IPM-QRB = 37/48

Cohen et al, 2014 (932)
RA, AC, F
Cervical disc herniation
or radiculopathy
Quality Scores:
Cochrane = 6/13
IPM-QRB = 24/48

Participants and
Interventions

Manchikanti et al 2013
(922)
RA, AC, DB, F
Cervical disc herniation
or radiculopathy
Quality Scores:
Cochrane = 12/13
IPM-QRB = 43/48

Study
Characteristics
Methodological
Quality Scoring

Within group
changes and
between group
changes, pain,
NRS, NDI

NRS, ONDI, PDI,
MPQ, PGIC,
DME, MQS

NRS, NDI,
employment
status, opioid
intake
Significant
improvement
> 50% pain
relief and > 50%
functional status
improvement

Outcome
Measures

Positive outcome:
Conservative group:
26.8%
Epidural group:
36.7%
Combination
therapy group:
56.9%

NRS standard
group:
Baseline: 6
3 months: 2.5
NRS targeted
catheter group:
Baseline: 7
3 months: 2
ONDI standard
group:
Baseline: 21
3 months: 15.5
ONDI targeted
group:
Baseline: 19
3 months: 10.5

Overall:
LA 83% vs LA with
steroid 70%
Responsive:
LA 91% vs LA with
steroid 84%

3 mos.

Positive
outcome:
Conservative
group: 23.6%
Epidural group:
25.5%
Combination
therapy group:
44%

NRS standard
group:
6 months: 2
NRS targeted
catheter group:
6 months: 2
ONDI standard
group:
6 months: 8
ONDI targeted
group:
6 months: 7.5

Overall:
LA 82% vs LA
with steroid
73%
Responsive:
LA 91% vs LA
with steroid
86%

6 mos.

Pain Relief and Function

Table 17. Characteristics of fluoroscopic cervical/thoracic interlaminar epidural injections.

NA

NA

Overall:
LA 72% vs LA
with steroid
68%
Responsive:
LA 77% vs LA
with steroid
82%

12 mos.

NA

NA

Overall:
LA 72% vs
LA with
steroid 68%
Responsive:
LA 77% vs
LA with
steroid 80%

24 mos.

U

P

P

Short-term
≤ 6 mos.

Results

NA

NA

P

>6
mos.

NA

NA

P

≥ 12
mos.

Long-Term

NA

NA

P

24
mos.

•Undetermined results at 3 months
for epidural steroid injection
without local anesthetic combined
with conservative management,
with borderline response in 36.7%
at 3 months and 25.5% at 6 months
with epidural injections.
•This trial included acute and
chronic pain patients. Number of
injections provided is not shown.
Local anesthetic was not utilized.
There was a large number of
patients who were not compliant
in conservative and combination
groups.

This is a prospective randomized
comparative trial of standard
interlaminar epidural injection
compared to targeted steroid
injection via epidural catheter
approach in unilateral cervical
radicular pain showing
effectiveness of both modalities
and no significant difference noted
between the modalities. The relief
with one injection lasted almost
6 months in responsive patients,
which is unusual based on the other
studies.

•Positive results in a randomized
large trial performed under
fluoroscopy with long-term
follow-up.
•Similar results with local
anesthetic or with local anesthetic
and steroids.
•Overall, a total of 5-6 injections
were administered over a period
of 2 years.

Comment(s)
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Total = 60
Local anesthetic only
= 30
Local anesthetic with
steroids = 30
Local anesthetic or with
Celestone
Average number of
injections = 3 to 4 for
1 year

Total = 120
Local anesthetic only
= 60
Local anesthetic with
steroids = 60
Local anesthetic or with
Celestone
Average number of
injections = 5 to 6 for
2 years

Total = 116
Local anesthetic only
= 58
Local anesthetic with
steroids = 58
Local anesthetic or with
Celestone
Average number of
injections = 5 to 6 for
2 years

Manchikanti et al 2014
(924)
RA, DB, AC, F
Cervical axial or
discogenic
Quality Scores:
Cochrane = 11/13
IPM-QRB = 44/48

Manchikanti et al, 2018
(927)
RA, AC, F
Cervical post-surgery
syndrome
Quality Scores:
Cochrane = 11/13
IPM-QRB = 42/48

Participants and
Interventions

Manchikanti et al, 2012
(925)
RA, AC, F
Cervical spinal stenosis
Quality Scores:
Cochrane = 11/13
IPM-QRB = 42/48

Study
Characteristics
Methodological
Quality Scoring

www.painphysicianjournal.com
NRS, NDI,
employment
status, opioid
intake
Significant
improvement
> 50% pain
relief and > 50%
functional status
improvement
Responsive
was defined as
those patients
responding with
at least 3 weeks
of improvement
with the first 2
procedures.

NRS, NDI,
opioid intake,
employment,
changes in weight
Significant
improvement
> 50% pain
relief and > 50%
functional status
improvement

NRS, NDI,
employment
status, opioid
intake
Significant
improvement
> 50% pain
relief and > 50%
functional status
improvement
Responsive
was defined as
those patients
responding with
at least 3 weeks
of improvement
with the first 2
procedures.

Outcome
Measures

NA

Overall:
LA 68% vs LA with
steroid 77%
Responsive:
LA 75% vs LA with
steroid 82%

Overall:
LA 77% vs LA with
steroid 87%
Responsive:
LA 79% vs LA with
steroid 82%

3 mos.

Overall:
LA 69% vs LA
with steroid
74%
Responsive:
LA 74% vs LA
with steroid
81%

Overall:
LA 67% vs LA
with steroid
73%
Responsive:
LA 73% vs LA
with steroid
79%

Overall:
LA 87% vs LA
with steroid
80%
Responsive:
LA 79% vs LA
with steroid
92%

6 mos.

Pain Relief and Function

Overall:
LA 74% vs LA
with steroid
69%
Responsive:
LA 79% vs LA
with steroid
81%

Overall:
LA 72% vs LA
with steroid
68%
Responsive:
LA 78% vs LA
with steroid
83%

Overall:
LA 73% vs LA
with steroid
70%
Responsive:
LA 90% vs LA
with steroid
89%

12 mos.

Table 17 (con’t). Characteristics of fluoroscopic cervical/thoracic interlaminar epidural injections.

Overall:
LA 69% vs
LA with
steroid 71%
Responsive:
LA 74% vs
LA with
steroid 79%

Overall:
LA 73% vs
LA with
steroid 70%
Responsive:
LA 78% vs
LA with
steroid 75%

NA

24 mos.

P

P

P

Short-term
≤ 6 mos.

Results

P

P

P

>6
mos.

P

P

P

≥ 12
mos.

Long-Term

P

P

NA

24
mos.

•An active-control trial conducted
with fluoroscopy with positive
results.
•Similar results with local
anesthetic or with local anesthetic
and steroids.
•On average, 3-4 injections were
provided during one-year and 5-6
injections for 2 years.

•Positive results of a large RCT
performed under fluoroscopy.
•Similar results with local
anesthetic or with local anesthetic
and steroids.
•A total of 5-6 injections on average
were provided over a period of 2
years.

•Preliminary results of a large
randomized trial performed under
fluoroscopy with positive results.
•Similar results with local
anesthetic or with local anesthetic
and steroids.
•Overall, 3-4 injections were
provided over a period of 1 year.

Comment(s)
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Total = 45
Injectate: 0.5%
bupivacaine 1 mL
mixed with 40 mg of
triamcinolone

Total: 65
Discal pathology = 26
Degenerative pathology
= 38
Spinal stenosis = 9
Injectate = a total
of 5 mL of 80 mg
of triamcinolone
acetonide with 3 mL of
bupivacaine 0.25%

Joswig et al, 2018 (937)
R, F
Cervical disc herniation

Beyaz & Eman, 2013
(940)
R, F
Cervical pain syndrome
NRS

VAS, NDI

NRS, ODI,
employment
status, opioid
intake
Significant
improvement
> 50% pain
relief and > 50%
functional status
improvement

Outcome
Measures

Satisfaction scores
were average 3.3
± 0.9
80% of patients
were classified as
perfect or good
satisfaction

66.7% responded
with pain relief and
improvement in
disability scores

Overall:
LA 78% vs LA with
steroid 82%
Responsive:
LA 88% vs LA with
steroid 86%

3 mos.

Satisfaction
scores were
average 3.3
± 0.9
80% of
patients were
classified as
perfect or good
satisfaction

NA

Overall:
LA 74% vs LA
with steroid
84%
Responsive:
LA 84% vs LA
with steroid
90%

6 mos.

Pain Relief and Function

Satisfaction
scores were
average 3.3
± 0.9
80% of
patients were
classified as
perfect or good
satisfaction

36 of 45
responded.
7 patients
received
a second
injection and
6 of them
responded
with one of
them be lost to
follow-up

Overall:
LA 71% vs LA
with steroid
84%
Responsive:
LA 80% vs LA
with steroid
90%

12 mos.

NA

NA

Overall:
LA 71% vs
LA with
steroid 80%
Responsive:
LA 80% vs
LA with
steroid 86%

24 mos.

P

P

P

Short-term
≤ 6 mos.

Results

P

P

P

>6
mos.

P

P

P

≥ 12
mos.

Long-Term

NA

NA

P

24
mos.

This study was a fluoroscopy
guided cervical interlaminar steroid
injection; however, bupivacaine
was injected which is not an
appropriate injection for cervical
epidural injections which may lead
to substantial complications even
though they have not reported
any complications. Overall, the
response was good with positive
results.

This is a study to assess the safety
of a second interlaminar epidural
injection in the cervical spine.
Results are rather amazing that
majority of the patients had oneyear relief and only 7 of 45 patients
required a second injection.
However, authors injected 0.5%
bupivacaine, which is considered
unsafe if subarachnoid leakage or
injection happened in advertently.

•First large randomized trial with
active control design and long-term
follow-up.
•Similar results with local
anesthetic or with local anesthetic
and steroids.
•On average, 5-6 total procedures
were performed over a period of
2 years.

Comment(s)

RA = Randomized; AC = Active Control; F = Fluoroscopy; DB = Double-Blind; SB = Single Blind; R = Retrospective; P = Positive; N = Negative; NA = Not Applicable; U = Unclear; LA = local anesthetic;
IPM-QRB = Interventional Pain Management techniques -- Quality Appraisal of Reliability and Risk of Bias Assessment; NRS = Numeric Rating Scale; NDI = Neck Disability Index; ONDI = Oswestry
Neck Disability Index; PDI = Pain Disability Index; MPQ = McGill Pain Questionnaire; PGIC = Patient Global Impression of Change; DME = daily morphine equivalents; MQS = Medication Quantification Scale III scores

Total = 110
Local anesthetic only
= 55
Local anesthetic with
steroids = 55
6 mL of local anesthetic
only or 6 mL of local
anesthetic with 6 mg
of nonparticulate
betamethasone
Average number of
injections = 5 - 6 for
2 years

Participants and
Interventions

Manchikanti et al, 2014
(588)
RA, AC, DB, F
Thoracic pain
Quality Scores:
Cochrane = 11/13
IPM-QRB = 43/48

Study
Characteristics
Methodological
Quality Scoring

Table 17. Characteristics of fluoroscopic cervical/thoracic interlaminar epidural injections.
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(942). Thus, the results of this trial are considered undetermined. Further, the authors did not provide information on the number of injections.
Multiple observational studies are available; however,
there were only 2 studies meeting inclusion criteria performed under fluoroscopic guidance (937,940). Joswig et
al (937) evaluated the role of repeat epidural steroid injections for cervical disc herniation. They performed cervical
epidural injections with the interlaminar approach in 45
patients for cervical disc herniation. They showed 30 of
them responded and 15 showed lack of response. Among
these, 8 of them underwent surgery, while 7 of them received a second injection. The initial response lasted for 12
months and a subsequent second injection response also
lasted 12 months in almost all patients with one patient
being lost to follow-up. The relief is somewhat superior to
previous studies. Further, they also injected 0.5% bupivacaine with steroid mixture of 2 mL, which we considered as
a risky technique in the cervical spine due to the potential
for subarachnoid leakage of the fluid or subarachnoid
puncture utilizing subarachnoid injection.
The second study was by Beyaz and Eman (940) utilizing fluoroscopically guided cervical interlaminar steroid injections in patients with cervical pain syndromes.
They used various types of conditions in their study
including disc herniation, degenerative disc disease,
and cervical spinal stenosis. Only 9 patients had stenosis
and 26 patients had discal pathology, all others had degenerative pathology among the 65 patients included
in the study. In this study, the authors injected a total
of 5 mL of 80 mg of triamcinolone acetonide with 3 mL
of bupivacaine 0.25% into the epidural space similar to
the other study which is considered to be risky in the US.
They reported significant improvement in pain scores
from before the injection to 12-month follow-up. Overall, 51 patients or 80% had perfect/good scores. They
reported no complications in the study.
Among the older studies, which were not included
in this analysis, but were included in the other previous
analysis, Castagnera et al (929), Stav et al (930), and
Pasqualucci et al (931) were utilized due to lack of multiple randomized trials, meeting appropriate inclusion
criteria of 50 patients. The patients included were 24 by
Castagnera et al (929), 42 by Stav et al (930), and 40 by
Pasqualucci et al (931). Overall, all 3 trials showed positive
results either comparing local anesthetic with steroids or
steroid plus morphine (929) with steroid plus morphine
showing positive results. Stav et al (930) compared local
anesthetic with steroids to intramuscular steroid and the
epidural local anesthetic with steroids injection group

www.painphysicianjournal.com

showed positive results. Pasqualucci et al (931) assessed
bupivacaine with methylprednisolone acetate, comparing single versus continuous infusion groups with significant improvement in both groups, with the continuous
improvement group showing better results.

8.9 Evidence Synthesis
Qualitative analysis was performed and quantitative analysis was obtained from previously published
studies (58,64).
The evidence synthesis based on the present review
of the available literature shows there were 3 RCTs
(922,932,941) studying cervical disc herniation. One
of the 2 observational studies focused on cervical disc
herniation (937). Among these studies, Manchikanti et
al (922) studied 120 patients with a 24-month follow-up
with multiple procedures performed as pain returned
with a total of 5-6 procedures per 2 years. They showed
significant improvement at 2-year follow-up with 72%
utilizing local anesthetics and 68% utilizing local anesthetic and steroids with significant improvement in
pain and function. However, in the responsive group,
it was 77% with local anesthetic and 80% with local
anesthetic and steroids. In a recent study, McCormick et
al (941) studied 76 patients and compared the standard
interlaminar epidural injection with targeted cervical
interlaminar epidural steroid injection with 40 and 36
patients in each group providing a 6-month follow-up.
This study showed positive results. Cohen et al (932)
compared a conservative treatment group with 59
medical therapy patients, an epidural injection group
with 58 patients and a combination therapy group with
55 patients where they administered epidural steroid
injection and pharmacotherapy with gabapentin and
physical modalities. They showed that 57% with positive
relief the combination therapy group at 3 months and
44% at 6 months. Combination therapy with various
components, along with drug therapy and a structured
exercise program or other physical interventions is the
common practice. Consequently, this can be judged as
a positive study. The observational report also showed
positive results in 45 patients (937). However, they used
0.5% bupivacaine 1 mL mixed with 40 mg of triamcinolone. Bupivacaine is not recommended for cervical
epidural injections due to its untoward effects in case of
leakage or subarachnoid puncture. Thus, overall the evidence is Level I with strong recommendation for interlaminar epidural injections in managing disc herniation.
In the assessment for spinal stenosis, a single RCT by
Manchikanti et al (925) utilizing 60 patients with one-
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year follow-up showed positive results in 73% with local
anesthetic and 70% with local anesthetic and steroids.
However, in the responsive group, overall significant improvement was higher with 90% in the local anesthetic
group versus 89% in the local anesthetic with steroids,
with overall 3 to 4 injections during the whole year. One
of the observational studies also included cervical spinal
stenosis patients. However, these numbers were extremely
low. Consequently, this does not provide any additional
evidence. Thus, based on one relevant high-quality RCT
(925), the evidence is Level II with moderate to strong
recommendation.
For axial discogenic pain or patients without facet
joint pain, a single study with 120 patients by Manchikanti
et al (924) with 2-year follow-up showed positive results in
overall groups in 73% with local anesthetic and 70% with
local anesthetic and steroids. However, the response was
better with 78% with local anesthetic versus 75% with
steroids at the end of 2 years with 5 to 6 cervical epidural
procedures over a period of 2 years. Thus, based on one
relevant high-quality RCT, evidence is Level II with moderate to strong recommendation.
In cervical post-surgery syndrome, there was only one
RCT (927) with inclusion of 116 patients with 58 patients
in each group with either local anesthetic or local anesthetic with steroids with 24-month follow-up showing in
all-inclusive patients, significant improvement in 69% in
the local anesthetic group and 71% in the local anesthetic
with steroid group. However, in the responsive groups,
positive response with local anesthetic was 74% versus
local anesthetic with steroid in 79%. Similar to other studies by this group, repeat injections were performed 3 to
4 during the first year and a total of 5 to 6 over a period
of 2 years. Consequently, the evidence is Level II to I with
moderate to strong recommendation.
For thoracic pain, there was only one RCT by
Manchikanti et al (588) with 110 patients with 55 patients
in each group with the inclusion of all types of thoracic
pain patients. At 24-month follow-up, the results showed
71% improvement with local anesthetic only and 80%
improvement with local anesthetic with steroid when all
patients were considered. However, the response was better if responsive patients were considered with 80% utilizing local anesthetic alone versus 86% with local anesthetic
and steroids with 5 to 6 total procedures during a period
of 2 years.
The evidence for thoracic epidural injections is Level II
with moderate to strong recommendation.
However, in the present review, the addition of
steroids may provide better improvement in the cervical

S120

spine based on RCTs and observational studies considering various issues with local anesthetic administration in
the cervical spine. It may be appropriate to avoid local
anesthetics except in certain circumstances with extreme
caution.
Cost utility analysis also was performed for cervical epidural injections and thoracic epidural injections
(943,944). In the assessment of the cost utility in cervical
disc herniation, post-surgery syndrome, or discogenic
pain, utilizing 2-year data, with 356 patients, average
cost including direct costs and indirect costs was $3,785.89
per one-year improvement in QOL (943). The cost was
somewhat higher for axial discogenic pain at $4,028.55,
compared to disc herniation at $3,475.38 and post-surgery
syndrome at $3,856. Evaluation of cost utility of the thoracic interlaminar epidural injections (944) showed with a
2-year follow-up with one-year QOL improvement including direct and indirect costs of $3,245; however, in only
responsive participants it was $3,148.73. In this study, the
authors also calculated cost utility in 10 nonresponsive participants, which was $45,440 per one-year improvement in
QoL. This emphasizes the fact that is inappropriate to use
patients in nonresponsive studies or negative studies for
cost utility analysis.
Multiple systematic reviews performed in the past
(58,60,64,70) have shown significant improvement with or
without steroids with significant evidence levels. Kaye et al
(60) showed Level II evidence for long-term management
of cervical disc herniation with interlaminar epidural injection. The evidence is Level II to III in managing thoracic
pain, and cervical spinal stenosis, cervical discogenic axial
pain, and cervical post-surgery syndrome. Mesregah et al
(64) showed the addition of steroids to anesthetic injectate was not associated with better pain and functional
score outcomes compared with anesthetic agent alone in
patients with chronic neck pain. Knezevic et al (58) also
showed no significant difference between local anesthetic
alone compared to local anesthetic with steroids.

8.10 Summary of Evidence
Analysis of summary of evidence for disc herniation,
spinal stenosis, discogenic pain, and post-surgery syndrome is presented based on the present review of the
evidence in conjunction with appropriately performed
systematic reviews published in the literature.

8.10.1 Disc Herniation
8.10.1.1 Caudal
For caudal epidural injections in managing disc
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herniation with multiple relevant, moderate to highquality fluoroscopically guided epidural injections
with or without steroids trials, and results of previous
systematic reviews, the evidence is Level I with strong
recommendation for long-term effectiveness.

8.10.1.2 Lumbar Interlaminar
For lumbar interlaminar epidural injections with
multiple relevant moderate to high-quality fluoroscopically guided epidural injections with or without steroids
trials, and relevant previous systematic reviews, the
evidence is Level I with strong recommendation for
long-term effectiveness.
8.10.1.3 Lumbar Transforaminal
For lumbar transforaminal epidural injections with
inclusion of multiple moderate to high-quality RCTs of
fluoroscopic transforaminal epidural injections with or
without steroids, and inclusion of findings of relevant
previous systematic reviews, the evidence is Level I with
strong recommendation for long-term effectiveness.
The evidence shows no significant difference
between caudal and interlaminar epidural injections,
whereas, the evidence also shows some superiority of
transforaminal epidural injections over caudal and interlaminar epidural injections in achieving long-term
improvement with epidural injections.
8.10.1.4 Percutaneous Adhesiolysis
Based on the present assessment with one relevant
high-quality, placebo-controlled, RCT, the evidence is
Level II with moderate to strong recommendation for
long-term effectiveness for percutaneous adhesiolysis
in patients nonresponsive to conservative management
and fluoroscopically guided epidural injections.
8.10.1.5 Cervical Interlaminar
In the cervical spine, for managing cervical disc
herniation, based on relevant moderate to high-quality
RCTs and published systematic reviews, fluoroscopically
guided cervical interlaminar epidural injections, show
evidence is Level I with strong recommendation for
long-term effectiveness.
8.10.1.6 Thoracic Interlaminar
In the thoracic spine, for thoracic disc herniation,
based on one relevant high-quality RCT using fluoroscopic
guidance with or without steroids and previously published
systematic reviews, the evidence is Level II with moderate
to strong recommendation for long-term effectiveness.
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8.10.2 Spinal Stenosis
8.10.2.1 Caudal
For lumbar central spinal stenosis, the evidence
based on present assessment and previously available
systematic reviews, based on one high-quality RCT,
the evidence is Level III to II with moderate to strong
recommendation for long-term improvement with fluoroscopically guided caudal epidural injections.
8.10.2.2 Lumbar Interlaminar
For lumbar central spinal stenosis, with evidence
synthesis with inclusion of relevant moderate to high
RCTs and previously published systematic reviews,
the evidence is Level II with moderate to strong
recommendation with fluoroscopically guided lumbar interlaminar epidural injections for long-term
improvement.
8.10.2.3 Lumbar Transforaminal
For lumbar spinal stenosis, based on the present
analysis of moderate to high-quality RCTs and previously
available systematic reviews, the evidence is Level IV to
III with moderate recommendation with fluoroscopically guided lumbar transforaminal epidural injections
for long-term improvement.
8.10.2.4 Percutaneous Adhesiolysis
The evidence of percutaneous adhesiolysis in
lumbar spinal stenosis with present evidence synthesis with relevant, moderate to high-quality RCTs,
observational studies and systematic reviews, is Level
II with moderate to strong recommendation for
long-term improvement after failure of conservative
management and fluoroscopically guided epidural
injections.
8.10.2.5 Cervical Interlaminar
For cervical spinal stenosis, based on present
evidence synthesis with one high-quality RCT and previously published systematic reviews, the evidence is
Level II with moderate to strong recommendation for
fluoroscopically guided cervical interlaminar epidural
injections with long-term improvement.

8.10.3 Axial Discogenic Pain
8.10.3.1 Caudal
The evidence for lumbar axial discogenic pain without facet joint pain or sacroiliac joint pain is Level II with
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moderate to strong recommendation for caudal epidural
injections based on one fluoroscopically guided highquality RCT for long-term effectiveness.

8.10.3.2 Lumbar Interlaminar
Based on one high-quality RCT with long-term follow-up and previous systematic reviews, the evidence is
Level II for discogenic pain after exclusion of facet joint
pain and sacroiliac joint pain with moderate to strong
recommendation for fluoroscopically guided lumbar
interlaminar epidural injections with or without steroids
for long-term effectiveness.
8.10.3.3 Cervical Interlaminar
Based on the present evidence synthesis with one
relevant high-quality RCT with long-term follow-up,
with fluoroscopically guided cervical interlaminar epidural injection with or without steroids, the evidence
is Level II with moderate to strong recommendation for
long-term effectiveness.

8.10.4 Post-surgery Syndrome
8.10.4.1 Caudal
The present evidence synthesis based on one
relevant high-quality RCT with long-term improvement and previously performed systematic reviews,
the evidence is Level II with moderate to strong recommendation with fluoroscopically guided caudal
epidural injections with or without steroids for longterm effectiveness.
8.10.4.2 Cervical Interlaminar
The present evidence synthesis based on one relevant high-quality RCT with long-term improvement and
previously performed systematic reviews, the evidence
is Level II to I with moderate to strong recommendation
with fluoroscopically guided cervical interlaminar epidural injections with or without steroids for long-term
effectiveness.
8.10.4.3 Percutaneous Adhesiolysis
Based on present evidence synthesis with multiple
moderate to high-quality RCTs in conjunction with previously published systematic reviews, the evidence for
percutaneous adhesiolysis in managing post-lumbar surgery syndrome is Level I with strong recommendation
for long-term improvement after failure of conservative management and fluoroscopically guided epidural
injections.
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9.0 Cost Utility Analysis
Interventions

for

Epidural

Key Question 7: What is the evidence for cost
effectiveness of epidural interventions including
percutaneous adhesiolysis in managing chronic spinal pain?
To understand the cost utility of epidural interventions, it is crucial to focus on the origins and relevance
of healthcare costs and the multiple means to reduce
the impact on healthcare without affecting access to
quality care and patient choices. Over the years, cost
utility analysis has taken an important pivotal role in
the provision of value-based healthcare with consideration of high-quality healthcare in conjunction with
either increasing the access or at least not curtailing it
(175-178,945-952). The economic impact of spinal pain is
described in Section 3.
The data available from cost utility or cost effectiveness analysis provides policymakers and providers with
knowledge to compare treatment strategies and to
choose appropriate resource allocation with optimization of relative priorities among various interventions
(951). While it is simple and easy to calculate the direct
costs of an intervention, it is often difficult to assess indirect costs, specifically in interventional pain management (795,853,943,944,953,954). Consequently, indirect
measures are utilized in measuring the overall costs.
Over the years, multiple cost utility or cost effectiveness studies have been performed in the US. Despite
this knowledge, healthcare costs in managing spinal
pain only continue to escalate with increasing disability.
However, based on the Affordable Care Act (ACA), cost
effectiveness is not utilized as a basis for coverage or
other analysis in the US (175,176,955-958). Thus, indirect
measures are utilized based on the utilization and overall
costs to the governmental programs, whereas private
insurers routinely utilize cost utility analysis in their
policy developments. In contrast, in other countries with
universal healthcare, such as the United Kingdom, cost
effectiveness and cost utility analysis are often utilized
as the basis for coverage (959). In the United Kingdom,
these assessments are based on health technology assessment guidance. However, even though in principle the
US does not consider cost utility analysis for coverage, in
action the importance of high-quality with low expenses
has been stressed with numerous public policy decisions
including the ACA, physician quality reporting systems
(PQRS), value-based payment (VBP) systems, merit-based
incentive payment systems (MIPS), and accountable interventional pain management (945,956-958).
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9.1 Cost Effectiveness or Cost Utility Analysis
The purpose of cost utility analysis in health economics is to estimate the ratio between the cost of
a health-related intervention and the benefit it produces in terms of numbers of years lived in full health
by the beneficiaries. Thus, it is considered as a special
case of cost-effective analysis, and both of the terms
are often used interchangeably. In the scenario of cost
utility analysis, cost is measured in monetary units;
however, in cost benefit analysis, benefits do not have
to be expressed in monetary terms. Among the earlier
publications, Kepler et al (946) showed that one-year
cost of QoL gained was less than $100,000 in only 45%
of the studies assessed. In a similar study by Indrakanti et al (947), a greater value was demonstrated on
studies of nonoperative treatments while comparing
surgical interventions. They showed highly variable
costs for QALY, ranging from $304 to $579,527, with a
median cost of $13,000.
Dagenais et al (951,952,960) assessed the cost of
illness and cost utility studies in the US and internationally and their role in informed decision-making
concerning interventions for low back pain. In their
assessment of cost of illness studies (951,952,960,961),
they provided a breakdown on direct costs. The largest proportion of direct medical costs for low back
pain was spent on physical therapy (17%) and inpatient services (17%), followed by pharmacy (13%) and
primary care (13%). In their assessment of the role
of cost utility evaluations (951), their results showed
most studies were from the United Kingdom and were
published 3 years prior to their publication in 2009.
The results have been highly variable for surgical interventions versus nonsurgical interventions,
specifically in relation to calculation of direct and
indirect expenses. Multiple studies comparing surgical
interventions with nonsurgical interventions showed
mixed results with surgical care with a significant
incremental benefit by some, with others showing
lack of advantage of surgical care. In fact, the most
quoted cost utility analysis comes from the data from
SPORT study. Tosteson et al (962) showed cost effectiveness of surgical treatment for lumbar disc herniation at $69,403 per QALY for the general population,
and $34,355 for the Medicare population per QALY.
They also studied cost effectiveness of spinal stenosis
surgeries (963). In this assessment (963), the results
showed cost effectiveness of spinal stenosis at $77,600
per QALY gained, with $115,600 per QALY gained for
degenerative spondylolisthesis. Cost effectiveness
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analysis of posterior cervical fusion for degenerative
spondylolisthesis showed a $20,547 per QALY in one
study (374). Anterior cervical discectomy and fusion in
obese patients was cost effective at $52,816. Further,
anterior cervical discectomy and fusion in obese patients was cost effective at QALY of $68,070 compared
to nonobese patients at $52,816 QALY, which was not
significantly different between the 2 (374).
Multiple studies also have been published on nonsurgical therapies, including epidural injections as an
inclusion therapy of various modalities, or individual
monotherapy (964-971). However, these studies were
more extensive in the lumbar spine than the cervical
spine.

9.2 Physical Therapy and Chiropractic
In studies performed with physical therapy in
managing low back pain, specified as nonspecific in
origin, the incremental cost effectiveness of $4,594
per QALY was shown with physical therapy (964).
However, a favorable cost utility of $2,216 per QALY
for spinal stabilization physiotherapy was demonstrated with individualized physiotherapy (965). Other
data also exists in relation to physiotherapy compared
to advice alone, which showed cost effectiveness of
physiotherapy in low back pain of 6 weeks duration,
at a cost utility of $6,379 per QALY (966). In another
study, cost effectiveness of primary care management, with or without early physical therapy for acute
low back pain (967), showed better QoL in patients
receiving early physical therapy after one year, even
though costs were higher, further calculating data in
this study (967). The incremental cost effectiveness
ratio was $32,058 per QALY. These results have been
stressed despite the costs to initiate early physical
therapy to reduce the risk of extensive advanced imaging or other invasive procedures for low back pain
(968-971). Physical therapy is also extensively recommended for strengthening purposes prior to surgical
interventions, or in conjunction with other modalities
of treatments, leading to structured exercise program,
and also after surgical interventions.
The evidence is minimal for the long-term effectiveness of physical therapy as an individual modality,
or even in conjunction with other modalities; however,
it may contribute to faster recovery in multidisciplinary
management (971-975). Adogwa et al (976,977), showed
the average cost per patient utilizing therapy to be
$4,010, with 67% of patients with lumbar spinal stenosis
undergoing physical therapy, most commonly combined
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with other medical management. Physical therapy costs
also include repeat therapy, need for additional durable
medical equipment such as lumbosacral arthrosis, TENS
units, and electronic stimulation units. Patient’s failure
in compliance with continuing to do home exercises
after being discharged may also account for suboptimal
outcomes (973). Lilly et al (978) nonoperative described
assessment of nonoperative management strategies in a
herniated lumbar disc population, showing positive results. Among the total of 278,000 patients with intervertebral disc herniation, 97% were successfully managed
with nonoperative treatments, while 3% failed maximal
nonoperative therapy (MNT) and underwent a lumbar
microdiscectomy. The treatments included physical
therapy, as well as other modalities.
Analysis of complementary and alternative medical
treatments, including chiropractic management for cost
effectiveness compared to no treatment, a placebo, physical therapy, or usual care in reducing pain immediately
or at short-term after initiation of the treatment, showed
significantly greater effectiveness of complementary and
alternative medical treatments (171,184,979-984). Alternative treatments have increased substantially over the
years reaching into a multibillion-dollar industry. In 2007,
a total cost of over $33 billion was spent out-of-pocket
on visits to complementary and alternative medicine
practitioners, and purchases of products, classes, and
materials (981). The estimates in 2020 show that complementary and alternative medicine market may be worth
over $296 billion by 2027. Thus, patients with spinal pain
spend considerable amounts out-of-pocket for medical
massage, acupuncture, Chinese medicine, and over-thecounter (OTC) and durable medical equipment. These
costs are often not measurable.
Clinical and cost effectiveness of chiropractic treatments have been studied in multiple investigations.
Coutler et al (184) in a systematic review and metaanalysis, which included 51 trials and 9 trials utilized for
meta-analysis, showed moderate quality evidence that
manipulation and mobilization are likely to reduce pain
and improve function for patients with chronic low back
pain. Herman et al (982) assessed multiple nonpharmacological interventions for cost effectiveness than usual
care. Utilizing a Marko model, the results showed that
from this societal perspective, all but 2 of the therapies
were cost effective at less than $50,000 per QALY for
typical patient mix and most were cost saving. From the
payer perspective, fewer were cost saving, but the same
number were cost effective. Assuming all patients in the
model have high impact chronic pain increases, the ef-
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fectiveness and cost effectiveness of most, but not all,
therapies indicating that substantial benefits are possible
in subpopulations. Coutler et al (171) showed the effectiveness of manipulation and mobilization for treating
chronic nonspecific neck pain. Hays et al (983) assessed
group and individual level change on health-related QoL
in chiropractic patients with chronic low back or neck
pain in a 3-month longitudinal study, which is rather
short-term. However, they showed that chiropractic care
was associated with significant group-level improvement
in health-related QoL over time, especially in pain. Only a
minority of the individuals in the sample got significantly
better. They concluded that this study suggested some
benefits of chiropractic on functioning and well-being of
patients with low back and neck pain.
Leininger et al (980) published a manuscript on the
cost effectiveness of spinal manipulative therapy, supervised exercise and home exercise in 241 older adults
with chronic mechanical neck pain. Results showed the
authors in this manuscript assessed the cost effectiveness of home exercises with advice (HEA), SMT plus
HEA and supervised rehabilitative exercise (SRE) plus
HEA. Total costs for SMT plus HEA were 5% lower than
HEA and 47% lower than SRE plus HEA. SMT plus HEA
resulted in a greater reduction of neck pain over the
year relative to HEA. Differences in disability and QALY’s
favored SMT plus HEA. The authors showed that the
probability that adding SMT to HEA is cost effectiveness
at willingness to pay thresholds of $50,000 to $200,000
per QALY gained ranges from 0.75 to 0.81. The results
also showed that if adopting a healthcare perspective,
cost for SMT plus HEA were 66% higher than HEA, resulting in an incremental cost-effectiveness ratio (ICER)
of $55,975 per QALY gained.

9.3 NonSurgical Treatments Compared to
Surgical Treatments
Evidence for the effectiveness of the interventional
techniques has been demonstrated and may be variable
due to multiple reasons, including the specialists assessing the cost utility providing the least effectiveness of
5% for nonoperative treatments, and not applying the
actual costs and QoL improvement for interventions
(976-978,985-991). While the cost of nonsurgical treatment may seem extensive, surgical treatments have
additional costs associated with risks of complications,
including costs of repeat operations and cost of care of
failed surgical interventions. A significant proportion of
the patients undergoing interventional pain management techniques have already undergone surgical inter-
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ventions on multiple occasions or surgical interventions
are not feasible.
Adogwa et al (977) performed a 5-year cost analysis
of long-term cost of maximum nonoperative treatments in patients with symptomatic lumbar stenosis or
spondylolisthesis that ultimately required surgery. They
assessed a total of 4,133 eligible patients from 498,000
(0.8%), undergoing one, 2, or 3-level posterior lumbar
instrumented fusion. A significant portion of patients
had comorbid factors with 20.8% smokers, 44.5% with
Type 2 diabetes mellitus, and 38.2% with obesity. They
showed the maximum nonoperative treatments utilization as 66.7% used NSAIDS, 84.4% used opioids, 58.6%
used muscle relaxants, 65.5% received lumbar epidural
steroid injections, 66.6% attended physical therapy or
occupation therapy, and 25% attended chiropractic management. They showed total direct costs associated with
all MNT prior to index fusion of $4,010 on nonoperative
treatments per patient. Overall, 45.5% of the cost was
on epidural injections, followed by 18% for NSAIDS, and
14.2% for opioid costs. Surprisingly in this assessment,
PT-OT with a greater number of patients attending had
lesser costs compared to chiropractic visits. However,
these patients were continuously active within the insurance system for at least 5 years before lumbar fusion. In
utilizing cost utility, authors have ignored the fact that
these patients have been active and have responded to
the treatments with improvement in quality of life. They
also ignored the fact of costs, not only for surgical intervention, but indirect costs, along with follow-up care,
failed surgery with returning to the same modalities of
treatments, including spinal cord stimulation or intrathecal infusion systems and repeat surgery.
Cummins et al (991) assessing cost and utilization of
nonoperative therapy for chronic back pain studied 1,411
patients within the SPORT. They analyzed the nonoperative treatment patients with intervertebral disc herniation, spinal stenosis, and degenerative spondylolisthesis
with stenosis received prior to enrollment. With regards
to patients with either spinal stenosis or degenerative
spondylolisthesis, they determined that prior opioid use
occurred in 29% and 27% of patients, OTC medication
use in 31% and 27%, chiropractic treatment in 33% and
26%, and emergency department presentation in 7%
and 4%. However, more importantly, 70% of the patients
with spinal stenosis or degenerative spondylolisthesis
with stenosis, 70% of the patients received preoperative
physical therapy, 55% to 60% had received injections,
and 50% to 60% used anti-inflammatory medication.
Daffner et al (992) retrospectively analyzed 30,709
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patients by identifying the charges involved in the
conservative management of lumbar disc herniation
eventually requiring discectomy in the 90 days preoperatively. The average cost per patient over this time
period was $3,445, with 32% of this total coming from
charges for injections, 31% from diagnostic imaging,
13% from outpatient visits, 11% from physical therapy
visits, 2% from chiropractic visits, and other expenses
less than 2%. In this analysis, they also included both
diagnostic as well as therapeutic charges.
Tosteson et al (993) in a study comparing surgical treatment of spinal stenosis without degenerative spondylolisthesis also published the nonsurgical
care and cost effectiveness. The analysis included 634
participants with stenosis and 601 participants with
degenerative spondylolisthesis with associated stenosis. Of these, 62% of the participants with stenosis and
61% of participants with degenerative spondylolisthesis had surgery. Total adjusted mean nonoperative
care costs were similar. Diagnostic tests were reported
more frequently among those treated surgically. For
either disease groups, epidural or trigger point use was
higher among patients treated nonoperatively. Among
patients with stenosis, 45% were nonoperative management and 30% were surgery recipients, whereas it
was 46% for nonoperative management and 29% for
surgery recipients for degenerative spondylolisthesis
with stenosis. Opioid use was higher among those receiving surgery in both groups, 71% surgery recipients
and 35% in the nonoperative management group. The
total costs for nonoperative management for spinal
stenosis were $13,359, whereas they were $16,046
for degenerative spondylolisthesis with spinal stenosis, which included total direct and indirect costs. In
contrast, for surgical interventions, they were $26,222
versus $42,081 for degenerative spondylolisthesis with
spinal stenosis. Cost effectiveness was 1.37 and 1.33 for
nonoperative management and it was 1.54 and 1.55 for
surgical interventions for spinal stenosis and degenerative spondylolisthesis with spinal stenosis. While there
seems to be not much difference in the calculated cost
effectiveness for QALY, they described that cost utility was better for surgical interventions. With stenosis
surgery, improved health with a QALY gain was 0.17,
at a cost of $77,600, ranging from $49,600 to $120,000
per QALY gained. For degenerative spondylolisthesis,
QALY gain was 0.23 at a cost of $115,600, ranging from
$90,800 to $144,900 per QALY gained.
Tosteson et al (962,963) also assessed cost effectiveness of surgical versus nonoperative treatment for lum-
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bar disc herniation over a period of 2 years. This analysis
showed total costs of $27,341 for surgery for disc herniation in a commercial population and $20,150 in a Medicare population. For nonoperative care, the costs were
$13,135. The mean cost per QALY gained for surgery
was $69,403 in the general population and $34,355 for
the Medicare population over a 2-year period. Tosteson
et al (993), in another manuscript, provided the data on
comparative effectiveness evidence from SPORT comparing surgical versus nonoperative care for spinal stenosis,
degenerative spondylolisthesis, and intervertebral disc
herniation. They showed that cost per QALY gained
decreased for spinal stenosis from $77,600 at 2 years to
$59,400 at 4 years, for degenerative spondylolisthesis,
costs decreased from $115,600 to $64,300 and for intervertebral disc herniation, from $34,355 to $20,600.
The same group, with Lurie as the first author
(994), published the 8-year results of the SPORT for
disc herniation. In this analysis, they showed that patients undergoing surgical intervention continued to
do better than nonoperative treatment. The results
after 10 years also showed continuing improvement
in the results (995).
Spinal cord stimulators were assessed for cost utility in multiple studies (996-998) in the management
of chronic pain of failed back surgery syndrome, complex regional pain syndrome (CRPS), peripheral arterial disease (PAD), and refractory and angina pectoris.
Kumar et al (996) showed cost utility at Canadian
dollars (CAD) $9,293, CAD $11,216, CAD $93,050, and
CAD $99,084 for failed back surgery syndrome, CRPS,
PAD, and refractory angina pectoris, respectively, per
QALY gained.
Taylor et al (997) demonstrated that the incremental cost effectiveness of spinal cord stimulation compared with conventional medical management was
£5,624 per QALY, with an 89% probability that spinal
cord stimulation is cost effective at a willingness to
pay the threshold of £20,000. They also showed that
compared with reoperation, the incremental cost effectiveness of spinal cord stimulation was £6,392 per
QALY, with an 82% probability of cost effectiveness at
the £20,000 threshold.
However, Hollingworth et al (998) in an analysis
of the cost effectiveness of spinal cord stimulation for
failed back surgery syndrome in a workers’ compensation population showed that the mean medical cost
per spinal cord stimulation patient over 24 months was
$52,091, which was $17,291 higher than the pain clinic
group and $28,128 higher than in the usual care group.
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9.4 Cost Utility of Epidural injections
Cost utility or cost effectiveness analysis of epidural interventions was published in multiple manuscripts as a single modality (795,853,854,943,944,953,
954,999). Earlier investigations and some more recent
investigations have utilized inaccurate methodology, extrapolating from patients who have failed to
respond to epidural injections (854,999,1000). Often
it is difficult to understand methodologies showing
inappropriate results with inappropriate calculation
of the economic impact of treatments (961). Dagenais et al (989) described cases with high income and
disproportionately excessive charges for treatments
received, showing a nonoperative cost of $53,595 for
one attack of acute radiculitis, with each transforaminal epidural injection costing $2,500. Inappropriate
analysis in interventional pain management appears
to be a common phenomenon.
Price et al (854), in an RCT of clinical and cost
utility analysis, showed interlaminar epidural injections with inappropriate design of the study. They
based their results on improvement at 3 weeks in
one patient, based on the trial protocol of £16,816 to
£23,963, depending on the number of epidural steroid injections needed to treat. They also showed that
if only one epidural was provided, the total charge
to purchasers to improve one patient at 3 weeks was
£7,936 to £11,306. Obviously, not only was the RCT
flawed, but also the cost utility analysis and all the inferences drawn on this study. It was performed without fluoroscopic guidance and has not been included
in many systematic reviews or guidelines.
Whynes et al (999) evaluated a small number of
patients modeling resource use and data from other
studies. They studied 39 patients over a period of 13
weeks showing the QALY gain. They showed mean
cost of an injection was £219, with a cost quality
ratio of 2 injections, amounting to £8,975 per QALY
gained. They also concluded that when provided in
an outpatient setting, epidural steroid injections are
short-term, but nevertheless, cost effective means of
managing chronic LBP. However, this study is faced
with extensive criticism due to a small number of patients and data extrapolation from 3 weeks of relief.
Carreon et al (1000) assessed in their surgical
practice from June 2012 to July 2013 if appropriate
outcome parameters were available. Their results
showed that of the 421 patients who had received
lumbar epidural steroid injections, 323 patients, or
77%, had data available with EQ-5D, 145 patients, or
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45%, had a QALY gain at a cost of $62,175 per QALY
gained (mean 0.117), 127, or 40%, had a loss in QALY
(mean 0.120), and 51 patients, or 15%, had no change
in QALY. Many of them were precluded from surgery.
The cost utility per QALY gained was at $62,175. The
assessment is very crude. There is significant bias as
patients may be seeing the surgeon to obtain surgical
intervention. Further, since these are surgical referrals, they may have already failed epidural injections
with expectation of surgical interventions with high
levels of nocebo experience and potential lack of
medical necessity. However, it is not acceptable in the
US to perform these procedures in Medicare patients
without documentation of adequate relief. They also
showed in some cases, patients have received 6 procedures per year, which is unusually high. Consequently,
the results of this study are unreliable for any type of
clinical utility.
Multiple studies were performed by Manchikanti
et al (795,853,920,943,944) including: caudal, lumbar,
cervical, and thoracic interlaminar epidural injections,
and lumbosacral percutaneous adhesiolysis.
A cost utility analysis of fluoroscopic caudal epidural injections with or without steroids (795) was
performed based on 4 RCTs with lumbar disc herniation, axial discogenic LBP, central spinal stenosis, and
post-lumbar surgery syndrome (765,766-768). A total
of 480 patients were studied with 120 patients in
each disc herniation and discogenic pain group, 140
patients in the post-surgery syndrome, and 100 patients in the spinal stenosis group, with utilization of
2-year data outcomes with calculation of 2-year data
of cost utility analysis as shown in Fig. 17 and Table
18. Significant improvement was seen in all groups
of patients with local anesthetic only or with steroids
except for the spinal stenosis group at 12 months
and 24 months. The average cost for improvement of
one-year quality of life, with inclusion of direct costs
and indirect costs were $3,628 with caudal epidural
injections. There were no differences among the costs
in each category (Table 18).
Cost utility analysis of lumbar interlaminar epidural injections (853) in the treatment of lumbar disc
herniation, central spinal stenosis, and axial discogenic low back pain was assessed in 360 patients utilizing
the data from 3 RCTs (797,799,801). As shown in Fig.
18, there was significant improvement clinically ranging from 65% to 73% at 2-year follow up. As shown
in Table 19, the total estimated cost including procedural costs, costs of medical and other indirect costs
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for one-year improvement in QoL was shown to be
$3,301 overall.
Response from RCTs was also performed in patients receiving cervical interlaminar epidural injections in the treatment of cervical disc herniation,
post-surgery syndrome, or discogenic pain (943) as
shown in Fig. 19. The results showed positive response
in 71% of the patients receiving cervical epidural injections with local anesthetic alone or with steroids at 24
months. There was no difference between 6-month follow up, 12-month follow up, and 24-month follow up.
The average costs, including direct and indirect costs,
were $3,785.89 for one-year improvement in QoL (Table
20).
Cost utility of thoracic interlaminar epidurals
was also evaluated (944). A single RCT with a 2-year
follow-up of clinical effectiveness was utilized. This
study showed significant improvement in these patients (Fig. 20). This study included 110 patients with
a 2-year follow-up (588). Methodology was similar
to the other studies by Manchikanti et al. Cost utility
analysis showed direct procedural cost of $1,943.19,
whereas total estimated cost per QALY was $3,245.12
(Table 21).
Cost utility of percutaneous adhesiolysis was performed (920) in post-lumbar surgery syndrome and
central spinal stenosis in the lumbar spine utilizing 2
RCTs (893,894).
The results of 2 RCTs of low back pain (891-894)
with 60 and 70 patients over a 2-year follow-up with the
actual reimbursement data showed direct cost expenses
of $2,652 for post-lumbar surgery syndrome and $2,649
for lumbar central spinal canal stenosis. With the addition of 67% for indirect costs, the total cost for one-year
quality of improvement is $4,429 for post-lumbar surgery syndrome and $4,424 for lumbar central spinal stenosis (920). Figure 21 and Table 22 show the outcomes
and cost utility analysis of percutaneous adhesiolysis.
Figure 22 shows ranges of cost utility analysis in
various commonly utilized procedures in the US. Thus,
the costs of epidural injections are within the range.
Further, the costs utility with one-year improvement of
all interventional pain management techniques, except
for spinal cord stimulation, were below $5,000. Appropriately performed studies show cost effectiveness,
whereas, inappropriate inclusion criteria and studies
favoring surgery show lack of effectiveness.
In addition to the procedures on the spine, cost
utility shows that it is lower than many other chronic
diseases. Tosteson et al (963) in their manuscript de-
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scribed that spinal stenosis fusion surgery at a cost of
$115,600 per QALY improvement may be considered as
too expensive. In another manuscript (995), they also
summarized the evidence from the SPORT by addressing outcomes and costs for 3 types of spine problems.
Their results showed that after 4-year follow-up, patients with 3 spine conditions that may be treated sur-

gically or nonoperatively, have systematic differences
in value endpoints. The average surgical patient enjoys
better health outcomes and higher treatment satisfaction but incurs higher costs. However, for those who
are not candidates for surgical interventions and those
who are opposed to surgery or their medical status
contraindicates surgery, treatment with epidural in-

Fig. 17. Proportion of patients with significant reduction in Numeric Rating Score and Oswestry Disability Index (≥ 50%
reduction from baseline) for caudal epidural injections.
Reproduced with permission from authors and Pain Physician journal.

Table 18. Analysis of cost effectiveness of caudal epidural injections in managing pain and disability of disc herniation, discogenic
pain, spinal stenosis, and post surgery syndrome in 480 patients.

Disc
Herniation

Axial or
Discogenic
Pain

Spinal
Stenosis

Post Surgery
Syndrome

Number of patients

120

120

100

140

480

Total number of procedures for 2 years

601

647

400

696

2344

5.0 ± 2.55

5.4 ± 2.63

4.0 ± 2.57

5.0 ± 2.76

4.9 ± 2.67

6294

7254

4305

7096

24949

9.4 ± 7.23

10.7 ± 8.25

9.7 ± 13.54

8.4 ± 6.14

9.5 ± 8.92

52.5 ± 38.46

60.4 ± 37.71

43.1 ± 41.52

50.7 ± 38.71

52.0 ± 39.33

Physician

$74,761.00

$81,729.00

$45,944.00

$88,776.00

$291,210.00

Facility

$192,225.00

$216,268.00

$132,468.00

$210,168.00

$751,129.00

Total

$266,986.00

$297,997.00

$178,412.00

$298,944.00

$1,042,339.00

Physician

$124.40

$126.30

$115.10

$127.60

$124.30

Facility

$319.80

$334.30

$332.00

$302.00

$320.60

Total

$444.20

$460.60

$447.10

$429.50

$444.90

Number of treatments for 2 years per patient (mean ) ± SD
Number of weeks with significant improvement for all
patients in the study in weeks for 2 years
Significant improvement in weeks per procedure (mean)
± SEM
Number of weeks with significant improvement per
patient for 2 years

Total

Total Cost ($)

Cost per procedure ($)

Cost per 1-week QALY ($)

$42.42

$41.08

$41.44

$42.13

$41.78

Cost per 1-year QALY ($)

$2,205.79

$2,136.18

$2,155.03

$2,190.68

$2,172.50

Cost per 2-year QALY ($)

$4,411.59

$4,272.36

$4,310.07

$4,381.37

$4,344.99

Average Total cost per patient for 2 years

$2,225.00

$2,483.00

$1,784.00

$2,135.00

$2,172.00
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terventions seems appropriate. They also showed that
longer follow-up periods after the surgery at 4 years
and 10 years, cost effectiveness per QALY improved
significantly (962,994).
Further, the epidural interventions may avoid the
surgery in a significant portion of patients (188,271274,278) providing better value.

10.0 Complications and Side Effects
Epidural Interventions

of

Key Question 8: What are the adverse consequences and harms and related precautions in providing epidural procedures?
Complications related to epidural injections are
rare, but can be serious and devastating , specifically
in cervical spine (623,866,1001-1038). They are usually

Fig. 18. Proportion of patients with significant reduction in Numeric Rating Score and Oswestry Disability Index (≥ 50%
reduction from baseline) with lumbar interlaminar epidural injections.
Reproduced with permission from authors and Pain Physician journal.

Table 19. Cost utility analysis of lumbar interlaminar epidural injections in managing pain and disability of disc herniation,
discogenic pain, and spinal stenosis.
Disc Herniation

Discogenic Pain

Spinal Stenosis

Number of patients

120

120

120

360

Total number of procedures for 2 years

682

714

644

2040

5.7 ± 2.5

6.0 ± 2.5

5.4 ± 2.6

5.7 ± 2.6

7667

7900

8074

23641

10.8 ± 5.7

10.5 ± 5.9

13.2 ± 12.7

11.5 ± 8.8

Number of treatments for 2 years per patient (mean ) ± SD
Number of weeks with significant improvement for all patients in the
study in weeks
Significant improvement in weeks per procedure (mean ) ± SD

Total

Direct procedural costs without drug costs ($)
Physician

$85,443

$93,250

$66,342

$245,036

Facility

$216,942

$227,649

$208,994

$653,585

Total

$302,385

$320,899

$275,336

$898,620

Physician

$125.28

$130.60

$103.02

$120.12

Facility

$318.10

$318.84

$324.52

$320.38

Total

$443.38

$449.44

$427.54

$440.50

Average total direct costs per patient in 2 years

$2,519.88

$2,674.16

$2,294.47

$2496.17

Direct procedural improvement in quality of life ($)

$2,050.87

$2,112.25

$1,773.28

$1,976.58

Indirect costs including drug costs for 1-year improvement in quality
of life ($)

$1,374.08

$1,791.68

$1,188.10

$1,324.31

$3,425

$3,527

$2,961

$3,301

Direct costs per procedure ($)

Total estimated costs including procedural costs, costs of medicine and
other indirect costs for 1-year improvement in quality of life ($)

Total costs ($) for one-year improvement of quality of life
www.painphysicianjournal.com
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Fig. 19. Proportion of patients with significant reduction in numeric rating score and neck disability index (≥ 50% reduction
from baseline) for cervical interlaminar epidurals.
Reproduced with permission from authors and Pain Physician journal.

Table 20. Analysis of cost effectiveness of cervical epidural injections in managing pain and disability of disc herniation, discogenic
pain, and post surgery syndrome.

Number of patients
Total number of procedures for 2 years
Number of treatments for 2 years per patient (mean ) ± SD
Number of weeks with significant improvement for all patients in the study
in weeks

Group I
Discogenic
Pain

Group II
Disc Herniation

Group III
Post surgery
Syndrome

Pooled

120

120

116

356

689

654

627

1971

5.7 + 2.4

5.4 + 2.7

5.4 + 2.6

5.5 + 2.5

8,093

7,900

7,254

23,247

11.6 + 7.7

12.6 + 12.0

11.4 + 8.6

11.9 + 9.6
$266,614

Average total relief in two year per patient
Significant improvement in weeks per procedure (mean ) ± SD
Total Cost ($)
Physician

$89,321

$95,130

$82,162

Facility

$286,117

$221,033

$239,971

$747,121

Total

$375,439

$316,163

$322,133

$1,013,735

Physician

$129.64

$145.46

$131.04

$135.27

Facility

$415.26

$337.97

$382.73

$379.06

Total

$544.90

$483.43

$513.77

$514.33

Average total direct costs per patient in 2 years

$3,128.66

$2,634.69

$2,777.01

$2,847.57

Direct procedural improvement in quality of life ($) per one year

$2,412.31

$2,081.07

$2,309.20

$2,267.57

Indirect costs including drug costs for 1-year improvement in quality of life
($)

$1,616.25

$1,394.32

$1,547.16

$1,519.27

Total estimated costs including procedural costs, costs of medicine and other
indirect costs for 1-year improvement in quality of life ($)

$4,028.55

$3,475.38

$3,856.36

$3,785.89

Cost per procedure ($)

All the payments based 2018 allowed rates
SD = standard deviation

related to either the needle placement or drug activity. Medical-legal analysis has revealed the causes of
injury are multifactorial, involving aspects of technical
execution, clinical judgment, communication with the
patient and other medical providers, and documentation (1019).
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Interventional pain management physicians approach the epidural space by a caudal, transforaminal, or
interlaminar technique. Transforaminal epidurals have
been associated with more adverse events after injection
of corticosteroids. This is due to an inadvertent injection
into or mechanical damage of the critical vasculatures
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Fig. 20. Illustration of reduction (at least 50%) in pain and Oswestry Disability Index from baseline for thoracic interlaminar
epidurals.
Reproduced with permission from authors and Pain Physician journal.

Table 21. Analysis of cost-utility of thoracic epidural injections.

Responsive
Participants

Nonresponsive
Participants

All Participants

Number of patients

100

10

110

Total number of procedures for 2 years

586

20

606

5.9 ± 2.3

2.0 ± 0.8

5.5 ± 2.5

Number of treatments for 2 years per patient (mean ± SD)
Number of weeks with significant improvement for all patients in the study in weeks

7879

18

7897

Average total relief in 2 years per patient

78.8 ± 25.6

1.8 ± 2.1

71.8 ± 3302

Significant improvement in weeks per procedure (mean ± SD)

13.6 ± 10.1

0.9 ± 1.1

13.2 ± 10.2

Physician

$66,765.68

$2252.75

$69,018.43

Facility

$218,918.99

$7165.98

$226,084.97

Total

$285,684.67

$9418.73

$295,103.40

Physician

$11.93

$112.64

$113.89

Facility

$373.58

$358.30

$373.08

Total

$487.52

$470.94

$486.97

Total cost

Cost per procedure ($)

Average total direct costs per patient in 2 years

$2856.85

$941.87

$2682.76

Direct procedural improvement in quality of life ($) per 1 year

$1885.47

$27,209.66

$1943.19

Indirect costs including drug costs for 1-year improvement in quality of life ($)

$1263.54

$18,230.47

$1301.93

Total estimated costs including procedural costs, costs of medicine and other indirect
costs for 1-year improvement in quality of life ($)

$3148.73

$45,440.13

$3245.12

All the payments based 2018 allowed rates

that supply the brain or spinal cord when injectates are
administered via this approach (886,1020,1021).
Caudal epidural steroid injections have been
thought to be a safer approach for treating pain in
lumbar stenosis. However, there are reports of rare neurological deficits that are transient or permanent. These
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include cauda equina syndrome in patients with spinal
stenosis, spinal infarction, chemo toxicity, vascularocclusion, and epidural hematoma (1020,1022).
Cervical and lumbar interlaminar epidural steroid injection and transforaminal epidural steroid injection are
2 distinct approaches that attempt to deliver medication
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to the irritated nerve roots. The transforaminal epidural
steroid injection allows for a more direct approach into
the anterolateral neuroforaminal space where inflammation due to a posterolateral disc displacement commonly
resides. Transforaminal epidural spread of corticosteroid
has been associated with improved pain and functional
outcome improvements, although the evidence has been
refuted in some of the literature.
In the last decade, the use of epidural steroid injections has come under scrutiny. In 2011, the label for tri-

amcinolone was updated, warning against epidural use.
In April 2014, the FDA issued a warning that epidural
steroid injections can cause “rare but serious adverse
events, including loss of vision, stroke, paralysis, and
death.” mainly based on case reports of direct spinal
cord injury and of infarctions related to cervical transforaminal placement of particulate steroids, although the
FDA warning and package insert revisions covered all
steroids including dexamethasone (1039). In the FDA’s
risk assessment between 1997 and 2014, a total of 90
serious and sometimes fatal neurologic events were reported to
the FDA Adverse Event Reporting
System (FAERS), including cases of
paraplegia, quadriplegia, spinal
cord infarction, and stroke. Further, compounded glucocorticoids
used in epidural injections also
have been associated with fungal
meningitis (1040-1049), but cases
involving contaminated products
were not included in the case
series under consideration. HowFig. 21. Proportion of patients with signiﬁcant reduction in Numeric Rating Score and
ever, potential causes of various
Oswestry Disability Index (≥ 50% reduction from baseline).
adverse events including multiple

Table 22. Analysis of cost-effectiveness of percutaneous adhesiolysis injections in managing pain and disability of lumbar spinal
stenosis and postsurgery syndrome.

Number of patients
Total number of procedures for 2 years
Number of treatments for 2 years per patient (mean ± SD)
Number of weeks with significant improvement for all patients in the study in weeks
Significant improvement in weeks per procedure (mean ± SD)

Spinal
Stenosis

Postsurgery
Sundrome

Total

70

60

130

397

385

782

5.7 ± 2.73

6.4 ± 2.32

6.0 ± 2.56

4,979

4,704

9,686

13.2 ± 12.6

11.7 ± 2.97

12.5 ± 9.47

87,082

83,112

170,140

Total cost ($)
Physician
Facility

166,891

156,529

323,420

Total

253,919

239,641

493,560

Cost per procedure ($)
Physician

219.21

215.88

217.57

Facility

420.38

406.56

413.58

Total

639.59

622.44

631.15

Cost for 1-week improvement in quality of life

51.00

50.94

50.96

Cost for 1-year improvement in quality of life

2,652

2,649

2,650

Cost for 2-year improvement in quality of life

5,304

5,298

5,299

Average total cost per patient for 2 years

3,627

3,994

3,797

$ is adjusted to 2012
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Fig. 22. Ranges of cost utility analysis in various commonly utilized procedures in the United States.
Reproduced with permission from authors and Pain Physician journal.

causes and those involving technique related problems
such as intrathecal injection, epidural hematoma, direct
spinal cord injury, and embolic infarction after inadvertent intra-arterial injection. The FDA sought to determine
the central question regarding the role of glucocorticoids
themselves in these adverse events (1050).
Inadvertent vascular mechanical or occlusive injury
is believed to be the leading cause of the infarctions.
This may be due to intravascular injection of particulate
steroids, arterial injury, dissection, dislodgement of
plaque causing embolism, or arterial muscle spasm. The
embolization path is believed to start through the periradicular arteries, which exit the neural foramen and
accompany the nerve to the spinal cord. Although most
complications have been seen with particulate steroid
and cervical spine transforaminal epidural steroid injections, case reports of spinal infarction have been seen
with nonparticulate lumbar steroid injections such as
dexamethasone as well (1021).
Transforaminal epidural steroid injections are associated with other complications as well. Transforaminal
epidural steroid injections, compared to interlaminar
epidural steroid injections, are associated with an
increased risk of intradiscal injection (1025,1026). Ad-
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ditionally, transforaminal epidural steroid injections do
not decrease the risk of known complications of interlaminar epidural steroid injections, such as dural and
subdural punctures, hematoma formation, and cauda
equina syndrome (1021,1022). Although complications
are rare, they can be catastrophic, and the implementation of safety guidelines based on common practice has
been attempted. The FDA convened a panel of experts,
including pain medicine experts, to determine specific
techniques of this procedure that may reduce potential
harm, but evidence was lacking, and consensus was not
reached on all the items (632,1039). Consequently, the
Multisociety Pain Workgroup (MPW), without inclusion
of the ASIPP, approved multiple safeguards to prevent
neurologic complications after epidural steroid injections (632); however, there were many issues involved.
Consequently, it was opposed by ASIPP (1039). Following this, ASIPP also petitioned the FDA asking them to
prevent the safeguards from being mandatory and also
requested them to remove the safety warning (1051).
However, the FDA denied the request to remove the
safety warning or limiting to cervical transforaminal
epidural injections, but agreed with the second item
that safeguards were not required (1050).
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As described by Racoosin et al (1050) in the assessment of the risk from the FDA in reference to serious
neurologic events after epidural corticosteroid injection,
they emphasized the fact that even though inadvertent
intra-arterial injection is one mechanism for serious
neurologic events, there were other potential causes.
They quoted a study by the American Society of Anesthesiologists (ASA) Closed Claims Project showing that
in cases of cervical procedures for chronic pain that led
to malpractice claims, direct needle trauma to a nerve
or the spinal cord was the most common procedure related event. Further, this study (1052) found that of the
cervical epidural procedures that were associated with
spinal cord injury, two-thirds were performed with an
interlaminar approach and one-third with the transforaminal approach (1052). The FDA also clarified that the
recently published clinical consideration for healthcare
providers (1050) recommendations came from the working group, not the agency, as had been requested by the
ASIPP petition (1051). Consequently, the class warning
published in 2014 for all injectable glucocorticoid products labels carrying, “serious neurologic events, some
resulting in death, have been reported with epidural
injection of corticosteroids” and the safety and that the
“safety and effectiveness of epidural administration of
corticosteroids have not been established and corticosteroids are not approved for this use (1050).” In their
final determination, the FDA determined that the class
warning was warranted based on its analysis of FAERS
cases and reports in the medical literature of serious
neurological events. Further, the warning did not distinguish any difference in the risk associated with the
various injection approaches, locations of spinal injections, or glucocorticoid formulation, because the data
suggested that each approach, location, and formulation was associated with some risk of neurologic injury.
At the same time, they have not approved or mandated
the safeguards recommended by MPW.
Epidural steroid injections are associated with a
number of minor complications and side effects, such
as exacerbation of pain, vasovagal reaction, and steroid
side effects such as facial flushing and hyperglycemia,
which do not involve any permanent impairment
(55,1027,1027). Of great concern however, are the
rare but major complications such as epidural abscess,
discitis, and hematoma formation, radiculo-medullary
artery injury due to needle or injection with particulate
steroids, spinal cord infarction, stroke and spinal cord
injury that can result in severe permanent disability,
paralysis, or death (7).
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Other complications include extra epidural placement with subcutaneous injection; subdural injection,
dural puncture with post-lumbar puncture headache
(more common in interlaminar lumbar epidurals), nerve
damage, intracranial air injection or increased intracranial pressure; and pulmonary embolism. Less common
complications include transient blindness (1029), retinal
hemorrhage and necrosis (1030,1031), spinal cord infarct by caudal (1006), placement of needle into filum
terminale (1005), serous chorioretinopathy (1032,1033),
persistent recurrent intractable hiccups (1034), pneumocephalus (1009), chemical meningitis (1035), arachnoiditis (1037), and discitis (1036).
Recommendations have been made to limit or
avoid the use of epidural steroid injections of corticosteroids in high-risk patients, such as the elderly, during
the COVID-19 pandemic (1053). Steroid distancing has
also been advocated as a result (55). Additionally, ASIPP
has issued guidelines on evidence-based risk mitigation
and stratification during COVID-19 for return to interventional pain practice as well as triaging interventional
pain procedures during COVID-19 or related elective
surgery restrictions that risk and acuity stratify epidural
steroid injections (51,52).
Apart from COVID-19 issues, steroids continue
to present with multiple problems including vascular
embolism related to particulate steroids when utilizing transforaminal epidural injections. These are seen
with particulate steroids such as triamcinolone or depomethylprednisolone. In contrast, betamethasone, which
is a smaller particulate steroid, shows less prevalence of
the side effects and lesser suppression of glucocorticoid
synthesis, leading to fewer complications (55).

10.1 Side Effects of Steroids
The pharmacokinetics of corticosteroids continues
to be complex. With intramuscular administration, absorption of the water-soluble sodium phosphate and
sodium succinate source is rapid, whereas the rate of absorption of lipid soluble acetate and acetonide is much
slower (1054-1058). The subject of interest for this discussion is the role of systematic absorption of epidural
steroids, which has been explored in multiple reports.
Janicki et al (1057) reported pharmacokinetic analysis
of methylprednisolone after epidural administration in
rabbits, with only traces of methylprednisolone being
detected at 6 and 12 hours after administration of the
highest epidural dose of the drug (5 mg/kg). Further,
plasma methylprednisolone doses at all sampling times
for the epidural doses of 2.5 and 1.25 mg/kg were also
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not detectable. Jacobs et al (1055) have also reported
being unable to detect methylprednisolone in blood
samples. Friedly et al (1058) in a study of the systemic
effects of epidural steroid injections for spinal stenosis
showed that of the 200 patients receiving corticosteroid, 32 patients or 20.3% experienced cortisol reduction at 3 weeks of ≥ 50% compared with 10 patients
(6.7%) treated with lidocaine only. The effect on
3-week cortisol changes did not differ by patient level
characteristics. They also showed that those treated
with methylprednisolone or triamcinolone had an average 3-week cortisol reduction of 41% and 41.6% from
baseline, respectively. Further comparison with patients
treated with betamethasone or dexamethasone, found
no significant changes with cortisol and they were similar to lidocaine alone. They concluded that the higher
rates of cortisol suppression at 3 weeks in those receiving epidural corticosteroid injections, particularly with
longer acting insoluble corticosteroid formulations, are
consistent with sustained systemic absorption of corticosteroid. Hooten et al (1059) showed that terminal
elimination half-life of lumbar epidurally administered
triamcinolone in a noncompartmental analysis was 523
hours (almost 22 days), and the peak triamcinolone concentration of 4.1 ng/mL was detected within 24 hours
after administration. This elimination half-life after
lumbar epidural administration is much longer than the
elimination half-life of intravenous administration and
is likely explained by the suspension and re-distribution
of the depo preparation within the epidural fat and the
epidural anatomy (1060).
Risk of reductions in bone density have been reported in high dose steroids (1061-1064), though lower
doses were potentially safe. Symptomatic hypothalamicpituitary-adrenal (HPA) suppression has been reported
occasionally. Abdul et al (1063) in 2017 reported that,
after one epidural injection of 80 mg of methylprednisolone, 87% of patients exhibited HPA axis suppression at
day 7 post-injection, 43% at day 14, and 7% at day 28.
Habib et al (1064) in 2013, found a dose dependent effect
in a study examining the magnitude and duration of this
suppression after a single epidural injection of methylprednisolone. Eighty-six percent of the patients who
received an 80 mg dose were reported to have laboratory
confirmed HPA axis suppression one week post-injection
compared to 53% of those receiving a 40 mg dose; 20%
of all participants had continued suppression at 4 weeks
post-injection. Steroid solubility is a factor in endocrine
influence; longer-acting agents (triamcinolone and
methylprednisolone) have been found to suppress corti-
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sol production for a longer duration than more soluble
agents (dexamethasone and betamethasone) (1058).
Corticosteroids have anti-inflammatory effects;
they reduce pain related to inflammation by downregulation of the immune function as well as reduction
of inflammatory cells and mediators (lymphocytes,
macrophages, and mast cells) (1065,1066). Although
it has not been directly studied, the endocrine disruption from a single epidural steroid injection suggests
similar systemic effects on immune response. The use of
systemic corticosteroids can adversely affect the innate
(immediate) immune response by impairing the ability
of neutrophils to migrate to infection sites as well as
macrophage and monocyte function. The adaptive immune response (which leads to immunological memory)
is also negatively affected by corticosteroids, as the
capability of plasma cells to produce immunoglobulins
IgG and IgA is reduced by 10 to 20% after exposure.
Injection therapy plausibly has similar effects to the oral
administration effects described in the literature.
Consequently, adverse immune influences of corticosteroids during an influenza infection is of increased
concern for those prescribed or injected with corticosteroids, with specific concern during the current COVID-19
pandemic. Meta-analysis of orally administered corticosteroid versus placebo demonstrates an increased risk of
influenza infection within the steroid group. One study
found a dose-dependent relationship for infection risk,
showing a relative risk of 1.5 with low doses of steroids
and a relative risk greater than 8 with doses above 40
mg/day (1067). In another study, rheumatoid arthritis
patients taking oral prednisone had relative risks ranging
from 1.4 (< 5 mg/day dose) to 2.3 (> 10 mg/day dose) for
hospitalization due to pneumonia compared to rheumatoid arthritis patients not taking oral prednisone (1068).
Although data for single-dose exposure to corticosteroids is limited, early evidence is provided in a report on
an observational cohort from the Mayo Clinic. Over five
influenza seasons, an increased incidence of influenza
infection was associated with steroid injection compared
to no injection (1069). There are currently no studies
specifically examining the relationship between corticosteroid injections and COVID-19, however, the findings
presented here raise concern for a potential relationship.
Thus, the literature surrounding infrequent adverse
effects of epidural corticosteroids continues to accumulate (1070-1072), with alterations in blood glucose levels
among patients with diabetes (1073,1074), and prolonged effects on the HPA axis (1075). Further, it has also
been reported that systemic side effects are common with
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long-term administration of steroids (1058,1076,1077).
Lamer et al (1070) in a study of 8 patients also assessed serum triamcinolone levels following cervical interlaminar
epidural injection. Data of the pharmacokinetics showed
peak triamcinolone concentration (C max) of 5.4 ng/mL
median value within 22.1 hours (T max) of administration. The terminal elimination half-life was 219 hours,
the median value. They also compared the results of this
study with the previous study of lumbar interlaminar epidural injections (1059) and showed similar patterns. This
comparison also showed that while the pharmacokinetic
profile is similar, the T max is earlier and T ½ is shorter
for the cervical compared to the lumbar epidural steroid
injection. In similar lines with other investigators, recently, Sim et al (105) assessed the relationship between
epidural steroid dose and separation of HPA access. In
the analysis of 30 patients with administration of triam-

cinolone, either 40 mg or 20 mg, they showed that 40
mg triamcinolone group showed longer HPA separation,
19.7 ± 3.1 days compared to triamcinolone 20 mg group
(8.0 ± 2.4 days) and the recovery rate of triamcinolone 40
mg group was lower than that of 20 mg group with a significant difference (P value > 0.015) as shown in Fig. 23.
In another manuscript, Chon and Moon (1078) reported that in all subjects who received epidural steroid
injections with triamcinolone acetate, 40 mg were suppressed temporarily but were restored after a mean of
19.9 ± 6.8 days.
The data also shows that intravenous triamcinolone
acetonide pharmacokinetics using the soluble form have
been previously determined, demonstrating a half-life
of approximately 1.5 to 2 hours (1079-1080). However,
in contrast to intravenous administration, intra-articular
knee injection of a suspension of acetonide showed
vastly different results wherein
triamcinolone acetonide was
detected in serum for more than
2 weeks and the half-life ranged
from 77 to 446 hours (1081). Thus,
it is crucial to understand the
different mechanisms of shortacting and long-acting drugs,
along with particulate sizes. It is
also hypothesized that there is
less sequestration of particulate
steroids in the cervical epidural
space, consequently with faster
absorption. Table 23 shows the
profile of commonly used epidural
steroids based on the data derived
Fig. 23. Changes with HPA separation and SC duration with lumbar epidural
from multiple sources (1054triamcinolone, either 40 mg or 20 mg.
Reproduced with permission from authors and Pain Physician journal.
1056,1076,1082-1084). Table 24

Table 23. Profile of commonly used epidural steroids.

Equivalent
Dose

Epidural
Dose

Antiinflammatory
Potency

Sodium
Retention
Capacity

Hydrocortisone

20 mg

NA

1

Depomethylprednisolone
(Depo-Medrol)

4 mg

40-80 mg

Triamcinolone acetonide
(Kenalog)

4 mg
0.6 mg

Drug

Betamethasone (Celestone
Soluspan)

Duration of Adrenal Suppression
IM

Single
Epidural

Three
Epidurals

1

NA

NA

NA

5

0.5

1-6 weeks

1-3 weeks

NA

40-80 mg

5

0

2-6 weeks

3-5 weeks

2-3
months

6-12 mg

25

0

1-2 weeks

NA

NA

NA = not applicable
Data adapted and modified from: McEvoy et al (1054), Jacobs et al (1055), Kay et al (1056), Hsu et al (1076), Mikhail et al (1083,1084), and Schimmer and Parker (1082).
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Table 24. Formulations of commonly used epidural steroids.

Amount of steroid

Depo-Medrol Methylprednisoline
20 mg/mL

40 mg/mL 80 mg/mL

Aristocort
Triamcinolone
Diacetate

Kenalog
Triamcinolone
Diacetate

Celestone
Betamethasone

40 mg/mL

40 mg/mL

6 mg/mL

Polyethylene glycol 3350

29.5

29.1

28.2

30

--

--

Polysorbate 80

1.97

1.94

1.88

2

0.4

--

Benzyl alcohol

6.9

6.8

6.59

--

--

3.4

Dibasic sodium phosphate

9.3

9.16

8.8

9

9

--

Edetate disodium

--

--

--

--

--

7.1

Edetate disodium

--

--

--

--

--

0.1

Benzalkonium chloride

--

--

--

--

--

0.2

shows formulations of commonly used epidural steroids. Dexamethasone is not being discussed since it
is a nonparticulate and short-acting steroid with the
least side effects, but it is associated with some side
effects.
Overall, systemic side effects are significant with
the influence of corticosteroids on the metabolism of
carbohydrates, fats, proteins, and purine. They can
also affect electrolyte and water balance and may affect the functions of the CNS and of the cardiovascular,
renal, endocrine, reproductive, and immune systems,
as well as the bones and muscles (1077). Long-term effects may be caused directly by excess glucocorticoid
in the circulation or indirectly through suppression of
the HPA. It is also common that patients presenting to
interventional pain management may be taking longterm steroids for multiple medical problems and also
may be receiving intra-articular steroid injections.
The specific effects on the immune system are
especially worrisome during the COVID-19 pandemic.
While there are no data available with regard to the
effects of epidural administration of glucocorticoids
on the immune system, there are data available regarding systemic administration with high dose glucocorticoid therapy, equivalent to doses of 40 mg or
more of prednisone per day. With high doses, there
is an immediate risk of infection due to inhibition of
phagocyte cell function, which abates after completion of therapy (1085). In patients with rheumatoid
arthritis, acute effects of 1 gm of intravenous methylprednisolone showed development of leukopenia
within 2 hours of the dose, which peaked at 6 hours,
and resolved by 24 hours. In addition, doses of less
than 40 mg, considered as low to moderate, have
been shown to reduce T lymphocytes with delayed
hypersensitivity responses. With long-term low dose
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usage, some inhibition of immune responses may increase with the duration of therapy (1086). Multiple
issues related to vaccination have been discussed in
the past (1087-1089); however, not specifically with
the COVID-19 virus. Considering the literature, shortterm therapy with low dose within appropriate duration of 6 to 13 weeks may not have any significant
effect. The Advisory Committee on Immunization
Practices (ACIP) (1090) and the CDC (1091) advise to
defer live vaccinations for at least one month after
discontinuation of high dose systemically absorbed
glucocorticoid therapy administered for 14 days.

10.2 Side Effects of Local Anesthetics
Historically, the use of procaine was extensively
utilized following cocaine; however, the introduction
of lidocaine in 1948 and bupivacaine, which was introduced in 1963, has been extensively used outside
of the epidural space with lidocaine also used for
intra-articular injections in chronic pain management.
The mechanism of action of intravenous lidocaine in
neuropathic pain cannot be explained by blockade of
voltage-gated Na+ channels alone. The clinical effects
include reduction of spontaneous pain, allodynia,
and hyperalgesia. Further, local anesthetic infusions
have been utilized in various types of pain providing longer term relief than the expected duration
of the local anesthetic (1092). Local anesthetics also
have systemic and local toxic effects. Systemic toxicity
relates to the relatively narrow difference between
therapeutic plasma levels and toxic levels (1093). Peak
plasma levels are determined by the dose and rate of
systemic absorption. The genes controlling the subunit of Na+ channels give rise to different pharmacological and biophysiological profiles of Na+ channels
through the body (1092). Overall, levobupivacaine
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has lower systemic toxicity than other amides because
of its lower affinity for cardiac channels (1094). Intraarticular local anesthetics may cause chondrotoxicity;
however, chondrotoxicity is worse with bupivacaine
or mepivacaine. While methemoglobinemia is a major
issue with prilocaine, benzocaine and lidocaine can
also cause methemoglobinemia (1095,1096).
Local anesthetic toxicity affects 2 organs that
inherently are less tolerant of anaerobic metabolism, the heart and brain. Cardiac toxicity is mostly
related to accidental intravascular injection, leading
to the conduction disturbances, contractile dysfunction, and ventricular arrhythmias that are seen in
local anesthetic induced cardiac toxicity (1097). More
importantly, for interventional pain physicians, the
incidence of cardiac toxicity increases with bupivacaine, a longer acting anesthetic. Bupivacaine blocks
inactive sodium channels during the cardiac potential
at a concentration of 0.2 mcg. Bupivacaine binding
is described as “fast-in, slow-out” fashion as it binds
very quickly to a large portion of sodium channels
during the cardiac action potential, but releases from
the channel slowly during diastole, resulting in a
large proportion of medication accumulating at 60 to
150 beats per minute. Local anesthetic toxicity may
become a serious issue, even though adverse effects
are rare. From minor symptoms to major cardiac or
CNS effects, local anesthetic system toxicity is an important consequence in interventional pain management. The epidemiology of local anesthetic toxicity
has been reported from zero events to 25 per 10,000
nerve blocks. One study reported seizures of 79 of
10,000 brachial plexus block procedures (1098,1099).
Lidocaine at 5 to 10 mcg/mL will also result in a
substantial sodium channel blockade during cardiac
action potential. However, in contrast to bupivacaine,
lidocaine follows the “fast-in, fast-out” principle,
meaning it releases from sodium channels rapidly
during diastole. This allows for a quick recovery, and
reduced incidence of cardiac toxicity even compared
to bupivacaine. Consequently, during a cardiac arrest,
it may be crucial to continue resuscitation measures
until bupivacaine is completely released. CNS changes
include agitation, confusion, dizziness, drowsiness,
dysphoria, auditory changes, tinnitus, perioral numbness, metallic taste, and dysarthria. Without adequate
recognition and treatment, these signs as symptoms
can progress to seizures, respiratory arrest, and/or
coma.
Historically, local anesthetic literature suggests
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that cardiac toxicity is often presented after antecedent CNS toxicity (1097). However, with more potent
local anesthetics, cardiac toxicity may precede CNS
toxicity. Lidocaine was utilized far more frequently
than bupivacaine. Subarachnoid blockade with bupivacaine may turn out to be a disaster, specifically in
the cervical spine. Consequently, injections of bupivacaine in the cervical or thoracic spine is contraindicated. Even then, lidocaine is also injected in extremely
low concentrations of 0.5%. In the cervical spine, one
must still be careful with appropriate visualization
of the epidural space without any subdural or subarachnoid filling. Failure to follow basic principles can
result in respiratory arrest, as well as cardiac arrest.

10.3 Radiation Safety
Other complications of epidural interventions
include radiation exposure, when guided under fluoroscopy. This is a potential problem with damage to
eyes, skin, and reproductive organs (1100-1104).
The ALARA principle should be respected when xray is used because excessive radiation to a patient or
a physician can cause radiation injury or a stochastic
effect such as neoplasm and genetic mutation (1104).
Radiation exposure used in pain procedures is
related to factors such as the skill of the operator, the
distance of the operator from the patient, the orientation of the operator’s head, the distance of the image
detector from the patient, the beam collimation, the
tube configuration, the tube voltage and filtration,
and the complexity of the procedure (1102).
Fortunately, most studies regarding radiation
exposure during fluoroscopy-guided pain interventions have concluded that exposure levels are below
the yearly limit established by the International Commission on Radiological Protection (ICRP). However,
exposure to low levels of ionizing radiation over the
long-term cannot be accurately predicted. These longterm, low-level ionizing radiation exposures may not
acutely destroy cells, but may lead to cell damage and
genetic mutations that can lead to sequelae years
later (1103).

10.4 Complications of Lysis of Adhesions and
Neuroplasty
Lysis of adhesion was first introduced into the
lexicon of interventional pain medicine techniques in
1989 (1105). Since that introduction, the procedure
has grown in acceptance and application to include
epiduroscopy and transforaminal approaches to the
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relief of pain secondary to adhesions (911,1105).
While the procedure was initially introduced in the
lumbar space, the application of the concept has expanded for use in the thoracic and cervical spine as
well (1106,1107). The complications that associated
with the procedure are well defined and include well
described procedure-related issues with neuraxial access and intervention such as post procedure discomfort, dural puncture/tears and post-dural puncture
headache, infection, nerve injury, transient neurologic syndrome, to the more rare and higher clinical
impact adverse events such as seizure, visual impairment, neurogenic bladder, cauda equina syndrome,
and contrast-induced rhabdomyolysis (7,1105-1108).
Reviewing more recent literature, to date, no
studies evaluating lysis of adhesions or neuroplasty
in the cervical spine have evaluated complications
or complication rates. The studies performed in this
region have only evaluated effectiveness (1106). One
randomized, double blinded, pilot study compared
mechanical lysis of adhesions with chemical lysis using
corticosteroid and hyaluronidase in the lumbar spine
(911). This study suggested an improved outcome with
steroid + hyaluronidase with regard at six months and
one year but no complication rate was noted (1109).
A recent study evaluated neuroplasty in 430 consecutive patients with single level lumbar disc herniation
demonstrating a tendency in the treatment group to
avoid need for decompressive surgery (911). Again, in
this study, the complication rate was not mentioned.
Including the Marchesini report (1110), 22 complications were reported in 246 subjects with no lasting
sequela though several of the transient symptoms
were ominous in nature upon presentation.

11.0 Implications Antithrombotic
Anticoagulant Therapy

and

Key Question 9: What are the implications of
antithrombotic and anticoagulant therapy and epidural interventions?
Implications of antithrombotic and anticoagulant
therapy during interventional procedures has been
updated and multiple guidelines have been developed
by various organizations (103,1111-1113). The use of
prescription medications to manage thrombosis risk
and the ease of availability of OTC and herbal products
that mediate or modulate the coagulation cascade is
increasing (103,1111-1127). Interventional pain physicians frequently encounter the challenge of the potential risk of bleeding or thrombosis in perioperative
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management of the patients receiving antithrombotic
and anticoagulant therapy (1031,1122,1126,11281150). Modulation of anticoagulant and antithrombotic therapy during performance of interventional
techniques is one of the major clinical decisions often
made without precise evidence-based literature to
support existing opinions (103,1122,1126,1128-1150).
Leading causes of morbidity and mortality worldwide
include cardiovascular and cerebrovascular disease
(1113,1114,1118,1121,1151-1154). Additionally, one
of the leading causes of disability and functional impairment across the globe is chronic persistent pain
(3-7,39,40,168,196-200,303). Therefore, the overlap
between chronic persistent pain and cardiovascular disease has a synergistic impact on physical and
psychological health, affecting the performance of
social responsibilities, including work and family life.
Antithrombotic therapy has a clear evidence-based
foundation with a favorable risk-benefit profile for
prevention and management of cardiovascular disease, including limiting the present and future burden of cardiac or cerebrovascular infarcts (103,11121114,1127,1155-1168). A significant portion of
patients with established cerebrovascular, cardiovascular, or peripheral vascular disease who are receiving
antithrombotic therapy, are commonly in need of
interventional pain management.
Based on published guidelines, derived by
clinical case reports and consensus, a large subset
of clinicians report stopping antiplatelet therapy
and consider this concept as a standard of care
(103,1126,1130,1133,1135,1169-1175).
Although
the overall incidence of bleeding complications
and epidural hematoma in the nonobstetric epidural literature has been reduced, the incidence
has been higher with procedures involving cervical
and thoracic spine in interventional procedures and
is growing, with or without anticoagulant therapy
(103,1128-1138,1148-1150,1176-1195).
Of
note,
the clinical literature reports of incidences of epidural hematoma cases accompanying interventional
techniques and neuraxial techniques are increasing rapidly (103,1126,1128,1138,1150,1196-1212).
While some reports indicate a decreasing incidence
of bleeding complications related to neuraxial techniques (1209), multiple studies have been performed
assessing the prevalence and risks related to bleeding complications and epidural hematoma with
neuraxial procedures, specifically epidural injections
(103,1126,1128-1138,1146,1147,1150,1204-1212). In
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fact, anticoagulants have been described to cause the
most serious adverse events in the US. According to
the CDC, in the US in 2011, 48% of the US population were taking a prescription medicine in any given
month, and 11% were taking 5 or more prescribed
medicines. The FDA estimated that the number of
reports it receives represents only the tip of the “iceberg” (1213). Among the healthcare providers and
patients, anticoagulant drugs, Warfarin and dabigatran, were on the top (1213).
Significant risks of withdrawing antiplatelet therapy include cardiovascular, cerebrovascular, and peripheral vascular thrombosis. In addition, the risks are
higher in chronic pain patients as chronic psychosocial
stress causes a hypercoagulable state, as reflected by
increased procoagulant molecular fibrinogen (or coagulation factor 7), reduced fibrinolytic capacity and
increased platelet activity (103,1111,1212,1214,1215).
Stress has been shown to affect coagulation activity
via an influence on the regulation of genes coding
for coagulation and fibrinolysis molecules (1215) with
increase in hormonal levels (1216-1218) and an underlying surge of catecholamine and cortisol induced
hypercoagulability (1218). A prior systematic review
and meta-analysis explored the hazards of discontinuing or altering aspirin regimens among patients at
risk for coronary artery disease (1157). Importantly, in
patients at moderate to high risk for coronary artery
disease, withdrawal or noncompliance with aspirin
therapy was associated with 3-fold higher risk of
major adverse cardiac events and the risk was magnified in patients with coronary stents. The findings
support the recommendation that aspirin discontinuation in this patient population should be advocated
only under circumstances where the risk of adverse
outcomes caused by bleeding risk clearly outweighs
that of catastrophic atherothrombotic events. These
findings have been confirmed in later studies (11581165,1212). Conversely, recently published large-scale
evidence (1123-1125) shows lack of benefit of aspirin
for primary prevention of cardiovascular events, but
aspirin therapy is associated with increased bleeding
episodes. Thus, current evidence suggests that the
risks of coronary events related to patients abstaining
from their antiplatelet medications during the perioperative period are more serious when compared to
the risks of continuing antiplatelet therapy through
the perioperative period.
Multiple publications (103,1129,1130,1138,1142,
1204,1207) have also supported the concept of con-
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tinuing antiplatelet/anticoagulant agents in patients
undergoing various interventional pain procedures in
light of identical complication rates as compared to
the patients who stop taking these for a particular
recommended period. It should be noted that there
are only a few clinical reports of an epidural hematoma available in patients undergoing interventional
therapies for chronic pain, which included patients
both continuing and discontinuing antithrombotic
therapy.

11.1 Prevalence and Risk Assessment of
Studies
Multiple studies have been published assessing the prevalence, as well as the risk of
bleeding with interventional techniques (11281131,1134,1137,1138,1146-1150). In a survey of practice patterns among interventional pain physicians
in 2012, Manchikanti et al (1128) showed that the
majority of physicians discontinued antithrombotic
agents; however, this study also showed that there
were a significantly higher number of complications
related to thromboembolic events of a total of 162
compared to hemorrhagic complications of a total of
55 in this population.
In a prospective evaluation of bleeding risks
for interventional techniques in chronic pain,
Manchikanti et al (1129) assessed the rates of adverse
events in patients undergoing interventional techniques on antithrombotic therapy with cessation or
without cessation and compared them to a group of
patients without antithrombotic therapy. While the
results showed differences in milder complications,
there were no reports of hemorrhagic complications
requiring any type of treatment. In this assessment,
the authors studied all types of procedures with 1,227
of 1,831 continuing aspirin compared to 604 of 1,831
discontinuing them. Similarly, they also studied 100
patients on clopidogrel with continuation, whereas,
226 patients were discontinued. Further, there were
128 patients with aspirin and other agents with continuation and 151 were discontinued. The procedures
performed included cervical epidural injections with
continued aspirin in 249 patients, thoracic epidural in
30 patients, lumbar interlaminar epidural in 128 patients, lumbar transforaminal in 144 patients, whereas
528 patients for caudal epidural injections, and 148
for percutaneous adhesiolysis. In reference to clopidogrel, it was continued in 10 patients undergoing
cervical epidural, one patient with thoracic epidural,
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14 patients with lumbar epidural, 44 patients with
caudal epidurals, 10 with lumbar transforaminal epidural, and 21 with percutaneous adhesiolysis. There
were a large number of facet joint interventions and
other treatments.
Warner et al (1150) in a manuscript describing
bleeding and neurological complications in 58,000
interventional pain procedures showed that preprocedural aspirin or nonsteroidal anti-inflammatory
drug therapy was prevalent in 17,825 procedures or
30.7% of the procedures without significant bleeding complications. Out of total of 58,066 procedures
performed in the study, 22.4% of the procedures
were performed with perioperative administration
of aspirin within 7 days, 12.1% of the patients with
administration of nonsteroidal anti-inflammatory
drugs within 7 days, 1.6% of clopidogrel within 7
days. The study also included 3,880 lumbar epidural
injections, 304 thoracic interlaminar injections with
a large number of epidural injections with over 50%
of the epidural injections not assigned to a region.
They concluded that bleeding complications were
rare in patients undergoing low or intermediate risk
pain procedures even in the presence of antiplatelet
medication.
Lagerkranser (1148), and Lagerkranser and
Lindquist (1149) have published an extensive review
of neuraxial blocks and spinal hematoma in 2 parts
from 1994 to 2015 covering demographics, risk factors, diagnosis, treatment, and outcome. They also
considered previous reviews published in 1992, 1994,
and 1996 case reviews, analyzing 29, 61, and 51 cases
of spinal hematoma after neuraxial blocks, respectively, between 1906 and 1996, in 147 manuscripts
(1149). In managing chronic pain with epidural injections, they identified 21 hematomas, 17 (5 cervical, 4
thoracic, and 8 lumbar) after epidural injections, and
4 after percutaneous application of spinal cord stimulators. However, they did not identify the number
of patients developing hematoma with appropriate
cessation of antithrombotic therapy based on recommended guidelines. Overall, they showed that 37% of
the patients who were not on antihemostatic drugs,
whereas 63% were on antihemostatic drugs with 47
of the cases, receiving more than one antihemostatic
drug, and 12 receiving 3 such drugs. Further, they
also had 6 reports which were indeterminate. Consequently, the number of patients without antithrombotic therapy, but with hematoma formation seems
to be almost 40%.
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Lagerkranser (1148) showed that an annual average of 7.5 published cases of spinal hematoma in
the years 1994 to 2015, compared to an average of
only 2.5 case reports per year from 1976 to 1993. They
also identified that there has been a transition from a
male to female dominance among patients suffering
from post-neuraxial blockade and spinal hematoma
particularly among the elderly women. They identified bloody tap at the introduction of a neuraxial
needle or catheter as a major risk factor, but multiple
attempts to reach the spinal canal do not seem to increase the risk of spinal hematoma. Their results also
showed that 80% of the patients developing spinal
hematoma had severe neurological symptoms with
paresis or paralysis. When compared over time, outcomes have improved significantly (1148). The results
showed that among patients subjected to surgical
evacuation of the hematoma, outcomes were best if
surgery was performed within 12 hours from the first
sign of motor dysfunction. However, even patients
operated on after more than 24 hours had relatively
favorable outcomes. Further, outcomes after surgical
evacuation of the epidural hematoma were satisfactory, compared to subdural hematoma, which had
poor outcomes. They recommended that suspicion
of spinal hematoma calls for the consultation of a
surgeon without delay. MRI was the recommended
diagnostic tool. Surgical evacuation within 12 hours
from the sign of motor dysfunction seems to lead to
the best outcome, even though many patients operated on as late as after more than 24 hours did regain
full motor function (1148).
Appendix Table 16 describes the studies assessing
the risk of thrombosis and bleeding with interventional pain management techniques. All but 2 studies
in this assessment are related to performing interventional techniques without cessation of antithrombotic
therapy (1128-1131,1134,1136-1138,1145,1147). Only
one study (1128) was related to an online physician
survey and study of spinal hematoma with neuraxial
blocks. Among all the studies, only 2 studies included
epidural injections (1129,1138). All others have performed a large portion of procedures with low risk or
intermediate risk including transforaminal epidural
injections.
A systematic review of risks and benefits of
seizing or continuing anticoagulant medication for
image-guided procedures for spine pain by Smith et al
(1130), including 14 manuscripts assessing the role of
antithrombotics in interventional pain management.
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They showed that procedures involving interlaminar
access carry a nonzero risk of hemorrhagic complications, regardless of whether anticoagulants are seized
or continued. For other procedures, hemorrhagic
complications have not been reported, and case series indicate that they are safe when performed in
patients who continue anticoagulants. Among the
reports they reviewed, 3 of them reported the adverse effects of seizing anticoagulants, with serious
consequences, including death. They concluded that
other than for interlaminar procedures, the evidence
does not support the view that anticoagulant and
antiplatelet medication must be seized before imageguided spine pain procedures.
Thus, based on the evidence presented from reviews and primary studies, it appears that there is no
significant difference whether antithrombotic therapy
is discontinued or continued in reference to the bleeding. A majority of the authors have studied intermediate and low risk procedures without the inclusion of
epidural injections. The only one study reviewing spinal
cord stimulation also showed lack of increased risk with
continuation of aspirin and other NSAIDs. Consequently,
cessation of anticoagulant medication is recommended
only for interlaminar epidural injections in consultation
with the patient and other healthcare providers managing antithrombotic medications, instead of seizing by
providing them with mandatory instructions to stop for
7 to 10 days, or even longer.

11.2 Reports of Thromboembolic Events
There have been multiple reports of thromboembolic events with the discontinuation of antithrombotics and anticoagulants prior to performance of
interventional procedures. Manchikanti et al (1128)

in an assessment of practice patterns of perioperative
management of antiplatelet and anticoagulant therapy in interventional pain management reported 162
thromboembolic events compared to 55 serious bleeding complications from epidural hematomas. This
study showed thromboembolic events were 3 times
more frequent than bleeding complications. Further,
they also showed bleeding complications from epidural hematomas were similar whether antiplatelet
therapy was continued or discontinued with an occurrence of 26 versus 29 respectively; in this survey
the sample sizes were not provided. Consequently, it
is difficult to assess the exact risk of bleeding complications and similarly thromboembolic events. Endres
et al (1138) reported 9 patients with thromboembolic
events after cessation of anticoagulant therapy out
of 1,626 procedures. These complications included 2
deaths 5 strokes, one pulmonary embolism, and one
myocardial infarction in patients when anticoagulants were stopped; however, they have not reported
any bleeding complications in patients where anticoagulants were continued. Kumar et al (1219) reported
a case of pulmonary embolism after discontinuation
of warfarin during a spinal cord stimulation trial. Linn
et al (1220) also reported right middle cerebral artery
infarction with persistent left hemiparesis, neglect
and dysarthria with L5-S1 epidural steroid injection
after discontinuation of warfarin for 9 days preprocedure. Manchikanti et al (1204) in providing 2 case
reports and a literature review described 2 cases of
thromboembolic complications with cessation of antithrombotic therapy. Table 25 shows reported thromboembolic and cardiovascular complications related
to discontinuation of antiplatelet or anticoagulation
therapy.

Table 25. Thromboembolic and cardiovascular complications related to discontinuation of antiplatelet or anticoagulation therapy.

Study

Type of study

Complications

Endres et al (1138)

Observational report of interventional
techniques

•
•
•
•

Kumar et al (1219)

Case report of dorsal column stimulator
trial

• Pulmonary embolism without lasting complications

Linn et al (1220)

Case report of L5/S1 epidural steroid
injection

• Right middle cerebral artery infarction with persistent left
hemiparesis, neglect, and dysarthria

Manchikanti et al (1128)

Online survey

• Reports of epidural hematoma: 55
• Reports of thromboembolic complications: 162

Manchikanti et al (1204)

Case report and literature review of
interventional techniques

• 2 cases of thromboembolic complications with cessation of
antithrombotic therapy.
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2 patients died
5 suffered strokes
1 suffered pulmonary embolism
1 suffered myocardial infarction
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11.3 Case Reports of Bleeding
Complications
There were multiple case reports discovered citing epidural hematoma in patients
with or without continued antithrombotic
therapy during an interventional technique
(1196-1204,1210,1221-1242).
Multiple reports of bleeding and epidural
hematoma associated with interventional techniques in patients without antithrombotic therapy
have been published (1176-1178,1180,1181,11831194,1202,1204,1207,12081222,1225,1227,1231,1233,1234,1238,1240,12421249), whereas several reports of bleeding in
patients with discontinued antithrombotic
therapy also have been published (1196,11991201,1204,1205,12101223,1228-1230,1232).
Reports of bleeding complications and epidural hematoma in patients with continuation
of antiplatelet therapy with interventional
techniques also have been published. Multiple reports of bleeding complications with
continuation of anticoagulant therapy during interventional techniques were identified
(1197-1199,1202,1203,1224,1239,1241).
Figures 24-26 show summary reports of
several epidural hematomas with epidural
injections, acupuncture and dry needling, and
spinal cord stimulation lead placement in patients without antithrombotic therapy, with
antithrombotic therapy withheld for an appropriate duration, and with antithrombotic
therapy continued. A total of 46 epidural hematomas were described in 43 case reports. There
were 23 in the cervical spine, 8 in the thoracic
spine, and 15 in the lumbar spine. Of these, 21
patients were not on antiplatelet therapy, 9 patients had their antithrombotic therapy discontinued, 14 continued antithrombotic therapy,
and 2 cases were due to fish oil and one case of
ketorolac and paroxetine. Further, as shown in
Fig. 26, epidural injections were responsible for
33 cases of hematomas, 7 cases were secondary
to acupuncture or dry needling and 6 were related to spinal cord stimulation. There was one
case report of caudal epidural injection with
cilostazol (1241), and in one case report, we
were unable to obtain full manuscript (1246).
Cases of chronic subdural hematoma and cases
of abdominal hematomas were not included.
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Fig. 24. Epidural hematoma incidence based on presence or absence of
anticoagulant/antiplatelet therapy following administration of epidural
injections.

Fig. 25. Epidural hematoma incidence based on spinal regions

Fig. 26. Epidural hematoma cases reported based type of procedure
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11.4 Guidelines and Recommendations
Guidelines and recommendations were based on
risk stratification, pharmacology of antithrombotics
and anticoagulants, and the application of available
evidence.

11.4.1 Risk Stratification
Interventional techniques performed in the spine
and other regions for chronic cancer and noncancer
pain patients face variable risks depending on anticoagulant or antithrombotic therapy, age, anatomy, the
specific region of interest, and obesity. Consequently,
various authors have described procedural classifications according to the potential risk for serious
bleeding.
Raj et al (1250) stratified risk scores based on
technique related bleeding risk and patient-related
bleeding risk factors. This risk classification took
various factors into consideration including a sharp
or blunt needle, as well as the use of fluoroscopy and
lack of fluoroscopy.
Breivik et al (1133), in a comprehensive topical review of reducing risk of spinal hematoma from spinal
epidural and pain procedures, based their recommendations on an extensive review of 166 case reports
published from 1994 through 2015 (1148,1149), phar-

macology of drugs, and available clinical evidence relating to complications whether the antithrombotics
were continued or discontinued.
Narouze et al (1111) provided guidance for interventional spine and pain procedures in patients
on antiplatelet and anticoagulant medications. They
provided an extensive review of the literature, considered pharmacology, and current literature with
development of risk stratification.
Deer et al (1112) provided recommendations on
bleeding and coagulation management in neurostimulation devices. They also provided bleeding risk
stratifications for neuromodulation procedures. Their
classification showed spinal cord stimulation trial and
implant, dorsal root ganglion stimulation, and intrathecal catheter and pump implant as high to intermediate risk neuromodulation procedures. Further,
they classified deep brain stimulation and motor cord
stimulation as high-risk neuromodulation procedures.
This is in contrast to other guidance where spinal cord
stimulation trial and implant, dorsal root ganglion
stimulation, and intrathecal catheter and pump implant are considered as high risk.
Oprea et al (1126) published risk stratification,
perioperative, and periprocedural management of
patients receiving anticoagulant therapy based on

Table 26. Classification of interventional techniques based on the potential risk for bleeding.

Low-Risk Procedures

Intermediate-Risk Procedures*

High-Risk Procedures*

1. Trigger point and muscular injections
(including piriformis injection)
2. Peripheral joints
3. Peripheral nerve blocks
4. Sacroiliac joint and ligament injections and
nerve blocks
5. Caudal epidural injections
6. Ganglion impar blocks

1. Facet joint interventions (intra-articular
injections, nerve blocks and radiofrequency
neurotomy)
2. Lumbar transforaminal epidural injections
at L4, L5, S1
3. Lumbar intradiscal procedures
4. Hypogastric plexus blocks
5. Lumbar sympathetic blocks
6. Peripheral nerve stimulation trial and
implant
7. Pocket revision and implantable pulse
regenerator/ intrathecal pump replacement
8. Caudal percutaneous adhesiolysis
9. Lumbar percutaneous disc decompression
(L4/5 or below)
10. Lumbar vertebral augmentation (below
L4)
11. Intervertebral spinous prosthesis
12. Lumbar discography

1. Cervical, thoracic, and lumbar interlaminar
epidurals
2. Cervical, thoracic and lumbar above L3
transforaminal epidural injections
3. Spinal cord stimulator trial and implant
4. Percutaneous adhesiolysis with interlaminar
or transforaminal approach
5. Percutaneous disc decompression (above
L4/5)
6. Sympathetic blocks (stellate ganglion;
thoracic splanchnic, celiac plexus)
7. Thoracic and cervical intradiscal
procedures
8. Vertebral augmentation, lumbar (above L4),
thoracic and cervical
9. Intrathecal catheter and pump implant
10. Interspinous prosthesis and MILD®

*Patients with high risk of bleeding (e.g., old age, history of bleeding tendency, concurrent uses of other anticoagulants/antiplatelets, liver cirrhosis
or advanced liver disease, and advanced renal disease) undergoing low or intermediate-risk procedures should be treated as intermediate or high
risk, respectively.
Source: Kaye AD, et al. Responsible, safe, and effective use of antithrombotics and anticoagulants in patients undergoing interventional techniques:
American Society of Interventional Pain Physicians (ASIPP) guidelines. Pain Physician 2019; 22:S75-S128 (103).

S144

www.painphysicianjournal.com

ASIPP Epidural Guidelines
bleeding risk for each procedure, pharmacology, and
evidence of the risk of the development of bleeding
complications as well as thromboembolic risks.
Lagerkranser (1148), and Lagerkranser and
Lindquist (1149), published an extensive review of
neuraxial blocks and spinal hematoma with review of
100 case reports published from 1994 to 2015 with
demographics and risk factors, as well as diagnosis,
treatment, and outcomes. They described multiple
risk factors related to hemostasis, elderly females, and
spinal disorders and complicated blocks, especially
spinal stenosis and “bloody taps,” whereas multiple
attempts do not seem to increase the risk of bleeding. Further, they conceded that in a large number of
cases, no risk factor was reported.
Multiple factors and the available literature in
reference to the adverse consequences of anticoagulant and antithrombotic therapy with interventional techniques were utilized in developing risk
stratification. The following classification for interventional techniques has been developed (Table 26)
(103,1126,1128-1136,1148,1149,1239,1250). The classification describes low risk, intermediate risk, and
high-risk procedures. However, based on comorbid
medical conditions and other risk factors of coagulopathies and concurrent use of other anticoagulants
and antiplatelets, the procedural risk classification
may be changed from low risk to intermediate, and
intermediate to high risk.
Of all the low risk procedures as shown in Table
26, the caudal epidural injection was the only one
which has reported an epidural hematoma with
continuation of cilostazol (1241). This is extremely unusual and probably coincidental. Consequently, with
caudal epidural injections and other low risk procedures, antithrombotic and anticoagulant therapy may
be continued with the appropriate guidelines.
Intermediate risk procedures include multiple
procedures performed, constituting a great proportion of the procedural prevalence. This risk stratification is somewhat different from the one proposed
by American Society of Regional Anesthesia and Pain
Medicine (ASRA) (1111). Justifiably, we have included
caudal percutaneous adhesiolysis into intermediate
risk procedures as there have not been any case reports. Further, lumbar transforaminal epidural injections at L4, L5, S1, and sympathetic blocks have been
included in these categories due to 2 case reports
of lumbar transforaminals resulting in hematoma
without antithrombotic therapy and 2 case reports
of sympathetic blocks. Lumbar interlaminar epidural
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injections performed between L5 and S1 are included
in the intermediate risk procedures; whereas, procedures performed at L4-5 and at higher levels are
included in the high risk procedures. A majority of
the lumbar epidural hematomas developed despite
the discontinuation of antithrombotic therapy, and
these were performed above the L5-S1 interspace.
If epidural hematoma develops at L5-S1 it will have
significantly higher space availability to be asymptomatic and to be managed conservatively.
The high-risk procedures include the majority of
the procedures performed in the cervical and thoracic spine. These guidelines are in contrast to ASRA
guidelines with the inclusion of cervical, thoracic, and
lumbar due to the available literature and potential
issues related to epidural hematoma requiring surgical exploration and spinal cord damage.

11.5 Pharmacologic Aspects and Hemostasis
Monitoring
The main categories of antithrombotics and
anticoagulants are described as; platelet inhibitors,
interfering with platelet aggregation (clumping) and
thrombus formation; anticoagulants interfering with
formation of the clotting, thereby reducing fibrin
formation and preventing clots from forming and
expanding; and fibrinolytics interfering with the final
clot.
Monitoring of hemostasis is performed with
multiple standard tests including platelet count, activated partial thromboplastin time (APTTa), and international normalized ratio (INR) (1133). A normal INR
is considered as 0.9 to 1.2. Consequently, for epidural
injections, an INR of less than 1.5 is ideal for high risk
and moderate risk procedures, and less than 1.8-2.00
is ideal for low risk procedures.
Additional advanced hemostatic tests for monitoring of hemostasis include multiple viscoelastic tests
like thromboelastography or thromboelastrometry
extensively used to evaluate liver disease (1251). However, this parameter has been studied for safe epidural
catheter removal with the conclusion that the tests
were not well validated in this context and there were
frequent false negative test results (1252,1253). Even
then, a clearly abnormal curve indicates deranged
hemostasis and must be taken seriously (1253,1254).

11.5.1 NSAIDS and Aspirin
NSAIDs inhibit cyclooxygenase enzymes COX1
and COX2, which inhibit prostaglandin production
to decrease the inflammatory response. Thus, NSAIDs
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Table 27. Characteristics of aspirin and NSAIDs.

Target

Aspirin or acetylsalicylic acid (Oral
Low Dose)

NSAIDs

COX -1 irreversible

COX-1 reversible, COX-2

Time to peak effect

0.5 hours

Varies

Plasma Half Life

0.5 hours

Variable from 1 to 72 hours

Renal elimination

+

+

3 days

1 day

Hours to C-Max

0.5 hours

~0.5 hours

Metabolism

Hepatic

Hepatic

Bioavailability

60%

50-95%

Antihemostatic effect

++

+

Time to 50% recovery of platelet function

NSAID = non-steroidal anti-inflammatory drug; COX = cyclo-oxygenase
Rating of antihemostatic effect and renal elimination: (+) = insignificant; + = low; ++ = moderate; +++ = pronounced; ++++ = high.
Source: Kaye AD, et al. Responsible, safe, and effective use of antithrombotics and anticoagulants in patients undergoing interventional techniques:
American Society of Interventional Pain Physicians (ASIPP) guidelines. Pain Physician 2019; 22:S75-S128 (103).

have analgesic effects and are used for minimizing
pain. Thromboxane A2 is produced via COX1 enzyme
activity, which is a potent thrombus activator. Aspirin
is an irreversible inhibitor of COX1 and has significant
clinical benefits for preventing thrombus formation.
In response to aspirin, more prostacyclin is produced
by endothelial cells, but there is no additional thromboxane made as there are no nuclei in platelets, thus,
there is a greater percent of prostacyclin to thromboxane, thinning the blood. Elevated bleeding risk is
a concern for a small portion of patients, but adverse
effects are rare. Prostacyclin (PGI2) synthesis from vascular endothelial cells is dependent on COX2 and has
anti-platelet effects. High doses of aspirin reduce PGI2
production which can abolish the anti-platelet effect
of low dose aspirin. Low-dose aspirin anti-platelet
effects last for 7-10 days, as bone marrow directed
platelet renewal is required for clotting to resume.
Low-dose aspirin therapy is well established to reduce
the risk of cardiovascular events in patients with acute
coronary syndromes, cerebral infarct, or occlusive
vascular disease (1255). However, recently published
large scale evidence (1121,1123-1125) shows a lack
of benefit with aspirin for the primary prevention of
cardiovascular events, while it does increase the risk
of bleeding.
Table 27 shows pharmacokinetic and pharmacodynamic characteristics of aspirin and NSAIDs. Time
to 50% recovery of platelet function with aspirin is
shown as 3 days (1133). Antiplatelet function of irreversible inhibitors is dependent mainly on platelet
regeneration than drug half-life.
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For other NSAIDs, unlike aspirin, the platelet effects of these drugs are directly related to systemic
plasma drug concentrations and influenced by the
pharmacokinetic clearance of these medications. It
takes approximately 5 half-lives for systematic elimination. Recommendations (103,1111,1112) have been
revised for aspirin, whether to continue or discontinue in the perioperative period for interventional
pain procedures. Decision-making is based on the reason for aspirin utilization, a multitude of risk factors
including vascular anatomy surrounding the target
area, degree of the invasiveness of the procedure,
and potential sequelae associated with perioperative
bleeding. Thus, aspirin for primary prophylaxis can be
stopped without any hesitation. The major consideration in withholding aspirin is the thromboembolic
risk. Based on the available evidence, it appears that
aspirin discontinuation for 4 days may be sufficient.
In contrast, for nonsteroid anti-inflammatory agents,
recommended discontinuation by ASRA is one day for
diclofenac, ibuprofen, and Ketoralac. Recommended
discontinuation time is 2 days for etodolac and indomethacin. Discontinuation is about 4 days for meloxicam and Naprosyn, 6 days for Nabumetone, and 10
days for piroxicam and Oxaprozin. However, the evidence for stopping NSAIDS agents other than aspirin
seems to be very limited. Stopping these drugs may
become a practical issue and patients may not like
it to stop all the drugs and complain of significantly
more pain. Consequently, based on the available,
very limited, evidence, the clinician may continue or
discontinue. In reference to ketorolac, this is used
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Table 28. Comparative pharmacokinetics/pharmacodynamics of ADP-receptor inhibitors.

Clopidogrel (Plavix®)

Prasugrel (Effient®)

Ticlopidine (Ticlid®)

Ticagrelor (Brilinta®)

Target

P2Y12ADP

P2Y12ADP

P2Y12ADP, also inhibits
liver CYP2C19 and
CYP2B6

P2Y12ADP

Antithrombotic
activity

++

+++

++

++++

Time to Cmax

3-7 days

3-5 days

8-11 days

2-4 hours

Time to peak effect

4 hours to 4 days

1 hour

3-5 days

2.5 hours

CYP metabolism

CYP1A2, CYP2B6,
CYP2C9, CYP2C19 and
CYP3A4/5

CYP450-mediated
(primarily CYP3A4 and
CYP2B6)

Cytochromes P450

CYP3A4

Bioavailability

> 50%

≥ 79%

> 80%

36%

Protein binding

94–98%

Active metabolite: ~98%

98%

>99.7%

Plasma half-life

7-8 hours (inactive
metabolite)

~7 hours (range 2 hours to
15 hours)

12 hours (single dose) 4-5
days (repeated dose)

7 hours (ticagrelor), 8.5
hours (active metabolite
AR-C124910XX)

Renal elimination

50% kidney, 46% biliary

Urine (~68% inactive
metabolites); feces (27%
inactive metabolites)

Renal and fecal

Biliary

Time to 50% recovery
of platelet function

3 days

3 days

6 days

1.5 days

CYP = cytochrome P450
Source: Kaye AD, et al. Responsible, safe, and effective use of antithrombotics and anticoagulants in patients undergoing interventional techniques:
American Society of Interventional Pain Physicians (ASIPP) guidelines. Pain Physician 2019; 22:S75-S128 (103).

intraoperatively or postoperatively. Consequently, it
is not advisable to administer ketorolac to patients
during or after epidural injections.

11.5.2 Adenosine Diphosphate Receptor Inhibitors
Adenosine diphosphate (ADP)-receptor inhibitors
inhibit platelet aggregation. The drugs in this category utilized for clinical applications include Clopidogrel (Plavix®),
Prasugrel (Effient®), Ticlopidine (Ticlid®), and Ticagrelor
(Brilinta®). Table 28 shows comparative pharmacokinetics
and pharmacodynamics of ADP-receptor inhibitors.
Clopidogrel is the prototypical thienopyridine drug
that inhibits the P2Y12 receptor. The P2Y12 receptor is
activated by ADP binding and promotes platelet aggregation. Depending on the dosage schedule, the maximal
platelet aggregation inhibitory effects of clopidogrel
are reached within 3 to 7 days. After discontinuation,
recovery of platelet inhibition occurs 50% after 3 days
and full recovery after one week (1256). Eighty percent
of subjects demonstrated normal platelet aggregation
by the 4th day (1256). Other studies have demonstrated
the recovery of platelet function after the cessation of
aspirin in volunteers in surgical patients after 3 days
in volunteers and within 4-6 days in surgical patients
(1257). In this study, by day 6 all of the subjects had
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restored platelet aggregation to at least 85% of the
baseline level.
Ticlopidine also belongs to the thienopyridine group
and is maximally aggregated after 8 to 11 days of a 500
mg per day dosage schedule. After withdrawal of 72 hours,
there is still a lingering effect as there is an irreversible inhibition of platelet function (1258). Prasugrel acts by antagonizing ADP at the platelet’s purine receptors, and aggregation is thus noncompetitively and irreversibly inhibited.
Prasugrel, or Effient, has significantly higher irreversible antiplatelet activity compared to clopidogrel
with time to peak effect of one hour. Thus, administration of the first dose results in around half of the platelets being inhibited within the first hour of taking this
medication. Following three to five days of therapy, the
steady-state inhibition of platelet aggregation reaches
around 70% (1259). As a prodrug, prasugrel is rapidly
metabolized to active and inactive metabolites. These
metabolites have varying elimination rates, although
the active metabolites have an elimination half-life of 7
hours, with a wide range of 2-15 hours (1260).
Lastly, a distinct ADP-receptor inhibitor is Ticagrelor, which directly inhibits P2Y12 receptors (1259-1263).
While Ticagrelor is metabolized to active metabolites, the
original compound is responsible for the majority of the
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inhibitory effects (1262,1263). A notable advantage of Ticagrelor is rapid effect, with peak platelet inhibition after
2 to 4 hours of intake (1264). These medications undergo
hepatic conversion to active metabolites, which are then
eliminated by the kidneys (1265). In addition, glycoprotein
IIB/IIIA receptors are less activated, causing a reduction in
fibrinogen fixation and platelet crosslinking.
ADP inhibitors were described as responsible for the
formation of an epidural hematoma after central neuraxial blockade in 2.5% of 160 cases or 4 cases. In the present assessment, clopidogrel either in combination with
aspirin or ticlopidine was utilized in a total of 3 cases, with
2 cases being discontinued appropriately and one case it
was continued. Thus, ADP inhibitors with reports available
for only one or 2 drugs showed any relevance in 8% of
the cases with only one case or 2.6% of cases where it was
continued and in 5% of the cases it was discontinued. This
is similar to the reports from Lagerkranser et al (1148).

ments in platelet aggregation have been demonstrated,
despite continuous prior dosing (1270).
There is a single case report of bleeding complications
associated with an interventional technique (1241). In this
case report, the patient underwent a caudal epidural injection developing an epidural hematoma extending from L2
through S1 with concomitant central canal compromise,
severe at L2-3 and L3-4 levels. This patient had received, in
the past, lumbar interlaminar epidural injection without
any side effects. Emergency decompression laminectomy
was carried out with the patient making full recovery.
This is the only case report in interventional techniques.
Cilostazol alone without aspirin is recommended to be
continued during interventional techniques. Lagerkranser
et al (1148) also reported 2 cases of phosphatase inhibitors
with dipyridamole with an incidence of 1.3% in 160 cases.
Overall cilostazol is considered as a low risk drug and its
continuation is appropriate.

11.5.3 Phosphodiesterase (PDE) Inhibitors

11.5.4 Glycoprotein GPIIb/IIIa Inhibitors

Phosphodiesterase inhibitors include Cilostazol (Pletal®) and Dipyridamole (Persantine®). These medications
selectively inhibit phosphodiesterase, which leads to an
increase in intracellular cyclic adenosine monophosphate
(cAMP) and subsequent reversible inhibition of platelet
aggregation (1266). Additionally, Dipyridamole blocks
thromboxane synthase, the thromboxane receptor, and
the cellular reuptake of adenosine into platelets, red blood
cells, and endothelial cells. This results in increased adenosine in the extracellular space and inhibition of formation of cytokines and proliferation of smooth muscle cells.
Absorption of Dipyridamole occurs in the gastrointestinal
tract and is pH dependent. Gastric acid suppressors and
proton pump inhibitors inhibit absorption, which can be
prevented via buffered additives added to the medication
(1267). An additional advantage of Cilostazol is inhibition
of PDE3A, which is selective to vascular smooth muscle cells
and results in vasodilatation. Cilostazol is administered at
100 mg twice daily and reaches maximum plasma levels
after three hours. It is eliminated via hepatic metabolism
and is excreted in the urine (1268). Thus, cilostazol is contraindicated in those with severe renal insufficiency. For
interventional procedures, phosphodiesterase inhibitors
have been considered as safe to continue. However, risk
may increase with the addition of aspirin. Limited data
exists evaluating the risk of perioperative surgical bleeding with cilostazol (1270) and no standard perioperative
guidelines are available (1269). Further, if the medication
is discontinued, at 50 hours (approximately 5 half-lives),
less than 5% of the drug remains in plasma and improve-

A final common component of platelet aggregation
is the glycoprotein IIb/IIIa receptor. Specialized medications inhibit this receptor, potently inhibiting platelet
aggregation while being reversible (1220).
Abciximab (ReoPro®) is a Fab fragment of a humanized monoclonal antibody directed against the GFPIIb
receptor. Abciximab inhibits over 80% of ADP-induced
platelet aggregation and is given via IV administration.
Additionally, thrombin generation is inhibited by Abciximab, which quickly binds to platelets with high affinity.
Eptifibatide (Integrilin®) is a cyclic peptide inhibitor
of the fibrinogen binding site on the GPIIb receptor.
Tirofiban (Aggrastat®) is an additional glycoprotein IIb/
IIIa receptor inhibitor, reaching maximum efficacy after
4 hours of administration, with 50-80% inhibition of
platelet aggregation (1271). Platelet function normalizes 8 to 24 h after stopping the IV infusion.
There were no case reports secondary to the development of epidural hematoma in patients receiving
glycoprotein IIB/IIIA. Additionally, it appears that these
drugs are not commonly used for prevention of thromboembolic activity.
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11.5.5 Low-Molecular Weight Heparin
Low molecular weight heparins (LMWHs) inhibit the
coagulation cascade via binding to antithrombin, which
leads to a conformational change of antithrombin, which
accelerates inhibition of factor Xa. LMWH has advantages:
relatively high bioavailability, longer half-life, and ability
for use once per day. Maximum efficacy levels are observed
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after 3-4 hours post subcutaneous administration, and
elimination occurs after 4-6 hours in those with normal
renal function (1272). High molecular weight heparins
(HMWH) catalyze the inhibition of clotting factors IXa,
Xa and thrombin by greatly enhancing antithrombin III
activity, by causing a conformational change in ATIII exposing its reactive site. Testing is required to determine
the dose effect on coagulation via partial thromboplastin
time (PTT). HMWH is not absorbed by GI tract due to its
large molecular weight, therefore IV or SC injection must
be used. The short half-life of (HMWH approximately 1h)
means frequent injections or continuous infusion, and it is
thus not considered suitable in an outpatient setting.
Low molecular weight heparin is one of the commonly used drugs and has been implicated in multiple cases of
epidural hematoma. Lagerkranser et al (1148) showed low
molecular weight heparin being responsible for the highest number of cases in 31% of the reports. Our reports also
show 2 cases of warfarin with bridging with LMWH being
responsible for epidural hematoma (1229,1230), both in
the lumbar spine.

11.5.6 Warfarin
Oral anticoagulants inhibit the synthesis of vitamin Kdependent clotting factors, which are factor II, VII, IX, and
X. Warfarin blocks the gamma-carboxylation of glutamate
residues in prothrombin and factors VII, IX, and X. This results in biologically inactive coagulation factor molecules.
Vitamin K epoxide reductase is the enzyme that catalyzes
the carboxylation reaction. Therapeutic doses of warfarin
inhibit vitamin K epoxide reductase, which prevents the
reductive metabolism of the inactive vitamin K epoxide
to its active hydroquinone form. Synthesis is the primary
target of oral anticoagulants (warfarin), therefore the
effects of these medications are not apparent until previously-existing clotting factor turnover has occurred. Factor
half-lives vary, from factor VII at 6-8 hours to factor II at
50-80 hours (1273). Thus, it has a slow onset of action (8-12
hours) as existing clotting factors must be depleted, and
the maximal effect occurs 3-5 days after administration.
Warfarin is monitored by PT and INR, which is a normalized
ratio of the patient’s PT to that of a control sample (1273).
Age, female gender, and preexisting medical conditions
such as hepatic, cardiac, and renal disease modify the patient’s response to warfarin. Asian patients, for example,
have higher sensitivity to warfarin and require lower doses
than those patients of European descent (1273). Dietary
changes may alter the patient’s clotting ability, and those
on Warfarin are advised to avoid grapefruit and cranberry
products, eat a consistent amount of leafy greens and
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other high vitamin K containing foods and are advised to
limit herbal supplement intake of garlic, ginger, gingko
biloba, ginseng, and fish oil. Warfarin may be reversed
with administration of vitamin K, which is associated with
multiple side effects.
Warfarin is one of the most common drugs utilized in
patients undergoing interventional techniques. Multiple
complications have been reported with case reports of
epidural hematoma in patients with warfarin, despite being stopped per the guidelines.
Lagerkranser et al (1148) reported warfarin contributing to spinal hematoma in 11% of the cases. They
showed cases of warfarin which were stopped appropriately with 2 of them also receiving enoxaparin with a
similar incidence of around 10%.

11.5.7 Direct Thrombin Inhibitors
Direct thrombin inhibitors include Dabigatran
(Pradaxa®), Argatroban (Acova™), Bivalirudin (Angiomax®), Lepirudin (Refludan®), Desirudin (IPRIVASK®), and
Hirudin as shown in Table 29. Of all the direct thrombin
inhibitors, Dabigatran may be reversed by Idarucizumab
(Praxbind®), which was approved in 2015.
Dabigatran etexilate is an oral anticoagulant and is a
prodrug that is converted to dabigatran in the plasma. After an oral dose, the peak effect is reached within 2 to four
hours, and plasma half-life is 13 hours on average (1274).
Dabigatran dose recommendations depend on renal efficacy in the patient receiving the medication. In those with a
creatinine clearance of greater than 30mL/minute, 150 mg
is taken orally twice daily. For patients with lower creatinine
clearance, 75mg twice daily is recommended. Dabigatran’s
function is via factor inhibition and not clotting factor
depletion, thus, the administration of clotting factors is
anticipated to be less effective in reversing the effects of
dabigatran. Dabigatran is mostly cleared by the kidneys. In
those with normal kidney function, dabigatran is excreted
in 1-2 days post-discontinuation. This also depends on renal
sufficiency of the patient taking the medication. There is
one case report with epidural hematoma despite its discontinuation for 7 days prior to interventional techniques
(1215). Lagerkranser et al (1148) also reported on a case of
spinal hematoma out of 160 cases.
Argatroban is a small molecule direct thrombin
inhibitor that is administered intravenously. It reaches
steady-state plasma concentrations in 1-3 hours and is metabolized via the liver. It has a half-life of 50 minutes and
is monitored by PTT. As it is metabolized hepatically, it is
a viable alternative for Dabigatran, which is metabolized
renally (1275).
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Table 29. Comparative pharmacokinetics/pharmacodynamics of direct thrombin inhibitor.

Target

Dabigatran
(Pradaxa)

Argatroban
(Acova)

Bivalirudin
(Angiomax)

Lepirudin
(Refludan)

Desirudin
(IPRIVASK)

Hirudin

Direct thrombin
inhibitor

Direct thrombin
inhibitor

Reversible
direct thrombin
inhibitor

Direct thrombin
inhibitor

Direct thrombin
inhibitor

Naturally
occurring peptide
anticoagulant

Time to Cmax

2-4 hours

1-3 hours

2 minutes

4 hours

1-3 hours

3 hours

Time to peak
effect

0.5 – 2 hours

2 hours

15 min

0.5-2 hours

2 hours

3-4 hours

Metabolism

Metabolized via
conjugation into 4
acyl glucuronides,
not mediated by
CYP450

CYP3A4

Proteolytic
cleavage

3-7%(Oral)

100% IV

100% IV
application only

100% (injection
or infusion)

100%

100% IV

Protein binding

35%

54%

no

n/a

n/a

n/a

Plasma half-life

13 hours

50 minutes

~25 minutes in
patients with
normal renal
function

1.3 hours

2-3 hours

80 minutes

80% urine

Liver

Yes

Yes

Yes

Renal, about 48%
(35% unchanged)

Bioavailability

Renal elimination
Linear PK

Lepirudin is
Metabolized by
thought to be
stepwise degradation
metabolized by
from the C-terminus
release of amino possibly catalyzed by
acids via catabolic carboxypeptidase(s)
hydrolysis of the
such as
parent drug
carboxypeptidase A

Proteolytic
cleavage

Yes

Yes

Yes

Yes

Yes

Yes

Time to 50%
recovery of
thrombin
function

12 hours

2 hours

0.5 hours

1.5 hours

2 hours

2 hours

Reversal agents

Praxbind

NA

NA

NA

NA

NA

CYP = cytochrome P450; IV = intravenous
Source: Kaye AD, et al. Responsible, safe, and effective use of antithrombotics and anticoagulants in patients undergoing interventional techniques:
American Society of Interventional Pain Physicians (ASIPP) guidelines. Pain Physician 2019; 22:S75-S128 (103).

Bivalirudin works by binding specifically to the
catalytic site, in addition to the anion-binding exosite of
circulating and clot-bound thrombin. Bivalirudin is cleared
by the kidney and thus is dose-dependent on overall renal
function. It has as a half-life of 25 minutes in those with
normal renal function, but this may be doubled in those
with severe renal insufficiency (1276).
Desirudin is a subcutaneously administered direct
thrombin inhibitor and is indicated for the prevention of
venous thromboembolism after total joint replacement.
It is recommended that dosage adjustment and aPTT be
monitored in patients with moderate-to-severe renal
impairment. After intravenous administration, desirudin
is removed rapidly via the renal system, with 90% of the
dose removed from the plasma within 2 hours. Plasma
concentrations decline with a mean half-life of 2-3 hours.
Subcutaneous administration demonstrates a half-life of
2 hours (1277).
Hirudin has specific activity on fibrinogen and binds
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to and inhibits only activated thrombin, making it an
extremely potent direct thrombin inhibitor. Thus, hirudin
dissolves the formation of clots and thrombi and has
therapeutic value in coagulation disorders. It is also able
to act on complexed thrombin and does not alter other
serum protein function or activity (1278). Hirudin has a
half-life of 2-3 hours and is monitored by a PTT, allowing
close titration over a wide range of anticoagulative clinical desires. Activated clotting time (ACT) and prothrombin
time (PT) are insensitive for monitoring hirudin.

11.5.8 Direct Factor Xa Inhibitors
Direct factor Xa inhibitors such as Rivaroxaban
(Xarelto®) have been commonly used in the US (Table 30).
Of multiple Xa inhibitors available, apixaban (Eliquis) and
rivaroxaban (Xarelto®) can be reversed by Andexanet alfa
(Andexxa®), a coagulation factor Xa (recombinant), which
has been approved by the FDA for the urgent reversal of
the anticoagulant effect in 2018 (1279).
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Table 30. Comparative pharmacokinetics/pharmacodynamics of direct factor Xa inhibitor.

Apixaban
(Eliquis)
Target

Rivaroxaban
(Xarelto)

Edoxaban
(Savaysa, Lixiana)

Betrixaban
(Bevyxxa)

Fondaparinux
(Arixtra)

Xa

Xa

Xa

Xa

Xa

Time to Cmax

1-3 hours

2-4 hours

1-2 hours

3-4 hours

2 hours

Time to peak effect

3-4 hours

2-4 hours

1-2 hours

3-4 hours

2-3 hours

15%

32%

NR

NR

n/a

CYP Metabolism
Bioavailability

66%

80%

>45%

34%

100%

Transporter

P-gp

P-gp/BCRP

P-gp

P-gp

P-gp

Protein binding

87%

>90%

55%

60%

94%

Plasma Half-life

8-15 hours

9-13 hours

8-10 hours

37 hours

17-21 hours

Renal elimination

25%

33%

35%

< 1%

100%

Linear PK

Yes

No

Yes

n/a

Yes

Time to 50% recovery
of Xa

12 hours

12 hours

12 hours

19-27 hours

12 hours

Reversal AGENTS

Andexxa

Andexxa

NA

NA

NA

BCRP = breast cancer resistance protein; CYP = cytochrome P450; NR – not reported; P-gp = P-glycoprotein
Source: Kaye AD, et al. Responsible, safe, and effective use of antithrombotics and anticoagulants in patients undergoing interventional techniques:
American Society of Interventional Pain Physicians (ASIPP) guidelines. Pain Physician 2019; 22:S75-S128 (103).

Rivaroxaban (Xarelto®) has dual renal and hepatic
clearance, with around one-third of the drug being
active with each route of metabolism. This dual route
of clearance makes accumulation less likely than other
medications that are solely hepatically or renally cleared.
Rivaroxaban is orally administered and has a half-life of
5.7 to 9.2 hours. Plasma protein binding of rivaroxaban
is 92-95%. One third of the absorbed dose is excreted in
the urine, and two-thirds of the dose is excreted as an
inactive metabolite in the feces and urine. Rivaroxaban
has the potential for drug interactions with medications
that are P-glycoprotein inhibitors and those metabolized by CYP3A4 (1280).
Apixaban (Eliquis®) is a specific factor Xa inhibitor like its counterpart, rivaroxaban. It is rapidly absorbed and reaches peak concentrations in 1-2 hours
(1281,1282). Apixaban has an oral availability of 45%
and has a relatively complex elimination pathway with
both direct renal and intestinal excretion, with the latter being the majority (1282,1283). Edoxaban (Savaysa®
or Lixiana®) was approved for the prevention of venous
thromboembolisms following lower limb orthopedic
surgery in 2011 and is an oral direct factor Xa inhibitor
that inhibits free factor A and prothrombinase activity.
It has also been approved for the prevention of stroke
and systemic embolism. Peak plasma concentrations
are reached 1.5 hours after oral administration, and it
has an elimination half-life of 10-14 hours when taken
at 60mg once daily. It is excreted via both hepatic and
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renal systems (1284). It is orally available, and not removed by dialysis.
Betrixaban (Bevyxxa®) is a potent oral factor Xa
inhibitor that recently received FDA approval. It has
exemplified promising results, as it has low hERG affinity and has reduced bleeding risk and prevented
thromboembolism in clinical trials for orthopedic knee
surgery (1285-1287). Betrixaban has the smallest percent of renal clearance, is INR/PTT insensitive, and has
minimal liver metabolism. Another selective factor Xa
inhibitor, Fondaparinux (Arixtra®) is 100% bioavailable
and achieves maximum concentration in 1.7 hours of
administration (1288). Its extended half-life of 17 to 21
hours allows once-daily dosing (1289).
There were no case reports in the present assessment; however, Lagerkranser et al (1148) showed 2
cases of spinal hematoma with rivaroxaban yielding
1.3% prevalence among 160 cases developing spinal
hematoma.

11.5.9 Thrombolytic Agents
Fibrinolysis is caused by thrombolytic agents via
conversion of plasminogen and thrombi to plasmin to
destroy clots. These “clot busters” such as recombinant
tissue-type plasminogen activator (tPA), streptokinase,
urokinase, tenecteplase, and reteplase are enzymes
that have effects on both circulating and tissue type
plasminogen. The half-life of these thrombolytic drugs
is generally a few hours, but the inhibition of plasmino-
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gen and fibrinogen may last for up to 27 hours after
administration (1290).
There were no reports of epidural hematoma development in patients receiving thrombolytic agents in
our analysis; however, Lagerkranser et al (1148) reported
4 cases or 2.5% in the review of 160 cases of spinal hematoma. Among the miscellaneous agents, Chien et al
(1198) reported a case of epidural hematoma in a patient
receiving fluoxetine, fish oil, and vitamin E. There was
also another case report by Jenkie et al (1203) with fish
oil and the development of cervical epidural hematoma
leading to surgical intervention for decompression. Lagerkranser et al (1148) also reported one patient on
selective serotonin receptor inhibitor of 160 cases.

11.5.10 Cannabis (TCH and CBD)
Cannabis is a genus of plants of the Cannabaceae family and contains more than 500 compounds
- 120 cannabinoids and 80 biologically active chemical
compounds (1291-1293). Cannabis interacts with the
endocannabinoid system, composed of a network of
receptors (CB1 and CB2), signaling molecules, and enzymes. Two common compounds found in cannabis are
Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD),
available as oral solid and semisolid dosage forms, oils,
topicals, and transdermal patches. However, because
medical cannabis is not regulated, exact doses and
contents of CBD:THC are unknown. Daily doses are
highly variable, generally, they should not exceed THC
daily dose-equivalent of 30 mg/day (1294). THC and
CBD provide differential effect with the THC eliciting
psychoactive effects with medical benefits particularly
for neurological disorders (1295,1296), whereas CBD can
help to moderate and subdue psychosis-inducing effects
of THC (1297). While they have shown benefit to some
extent for neurodegenerative disorders such as multiple
sclerosis, glaucoma, food intake disorders, involuntary
motor disorders, schizophrenia, and sleep conditions,
they have been used frequently in chronic pain legally or
illegally. Thus, patients on THC and CBD may present for
interventional techniques. Side effects of cannabis and
anticoagulant or antiplatelet agents has been described.
Cannabis has the potential to interfere with the effectiveness of multiple antithrombotic and anticoagulant
agents and may cause antithrombotic effects. Greger et
al (1291) published a review of cannabis and interactions
with anticoagulant and antiplatelet agents. With metabolism of THC and CBD, primarily by the hepatic P450
enzymatic pathway and UPD-glucuronosyltransferase
(UGT), the interactions are proposed (1298-1301). Case
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reports with increased INR in patients on warfarin with
smoking THC have been described (1302-1305). Cannabis
may also alter concentrations of direct-acting oral coagulants including rivaroxaban, dabigatran, and edoxaban
(1306-1309). CBD also may impact the metabolism of
direct acting oral anticoagulants leading to increased
concentrations (1310). Interactions have been reported
with clopidogrel with cannabis as it has been shown to
inhibit CYP2C19 and enzyme responsible for converting
clopidogrel to its active metabolite (1311,1312).
The current knowledge is limited in reference to the
effects on interventional techniques. While interactions
with warfarin may be monitored with INR, interactions
with other drugs is more difficult. There have not been
any reports of epidural hematoma associated with THC
or CBD; however, there have been suggestions of withholding cannabis and CBD for 5 days prior to high-risk
interventional procedures.

11.5.11 Omega-3 Fatty Acids and Vitamin E
Vitamin E is a fat-soluble plasma antioxidant, composed naturally of 4 tocopherols (α, β, γ, and δ) and 4
tocotrienols. Vitamin E is most commonly utilized as a
dietary supplement. As an antioxidant, vitamin E has
been promoted as a therapeutic agent in cardiovascular
disease. Platelet aggregation is abnormally increased in
patients with cardiovascular disease to modulate platelet aggregation. Vitamin E has been shown in animal
and human studies to normalize the bioactivity of nitric
oxide, but the precise mechanism of action is unknown
(1313,1314). Vitamin E has been shown to attenuate
platelet aggregation and delay thrombus formation
by a decrease in free radical generation, as well as an
increase in endogenous superoxide dismutase and nitric oxide synthase expression and activity (1315-1317).
However, in vivo reports have been less convincing.
Even then, it is a common practice to advise patients
preparing for surgical procedures or epidural injections
to temporarily refrain from the use of vitamin E, along
with other antiplatelet agents. Several studies have
convincingly shown that coagulation (PT, PTT, bleeding
time) is not affected by the dietary supplementation of
vitamin E (1318-1320). A study by Dereska et al (1313)
investigated the effect of vitamin E supplementation on
platelet aggregation, coagulation profile, and bleeding
time in healthy individuals. In this experiment with 42
healthy volunteers with a 2 week abstinence period
from the use of antiplatelet agents, followed by determination of baseline platelet aggregation properties
and coagulation studies, patients were given moderate
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dose vitamin E (800 IU of dl-α-tocopherol acetate) for
14 days with reevaluation of platelet aggregation and
coagulation profile. The results showed that dietary
supplementation with moderate dosage of synthetic
vitamin E did not significantly prolong bleeding or
platelet aggregation in vivo. The effect of vitamin E
on platelet aggregation in vitro does not appear to be
reproducible in vivo. Therefore, they concluded that,
perioperative discontinuation of vitamin E may not be
necessary. Even though vitamin E has been discontinued
commonly, specifically prior to interlaminar epidural
procedures, similar to aspirin and antithrombotics, there
have not been any case reports of epidural hematoma
with either with any of the interventional procedures,
including spinal cord stimulation.
Similar to vitamin E, fish oil or omega-3 fatty acids
have been used as dietary supplements. Fish oil has been
used to treat a number of conditions, which include
asthma, diabetes mellitus, rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus,
hyperlipidemia, and cardiovascular disease. In patients
who take fish oil supplements, the omega-3 fatty acids
compete for incorporation into the platelet cell membranes, thereby increasing the ratio of omega-3 fatty
acids. These effects translate to increases in bleeding
time and a reduction in ADP, collagen, and epinephrine-induced platelet aggregation in patients taking
omega-3 fatty acid supplements (1321,1322). Begtrup
et al (1322) performed a systematic review and showed
there was no impact of fish oil supplements on bleeding
risk. In this review, they identified 52 publications with
32 publications on healthy subjects and 20 publications
on patients undergoing surgery. They concluded that
fish oil supplements reduced platelet aggregation in
healthy subjects. However, this biochemical effect was
not reflected in increased bleeding risk during or after
surgery evaluated in RCTs. Consequently, this systematic
review did not support the need for discontinuation of
fish oil supplements prior to surgery or other invasive
procedures. Two case reports have been published with
cervical epidural hematomas following cervical epidural
injection (1176,1203). These 2 case reports do not confirm that fish oil is the causative agent; however, it is
essential to exert significant caution.

cascade. It is released from dense intercellular granules
and acts as a platelet agonist causing activation and
recruitment of additional platelets. This antiplatelet effect may explain why bleeding and bruising (1206) and
possibly even treatment of acute coronary syndrome
has been reported for patients taking SSRIs (1323,1324).
Consequently, SSRIs have been shown to have significant effect on platelet aggregation and thus primary
hemostasis (1323-1326). SSRIs deplete serotonin in platelets, decreasing platelet binding affinity, and platelet
secretion (1327,1328). Paroxetine has been shown to
decrease intraplatelet serotonin concentration by 83%
and inhibit platelet plug formation as reflected by a
32% prolongation of closure time (1329).
Auerbach et al (1330) in a multicenter retrospective
study conducted to examine the perioperative use of
SSRIs, analyzing more than 500,000 patients. The results
showed that patients receiving SSRIs had increased risk
for adverse events, including higher odds of bleeding
(1330). Thus, there is a potential for SSRIs to be causative of bleeding with epidural injections; however,
their significance as a single factor is not known.

11.5.13 Herbal/Alternative Therapies
Garlic has a dose-dependent effect on bleeding, as
it contains a compound called ajoene. Derived from allicin, the compound that provides garlic’s flavor, ajoene
inhibits granule release and fibrinogen binding and additionally inhibits aggregation of platelets via a variety
of mechanisms. Prostacyclin, forskolin, indomethacin,
and dipyridamole are all altered via ajoenes inhibition of
granule release (1331,1332). Ginkgo Biloba has been used
for thousands of years, and its mechanism is not entirely
understood. Ginkgo is thought to antagonize platelet
activating factor (PAF) and collagen leading to inhibition
of platelet aggregation, resulting in several reports of
spontaneous bleeding. Flavonol glycosides and terpene
glycosides have been suggested to be the chemical compounds responsible for the increased bleeding events
after intake of this medication (1333,1334). Ginseng is
commonly used and reduces the effect of warfarin, declining peak INR levels. Ginsenosides are the major active
ingredient of ginseng, and possibly induce cytochrome
P450 enzymes to increase the metabolism of Warfarin
and thus reduce its effect (1335).

11.5.12 Selective Serotonin-Norepinephrine
Reuptake Inhibitors (SSRIs)

11.6 Recommendations

Selective serotonin reuptake inhibitors (SSRIs) have
also been implicated in alteration of bleeding since
serotonin is an integral component in the hemostatic

Table 31 shows guidelines for antithrombotic medication management during interventional spine procedures. This table also shows comparisons of ASIPP and
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Continue or may
stop for 3 days

High Dose Aspirin

Stop for 4 days

Stop for 4 days

NA

May continue

May continue

Cilostazol (Pletal)

Aggrenox
(dipyridamole plus
aspirin)

May continue

Ticagrelor (Brilinta)

Warfarin

May stop for 2 days
INR ≤ 3.0

May continue

Ticlopidine (Ticlid)

Vitamin K Antagonists

May continue

May continue

Prasugrel (Effient)

Clopidogrel (Plavix)

Platelet Aggregation Inhibitors

May continue

Dipyridamole
(Persantine)

INR < 3.0

Continue

NA

May continue

May continue

Stop for 4 days

May continue

May continue

Antiplatelet Agents (Phosphodiesterase Inhibitors)

Continue or may
stop for 3 days

Low-Dose Aspirin

Aspirin

May continue or
stop 1-10 days

THC/CBD

Stop 1-10 days
due to lack of
protective effect

Stop for 2-5 days
INR ≤ 2

May continue or
stop for 3 days

May continue or
stop for 7 days

May continue or
stop for 6 days

May continue or
stop for 5 days

May continue

May continue

May continue

Continue or may
stop for 3 days

Continue or may
stop for 3 days

May continue or
stop 1-10 days

May continue or
stop 1-10 days
due to lack of
protective effect

ASIPP

Stop for 5 days
INR normalize

NA

NA

Stop for 7-10 days

Stop for 7 days

Stop for 4 days

May continue

May continue

Stop for 4 days

Stop for 4 days

NA

Stop for 2-5 days
INR ≤ 1.5

Stop for 3-5 days

Stop for 7-10 days

Stop for 6 days

Stop for 5 days

Stop for 5 days

May continue or stop
for 2 days

May continue or stop
for 2 days

Stop for 5 days

Stop for 5 days

Stop for 5 days

ASIPP

Stop for 5 days
INR normalize

Stop for 5-10 days

NA

Stop for 7-10 days

Stop for 7 days

Stop for 6 days

Stop for 2 days

Stop for 2 days

Stop for 6 days

Stop for 6 days

NA

24 hours

24 hours

24 hours

24 hours

12 hours

24 hours

12 hours

12 hours

24 hours

24 hours

24 hours

24 hours

24 hours

24 hours

24 hours

12 hours

24 hours

12 hours

12 hours

24 hours

24 hours

NA

24 hours

ASRA (1111)

Timing of Therapy restoration
or Restarting

Stop 1-10 days due 24 hours
to lack of protective
effect

ASRA (1111)

(Cervical, Thoracic, and Lumbar
interlaminar Epidural)

Time to Wait After Last Dose
of Medication Before High Risk
Interventional Techniques Are
Performed

Stop 1-10 days due May continue or stop
to lack of protective 1-10 days due to lack
effect
of protective effect

ASRA (1111)

ASIPP

ASIPP

ASRA (1111)

(Lumbar Transforaminal)

(Caudal Epidural)

May continue or
stop 1-10 days
due to lack of
protective effect

Time to Wait After Last Dose of
Medication Before Moderate Risk
Interventional Techniques Are
Performed

Time to Wait After Last Dose
of Medication Before Low Risk
Interventional Techniques Are
Performed

NSAIDS
(COX 1)
(COX 2)

Medication

Table 31. Guidelines for antithrombotic medication management and spinal procedures (risk stratification described in Table 13).
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May continue or
stop for 1 day

May continue or
stop for 1 day

Rivaroxaban (Xarelto)

Edoxaban (Savaysa,
Lixiana)

Discontinue for 24
hours

Low Molecular Weight
Heparin

Fondaparinux
(Arixtra)

May continue

May continue

May continue

Tirofiban (Aggrastat)

Miscellaneous

May continue

May continue

May continue

May continue

May continue

Discontinue for
24 hours

Discontinue for
8-10 hours

Discontinue for 4
hours

NA

May continue or
stop for 1 day

May continue or
stop for 2 days

May continue or
stop for 2 days

Eptifibatide (Integrilin) May continue

Abciximab (ReoPro)

GPIIb/IIIa Inhibitors

TPA, Streptokinase,
Alteplase, Reteplase

May continue

Discontinue for
8-10 hours

Heparin (treatment)
- SC

Thrombolytic Agents

Discontinue for 4
hours

Heparin (treatment)
- IV

Heparins

May continue or
stop for 2 days

May continue or
stop for 2 days

Discontinue for
8-10 hours

Discontinue for 4
hours

NA

Stop for 3 days

Stop for 3-5 days

Stop for 4-5 days
6 days - renal

Stop for 4 days

Stop for 8 hours

Stop for 8 hours

Stop for 1-2 days

Stop for 2 days

Stop for 4 days

Stop for 8-24 hours

Stop for 8-24 hours

Stop for 2-5 days

Stop for 2 days

Discontinue for 24 Discontinue for 24
hours
hours

Discontinue for
8-10 hours

Discontinue for 4
hours

Stop for 3 days

Stop for 2 days

Stop for 3-5 days

Stop for 4-5 days
6 days - renal

ASIPP

ASIPP

ASRA (1111)

(Lumbar Transforaminal)

(Caudal Epidural)
ASRA (1111)

Time to Wait After Last Dose of
Medication Before Moderate Risk
Interventional Techniques Are
Performed

Time to Wait After Last Dose
of Medication Before Low Risk
Interventional Techniques Are
Performed

Apixaban (Eliquis)

Anti-Xa Agents

Dabigatran (Pradaxa)

Thrombin Inhibitors

Medication

Stop for 4 days

Stop for 8 hours

Stop for 8 hours

Stop for 1-2 days

Stop for 2 days

Discontinue for 24
hours

Discontinue for 8-10
hours

Discontinue for 4
hours

Stop for 3 days

Stop for 2 days

Stop for 3-5 days

Stop for 4-5 days
6 days - renal

ASIPP

Stop for 4 days

Stop for 8-24 hours

Stop for 8-24 hours

Stop for 2-5 days

Stop for 2 days

Discontinue for 24
hours

Discontinue for
8-10 hours

Discontinue for 4
hours

NA

Stop for 3 days

Stop for 3-5 days

Stop for 4-5 days
6 days - renal

ASRA (1111)

(Cervical, Thoracic, and Lumbar
interlaminar Epidural)

Time to Wait After Last Dose
of Medication Before High Risk
Interventional Techniques Are
Performed

Table 31 (cont.). Guidelines for antithrombotic medication management and spinal procedures (risk stratification described in Table 13).

8-12 hours

8-12 hours

8-12 hours

8-12 hours

24 hours

24 hours

24 hours

24 hours

24 hours

24 hours

24 hours

24 hours

ASIPP

8-12 hours

8-12 hours

8-12 hours

8-12 hours

24 hours

24 hours

24 hours

24 hours

24 hours

24 hours

24 hours

24 hours

ASRA (1111)

Timing of Therapy restoration
or Restarting
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ASRA guidelines. These recommendations differ from
our previously published guidelines, as well as from ASRA
guidelines based on the present analysis of the evidence.
General recommendations based on ASRA guidelines (1111) are to discontinue the drugs for 5 half-lives;
however, the exception to the 5 half-life recommendation should occur in individuals with hepatic dysfunction,
and renal dysfunction including nephrotic syndrome.

12.0 Guidelines
Interventions

for

Therapeutic Epidural

`These guidelines for the delivery of therapeutic
epidural interventions provide an algorithmic approach
based on the best available evidence on the epidemiology of various identifiable sources of chronic spinal
pain, specifically epidural interventions. This approach is
designed to promote the efficient use of interventional
pain management techniques based on the best available evidence. However, this may not be applicable in
each and every patient. The purpose of the described
approach is to provide a disciplined approach to the use
of spinal interventional techniques in managing spinal
pain. This approach includes evaluation, diagnostic, and
therapeutic approaches, which in turn avoid unnecessary care, as well as poorly documented practices.
This algorithmic approach does not dictate the
standard of care – these are guidelines. Furthermore,
with space constraints, details of comprehensive initial
evaluations and all the findings are not provided. Only
relevant descriptions are provided.

12.1 Documentation Requirements
Documentation is to provide evidence of information. Documentation includes evaluation and management services, procedural services, and billing and coding. While the purpose of documentation is to provide
information, it reflects the competency and character of
the physician (7,504,1336-1339).
Medical necessity requires appropriate diagnosis and coding by the International Classification of
Diseases, 10th Revision, (ICD-10-CM) to justify services
rendered and indicates the severity of a patient’s condition (1340). The Balanced Budget Act (HR 2015, Section 4317) requires all physicians to provide diagnostic
information for all Medicare/Medicaid patients starting
from January 1, 1998 (1340-1343). Medical necessity
is defined in numerous ways (1344,1345). The Centers
for Medicare and Medicaid Services (CMS) (1342,1343)
defines medical necessity as follows: “. . .no payment
may be made under part A or part B for any expense incurred for items or services which . . .are not reasonable
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and necessary for the diagnosis or treatment of illness
or injury or to improve the functioning of a malformed
body member.”
Further, reasonable and necessary are defined as
follows (1342):
•
Service must be:
•
Safe and effective
•
Not experimental or investigational
Appropriate, including the duration and frequency that is
considered appropriate for the service in terms of
whether it is:
•
Furnished in accordance with accepted standards of medical practice for the diagnosis
or treatment of the patient’s condition or to
improve the patient’s function
•
Furnished in a setting appropriate to the patient’s medical needs and condition
•
Ordered and/or furnished by qualified
personnel
•
One that meets, but does not exceed, the patient’s medical need
•
At least as beneficial as an existing and available medically appropriative alternative.

12.1.1 Elements of Documentation
Federal, state, third party payer, and managed care
plans rely heavily on provider documentation when assessing the claims for various parameters. These include:
•
Was the billed service actually rendered or provided
to the patient?
•
Was the level of service or extent of the service accurately reported?
•
Was the service or procedure medically necessary?
•
Was the claim sent to the correct primary insurer
for the service or procedure performed?

12.1.2 Types of Documentation
Documentation includes evaluation and management services and interventional techniques. Documentation for spinal interventional techniques may
vary based on whether the procedure was performed
in a facility setting such as hospital outpatient department or ambulatory surgery center versus in a physician’s office.

12.1.2.1 Documentation of Interventional Procedures
All spinal interventional techniques are considered
surgical procedures.
Documentation requirements are as follows:
•
History and physical.
•
Indications and medical necessity.
www.painphysicianjournal.com
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•
•
•

Intra-operative procedural description.
Post-operative monitoring and ambulation.
Discharge/disposition.

12.1.2.2 History and Physical
The physician’s history should include the following
elements:
•
Documentation of the signs and symptoms warranting the interventional procedure.
•
A listing of the patient’s current medications
including dosages, route, and frequency of
admission.
•
Any existing co-morbid conditions and previous surgeries.
•
Documentation of any social history or conditions which would have an impact on the
patient’s care upon discharge from the facility
following the procedure.
The physician’s physical examination should not
only reflect the relevance of the interventional procedure, but also the type of anesthesia planned. Generally, for interventional techniques, if no anesthesia is to
be administered, the physical examination is limited to
the assessment of the patient’s mental status and an examination specific to the proposed procedure, including
any co-morbid conditions.
However, if intravenous sedation or any other
type of anesthesia is planned, the physical examination should also include documentation of the results
of an auscultatory examination of the heart and lungs,
and an assessment and written statement about the
patient’s general health, in addition to the assessment
of mental status and an examination specific to the
proposed procedure and any co-morbid conditions.

12.1.2.3 Documentation of Indications and Medical
Necessity
Medical necessity must be established for each
and every procedure and encounter (1337,1338,1342).
General documentation requirements for all spinal
interventional techniques for indications and medical
necessity are as follows:
1. Complete initial evaluation including history and
physical examination.
2. Physiological and functional assessment, as necessary and feasible.
3. Definition of indications and medical necessity, as
follows:
•
Suspected organic problem.
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•
•
•

•

•

Nonresponsiveness to conservative modalities
of treatment.
Pain and disability of moderate-to-severe
degree.
No evidence of contraindications such as severe
spinal stenosis resulting in intraspinal obstruction, infection, or predominantly psychogenic
pain.
Responsiveness to prior interventions with improvement in physical and functional status for
repeat blocks or other interventions.
Repeating interventions only upon return of
pain and deterioration in functional status.

12.1.2.4 Procedural Documentation
This includes a description of the procedure, postoperative monitoring, and discharge/disposition (1338)
(Table 32).

12.2 Comprehensive Algorithm
Figure 27 illustrates an algorithmic approach for
the evaluation and management of a chronic pain
patient (7). Appropriate history, physical examination, and medical decision-making are essential to the
provision of appropriate documentation and patient
care. Not covered in this algorithm are socioeconomic
issues and psychosocial factors that may be important
in the clinical decision-making process. A comprehensive and complete evaluation will assist in complying
with regulations, providing appropriate care, and
fulfilling an algorithmic approach.

12.3 Lumbar Epidural Interventions
Based on the comprehensive review of literature
and available evidence, there is Level I evidence with a

Table 32. Procedural documentation guidelines for
interventional techniques.
1. History and physical
2. Indications and medical necessity
3. Description of the procedure
Consent
Monitoring
Sedation
Positioning
Site preparation
Fluoroscopy
Drugs utilized
Needle placement
Complications
4. Post-operative monitoring
5. Discharge and instructions
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Fig. 27. A comprehensive algorithm for the evaluation and management of chronic spinal pain.
Reproduced with permission from authors and Pain Physician journal.

strong recommendation for caudal epidural injections,
lumbar interlaminar epidural injections, and lumbar
transforaminal epidural injections in managing radicular pain or disc herniation. Additionally, the evidence is

S158

Level III to II with a moderate to strong recommendation for caudal, Level II for lumbar interlaminar epidural
injections with moderate to strong recommendation in
managing spinal stenosis. The level of evidence is IV to
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Fig. 28. A suggested algorithm for therapeutic interventional techniques in management of chronic low back pain.
Reproduced with permission from authors and Pain Physician journal.

III with moderate recommendation for lumbar transforaminal epidurals in managing lumbar spinal stenosis.
The evidence for post-surgery syndrome is Level II with
a moderate to strong recommendation for caudal epidural injections. The evidence for axial discogenic pain
is Level II with moderate to strong recommendation for
caudal and lumbar interlaminar epidural injections. The
evidence assessment is based on contemporary practice
in interventional pain management settings for all the
procedures performed under fluoroscopy (Fig. 28).
In patients with post-lumbar surgery syndrome,
spinal stenosis, and recalcitrant stenosis after failure to
respond to fluoroscopically directed epidural injections,
percutaneous adhesiolysis is considered (72-76,895).
Based on the current literature, the evidence is Level I
with a strong recommendation for percutaneous adhesiolysis in managing post-lumbar surgery syndrome and
Level II with a moderate to strong recommendation in
managing lumbar spinal stenosis and recalcitrant disc
herniation with chronic low back and/or lower extremity
pain nonresponsive to conservative modalities including
fluoroscopically directed epidural injections.
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The next step in the radicular pain algorithm is
implantable therapy with spinal cord stimulation or
implantable infusion systems. Spine cord stimulation
is recommended to the patient population for whom
all other appropriate medical options have been tried
without sufficient improvement in pain control.

12.4 Cervical Epidural Procedures
The current evidence for cervical interlaminar
epidural injections in disc herniation is Level I with
strong recommendation. The evidence in discogenic
pain and spinal stenosis is Level II with moderate to
strong recommendation and Level II to I with moderate to strong recommendation for post-surgery syndrome (Fig. 29).

12.5 Thoracic Epidural Procedures
Disc protrusions and herniations are much less common in the thoracic spine than the lumbar or cervical
spine. Nonetheless, very few patients who present with
thoracic radiculitis, post-surgery syndrome, spinal stenosis, and radiculitis without disc protrusion, and patients
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Fig. 29. A suggested algorithm for therapeutic interventional techniques in management of chronic low back pain.
Reproduced with permission from authors and Pain Physician journal.

Fig. 30. A suggested algorithm for therapeutic interventional techniques in the management of chronic thoracic pain.
Reproduced with permission from authors and Pain Physician journal.

failing to show evidence of facet joint pain are candidates
for epidural injections (Fig. 30). Epidural injections are
most commonly provided through an interlaminar route
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rather than transforaminal which is associated with high
risk. Thoracic interlaminar epidural injections show Level
II evidence with moderate to strong recommendation.
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12.6 Therapeutic Lumbar Epidural
Interventions
Epidural procedures are applied in the cervical,
thoracic, and lumbosacral regions. While these include
diagnostic, as well as therapeutic interventions, these
therapeutic and diagnostic interventions hold much less
importance for epidural procedures rather than diagnostic
facet joint interventions.
The indications, frequency, and total number of interventions have been considered important issues, even
though debated and poorly addressed. These are based
on flawed assumptions from nonexistent evidence. Over
the years, some authors have recommended one injection
for diagnostic as well as therapeutic purposes. Some have
preached 3 injections in a series irrespective of a patient’s
progress or lack thereof; whereas, others suggest 3 injections followed by a repeat course of 3 injections after 3-,
6-, or 12-month intervals. There are also proponents who
propose that an unlimited number of injections with no
established goals or parameters should be available. A
limitation of 3 mg per kilogram of body weight of steroid
or 210 mg per year in an average person and a lifetime
dose of 420 mg of steroid also have been advocated; however, with no scientific basis. The comprehensive review of
the literature in preparation of these guidelines and review of all the systematic reviews has not shown any basis
for the above reported assumptions and limitations. The
administration must be based solely on patients’ response,
safety profile of the drug, experience of the patient, and
pharmacological and chemical properties such as duration
of action and suppression of adrenals (55). Further, multiple well controlled trials have illustrated no significant
difference with local anesthetic alone, or in combination
with local anesthetic and steroids (58).
Side effects of steroids are significant based on the
complex pharmacokinetics and systemic absorption of
epidurally administered steroids which has been explored
in multiple reports. Friedly et al (1058) assessed systemic
of epidural steroid injections for spinal stenosis in 200 patients receiving corticosteroids, with 32 patients (20.3%)
experiencing cortisol reduction at 3 weeks of greater
than 50% compared with 10 patients (6.7%) treated with
lidocaine only. The effect on a 3-week cortisol changes did
not differ by patient level characteristic. Further, those
patients who were treated with methylprednisolone or
triamcinolone had an average 3-week cortisol reduction
of 41% and 41.6% from baseline respectively. In addition,
patients treated with betamethasone or dexamethasone,
found no significant changes with cortisol that they were
similar to lidocaine alone. Hooten et al (1059) showed tri-
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amcinolone concentrations almost 22 days. Multiple others
have described HPA axis suppression (1075) and other side
effects with increase in blood glucose levels along with
adverse immune influence leading to influenza infections
with specific concerns during COVID (1061-1064). In a dose
dependant evaluation, Habib et al (1064) in 2013, examined the magnitude and duration of the suppression of a
single epidural injection of methylprednisolone. Eighty-six
percent of the patients who received 80 mg dose were
reported to have laboratory confirmed HPA axis suppression one week post injection compared to 53% of those
receiving 40 mg dose. Further, 20% of all participants had
continued suppression at 4 weeks post injection.
Thus, the frequency may be based on the type of
injectate with no significant effect with local anesthetics
with potential repeat of injection therapy if necessary
after a 2 week waiting period, for dexamethasone and betamethasone of 2 to 4 weeks and for methylprednisolone
and triamcinolone 4 weeks and 4 to 6 weeks based on the
dosage.
Manchikanti et al performed multiple randomized
controlled trials with inclusion of over 12,000 patients
with local anesthetic alone or with steroids utilizing a low
dose betamethasone (i.e., 6 mg) has not reported any
complications.
During COVID-19 pandemic it may be crucial to follow these rules from the CDC, as well as guidance from
multiple organizations including ASIPP (51,52,55,58).

12.6.1 Lumbar Epidural Injections
Lumbar epidural injections include caudal, interlaminar, and transforaminal. Common indications are as
follows:
•
Chronic low back and/or lower extremity pain of at
least 3 months duration which has failed to respond
or poorly responded to noninterventional and nonsurgical conservative management resulting from:
•
Disc herniation/lumbar radiculitis: (evidence –
Level I with strong recommendation for caudal,
interlaminar, and transforaminal)
•
Lumbar spinal stenosis: (evidence – Level II for
caudal with moderate to strong recommendation, Level II for lumbar interlaminar with moderate to strong recommendation and Level IV to
III with moderate recommendation for lumbar
transforaminal)
•
Post-lumbar surgery syndrome: (evidence –
Level II for caudal with moderate to strong
recommendation)
•
Axial or discogenic low back pain without facet
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•
•

•

joint or sacroiliac joint pain or disc herniation: (evidence – Level II for caudal and lumbar interlaminar with moderate to strong recommendation)
Moderate to severe pain causing functional disability.
Lumbar interlaminar may be performed in post-surgery syndrome only if the access to the epidural space
is obtained outside the scar (caudal and transforaminal are preferred modalities).
Acute proven disc herniation with radiculitis with disabling pain or to avoid surgical intervention, herpes
zoster, post herpetic neuralgia, CRPS I and II, epidural
injections may be performed at physician discretion
without above requirements.

•

•

12.6.2 Cervical Epidural
While cervical epidural injections may be administered either by the interlaminar or transforaminal approach, only the interlaminar approach has been studied
with appropriate indications and effectiveness. Further,
cervical transforaminal epidural injections are associated
with high risk. Common indications for cervical interlaminar epidurals are as follows:|
•
Chronic neck and/or upper extremity pain of at least
3 months duration which has failed to respond or
poorly responded to noninterventional and nonsurgical conservative management resulting from:
•
Disc herniation/cervical radiculitis (evidence –
Level I with strong recommendation)
•
Cervical spinal stenosis (evidence – Level II with
moderate to strong recommendation)
•
Post cervical surgery syndrome (evidence – Level
II to I with moderate to strong recommendation)
•
Axial or discogenic pain without facet joint pathology or disc herniation (evidence – Level II
with moderate to strong recommendation)
•
Intermittent or continuous pain causing functional
disability.
•
Acute proven disc herniation with radiculitis with disabling pain or to avoid surgical intervention, herpes
zoster, post herpetic neuralgia, CRPS I and II, epidural
injections may be performed at physician discretion
without above requirements.

12.7 Frequency of Epidural Procedures
•

•

•

•

•

12.6.3 Thoracic Epidural
Thoracic epidural injections may be performed either
with an interlaminar approach or a transforaminal approach. The literature is scant in reference to thoracic epidural injections, with Level II evidence. Consequently, only
interlaminar epidural injections are described herewith.
Common indications are as follows:
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Chronic mid back or upper back pain of at least 3
months duration which has failed to respond or
poorly responded to noninterventional and nonsurgical conservative management resulting from:
•
Thoracic disc herniation/radiculitis
•
Thoracic spinal stenosis
•
Thoracic post-surgery syndrome
•
Axial or discogenic pain without facet joint pathology or disc herniation
•
Moderate to severe pain causing functional
disability.
Acute proven disc herniation with radiculitis with disabling pain or to avoid surgical intervention, herpes
zoster, post herpetic neuralgia, CRPS I and II, epidural
injections may be performed at physician discretion
without above requirements.

•

Guidelines of frequency of interventions apply
to epidural injections caudal, interlaminar, and
transforaminal.
In the diagnostic phase, a patient may receive 2
procedures at intervals of no sooner than 2 weeks,
preferably 4-6 weeks based on the type and dosage
of steroid used.
In the therapeutic phase (after the diagnostic phase
is completed), the suggested frequency of interventional techniques should be 2½ to 3 months or longer
between each injection, provided that > 50% relief
is obtained for 2½ to 3 months, not exceeding 4 per
year, per region.
If neural blockade is applied for different regions,
they may be performed at intervals of no sooner than
one week and preferably 2 weeks for most types of
procedures. The therapeutic frequency may remain
at intervals of at least 2 months for each region. It is
further suggested that all regions be treated at the
same time, provided all procedures can be performed
safely.
In the treatment or therapeutic phase, the epidural
injections should be repeated only as necessary according to medical necessity criteria, and it is suggested that these be limited to a maximum of 4 times
per year.
Cervical and thoracic regions are considered as one
region and lumbar and sacral are considered as one
region.

12.8 Percutaneous Adhesiolysis
At the present time, the evidence is available for
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percutaneous adhesiolysis in the lumbar region only utilizing a caudal approach. Evidence for the cervical and
thoracic regions and transforaminal approach in the
lumbar region is only emerging. Common indications
for percutaneous adhesiolysis with a caudal approach in
lumbar region are as follows:
•
Chronic low back and/or lower extremity pain of
at least 6 months duration which failed to respond
to or poorly responded to noninterventional and
nonsurgical conservative management and fluoroscopically directed epidural injections secondary to:
•
Post-surgery syndrome (evidence – Level I with
strong recommendation).
•
Central spinal stenosis (evidence – Level II with
moderate to strong recommendation)
•
Disc herniation/radiculitis/severe degenerative
disc disease (evidence – Level II with moderate
to strong recommendation)
•
Intermittent or continuous pain causing functional
disability.

12.8.1 Frequency of Interventions
•

The number of procedures is preferably limited to:
•
•

2 interventions per year, with a 3-day
protocol
4 interventions per year, with a one-day protocol.
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Appendix Table 1. Sources of risk of bias from Cochrane Review collaboration.

Bias
Domain

Selection

Source of Bias

(1) Was the method
of randomization
adequate?

A random (unpredictable) assignment sequence. Examples of adequate methods are coin
toss (for studies with 2 groups), rolling a dice (for studies with 2 or more groups), drawing
of balls of different colors, drawing of ballots with the study group labels from a dark bag,
computer-generated random sequence, preordered sealed envelopes, sequentially-ordered
vials, telephone call to a central office, and preordered list of treatment assignments.

Possible
Answers

Yes/No/Unsure

Examples of inadequate methods are: alternation, birth date, social insurance/security
number, date in which they are invited to participate in the study, and hospital registration
number.

Selection

(2) Was the treatment
allocation concealed?

Assignment generated by an independent person not responsible for determining the
eligibility of the patients. This person has no information about the persons included
in the trial and has no influence on the assignment sequence or on the decision about
eligibility of the patient.

Yes/No/Unsure

Performance

(3) Was the patient
blinded to the
intervention?

Index and control groups are indistinguishable for the patients or if the success of blinding
was tested among the patients and it was successful.

Yes/No/Unsure

Performance

(4) Was the care
provider blinded to the
intervention?

Index and control groups are indistinguishable for the care providers or if the success of
blinding was tested among the care providers and it was successful.

Yes/No/Unsure

Adequacy of blinding should be assessed for each primary outcome separately. This item
should be scored ‘‘yes’’ if the success of blinding was tested among the outcome assessors
and it was successful or:

Detection

(5) Was the outcome
assessor blinded to the
intervention?

•

for patient-reported outcomes in which the patient is the outcome assessor (e.g.,
pain, disability): the blinding procedure is adequate for outcome assessors if
participant blinding is scored ‘‘yes’’

•

for outcome criteria assessed during scheduled visit and that supposes a contact
between participants and outcome assessors (e.g., clinical examination): the blinding
procedure is adequate if patients are blinded, and the treatment or adverse effects of
the treatment cannot be noticed during clinical examination

•

for outcome criteria that do not suppose a contact with participants (e.g.,
radiography, magnetic resonance imaging): the blinding procedure is adequate if the
treatment or adverse effects of the treatment cannot be noticed when assessing the
main outcome

•

for outcome criteria that are clinical or therapeutic events that will be determined
by the interaction between patients and care providers (e.g., cointerventions,
hospitalization length, treatment failure), in which the care provider is the outcome
assessor: the blinding procedure is adequate for outcome assessors if item ‘‘4’’
(caregivers) is scored ‘‘yes’’

•

for outcome criteria that are assessed from data of the medical forms: the blinding
procedure is adequate if the treatment or adverse effects of the treatment cannot be
noticed on the extracted data

Yes/No/Unsure

Attrition

(6) Was the drop-out
rate described and
acceptable?

The number of participants who were included in the study but did not complete the
observation period or were not included in the analysis must be described and reasons
given. If the percentage of withdrawals and drop-outs does not exceed 20% for short-term
follow-up and 30% for long-term follow-up and does not lead to substantial bias a ‘‘yes’’ is
scored (N.B. these percentages are arbitrary, not supported by literature).

Yes/No/Unsure

Attrition

(7) Were all
randomized
participants analyzed in
the group to which they
were allocated?

All randomized patients are reported/analyzed in the group they were allocated to by
randomization for the most important moments of effect measurement (minus missing
values) irrespective of noncompliance and cointerventions.

Yes/No/Unsure

Reporting

(8) Are reports of the
study free of suggestion
of selective outcome
reporting?

All the results from all prespecified outcomes have been adequately reported in the
published report of the trial. This information is either obtained by comparing the
protocol and the report, or in the absence of the protocol, assessing that the published
report includes enough information to make this judgment.

Yes/No/Unsure
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Appendix Table 1 (con’t). Sources of risk of bias from Cochrane Review collaboration.

Bias
Domain

Selection

Possible
Answers

Source of Bias

(1) Was the method
of randomization
adequate?

A random (unpredictable) assignment sequence. Examples of adequate methods are coin
toss (for studies with 2 groups), rolling a dice (for studies with 2 or more groups), drawing
of balls of different colors, drawing of ballots with the study group labels from a dark bag,
computer-generated random sequence, preordered sealed envelopes, sequentially-ordered
vials, telephone call to a central office, and preordered list of treatment assignments.

Yes/No/Unsure

Examples of inadequate methods are: alternation, birth date, social insurance/security
number, date in which they are invited to participate in the study, and hospital registration
number.

Selection

(2) Was the treatment
allocation concealed?

Assignment generated by an independent person not responsible for determining the
eligibility of the patients. This person has no information about the persons included
in the trial and has no influence on the assignment sequence or on the decision about
eligibility of the patient.

Yes/No/Unsure

Performance

(3) Was the patient
blinded to the
intervention?

Index and control groups are indistinguishable for the patients or if the success of blinding
was tested among the patients and it was successful.

Yes/No/Unsure

Performance

(4) Was the care
provider blinded to the
intervention?

Index and control groups are indistinguishable for the care providers or if the success of
blinding was tested among the care providers and it was successful.

Yes/No/Unsure

Adequacy of blinding should be assessed for each primary outcome separately. This item
should be scored ‘‘yes’’ if the success of blinding was tested among the outcome assessors
and it was successful or:

Detection

(5) Was the outcome
assessor blinded to the
intervention?

•

for patient-reported outcomes in which the patient is the outcome assessor (e.g.,
pain, disability): the blinding procedure is adequate for outcome assessors if
participant blinding is scored ‘‘yes’’

•

for outcome criteria assessed during scheduled visit and that supposes a contact
between participants and outcome assessors (e.g., clinical examination): the blinding
procedure is adequate if patients are blinded, and the treatment or adverse effects of
the treatment cannot be noticed during clinical examination

•

for outcome criteria that do not suppose a contact with participants (e.g.,
radiography, magnetic resonance imaging): the blinding procedure is adequate if the
treatment or adverse effects of the treatment cannot be noticed when assessing the
main outcome

•

for outcome criteria that are clinical or therapeutic events that will be determined
by the interaction between patients and care providers (e.g., cointerventions,
hospitalization length, treatment failure), in which the care provider is the outcome
assessor: the blinding procedure is adequate for outcome assessors if item ‘‘4’’
(caregivers) is scored ‘‘yes’’

•

for outcome criteria that are assessed from data of the medical forms: the blinding
procedure is adequate if the treatment or adverse effects of the treatment cannot be
noticed on the extracted data

Yes/No/Unsure

Attrition

(6) Was the drop-out
rate described and
acceptable?

The number of participants who were included in the study but did not complete the
observation period or were not included in the analysis must be described and reasons
given. If the percentage of withdrawals and drop-outs does not exceed 20% for short-term
follow-up and 30% for long-term follow-up and does not lead to substantial bias a ‘‘yes’’ is
scored (N.B. these percentages are arbitrary, not supported by literature).

Yes/No/Unsure

Attrition

(7) Were all
randomized
participants analyzed in
the group to which they
were allocated?

All randomized patients are reported/analyzed in the group they were allocated to by
randomization for the most important moments of effect measurement (minus missing
values) irrespective of noncompliance and cointerventions.

Yes/No/Unsure

Reporting

(8) Are reports of the
study free of suggestion
of selective outcome
reporting?

All the results from all prespecified outcomes have been adequately reported in the
published report of the trial. This information is either obtained by comparing the
protocol and the report, or in the absence of the protocol, assessing that the published
report includes enough information to make this judgment.

Yes/No/Unsure
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Appendix Table 1 (con’t). Sources of risk of bias from Cochrane Review collaboration.

Bias
Domain

Source of Bias

Selection

(9) Were the groups
similar at baseline
regarding the most
important prognostic
indicators?

Performance

(10) Were
If there were no cointerventions or they were similar between the index and control
cointerventions avoided
groups.
or similar?

Performance

(11) Was the
compliance acceptable
in all groups?

Detection

(12) Was the timing of
Timing of outcome assessment should be identical for all intervention groups and for all
the outcome assessment
primary outcome measures.
similar in all groups?

Groups have to be similar at baseline regarding demographic factors, duration and severity
of complaints, percentage of patients with neurological symptoms, and value of main
outcome measure(s).

The reviewer determines if the compliance with the interventions is acceptable, based
on the reported intensity, duration, number and frequency of sessions for both the
index intervention and control intervention(s). For example, physiotherapy treatment
is usually administered for several sessions; therefore it is necessary to assess how many
sessions each patient attended. For single-session interventions (e.g., surgery), this item is
irrelevant.

Possible
Answers

Yes/No/Unsure

Yes/No/Unsure

Yes/No/Unsure

Yes/No/Unsure

Other types of biases. For example:
•
Other

(13) Are other sources
of potential bias
unlikely?

•

When the outcome measures were not valid. There should be evidence from a
previous or present scientific study that the primary outcome can be considered
valid in the context of the present.
Industry-sponsored trials. The conflict of interest (COI) statement should explicitly
state that the researchers have had full possession of the trial process from planning
to reporting without funders with potential COI having any possibility to interfere in
the process. If, for example, the statistical analyses have been done by a funder with a
potential COI, usually ‘‘unsure’’ is scored.

Yes/No/Unsure

Source: Furlan AD, et al; Editorial Board of the Cochrane Back, Neck Group. 2015 updated method guideline for systematic reviews in the Cochrane Back
and Neck Group. Spine (Phila Pa 1976) 2015; 40:1660-1673 (154).
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Appendix Table 2. Item checklist for assessment of randomized controlled trials of IPM techniques utilizing IPM – QRB.

Scoring
I.

TRIAL DESIGN AND GUIDANCE REPORTING

1.

CONSORT or SPIRIT
Trial designed and reported without any guidance

0

Trial designed and reported utilizing minimum criteria other than CONSORT or SPIRIT criteria or trial was conducted
prior to 2005

1

Trial implies it was based on CONSORT or SPIRIT without clear description with moderately significant criteria for
randomized trials or the trial was conducted before 2005

2

Explicit use of CONSORT or SPIRIT with identification of criteria or trial conducted with high level reporting and criteria
or conducted before 2005

3

II.

DESIGN FACTORS

2.

Type and Design of Trial

3.

4.

5.

6.

Poorly designed control group (quasi selection, convenient sampling)

0

Proper active-control or sham procedure with injection of active agent

2

Proper placebo control (no active solutions into active structures)

3

Setting/Physician
General setting with no specialty affiliation and general physician

0

Specialty of anesthesia/PMR/neurology/radiology/ortho, etc.

1

Interventional pain management with interventional pain management physician

2

Imaging
Blind procedures

0

Ultrasound

1

CT

2

Fluoro

3

Sample Size
Less than 50 participants in the study without appropriate sample size determination

0

Sample size calculation with less than 25 patients in each group

1

Appropriate sample size calculation with at least 25 patients in each group

2

Appropriate sample size calculation with 50 patients in each group

3

Statistical Methodology
None or inappropriate

0

Appropriate

1

III.

PATIENT FACTORS

7.

Inclusiveness of Population

7a.

For epidural procedures:

7b.

8.

4

Poorly identified mixed population

0

Clearly identified mixed population

1

Disorders specific trials (i.e. well defined spinal stenosis and disc herniation, disorder specific, disc herniation or spinal
stenosis or post-surgery syndrome)

2

For facet or sacroiliac joint interventions:
No diagnostic blocks

0

Selection with single diagnostic blocks

1

Selection with placebo or dual diagnostic blocks

2

Duration of Pain
Less than 3 months

0

3 to 6 months

1
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Appendix Table 2. Item checklist for assessment of randomized controlled trials of IPM techniques utilizing IPM – QRB.
(continued)

Scoring
> 6 months
9.

2

Previous Treatments
Conservative management including drug therapy, exercise therapy, physical therapy, etc.

10.

Were not utilized

0

Were utilized sporadically in some patients

1

Were utilized in all patients

2

Duration of Follow-up with Appropriate Interventions
Less than 3 months or 12 weeks for epidural or facet joint procedures, etc. and 6 months for intradiscal procedures and
implantables

0

3 to 6 months for epidural or facet joint procedures, etc., or 1 year for intradiscal procedures or implantables

1

6 months to 17 months for epidurals or facet joint procedures, etc., and 2 years or longer for discal procedures and
implantables

2

18 months or longer for epidurals and facet joint procedures, etc., or 5 years or longer for discal procedures and
implantables

3

IV.

OUTCOMES

11.

Outcomes Assessment Criteria for Significant Improvement

12.

13.

14.

15.

No descriptions of outcomes
OR
< 20% change in pain rating or functional status

0

Pain rating with a decrease of 2 or more points or more than 20% reduction
OR
functional status improvement of more than 20%

1

Pain rating with decrease of ≥ 2 points
AND
≥ 20% change or functional status improvement of 20%

2

Pain rating with a decrease of 3 or more points or more than 50% reduction
OR
functional status improvement with a 50% or 40% reduction in disability score

2

Significant improvement with pain and function ≥ 50% or 3 points and 40% reduction in disability scores

4

Analysis of all Randomized Participants in the Groups
Not performed

0

Performed without intent-to-treat analysis without inclusion of all randomized participants

1

All participants included with or without intent-to-treat analysis

2

Description of Drop Out Rate
No description of dropouts, despite reporting of incomplete data or ≥ 20% withdrawal

0

Less than 20% withdrawal in one year in any group

1

Less than 30% withdrawal at 2 years in any group

2

Similarity of Groups at Baseline for Important Prognostic Indicators
Groups dissimilar with significant influence on outcomes with or without appropriate randomization and allocation

0

Groups dissimilar without influence on outcomes despite appropriate randomization and allocation

1

Groups similar with appropriate randomization and allocation

2

Role of Co-Interventions
Co-interventions were provided but were not similar in the majority of participants

0

No co-interventions or similar co-interventions were provided in the majority of the participants

1

V.

RANDOMIZATION

16.

Method of Randomization
Quasi randomized or poorly randomized or not described
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Appendix Table 2. Item checklist for assessment of randomized controlled trials of IPM techniques utilizing IPM – QRB.
(continued)

Scoring
I.

TRIAL DESIGN AND GUIDANCE REPORTING

1.

CONSORT or SPIRIT
Trial designed and reported without any guidance

0

Trial designed and reported utilizing minimum criteria other than CONSORT or SPIRIT criteria or trial was conducted
prior to 2005

1

Trial implies it was based on CONSORT or SPIRIT without clear description with moderately significant criteria for
randomized trials or the trial was conducted before 2005

2

Explicit use of CONSORT or SPIRIT with identification of criteria or trial conducted with high level reporting and criteria
or conducted before 2005

3

II.

DESIGN FACTORS

2.

Type and Design of Trial

3.

4.

5.

6.

Poorly designed control group (quasi selection, convenient sampling)

0

Proper active-control or sham procedure with injection of active agent

2

Proper placebo control (no active solutions into active structures)

3

Setting/Physician
General setting with no specialty affiliation and general physician

0

Specialty of anesthesia/PMR/neurology/radiology/ortho, etc.

1

Interventional pain management with interventional pain management physician

2

Imaging
Blind procedures

0

Ultrasound

1

CT

2

Fluoro

3

Sample Size
Less than 50 participants in the study without appropriate sample size determination

0

Sample size calculation with less than 25 patients in each group

1

Appropriate sample size calculation with at least 25 patients in each group

2

Appropriate sample size calculation with 50 patients in each group

3

Statistical Methodology
None or inappropriate

0

Appropriate

1

III.

PATIENT FACTORS

7.

Inclusiveness of Population

7a.

For epidural procedures:

7b.

8.

6

Poorly identified mixed population

0

Clearly identified mixed population

1

Disorders specific trials (i.e. well defined spinal stenosis and disc herniation, disorder specific, disc herniation or spinal
stenosis or post-surgery syndrome)

2

For facet or sacroiliac joint interventions:
No diagnostic blocks

0

Selection with single diagnostic blocks

1

Selection with placebo or dual diagnostic blocks

2

Duration of Pain
Less than 3 months

0

3 to 6 months

1

> 6 months

2
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Appendix Table 3. Degree of evidence as described by SIGN.
1++

- High-quality meta-analysis and systematic review conducted by randomized clinical trials
- RCTs with a very low risk of bias

1+

- Well-designed meta-analysis and systematic review conducted by randomized or non-randomized clinical trials
- Randomized or non-randomized clinical trials with a low risk of bias

1-

- Meta analysis and systematic review conducted by randomized or non-randomized clinical trials
- Randomized or non-randomized clinical trials with a high risk of bias

2++

High-quality systematic review conducted by a patient control study, cohort study, or diagnosis analytic study
- High-quality patient control study, cohort study, or diagnosis analytic study of very low risk of confounding, bias or contingency, or
a high possibility of cause and effect relationship

2+

- High-quality patient control study, cohort study, or diagnosis analytic study of the low risk of a confounding, bias or contingency, or
the normal possibility of a cause and effect relationship

2-

- Patient control study, cohort study, or diagnosis analytic study of the high risk of a confounding bias or contingency, or the low
possibility of a cause and effect relationship

3

- Non-analytic studies, e.g., before-and-after study, case series, case report

4

- Expert opinion

Source: Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001; 323:334-336 (125).
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Appendix Table 4. IPM checklist for assessment of nonrandomized or observational studies of IPM techniques utilizing IPMQRBNR.

Scoring
I.

STUDY DESIGN AND GUIDANCE REPORTING

1.

STROBE or TREND Guidance
Case Report/Case Series

0

Study designed without any guidance

1

Study designed with minimal criteria and reporting with or without guidance

2

Study designed with moderately significant criteria or implies it was based on STROBE or TREND without clear
description or the study was conducted before 2011 or similar criteria utilized with study conducted before 2011

3

Designed with high level criteria or explicitly uses STROBE or TREND with identification of criteria or conducted prior
to 2011

4

II.

DESIGN FACTORS

2.

Study Design and Type

3.

4.

5.

6.

Case report or series (uncontrolled – longitudinal)

0

Retrospective cohort or cross-sectional study

1

Prospective cohort case-control study

2

Prospective case control study

3

Prospective, controlled, nonrandomized

4

Setting/Physician
General setting with no specialty affiliation and general physician

0

Specialty of anesthesia/PMR/neurology, etc.

1

Interventional pain management with interventional pain management physician

2

Imaging
Blind procedures

0

Ultrasound

1

CT

2

Fluoro

3

Sample Size
Less than 100 participants without appropriate sample size determination

0

At least 100 participants in the study without appropriate sample size determination

1

Sample size calculation with less than 50 patients in each group

2

Appropriate sample size calculation with at least 50 patients in each group

3

Appropriate sample size calculation with 100 patients in each group

4

Statistical Methodology
None

0

Some statistics

1

Appropriate

2

III.

PATIENT FACTORS

7.

Inclusiveness of Population

7a.

For epidural procedures:

7b.

8

Poorly identified mixed population

1

Poorly identified mixed population with large sample (≥ 200)

2

Clearly identified mixed population

3

Disorders specific trials (i.e. well defined spinal stenosis and disc herniation, disorder specific, disc herniation or spinal
stenosis or post-surgery syndrome)

4

For facet or sacroiliac joint interventions:
www.painphysicianjournal.com
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Appendix Table 4. IPM checklist for assessment of nonrandomized or observational studies of IPM techniques utilizing IPMQRBNR. (continued)

Scoring

8.

9.

No specific selection criteria

1

No diagnostic blocks based on clinical symptomatology

2

Selection with single diagnostic blocks

3

Selection with placebo or dual diagnostic blocks

4

Duration of Pain
Less than 3 months

0

3 to 6 months

1

> 6 months

2

Previous Treatments
Conservative management including drug therapy, exercise therapy, physical therapy, etc.

10.

Were not utilized

0

Were utilized sporadically in some patients

1

Were utilized in all patients

2

Duration of Follow-up with Appropriate Interventions
Less than 3 months or less for epidural or facet joint procedures, etc., and 6 months for intradiscal procedures and
implantables

1

3-6 months for epidural or facet joint procedures, etc., or one year for intradiscal procedures or implantables

2

6-12 months for epidurals or facet joint procedures, etc., and 2 years or longer for discal procedures and implantables

3

18 months or longer for epidurals and facet joint procedures, etc., or 5 years or longer for discal procedures and
implantables

4

IV.

OUTCOMES

11.

Outcomes Assessment Criteria for Significant Improvement

12.

13.

14.

No descriptions of outcomes
OR
< 20% change in pain rating or functional status

0

Pain rating with a decrease of 2 or more points or more than 20% reduction
OR
functional status improvement of more than 20%

1

Pain rating with decrease of ≥ 2 points
AND
≥ 20% change or functional status improvement of 20%

2

Pain rating with a decrease of 3 or more points or more than 50% reduction
OR
functional status improvement with a 50% or 40% reduction in disability score

2

Significant improvement with pain and function ≥ 50% or 3 points and 40% reduction in disability scores

4

Description of Drop Out Rate
No description despite reporting of incomplete data or more than 30% withdrawal

0

Less than 30% withdrawal in one year in any group

1

Less than 40% withdrawal at 2 years in any group

2

Similarity of Groups at Baseline for Important Prognostic Indicators
No groups or groups dissimilar with significant influence on outcomes

0

Groups dissimilar without significant influence on outcomes

1

Groups similar

2

Role of Co-Interventions
Dissimilar co-interventions or similar co-interventions in some of the participants

1

No co-interventions or similar co-interventions in majority of the participants

2

www.painphysicianjournal.com
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Appendix Table 4. IPM checklist for assessment of nonrandomized or observational studies of IPM techniques utilizing IPMQRBNR. (continued)

Scoring
V.

ASSIGNMENT

15.

Method of Assignment of Participants
Case report/case series or selective assignment based on outcomes or retrospective evaluation based on clinical criteria

1

Prospective study with inclusion without specific criteria

2

Retrospective method with inclusion of all participants or random selection of retrospective data

3

Prospective, well-defined assignment of methodology and inclusion criteria (quasi randomization, matching,
stratification, etc.)

4

VI.

CONFLICTS OF INTEREST

16.

Funding and Sponsorship
Trial included industry employees with or without proper disclosure

-3

Industry employees involved; high levels of funding with remunerations by industry or an organization funded with
conflicts

-3

Industry or organizational funding with reimbursement of expenses with some involvement or no information available

0

Industry or organization funding of expenses without involvement

1

Funding by internal resources only

2

Governmental funding without conflict such as NIH, NHS, AHRQ

3

TOTAL MAXIMUM

48

Source: Manchikanti L, et al. Development of an interventional pain management specific instrument for methodologic quality assessment of nonrandomized studies of interventional techniques. Pain Physician 2014; 17:E291-E317 (157).
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Y

Y

Y

Y

Y

Y

Y

Y

12/13

Drop-out rate described

All randomized
participants analyzed in
the group

Reports of the study free
of suggestion of selective
outcome reporting

Groups similar at baseline
regarding most important
prognostic indicators

Co-interventions avoided
or similar

Compliance acceptable in
all group

Time of outcome
assessment in all groups
similar

Are other sources of
potential bias not likely

SCORE

8/13

Y

Y

Y

Y

Y

Y

Y

Y

N

10/13

Y

Y

Y

N

Y

Y

Y

Y

N

N

Y

Y

Y

8/13

Y

Y

Y

N

N

Y

Y

Y

N

N

Y

N

Y

12/13

Y

Y

Y

Y

Y

Y

Y

Y

N

Y

Y

Y

Y

12/13

Y

Y

Y

Y

Y

Y

Y

Y

N

Y

Y

Y

Y

Murakibhavi
Manchikanti Manchikanti
& Khemka
et al (767)
et al (762)
(786)

12/13

Y

Y

Y

Y

Y

Y

Y

Y

N

Y

Y

Y

Y

Manchikanti
et al (766)

9/13

Y

Y

U

Y

Y

Y

N

N

Y

N

Y

Y

Y

Kamble et
al (770)

8/13

Y

Y

Y

Y

Y

Y

Y

Y

N

N

N

N

N

Pandey
(769)

8/13

Y

Y

Y

Y

Y

Y

Y

Y

N

N

N

N

N

Singh et al
(779)

Y = Yes; N = No; U = Unclear
Source: Furlan AD, et al; Editorial Board of the Cochrane Back, Neck Group. 2015 updated method guideline for systematic reviews in the Cochrane Back and Neck Group. Spine (Phila Pa
1976) 2015; 40:1660-1673 (154).

N

Outcome assessor blinded

N

N

Y

Y

Patient blinded

Care provider blinded

N

Y

Concealed treatment
allocation

N

Y

Randomization adequate

Ackerman Dashfield
Manchikanti
& Ahmad et al
et al (765)
(783)
(784)
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12

Concealed Treatment Allocation

17.

Outcome Assessor Blinding

CONFLICTS OF INTEREST

Funding and Sponsorship

Conflicts of Interest

20.

VIII.

21.

22.
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30

2

2

0

0

0

0

0

2

44

3

2

0

1

1

2

2

1

1

2

2

4

3

2

2

2

1

3

3

2

25

3

1

0

0

0

0

0

1

1

2

2

1

2

0

1

2

1

1

3

2

2

0

33

3

2

0

0

1

2

2

1

1

2

2

2

2

0

2

1

1

1

3

2

2

1

Dashfield
et al (784)

27

1

0

0

0

1

2

0

0

0

2

2

4

1

0

1

2

1

2

3

1

2

2

Murakibhavi
& Khemka
(786)

44

3

2

0

1

1

2

2

1

1

2

2

4

3

2

2

2

1

3

3

2

2

3

44

3

2

0

1

1

2

2

1

1

2

2

4

3

2

2

2

1

3

3

2

2

3

Manchikanti Manchikanti
et al (767)
et al (762)

44

3

2

0

1

1

2

2

1

1

2

2

4

3

2

2

2

1

3

3

2

2

3

Manchikanti
et al (766)

29

3

2

0

0

0

0

0

1

1

2

2

2

2

2

2

2

1

1

2

2

2

0

Pandey
(769)

32

3

2

1

0

1

2

2

1

1

0

2

2

1

2

1

2

1

2

2

2

2

0

Kamble et
al (770)

Source: Manchikanti L, et al. Assessment of methodologic quality of randomized trials of interventional techniques: Development of an interventional pain management specific instrument.
Pain Physician 2014; 17:E263-E290 (153).

TOTAL

Patient Blinding

Care Provider Blinding

18.

19.

BLINDING

ALLOCATION CONCEALMENT

VI.

VII.

Method of Randomization

Similarity of Groups at Baseline for
Important Prognostic Indicators

14.

16.

1

Description of Drop Out Rate

13.

1

2

Analysis of all Randomized
Participants in the Groups

12.

Role of Co-Interventions

2

Outcomes Assessment Criteria for
Significant Improvement

11.

RANDOMIZATION

2

OUTCOMES

IV.

15.

1

10.

V.

2

Previous Treatments

Duration of Follow-up with
Appropriate Interventions

2

2

1

2

3

2

2

1

9.

Inclusiveness of Population

Duration of Pain

7.

PATIENT FACTORS

III.

8.

Sample Size

Statistical Methodology

5.

Imaging

4.

6.

Type and Design of Trial

Setting/Physician

2.

3.

CONSORT or SPIRIT

DESIGN FACTORS

1.

3

Manchikanti Ackerman
& Ahmad
et al (765)
(783)

TRIAL DESIGN AND GUIDANCE REPORTING

II.

I.

Singh et
al (779)

Appendix Table 6. Methodologic quality assessment of randomized trials of caudal epidural injections utilizing IPM-QRB.
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Y

Y
Y
Y
Y
Y

Reports of the study free
of suggestion of selective
outcome reporting

Groups similar at baseline
regarding most important
prognostic indicators

Co-interventions avoided
or similar

Compliance acceptable in
all group

Time of outcome assessment
in all groups similar

Are other sources of
potential bias not likely
9/13

Y

Y

Y

Y

Y

Y

Y

Y

N

12/13

Y

Y

Y

Y

Y

Y

N

Y

Y

Y

Y

Y

Y

Amr
(823)

11/13

Y

Y

Y

Y

N

Y

Y

Y

N

Y

Y

Y

Y

Manchikanti
et al (799)

11/13

Y

Y

Y

Y

N

Y

Y

Y

N

Y

Y

Y

Y

Manchikanti
et al (801)

11/13

Y

Y

Y

Y

N

Y

Y

Y

N

Y

Y

Y

Y

Manchikanti
et al (797)

8/13

N

Y

Y

Y

Y

N

Y

Y

N

N

N

Y

Y

Friedly et al
(278,818)

10/13

Y

Y

Y

Y

Y

Y

Y

Y

N

N

N

Y

Y

Ghai et
al (617)

10/13

Y

Y

Y

Y

Y

Y

Y

N

N

N

Y

Y

Y

Ghai
et al
(804)

10/13

Y

Y

Y

Y

Y

Y

Y

Y

N

N

N

Y

Y

Candido
et al
(843)

12/13

Y

Y

Y

Y

Y

Y

N

Y

Y

Y

Y

Y

Y

Ökmen
and
Ökmen
(817)

9/13

Y

Y

U

Y

Y

Y

N

N

Y

N

Y

Y

Y

Kamble
et al
(770)

8/13

Y

Y

Y

Y

Y

Y

Y

Y

N

N

N

N

N

Pandey
(769)

Y = Yes; N = No; U = Unclear
Source: Furlan AD, et al; Editorial Board of the Cochrane Back, Neck Group. 2015 updated method guideline for systematic reviews in the Cochrane Back and Neck Group. Spine (Phila Pa
1976) 2015; 40:1660-1673 (154).

8/13

Y

All randomized participants
analyzed in the group

SCORE

Y

Drop-out rate described

N

N
N

Care provider blinded

Outcome assessor blinded

N

N

Patient blinded

N

N

Y

N

Randomization adequate

Rados et
al (821)

Concealed treatment
allocation

Ackerman
& Ahmad
(783)
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Appendix Table 8. Methodologic quality assessment of randomized trials assessing fluoroscopic lumbar interlaminar epidural
injections utilizing IPM-QRB.

Ackerman &
Ahmad (783)

Rados et
al (821)

Amr
(823)

Manchikanti
et al (799)

Manchikanti
et al (801)

Manchikanti
et al (797)

0

2

2

3

3

3

I.

TRIAL DESIGN AND GUIDANCE REPORTING

1.

CONSORT or SPIRIT

II.

DESIGN FACTORS

2.

Type and Design of Trial

2

2

2

2

2

2

3.

Setting/Physician

2

3

3

2

2

2

4.

Imaging

3

3

3

3

3

3

5.

Sample Size

1

1

3

3

3

3

6.

Statistical Methodology

1

1

1

1

1

1

III.

PATIENT FACTORS

7.

Inclusiveness of Population

2

1

2

2

2

2

8.

Duration of Pain

1

2

2

2

2

2

9.

Previous Treatments

0

0

2

2

2

2

10.

Duration of Follow-up with
Appropriate Interventions

2

2

3

3

3

3

IV.

OUTCOMES

11.

Outcomes Assessment Criteria
for Significant Improvement

1

2

2

4

4

4

12.

Analysis of all Randomized
Participants in the Groups

2

2

1

2

2

2

13.

Description of Drop Out Rate

2

2

2

2

2

2

14.

Similarity of Groups at Baseline
for Important Prognostic
Indicators

1

2

2

0

1

1

15.

Role of Co-Interventions

1

1

1

1

1

1

V.

RANDOMIZATION

16.

Method of Randomization

0

2

2

2

2

2

VI.

ALLOCATION CONCEALMENT

17.

Concealed Treatment Allocation

0

0

2

2

2

2

VII.

BLINDING

18.

Patient Blinding

0

0

1

1

1

1

19.

Care Provider Blinding

0

0

1

1

1

1

20.

Outcome Assessor Blinding

0

0

1

0

0

0

VIII.

CONFLICTS OF INTEREST

21.

Funding and Sponsorship

1

0

0

2

2

2

22.

Conflicts of Interest

3

2

0

3

3

3

25

30

38

43

44

44

TOTAL

Source: Manchikanti L, et al. Assessment of methodologic quality of randomized trials of interventional techniques: Development of an interventional pain management specific instrument. Pain Physician 2014; 17:E263-E290 (153).
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Appendix Table 8 (cont.). Methodologic quality assessment of randomized trials assessing fluoroscopic lumbar interlaminar epidural
injections utilizing IPM-QRB.

Friedly et al Ghai et
(278,818)
al (617)
I.

Ghai et
al (804)

Candido
et al
(843)

Ökmen and
Pandey
Ökmen
(769)
(817)

Kamble
et al
(770)

TRIAL DESIGN AND GUIDANCE REPORTING

1.

CONSORT or SPIRIT

II.

DESIGN FACTORS

2.

Type and Design of Trial

3

3

3

2

2

0

0

2

2

2

2

2

2

2
2

3.

Setting/Physician

2

2

2

2

2

2

4.

Imaging

3

3

3

3

3

2

2

5.

Sample Size

3

2

2

2

3

1

2

0

1

1

1

1

1

1

1

2

2

2

2

2

2

6.

Statistical Methodology

III.

PATIENT FACTORS

7.

Inclusiveness of Population

8.

Duration of Pain

1

2

1

1

2

2

1

9.

Previous Treatments

1

2

1

2

2

2

2

10.

Duration of Follow-up with
Appropriate Interventions

0

3

3

2

2

2

1

IV.

OUTCOMES

11.

Outcomes Assessment Criteria for
Significant Improvement

0

4

4

2

2

2

2

12.

Analysis of all Randomized
Participants in the Groups

2

2

2

2

1

2

2

13.

Description of Drop Out Rate

2

2

0

2

2

2

0

14.

Similarity of Groups at Baseline for
Important Prognostic Indicators

2

2

2

2

2

1

1

15.

Role of Co-Interventions

0

1

1

1

1

1

1

V.

RANDOMIZATION
2

2

2

2

2

0

2

2

2

2

2

2

0

2

16.

Method of Randomization

VI.

ALLOCATION CONCEALMENT

17.

Concealed Treatment Allocation

VII.

BLINDING

18.

Patient Blinding

0

0

1

0

1

0

1

19.

Care Provider Blinding

0

0

0

0

0

0

0

20.

Outcome Assessor Blinding

0

0

0

0

1

0

1

VIII.

CONFLICTS OF INTEREST
2

21.

Funding and Sponsorship

3

2

2

2

2

2

22.

Conflicts of Interest

1

3

3

3

3

3

3

30

42

39

37

40

29

32

TOTAL

Source: Manchikanti L, et al. Assessment of methodologic quality of randomized trials of interventional techniques: Development of an interventional pain management specific instrument. Pain Physician 2014; 17:E263-E290 (153).
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Reports of the study free
of suggestion of selective
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Co-interventions avoided
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all group

Time of outcome
assessment in all groups
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Are other sources of
potential bias not likely
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Y
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Y

Y

Karppinen
et al (856)

10/13

Y

Y

Y

Y

Y

Y

Y

Y
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Y

U

U
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Y

Y

Y

Y

U

Y

Y

Y

Y
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Y

U

U
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Y

Y

Y

Y
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N

Y

N

Y

Y

Y

Y
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al (881)
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Y

Y

U

Y

Y

Y

N

N

U

N

N

N

U
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et al
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Y

Y

Y

Y

N

Y

Y

Y

N

Y

Y

Y

Y
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et al (860)
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Y

Y

Y

Y
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Y
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N
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N

Y

Y

Friedly
et al
(278,818)
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Y

Y

Y

Y

Y

Y

Y

Y

N

N

N

Y

Y

Ghai
et al
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Y

Y

Y

Y

Y

Y

Y

Y

N

N

N

Y

Y

Kennedy
et al
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Y

Y

U

Y

Y

Y

N

N

Y

N

Y

Y

Y

8/13

Y

Y

Y

Y

Y

Y

Y

Y

N

N

N

N

N

Kamble Pandey
et al
(769)
(770)

Y = Yes; N = No; U = Unclear
Source: Furlan AD, et al; Editorial Board of the Cochrane Back, Neck Group. 2015 updated method guideline for systematic reviews in the Cochrane Back and Neck Group. Spine (Phila Pa
1976) 2015; 40:1660-1673 (154).
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Appendix Table 10. Methodologic quality assessment of randomized trials of fluoroscopic transforaminal epidural injections utilizing
IPM-QRB.
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6.

Statistical Methodology

1

1

1

1

1

1

1

III.

PATIENT FACTORS

7.

Inclusiveness of Population

2

1

2

1

2

1

2

8.

Duration of Pain

1

2

0

0

1

1

0

9.

Previous Treatments

0

0

0

0

2

2

0

10.

Duration of Follow-up with
Appropriate Interventions

2

2

1

2

2

1

1

IV.

OUTCOMES

11.

Outcomes Assessment
Criteria for Significant
Improvement

1

2

2

2

1

2

2

12.

Analysis of all Randomized
Participants in the Groups

2

2

2

2

2

1

0

13.

Description of Drop Out Rate

2

2

1

2

2

1

0

14.

Similarity of Groups at
Baseline for Important
Prognostic Indicators

1

2

2

2

2

1

0

15.

Role of Co-Interventions

1

1

0

1

0

1

1

V.

RANDOMIZATION
0

2

2

1

1

2

0

0

0

2

0

0

2

0

16.

Method of Randomization

VI.

ALLOCATION CONCEALMENT

17.

Concealed Treatment
Allocation

VII.

BLINDING

18.

Patient Blinding

0

0

1

1

1

1

0

19.

Care Provider Blinding

0

0

1

0

1

1

0

20.

Outcome Assessor Blinding

0

0

1

1

0

0

0

VIII.

CONFLICTS OF INTEREST

21.

Funding and Sponsorship

1

0

2

2

2

2

0

22.

Conflicts of Interest

3

2

3

2

3

3

2

25

30

34

31

32

32

16

TOTAL
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Appendix Table 10 (cont.). Methodologic quality assessment of randomized trials of fluoroscopic transforaminal epidural injections
utilizing IPM-QRB.

Manchikanti
et al (860)
I.

Friedly et al
(278,818)

Ghai et al
(617)

Kennedy et
al (273)

Pandey
(769)

Kamble et
al (770)

TRIAL DESIGN AND GUIDANCE REPORTING

1.

CONSORT or SPIRIT

II.

DESIGN FACTORS

2.

Type and Design of Trial

3.

Setting/Physician

2

2

2

2

2

2

4.

Imaging

3

3

3

3

2

2

5.

Sample Size

3

3

2

2

1

2

1

0

1

1

1

1

2

1

2

2

2

2

6.

Statistical Methodology

III.

PATIENT FACTORS

7.

Inclusiveness of Population

3

3

3

3

0

0

2

2

2

2

2

2

8.

Duration of Pain

2

1

2

0

2

1

9.

Previous Treatments

2

1

2

2

2

2

10.

Duration of Follow-up with
Appropriate Interventions

3

0

3

1

2

1

IV.

OUTCOMES

11.

Outcomes Assessment
Criteria for Significant
Improvement

4

0

4

2

2

2

12.

Analysis of all Randomized
Participants in the Groups

2

2

2

2

2

2

13.

Description of Drop Out Rate

2

2

2

1

2

0

14.

Similarity of Groups at
Baseline for Important
Prognostic Indicators

1

2

2

2

1

1

1

0

1

1

1

1

15.

Role of Co-Interventions

V.

RANDOMIZATION

16.

Method of Randomization

2

2

2

2

0

2

17.

Concealed Treatment
Allocation

2

2

2

2

0

2

VII.

BLINDING

VI.

18.

Patient Blinding

1

0

0

0

0

1

19.

Care Provider Blinding

1

0

0

0

0

0

20.

Outcome Assessor Blinding

0

0

0

0

0

1

VIII.

CONFLICTS OF
INTEREST

21.

Funding and Sponsorship

2

3

2

0

2

2

22.

Conflicts of Interest

3

1

3

0

3

3

44

30

42

30

29

32

TOTAL

Source: Manchikanti L, et al. Assessment of methodologic quality of randomized trials of interventional techniques: Development of an interventional pain management specific instrument. Pain Physician 2014; 17:E263-E290 (153).
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Appendix Table 11. Methodological quality assessment of randomized trials of percutaneous adhesiolysis procedures utilizing
Cochrane review criteria.
Chunjing et al
(896)

Manchikanti
et al
(893,894)

Heavner
et al
(899)

Manchikanti
et al (897)

Akbas et
al (901)

Veihelmann
et al (898)

Karm
et al
(900)

Randomization
adequate

Y

Y

U

Y

Y

Y

Y

Y

Y

Concealed treatment
allocation

Y

Y

U

Y

Y

Y

Y

Y

Y

Patient blinded

Y

Y

Y

Y

Care provider
blinded

N

Y

Y

N

Y

N

N

N

N

N

Y

N

N

N

Outcome assessor
blinded

Y

U

Y

Y

NA

Y

N

Y

N

Drop-out rate
described

Y

Y

Y

Y

Y

Y

Y

U

Y

All randomized
participants analyzed
in the group

Y

Y

Y

Y

Y

Y

Y

Y

Y

Reports of the study
free of suggestion of
selective outcome
reporting

Y

Y

Y

Y

Y

Y

Y

Y

Y

Groups similar at
baseline regarding
most important
prognostic indicators

Y

Y

Y

Y

Y

Y

Y

U

Y

Co-interventions
avoided or similar

Y

Y

Y

Y

Y

Y

Y

N

Y

Compliance
acceptable in all
group

Y

Y

Y

Y

Y

Y

Y

Y

Y

Time of outcome
assessment in all
groups similar

Y

Y

Y

Y

Y

Y

Y

Y

Y

Are other sources
of potential bias not
likely

Y

Y

Y

Y

Y

Y

Y

Y

Y

12/13

11/13

10/13

12/13

9/13

13/13

11/13

8/13

11/13

SCORE

Gerdesmeyer Manchikanti
et al (895) et al (891,892)

Y = Yes; N = No; U = Unclear
Source: Furlan AD, et al; Editorial Board of the Cochrane Back, Neck Group. 2015 updated method guideline for systematic reviews in the Cochrane
Back and Neck Group. Spine (Phila Pa 1976) 2015; 40:1660-1673 (154).
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1

2
2
1
2

DESIGN FACTORS

Type and Design of Trial

Setting/Physician

Imaging

Sample Size

Statistical Methodology

PATIENT FACTORS

Inclusiveness of Population

Duration of Pain

Previous Treatments

Duration of Follow-up with
Appropriate Interventions

OUTCOMES

Outcomes Assessment Criteria for
Significant Improvement

Analysis of all Randomized
Participants in the Groups

Description of Drop Out Rate

Similarity of Groups at Baseline for
Important Prognostic Indicators

Role of Co-Interventions

RANDOMIZATION

Method of Randomization

ALLOCATION CONCEALMENT

Concealed Treatment Allocation

BLINDING

Patient Blinding

Care Provider Blinding

Outcome Assessor Blinding

CONFLICTS OF INTEREST

Funding and Sponsorship

Conflicts of Interest

II.

2.

3.

4.

5.

6.

III.

7.

8.

9.

10.

IV.

11.

12.

13.

14.

15.

V.

16.

VI.

17.

VII.

18.

19.

20.

VIII.

21.

22.
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34

3

2

1

0

1

2

2

1

1

2

1

2

3

1

2

42

3

2

0

0

1

2

2

1

2

1

2

4

2

2

2

2

1

3

3

2

2

3

Manchikanti et
al (893,894)

23

0

2

0

0

1

1

0

1

2

0

1

0

2

2

2

1

1

0

3

2

2

0

Heavner et
al (899)

37

3

2

1

0

1

1

2

1

2

1

2

2

2

2

2

1

1

2

3

2

2

3

Manchikanti
et al (897)

35

3

2

0

0

0

2

2

1

2

0

2

2

1

2

2

2

1

2

3

2

2

2

Akbas et al
(901)

44

3

2

1

1

1

2

2

1

2

1

2

4

2

2

2

2

1

2

3

2

3

3

Gerdesmeyer
et al (895)

36

2

2

0

0

1

1

2

1

1

1

1

4

2

2

2

2

1

2

3

2

2

2

Manchikanti
et al (891,892)

30

1

2

1

0

0

1

1

1

1

0

1

4

2

2

2

2

1

2

3

1

2

0

Veihelmann
et al (898)

34

2

2

0

0

1

2

2

1

1

1

1

2

2

2

2

2

1

1

3

2

2

2

Karm et al
(900)

Source: Manchikanti L, et al. Assessment of methodologic quality of randomized trials of interventional techniques: Development of an interventional pain management specific instrument.
Pain Physician 2014; 17:E263-E290 (153).

TOTAL

2

CONSORT or SPIRIT

1.

0

TRIAL DESIGN AND GUIDANCE REPORTING

I.

Chun-jing
et al (896)

Appendix Table 12. Methodologic quality assessment of randomized trials of percutaneous adhesiolysis procedures utilizing IPM-QRB.
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ASIPP Epidural Guidelines
Appendix Table 13. Assessment of nonrandomized or observational studies of
percutaneous adhesiolysis procedures in lumbar spinal stenosis meeting inclusion criteria
utilizing IPM-QRBNR.

Choi et al
(908)

Choi et al
(910)

2

2

I.

STUDY DESIGN AND GUIDANCE REPORTING

1.

STROBE or TREND GUIDANCE

II.

DESIGN FACTORS

2.

Study Design and Type

3

2

3.

Setting/Physician

2

2

4.

Imaging

3

3

5.

Sample Size

0

0

6.

Statistical Methodology

2

2

III.

PATIENT FACTORS

7.

Inclusiveness of Population

2

0

8.

Duration of Pain

2

2

9.

Previous Treatments

2

2

10.

Duration of Follow-up with Appropriate
Interventions

2

1

IV.

OUTCOMES

11.

Outcomes Assessment Criteria for Significant
Improvement

2

2

12.

Description of Drop Out Rate

0

1

13.

Similarity of Groups at Baseline for Important
Prognostic Indicators

0

0

14.

Role of Co-Interventions

2

2

V.

ASSIGNMENT

15.

Method of Assignment of Participants

2

0

VI.

CONFLICTS OF INTEREST

16.

Funding and Sponsorship

TOTAL

2

2

28

24

Source: Manchikanti L, et al. Development of an interventional pain management specific instrument for methodologic quality assessment of nonrandomized studies of interventional techniques.
Pain Physician 2014; 17:E291-E317 (157).
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Appendix Table 14. Methodological quality assessment of randomized trials assessing fluoroscopic cervical/thoracic interlaminar
epidural injections utilizing Cochrane review criteria.

Manchikanti Manchikanti
et al (922)
et al (924)

Manchikanti Manchikanti Manchikanti
et al (925)
et al (927)
et al (588)

Cohen et
al (932)

McCormick
et al (941)

Randomization adequate

Y

Y

Y

Y

Y

Y

Y

Concealed treatment
allocation

Y

Y

Y

Y

Y

N

Y

Patient blinded

Y

Y

Y

Y

Y

N

N

Care provider blinded

Y

Y

Y

Y

Y

N

N

Outcome assessor blinded

N

N

N

N

N

N

N

Drop-out rate described

Y

Y

Y

Y

Y

Y

Y

All randomized participants
analyzed in the group

Y

Y

Y

Y

Y

N

Y

Reports of the study free
of suggestion of selective
outcome reporting

Y

Y

Y

Y

Y

Y

Y

Groups similar at baseline
regarding most important
prognostic indicators

Y

N

N

N

N

Y

Y

Co-interventions avoided or
similar

Y

Y

Y

Y

Y

Y

Y

Compliance acceptable in all
group

Y

Y

Y

Y

Y

N

Y

Time of outcome assessment
in all groups similar

Y

Y

Y

Y

Y

Y

Y

Are other sources of potential
bias not likely

Y

Y

Y

Y

Y

N

Y

12/13

11/13

11/13

11/13

11/13

6/13

10/13

SCORE

Y = Yes; N = No; U = Unclear
Source: Furlan AD, Malmivaara A, Chou R, et al; Editorial Board of the Cochrane Back, Neck Group. 2015 updated method guideline for systematic
reviews in the Cochrane Back and Neck Group. Spine (Phila Pa 1976) 2015; 40:1660-1673 (154).
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Appendix Table 15. Methodologic quality assessment of randomized trials assessing fluoroscopic cervical/thoracic interlaminar
epidural injections utilizing IPM-QRB.
Manchikanti Manchikanti Manchikanti Manchikanti
et al (922)
et al (924)
et al (925)
et al (927)
I.

Cohen et
al (932)

McCormick
et al (941)

Manchikanti
et al (588)

3

3

3

TRIAL DESIGN AND GUIDANCE REPORTING

1.

CONSORT or SPIRIT

II.

DESIGN FACTORS

3

3

3

3

2.

Type and Design of Trial

2

2

2

2

2

2

2

3.

Setting/Physician

2

2

2

2

2

2

2

4.

Imaging

3

3

3

3

3

3

3

5.

Sample Size

3

3

2

2

3

2

3

6.

Statistical Methodology

1

1

1

1

1

1

1

III.

PATIENT FACTORS
2

7.

Inclusiveness of Population

2

2

2

2

2

2

8.

Duration of Pain

2

2

2

2

0

0

2

9.

Previous Treatments

2

2

2

2

0

2

2

10.

Duration of Followup with Appropriate
Interventions

3

3

2

2

1

1

3

IV.

OUTCOMES

11.

Outcomes Assessment
Criteria for Significant
Improvement

4

4

4

4

0

2

4

12.

Analysis of all Randomized
Participants in the Groups

2

2

2

2

0

2

2

13.

Description of Drop Out
Rate

2

2

2

2

2

2

2

14.

Similarity of Groups at
Baseline for Important
Prognostic Indicators

0

1

1

1

1

2

0

15.

Role of Co-Interventions

1

1

1

1

0

1

1

V.

RANDOMIZATION
2

2

2

2

2

2

2

2

2

2

2

0

2

2

16.

Method of Randomization

VI.

ALLOCATION CONCEALMENT

17.

Concealed Treatment
Allocation

VII.

BLINDING

18.

Patient Blinding

1

1

1

1

0

1

1

19.

Care Provider Blinding

1

1

1

1

0

0

1

20.

Outcome Assessor
Blinding

0

0

0

0

0

0

0

VIII.

CONFLICTS OF
INTEREST

21.

Funding and Sponsorship

2

2

2

2

1

2

2

22.

Conflicts of Interest

3

3

3

3

1

3

3

TOTAL
43
44
42
42
24
37
43
Source: Manchikanti L, et al. Assessment of methodologic quality of randomized trials of interventional techniques: Development of an interventional pain management specific instrument. Pain Physician 2014; 17:E263-E290 (153).
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Petraglia et al,
2016 (1137)

Moeschler et
al, 2016 (1131)

Of the 8,326 patients meeting
inclusion criteria receiving
spinal cord stimulation, 5,458
were percutaneous and 2,868
were paddle leads. The overall
incidence of spinal cord
injury was 177 or 2.13% with
percutaneous lead placement
attributing to 128 or 2.35%
incidences versus paddle leads
contributing to 49 or 1.71%
incidence.

A total of 642 percutaneous SCS
procedures were performed on
421 unique patients, including
346 SCS trials, 255 SCS
implantations, and 41 revision
surgeries. Patients had received
aspirin or NSAIDs within 7
days of needle placement for
101 procedures (15.7%).

Manchikanti et
al, 2011 (1129)

Of the 8,326 patients meeting
inclusion criteria receiving spinal cord
stimulation, 5,458 were percutaneous
and 2,868 were paddle leads. The
overall incidence of spinal cord injury
was 177 or 2.13% with percutaneous
lead placement attributing to 128 or
2.35% incidences versus paddle leads
contributing to 49 or 1.71% incidence.

There were no bleeding or neurological
complications identified in this cohort.

They performed 642 percutaneous
spinal cord stimulation procedures, trial,
revision, or implantation in 421 patients.
No major bleeding complications.
They have performed 101 procedures
on patients who had taken aspirin or
NSAIDS within 7 days of procedure.

There was no difference in significant
side effect rate with or without
continuation of antithrombotic therapy.

Authors concluded that this study showed
overall a low incidence supporting that SCS is a
safe procedure.

This is a large database in the United
States; however, the study was up
from 2000 to 2009. There seems to be
exponential increase of spinal cord
stimulator placements since 2009;
consequently, this data may not reflect
present literature.

Further, this agrees with older guidance
of continuation of NSAIDs and aspirin in
the perioperative period, even though it
is contradictory to more recent guidelines
(1111).

Even though authors have shown no
complications with continuation of
NSAIDs or aspirin within 7 days in
approximately 16% of the patients, the
study consists of a small number of
patients.

The prospective evaluation
of measurable outcomes
of intravascular entry of
the needle, bruising, local
bleeding, profuse bleeding,
local hematoma, oozing, and
postoperative soreness.

Although the incidence of epidural hematoma is
low, the development of bleeding complications
following SCS lead placement can be
devastating. In the present investigation, we
identified no cases of epidural hematoma
following percutaneous SCS lead placement,
including more than 100 patients receiving
aspirin or NSAIDs. Future investigations with
larger numbers are needed to better define
the relationships between periprocedural
aspirin and NSAID utilization and bleeding
complications.

This study essentially showed that there
is no significant difference in bleeding
patterns whether antithrombotic agents
are continued or discontinued except for
warfarin with no fatal incidents in a large
proportion of patients.

Of the 1,831 patients receiving aspirin 604
discontinued and 1,227 continued and all of
them received epidural injections including
cervical, thoracic, lumbar interlaminar, and
caudal epidural injections. Of the total 326
patients undergoing epidural injections on
clopidogrel 226 discontinued and 100 continued
with patients undergoing all types of epidural
injections including cervical, thoracic, and
lumbar interlaminar epidural injections.
However, for cervical epidural injections a large
proportion discontinued (67) versus continued
(10).
There was no clinical or statistical difference in
any of the major aspects of bleeding.

Manchikanti et
al, 2012 (1128)

In this study, one-quarter (3,087)
of patient encounters undergoing
interventional pain management
procedures, were on antithrombotic
therapy. Antithrombotic therapy was
continued in 55% of the patients or
1,711 encounters, whereas, it was
discontinued in 45% of the patients or
1,376 encounters.

This study essentially shows that even
though there is no evidence of increased
risk of epidural hematoma, the majority
of physicians discontinue antiplatelet
therapy despite increased risk of
thromboembolic complications.

The authors concluded that clinicians must
balance the risks of thromboembolism and
bleeding in each patient prior to the routine
discontinuation of antiplatelet therapy.

An online physician survey
of antithrombotics with
complications with or
without discontinuation of
various antithrombotics and
anticoagulants.

Author Conclusions of the Review

Conclusions by the Study Authors

Results
The results illustrated an overwhelming
pattern of discontinuing antiplatelet
and warfarin therapy as well as
aspirin and other NSAIDs prior
to performing interventional pain
management techniques. However,
thromboembolism complications were
3 times more prevalent than epidural
hematomas (162 versus 55 events).

Methods

Study/Year

Appendix Table 16. Studies assessing the risk of thrombosis and bleeding with interventional pain management techniques.
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Continuation of clopidogrel or warfarin for
lumbar transforaminal epidural and posteriorapproach facet joint injections may be
reasonable. Interlaminar injections carry greater
bleeding risk and merit consideration of holding
anticoagulant/antiplatelet agents.

Authors concluded that there were no
hemorrhagic complications in performing these
procedures and they were safe.

Authors identified 490 patients of total
of 2,204 patients on antithrombotic
medications which included aspirin,
P2Y12 inhibitors, warfarin, heparin,
factor Xa inhibitors, and dipyridamole.
The procedures included facet
joint nerve blocks and facet joint
radiofrequency in all spine regions and
sacroiliac joint injections.

Retrospective review of the
safety of low to intermediate
risk spine procedures in
patients with continued
antithrombotic therapy.

Goodman et al,
2017 (1146)

van Helmond
et al, 2017
(1147)

22% of the patients received aspirin
within 7 days, 12% of the patients
received nonsteroidal antiinflammatory
drugs within 7 days, 2% clopidogrel
within 7 days, and Coumadin within
7 days in 3% of the patients. They also
maintained INR of 1.0.
Overall incidence of spinal epidural
hematoma for all procedures
studied was one in 4,047 procedures
(0.02%, 95% CI ¼ 0.00–0.15%). No
thromboembolic events (myocardial
infarction, cerebrovascular accident, or
critical limb ischemia) were observed
within 24–48 hours after spinal injection
for all patients in the study.

A total of 58,066 procedures
were performed on 24,590
patients. Antiplatelet therapy
included preprocedural
aspirin or nonsteroidal
antiinflammatory drug
therapy in 17,825 procedures
comprising of 30.7%.

Authors concluded that bleeding complications
are rare in patients undergoing low or
intermediate pain procedures, even in the
presence of antiplatelet medications.

Lumbar transforaminal epidural injections,
lumbar facet joint nerve blocks, trigger point
injections, and sacroiliac joint blocks appear to
be safe in patients who continue anticoagulants.
In patients discontinuing anticoagulants, serious
complications are observed in a low proportion
of patients with 0.2%.

Conclusions by the Study Authors

A prospective descriptive
evaluation of patients
undergoing interventional
pain procedures on various
antiplatelet and anticoagulant
agents at a single interventional
physiatry practice.

Warner et al,
2017 (1150)

Endres et al,
2017 (1138)

The study included 3,880 lumbar
epidural injections, 304 thoracic
interlaminar injections with a large
number of epidural injections with over
50% unassigned to a region.

No complications attributable to
anticoagulants were encountered
in 4,766 procedures in which
anticoagulants were continued;
however, in 2,296 procedures in which
anticoagulants were discontinued,
according to the guidelines, 9 patients
suffered serious morbidity, including 2
deaths.

The study was performed as an
observational study in a private
practice in which some partners
continued anticoagulants
while other partners routinely
discontinued anticoagulants.
They studied 4,766 procedures
in which anticoagulants were
continued and 2,296 procedures
in which anticoagulants were
discontinued.

Retrospective cohort of adult
patients undergoing low
and intermediate risk pain
procedures were assessed from
2005 through 2014 at a single
academic tertiary care center.

Results

Methods

Study/Year

Appendix Table 16 (con’t). Studies assessing the risk of thrombosis and bleeding with interventional pain management techniques.

The results are in a small number of
patients with low risk and intermediate
risk procedures of facet joint interventions
and sacroiliac joint interventions without
inclusion of high risk procedures of
interlaminar epidural injections.

Authors have not provided any conclusive
evidence if one procedure is safer to
perform than the other while patient
continues the anti-thrombotic agents.

The study also included 3,880 lumbar
epidural injections, 304 thoracic
interlaminar injections with a large
number of epidural injections with
over 50% of the epidural injections not
assigned to a region.

Authors studied low and intermediate risk
procedures in patients on nonsteroidal
antiinflammatory agents including
aspirin. Of these, 22% of the patients
received aspirin within 7 days.

Further, authors conclusions are
appropriate correlating with other
conclusions that risk of serious
complications of discontinuing
anticoagulant therapy, even though this
risk is low at 0.2%.

This is an observational study in a large
number of patients; however, interlaminar
epidural injections or other high risk
procedures were not included.

Author Conclusions of the Review
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37% of patients with
hematoma were not receiving
antithrombotic therapy.

They utilized extensive search
criteria in various languages
across the globe. They also
compared the previous reports
published in 1992, 1994, and
1996.

Authors concluded that anti-hemostatic drugs,
heparins in particular, are still major risk factors
for developing spinal bleeding. Other risk
factors were hemostatic and spinal disorders
and complicated blocks, especially bloody taps,
whereas multiple attempts did not seem to
Authors identified 21 cases of hematoma increase the risk of bleeding.
from epidural injections with 17 after
They recommended that suspicion of spinal
steroid injections, 5 in cervical, 4 in
thoracic, and 8 in lumbar regions. They hematoma calls for the consultation of surgeon
without delay. MRI was the recommended
also identified 4 after percutaneous
diagnostic tool. Surgical evacuation within 12
application of spinal cord stimulators.
hours from the sign of motor dysfunction seems
The authors identified spinal stenosis as to lead to the best outcome, even though many
the most common spinal disease, which patients operated as late as after more than 24
hours did regain full motor function.
was identified as the most common of
all spinal diseases in 14 cases with spinal
disease reported in 37 cases of 166 cases.

Authors concluded that epidural steroid
injection is safe in patients receiving aspirin-like
antiplatelet medications. Minor worsening of
neurologic function may occur after epidural
steroid injection and must be differentiated from
etiologies requiring interventions.

Conclusions by the Study Authors

Limitations include lack of assessment
after appropriate cessation of
antithrombotic therapy.

Significant information is provided in
this review indicating the risk of bloody
taps, and prompt surgical intervention to
improve outcomes.

Hematomas were identified in 37% of
patients without antithrombotic therapy.

This report is an extensive review
of epidural hematoma of all origins,
specifically of epidural injections for
chronic pain with a prevalence of 21 cases
of hematomas and 3 cases hematoma after
spinal cord stimulation.

The results of this study strongly show
that discontinuation of antiplatelet
therapy and continued therapy with
Aspirin was not essential and is not
associated with major hemorrhagic
complications.

Author Conclusions of the Review

NSAIDs= nonsteroidal anti-inflammatory drugs; SCS = spinal cord stimulator; MRI = magnetic resonance imaging
Source: Kaye AD, et al. Responsible, safe, and effective use of antithrombotics and anticoagulants in patients undergoing interventional techniques: American Society of Interventional Pain
Physicians (ASIPP) guidelines. Pain Physician 2019; 22:S75-S128 (103).

Lagerkranser
et al 2017
(1148,1149)

Horlocker et al,
2002 (1134)

They identified 166 case reports on
spinal hematoma after central neuraxial
blockade during the years between 1994
and 2015. The annual number of case
reports published during this period
almost tripled compared with the 2
preceding decades.

There were no major hemorrhage
complications with spinal hematomas.
NSAIDS did not increase the frequency
of minor hemorrhagic complications.
Increased age, needle gauge, needle
approach, needle insertion at multiple
interspaces, number of needle passes,
volume of injectate, and accidental dural
puncture were all significant risk factors
for minor hemorrhagic complications.

Authors in these 2 manuscripts
studied neuraxial blocks and
spinal hematoma with review of
166 case reports published from
1994 to 2015 with descriptions
of demographics, risk factors,
diagnosis, treatment, and
outcomes.

Results

Methods

A prospective study of 1,214
epidural steroid injections in
ambulatory pain centers. 32%
of the patients were receiving
nonsteroidal antiinflammatory
agents including 34 patients on
multiple medications. Aspirin
was the most common NSAID
and was noted by 158 patients
including 140 patients on 325
mg or less per day. .

Study/Year
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Appendix Fig. 1. Percentage change in 12-months ending provisionala data on all fatal drug overdosesb, 50 states, the District of
Columbia, and New York City: Overdose deaths from 12-months ending in June 2019 to 12-months ending in May 2020c.
a
Provisional drug overdose death counts are based on death records received and processed by NCHS. Provisional drug overdose death
data are often incomplete, and the degree of completeness varies by jurisdiction and 12-month ending period. Consequently, the numbers
of drug overdose deaths are underestimated based on provisional data relative to final data and are subject to random variation. Provisional
data are based on available records that meet certain data quality criteria at the time of analysis and may not include all deaths that occurred
during a given time period. Therefore, they should not be considered comparable with final data and are subject to change. The counts used
in this analysis are the “predicted” values. Predicted provisional counts represent estimates of the number of deaths adjusted for incomplete
reporting.

Deaths were classified using the International Classification of Diseases, Tenth Revision (ICD–10). Drug overdose deaths were identified
using underlying cause-of-death codes X40–X44, X60–X64, X85, and Y10–Y14.

b

Included time periods will have some amount of overlap. For example, the 12-months ending in June 2019 (i.e., July 2018 to June 2019)
includes deaths occurring in June 2019, which is also included separately in 12-months ending in May 2020 (i.e., June 2019 to May 2020).
c
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Fig. 30. A suggested algorithm for therapeutic interventional techniques in the management of chronic thoracic pain.
Reproduced with permission from authors and Pain Physician journal.
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data are based on available records that meet certain data quality criteria at the time of analysis and may not include all deaths that occurred
during a given time period. Therefore, they should not be considered comparable with final data and are subject to change. The counts used
in this analysis are the “predicted” values. Predicted provisional counts represent estimates of the number of deaths adjusted for incomplete
reporting.

Deaths were classified using the International Classification of Diseases, Tenth Revision (ICD–10). Drug overdose deaths were identified
using underlying cause-of-death codes X40–X44, X60–X64, X85, and Y10–Y14.
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